6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O prescribing/O information/O :/O Peripheral/B-AdverseReaction Neuropathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Anaphylaxis/B-AdverseReaction and/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hematologic/B-AdverseReaction Toxicities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Serious/B-Severity Infections/B-AdverseReaction and/O Opportunistic/B-AdverseReaction Infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Increased/B-AdverseReaction Toxicity/I-AdverseReaction in/O the/O Presence/O of/O Severe/O Renal/O Impairment/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Increased/B-AdverseReaction Toxicity/I-AdverseReaction in/O the/O Presence/O of/O Moderate/O or/O Severe/O Hepatic/O Impairment/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Progressive/B-AdverseReaction Multifocal/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O Pulmonary/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O Serious/B-Severity Dermatologic/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.11/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O were/O :/O Relapsed/O classical/O HL/O and/O relapsed/O sALCL/O :/O neutropenia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction (/O 6.1/O )/O ./O
Classical/O HL/O post/O -/O auto/O -/O HSCT/O consolidation/O :/O neutropenia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Seattle/O Genetics/O ,/O Inc./O at/O 1/O -/O 855/O -/O 473/O -/O 2436/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O data/O below/O reflect/O exposure/O to/O ADCETRIS/O as/O monotherapy/O in/O 327/O patients/O with/O classical/O Hodgkin/O lymphoma/O (/O HL/O )/O and/O systemic/O anaplastic/O large/O cell/O lymphoma/O (/O sALCL/O )/O ,/O including/O 160/O patients/O in/O two/O uncontrolled/O single/O -/O arm/O trials/O (/O Studies/O 1/O and/O 2/O )/O and/O 167/O patients/O in/O one/O placebo/O -/O controlled/O randomized/O trial/O (/O Study/O 3/O )/O ./O
In/O Studies/O 1/O and/O 2/O ,/O the/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O ,/O regardless/O of/O causality/O ,/O were/O neutropenia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O occurring/O in/O at/O least/O 10/O %/O of/O patients/O in/O either/O Study/O 1/O or/O 2/O ,/O regardless/O of/O causality/O ,/O using/O the/O NCI/O Common/O Toxicity/O Criteria/O (/O CTC/O )/O Version/O 3.0/O ,/O are/O shown/O in/O Table/O 2/O ./O
In/O Study/O 3/O ,/O the/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O in/O the/O ADCETRIS/O -/O treatment/O arm/O ,/O regardless/O of/O causality/O ,/O were/O neutropenia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O occurring/O in/O at/O least/O 10/O %/O of/O patients/O ,/O using/O the/O NCI/O CTC/O Version/O 4/O ,/O are/O shown/O in/O Table/O 3/O ./O
Experience/O in/O Classical/O Hodgkin/O Lymphoma/O Summary/O of/O Clinical/O Trial/O Experience/O in/O Relapsed/O Classical/O HL/O (/O Study/O 1/O )/O ADCETRIS/O was/O studied/O in/O 102/O patients/O with/O classical/O HL/O in/O a/O single/O arm/O clinical/O trial/O in/O which/O the/O recommended/O starting/O dose/O and/O schedule/O was/O 1.8/O mg/O kg/O intravenously/O every/O 3/O weeks/O ./O
Median/O duration/O of/O treatment/O was/O 9/O cycles/O (/O range/O ,/O 1/O -/O 16/O )/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
The/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O ,/O regardless/O of/O causality/O ,/O were/O neutropenia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction ./O
Summary/O of/O Clinical/O Trial/O Experience/O in/O Classical/O HL/O Post/O -/O auto/O -/O HSCT/O Consolidation/O (/O Study/O 3/O )/O ADCETRIS/O was/O studied/O in/O 329/O patients/O with/O classical/O HL/O at/O high/O risk/O of/O relapse/O or/O progression/O post/O -/O auto/O -/O HSCT/O in/O a/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O clinical/O trial/O in/O which/O the/O recommended/O starting/O dose/O and/O schedule/O was/O 1.8/O mg/O kg/O of/O ADCETRIS/O administered/O intravenously/O over/O 30/O minutes/O every/O 3/O weeks/O or/O placebo/O for/O up/O to/O 16/O cycles/O ./O
Of/O the/O 329/O enrolled/O patients/O ,/O 327/O (/O 167/O brentuximab/O vedotin/O ,/O 160/O placebo/O )/O received/O at/O least/O one/O dose/O of/O study/O treatment/O ./O
The/O median/O number/O of/O treatment/O cycles/O in/O each/O study/O arm/O was/O 15/O (/O range/O ,/O 1/O -/O 16/O )/O and/O 80/O patients/O (/O 48/O %/O )/O in/O the/O ADCETRIS/O -/O treatment/O arm/O received/O 16/O cycles/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
Standard/O international/O guidelines/O were/O followed/O for/O infection/O prophylaxis/O for/O herpes/O simplex/O virus/O (/O HSV/O )/O ,/O varicella/O -/O zoster/O virus/O (/O VZV/O )/O ,/O and/O Pneumocystis/O jiroveci/O pneumonia/O (/O PCP/O )/O post/O -/O auto/O -/O HSCT/O ./O
Overall/O ,/O 312/O patients/O (/O 95/O %/O )/O received/O HSV/O and/O VZV/O prophylaxis/O with/O a/O median/O duration/O of/O 11.1/O months/O (/O range/O ,/O 0/O -/O 20/O )/O and/O 319/O patients/O (/O 98/O %/O )/O received/O PCP/O prophylaxis/O with/O a/O median/O duration/O of/O 6.5/O months/O (/O range/O ,/O 0/O -/O 20/O )/O ./O
Experience/O in/O Systemic/O Anaplastic/O Large/O Cell/O Lymphoma/O Summary/O of/O Clinical/O Trial/O Experience/O in/O Relapsed/O sALCL/O (/O Study/O 2/O )/O ADCETRIS/O was/O studied/O in/O 58/O patients/O with/O sALCL/O in/O a/O single/O arm/O clinical/O trial/O in/O which/O the/O recommended/O starting/O dose/O and/O schedule/O was/O 1.8/O mg/O kg/O intravenously/O every/O 3/O weeks/O ./O
Median/O duration/O of/O treatment/O was/O 7/O cycles/O (/O range/O ,/O 1/O -/O 16/O )/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
The/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O ,/O regardless/O of/O causality/O ,/O were/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O pain/B-AdverseReaction ./O
Table/O 2/O :/O Most/O Commonly/O Reported/O (/O 10/O %/O )/O Adverse/O Reactions/O in/O Studies/O 1/O and/O 2/O Classical/O HL/O sALCL/O Total/O N/O 102/O %/O of/O patients/O Total/O N/O 58/O %/O of/O patients/O Adverse/O Reaction/O AnyGrade/O Grade3/O Grade4/O AnyGrade/O Grade3/O Grade4/O Blood/O and/O lymphatic/O system/O disorders/O Neutropenia/B-AdverseReaction 54/O 15/O 6/O 55/O 12/O 9/O Anemia/B-AdverseReaction 33/O 8/O 2/O 52/O 2/O -/O Thrombocytopenia/B-AdverseReaction 28/O 7/O 2/O 16/O 5/O 5/O Lymphadenopathy/B-AdverseReaction 11/O -/O -/O 10/O -/O -/O Nervous/O system/O disorders/O Peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction 52/O 8/O -/O 53/O 10/O -/O Peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction 16/O 4/O -/O 7/O 3/O -/O Headache/B-AdverseReaction 19/O -/O -/O 16/O 2/O -/O Dizziness/B-AdverseReaction 11/O -/O -/O 16/O -/O -/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 49/O 3/O -/O 41/O 2/O 2/O Pyrexia/B-AdverseReaction 29/O 2/O -/O 38/O 2/O -/O Chills/B-AdverseReaction 13/O -/O -/O 12/O -/O -/O Pain/B-AdverseReaction 7/O -/O -/O 28/O -/O 5/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 4/O -/O -/O 16/O -/O -/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 47/O -/O -/O 12/O -/O -/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 42/O -/O -/O 38/O 2/O -/O Diarrhea/B-AdverseReaction 36/O 1/O -/O 29/O 3/O -/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 25/O 2/O 1/O 9/O 2/O -/O Vomiting/B-AdverseReaction 22/O -/O -/O 17/O 3/O -/O Constipation/B-AdverseReaction 16/O -/O -/O 19/O 2/O -/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 27/O -/O -/O 31/O -/O -/O Pruritus/B-AdverseReaction 17/O -/O -/O 19/O -/O -/O Alopecia/B-AdverseReaction 13/O -/O -/O 14/O -/O -/O Night/B-AdverseReaction sweats/I-AdverseReaction 12/O -/O -/O 9/O -/O -/O Dry/B-AdverseReaction skin/I-AdverseReaction 4/O -/O -/O 10/O -/O -/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 25/O -/O -/O 17/O -/O -/O Dyspnea/B-AdverseReaction 13/O 1/O -/O 19/O 2/O -/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 11/O -/O -/O 9/O -/O -/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 19/O -/O -/O 9/O -/O -/O Myalgia/B-AdverseReaction 17/O -/O -/O 16/O 2/O -/O Back/B-AdverseReaction pain/I-AdverseReaction 14/O -/O -/O 10/O 2/O -/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 10/O -/O -/O 10/O 2/O 2/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 9/O -/O -/O 10/O 2/O -/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 14/O -/O -/O 16/O -/O -/O Anxiety/B-AdverseReaction 11/O 2/O -/O 7/O -/O -/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 11/O -/O -/O 16/O 2/O -/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 6/O -/O -/O 12/O 3/O -/O Table/O 3/O :/O Most/O Commonly/O Reported/O (/O 10/O %/O in/O the/O ADCETRIS/O arm/O )/O Adverse/O Reactions/O in/O Study/O 3/O ADCETRIS/O Placebo/O Total/O N/O 167/O %/O of/O patients/O Total/O N/O 160/O %/O of/O patients/O Adverse/O Reaction/O AnyGrade/O Grade3/O Grade4/O AnyGrade/O Grade3/O Grade4/O Blood/O and/O lymphatic/O system/O disorders/O Neutropenia/B-AdverseReaction 78/O 30/O 9/O 34/O 6/O 4/O Thrombocytopenia/B-AdverseReaction 41/O 2/O 4/O 20/O 3/O 2/O Anemia/B-AdverseReaction 27/O 4/O -/O 19/O 2/O -/O Nervous/O system/O disorders/O Peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction 56/O 10/O -/O 16/O 1/O -/O Peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction 23/O 6/O -/O 2/O 1/O -/O Headache/B-AdverseReaction 11/O 2/O -/O 8/O 1/O -/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 26/O -/O -/O 23/O 1/O -/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 24/O 2/O -/O 18/O 3/O -/O Pyrexia/B-AdverseReaction 19/O 2/O -/O 16/O -/O -/O Chills/B-AdverseReaction 10/O -/O -/O 5/O -/O -/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 22/O 3/O -/O 8/O -/O -/O Diarrhea/B-AdverseReaction 20/O 2/O -/O 10/O 1/O -/O Vomiting/B-AdverseReaction 16/O 2/O -/O 7/O -/O -/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 14/O 2/O -/O 3/O -/O -/O Constipation/B-AdverseReaction 13/O 2/O -/O 3/O -/O -/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 21/O -/O -/O 16/O -/O -/O Dyspnea/B-AdverseReaction 13/O -/O -/O 6/O -/O 1/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 19/O 1/O -/O 6/O -/O -/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 18/O 1/O -/O 9/O -/O -/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 11/O -/O -/O 6/O -/O -/O Myalgia/B-AdverseReaction 11/O 1/O -/O 4/O -/O -/O Skin/O and/O subcutaneous/O tissue/O disorders/O Pruritus/B-AdverseReaction 12/O 1/O -/O 8/O -/O -/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 12/O 1/O -/O 6/O -/O -/O Additional/O Important/O Adverse/O Reactions/O Peripheral/O neuropathy/O In/O Studies/O 1/O and/O 2/O ,/O 54/O %/O of/O patients/O experienced/O any/O grade/O of/O neuropathy/B-AdverseReaction ./O
Of/O these/O patients/O ,/O 49/O %/O had/O complete/O resolution/O ,/O 31/O %/O had/O partial/O improvement/O ,/O and/O 20/O %/O had/O no/O improvement/O ./O
Of/O the/O patients/O who/O reported/O neuropathy/B-AdverseReaction ,/O 51/O %/O had/O residual/B-AdverseReaction neuropathy/I-AdverseReaction at/O the/O time/O of/O their/O last/O evaluation/O ./O
In/O Study/O 3/O ,/O 67/O %/O of/O patients/O treated/O with/O ADCETRIS/O experienced/O any/O grade/O of/O neuropathy/B-AdverseReaction ./O
The/O median/O time/O to/O first/O onset/O of/O any/O grade/O was/O 14/O weeks/O (/O range/O ,/O 0.1/O -/O 47/O )/O ,/O of/O Grade/O 2/O was/O 27/O weeks/O (/O range/O ,/O 0.4/O -/O 52/O )/O and/O of/O Grade/O 3/O was/O 34/O weeks/O (/O range/O ,/O 7/O -/O 106/O )/O ./O
The/O median/O time/O from/O onset/O to/O resolution/O or/O improvement/O of/O any/O grade/O was/O 23/O weeks/O (/O range/O ,/O 0.1/O -/O 138/O )/O ,/O of/O Grade/O 2/O was/O 24/O weeks/O (/O range/O ,/O 1/O -/O 108/O )/O and/O of/O Grade/O 3/O was/O 25/O weeks/O (/O range/O ,/O 2/O -/O 98/O )/O ./O
Of/O the/O patients/O who/O reported/O neuropathy/B-AdverseReaction ,/O 59/O %/O had/O complete/O resolution/O and/O 41/O %/O had/O residual/B-AdverseReaction neuropathy/I-AdverseReaction (/O 26/O %/O partial/O improvement/O ,/O 15/O %/O no/O improvement/O )/O at/O the/O time/O of/O their/O last/O evaluation/O ./O
Infusion/O reactions/O Two/O cases/O of/O anaphylaxis/B-AdverseReaction were/O reported/O in/O the/O dose/O -/O finding/O trials/O ./O
There/O were/O no/B-Negation Grade/B-Severity 3/I-Severity or/O 4/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O reported/O in/O Studies/O 1/O and/O 2/O ;/O however/O ,/O Grade/B-Severity 1/I-Severity or/O 2/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O were/O reported/O for/O 19/O patients/O (/O 12/O %/O )/O ./O
In/O Studies/O 1/O and/O 2/O ,/O the/O most/O common/O adverse/O reactions/O (/O 2/O %/O )/O associated/O with/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O were/O chills/B-AdverseReaction (/O 4/O %/O )/O ,/O nausea/B-AdverseReaction (/O 3/O %/O )/O ,/O dyspnea/B-AdverseReaction (/O 3/O %/O )/O ,/O pruritus/B-AdverseReaction (/O 3/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O cough/B-AdverseReaction (/O 2/O %/O )/O ./O
In/O Study/O 3/O ,/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O were/O reported/O in/O 25/O patients/O (/O 15/O %/O )/O in/O the/O ADCETRIS/O -/O treated/O arm/O and/O 3/O patients/O (/O 2/O %/O )/O in/O the/O placebo/O arm/O ./O
Grade/O 3/O events/O were/O reported/O in/O 3/O of/O the/O 25/O patients/O treated/O with/O ADCETRIS/O who/O experienced/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O ./O
No/B-Negation Grade/B-Severity 4/I-Severity infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O were/O reported/O ./O
The/O most/O common/O adverse/O reactions/O (/O 2/O %/O )/O associated/O with/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O were/O nausea/B-AdverseReaction (/O 4/O %/O )/O ,/O chills/B-AdverseReaction (/O 4/O %/O )/O ,/O dyspnea/B-AdverseReaction (/O 2/O %/O )/O ,/O headache/B-AdverseReaction (/O 2/O %/O )/O ,/O pruritus/B-AdverseReaction (/O 2/O %/O )/O ,/O rash/B-AdverseReaction (/O 2/O %/O )/O ,/O back/B-AdverseReaction pain/I-AdverseReaction (/O 2/O %/O )/O ,/O and/O vomiting/B-AdverseReaction (/O 2/O %/O )/O ./O
Pulmonary/O Toxicity/O In/O a/O trial/O in/O patients/O with/O classical/O HL/O that/O studied/O ADCETRIS/O with/O bleomycin/O as/O part/O of/O a/O combination/O regimen/O ,/O the/O rate/O of/O non/B-AdverseReaction -/I-AdverseReaction infectious/I-AdverseReaction pulmonary/O toxicity/O was/O higher/O than/O the/O historical/O incidence/O reported/O with/O ABVD/O (/O adriamycin/O ,/O bleomycin/O ,/O vinblastine/O ,/O dacarbazine/O )/O ./O
Patients/O typically/O reported/O cough/B-AdverseReaction and/O dyspnea/B-AdverseReaction ./O
Interstitial/O infiltration/O and/or/O inflammation/O were/O observed/O on/O radiographs/O and/O computed/O tomographic/O imaging/O of/O the/O chest/O ./O
Most/O patients/O responded/O to/O corticosteroids/O ./O
The/O concomitant/O use/O of/O ADCETRIS/O with/O bleomycin/O is/O contraindicated/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Cases/O of/O pulmonary/B-AdverseReaction toxicity/I-AdverseReaction have/O also/O been/O reported/O in/O patients/O receiving/O ADCETRIS/O ./O
In/O Study/O 3/O ,/O pulmonary/B-AdverseReaction toxicity/I-AdverseReaction was/O reported/O in/O 8/O patients/O (/O 5/O %/O )/O in/O the/O ADCETRIS/O -/O treated/O arm/O and/O 5/O patients/O (/O 3/O %/O )/O in/O the/O placebo/O arm/O ./O
A/O causal/O association/O with/O single/O -/O agent/O ADCETRIS/O has/O not/O been/O established/O ./O
Serious/O adverse/O reactions/O In/O Studies/O 1/O and/O 2/O ,/O serious/O adverse/O reactions/O ,/O regardless/O of/O causality/O ,/O were/O reported/O in/O 31/O %/O of/O patients/O receiving/O ADCETRIS/O ./O
The/O most/O common/O serious/O adverse/O reactions/O experienced/O by/O patients/O with/O classical/O HL/O include/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction (/O 4/O %/O )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 3/O %/O )/O ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 2/O %/O )/O ,/O pneumonitis/B-AdverseReaction (/O 2/O %/O )/O ,/O pneumothorax/B-AdverseReaction (/O 2/O %/O )/O ,/O pyelonephritis/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O pyrexia/B-AdverseReaction (/O 2/O %/O )/O ./O
The/O most/O common/O serious/O adverse/O reactions/O experienced/O by/O patients/O with/O sALCL/O were/O septic/B-AdverseReaction shock/I-AdverseReaction (/O 3/O %/O )/O ,/O supraventricular/B-AdverseReaction arrhythmia/I-AdverseReaction (/O 3/O %/O )/O ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction (/O 3/O %/O )/O ,/O and/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 3/O %/O )/O ./O
Other/O important/O serious/O adverse/O reactions/O reported/O include/O PML/B-AdverseReaction ,/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O and/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction ./O
In/O Study/O 3/O ,/O serious/O adverse/O reactions/O ,/O regardless/O of/O causality/O ,/O were/O reported/O in/O 25/O %/O of/O ADCETRIS/O -/O treated/O patients/O ./O
The/O most/O common/O serious/O adverse/O reactions/O were/O pneumonia/B-AdverseReaction (/O 4/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 4/O %/O )/O ,/O vomiting/B-AdverseReaction (/O 3/O %/O )/O ,/O nausea/B-AdverseReaction (/O 2/O %/O )/O ,/O hepatotoxicity/B-AdverseReaction (/O 2/O %/O )/O and/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction (/O 2/O %/O )/O ./O
Dose/O modifications/O Adverse/O reactions/O that/O led/O to/O dose/O delays/O in/O more/O than/O 5/O %/O of/O patients/O in/O Studies/O 1/O and/O 2/O were/O neutropenia/B-AdverseReaction (/O 14/O %/O )/O and/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction (/O 11/O %/O )/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Adverse/O reactions/O that/O led/O to/O dose/O delays/O in/O more/O than/O 5/O %/O of/O ADCETRIS/O -/O treated/O patients/O in/O Study/O 3/O were/O neutropenia/B-AdverseReaction (/O 22/O %/O )/O ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction (/O 16/O %/O )/O ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 6/O %/O )/O ,/O and/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction (/O 6/O %/O )/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Discontinuations/O Adverse/O reactions/O led/O to/O treatment/O discontinuation/O in/O 21/O %/O of/O patients/O in/O Studies/O 1/O and/O 2/O ./O
Adverse/O reactions/O that/O led/O to/O treatment/O discontinuation/O in/O 2/O or/O more/O patients/O with/O classical/O HL/O or/O sALCL/O were/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction (/O 8/O %/O )/O and/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction (/O 3/O %/O )/O ./O
Adverse/O reactions/O led/O to/O treatment/O discontinuation/O in/O 32/O %/O of/O ADCETRIS/O -/O treated/O patients/O in/O Study/O 3/O ./O
Adverse/O reactions/O that/O led/O to/O treatment/O discontinuation/O in/O 2/O or/O more/O patients/O were/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction (/O 14/O %/O )/O ,/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction (/O 7/O %/O )/O ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction (/O 1/O %/O )/O ,/O paraesthesia/B-AdverseReaction (/O 1/O %/O )/O and/O vomiting/B-AdverseReaction (/O 1/O %/O )/O ./O
6.2/O Post/O Marketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O ADCETRIS/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Blood/O and/O lymphatic/O system/O disorders/O :/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Hepatobiliary/O disorders/O :/O hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O ./O
Infections/O :/O PML/B-AdverseReaction [/O see/O Boxed/O Warning/O ,/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O ,/O serious/B-Severity infections/B-AdverseReaction and/O opportunistic/B-AdverseReaction infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Metabolism/O and/O nutrition/O disorders/O :/O hyperglycemia/B-AdverseReaction ./O
Gastrointestinal/O disorders/O :/O Pancreatitis/B-AdverseReaction (/O including/O fatal/B-AdverseReaction outcomes/O )/O ./O
Consider/O the/O diagnosis/O of/O pancreatitis/O for/O patients/O presenting/O with/O severe/O abdominal/O pain/O ./O
Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O noninfectious/B-AdverseReaction pulmonary/I-AdverseReaction toxicity/I-AdverseReaction including/O pneumonitis/B-AdverseReaction ,/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction ,/O and/O ARDS/B-AdverseReaction (/O some/O with/O fatal/B-AdverseReaction outcomes/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction outcomes/O [/O see/O Warnings/O and/O Precautions/O (/O 5.11/O )/O ]/O ./O
6.3/O Immunogenicity/O Patients/O with/O classical/O HL/O and/O sALCL/O in/O Studies/O 1/O and/O 2/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O were/O tested/O for/O antibodies/O to/O brentuximab/O vedotin/O every/O 3/O weeks/O using/O a/O sensitive/O electrochemiluminescent/O immunoassay/O ./O
Approximately/O 7/O %/O of/O patients/O in/O these/O trials/O developed/O persistently/O positive/O antibodies/O (/O positive/O test/O at/O more/O than/O 2/O timepoints/O )/O and/O 30/O %/O developed/O transiently/O positive/O antibodies/O (/O positive/O in/O 1/O or/O 2/O post/O -/O baseline/O timepoints/O )/O ./O
The/O anti/O -/O brentuximab/O antibodies/O were/O directed/O against/O the/O antibody/O component/O of/O brentuximab/O vedotin/O in/O all/O patients/O with/O transiently/O or/O persistently/O positive/O antibodies/O ./O
Two/O of/O the/O patients/O (/O 1/O %/O )/O with/O persistently/O positive/O antibodies/O experienced/O adverse/O reactions/O consistent/O with/O infusion/B-AdverseReaction reactions/I-AdverseReaction that/O led/O to/O discontinuation/O of/O treatment/O ./O
Overall/O ,/O a/O higher/O incidence/O of/O infusion/B-AdverseReaction related/I-AdverseReaction reactions/I-AdverseReaction was/O observed/O in/O patients/O who/O developed/O persistently/O positive/O antibodies/O ./O
A/O total/O of/O 58/O patient/O samples/O that/O were/O either/O transiently/O or/O persistently/O positive/O for/O anti/O -/O brentuximab/O vedotin/O antibodies/O were/O tested/O for/O the/O presence/O of/O neutralizing/O antibodies/O ./O
Sixty/O -/O two/O percent/O of/O these/O patients/O had/O at/O least/O one/O sample/O that/O was/O positive/O for/O the/O presence/O of/O neutralizing/O antibodies/O ./O
The/O effect/O of/O anti/O -/O brentuximab/O vedotin/O antibodies/O on/O safety/O and/O efficacy/O is/O not/O known/O ./O
Immunogenicity/O assay/O results/O are/O highly/O dependent/O on/O several/O factors/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O incidence/O of/O antibodies/O to/O ADCETRIS/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O PROGRESSIVE/B-AdverseReaction MULTIFOCAL/I-AdverseReaction LEUKOENCEPHALOPATHY/I-AdverseReaction (/O PML/B-AdverseReaction )/O WARNING/O :/O PROGRESSIVE/B-AdverseReaction MULTIFOCAL/I-AdverseReaction LEUKOENCEPHALOPATHY/I-AdverseReaction (/O PML/B-AdverseReaction )/O JC/B-AdverseReaction virus/I-AdverseReaction infection/I-AdverseReaction resulting/O in/O PML/B-AdverseReaction and/O death/B-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O ADCETRIS/O [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ,/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O EXCERPT/O :/O WARNING/O :/O PROGRESSIVE/B-AdverseReaction MULTIFOCAL/I-AdverseReaction LEUKOENCEPHALOPATHY/I-AdverseReaction (/O PML/B-AdverseReaction )/O See/O Full/O Prescribing/O Information/O for/O complete/O boxed/O warning/O ./O
JC/B-AdverseReaction virus/I-AdverseReaction infection/I-AdverseReaction resulting/O in/O PML/B-AdverseReaction and/O death/B-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O ADCETRIS/O (/O 5.9/O ,/O 6.2/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction :/O Monitor/O patients/O for/O neuropathy/O and/O institute/O dose/O modifications/O accordingly/O (/O 5.1/O )/O ./O
Anaphylaxis/B-AdverseReaction and/O infusion/B-AdverseReaction reactions/I-AdverseReaction :/O If/O an/O infusion/O reaction/O occurs/O ,/O interrupt/O the/O infusion/O ./O
If/O anaphylaxis/O occurs/O ,/O immediately/O discontinue/O the/O infusion/O (/O 5.2/O )/O ./O
Hematologic/B-AdverseReaction toxicities/I-AdverseReaction :/O Monitor/O complete/O blood/O counts/O prior/O to/O each/O dose/O of/O ADCETRIS/O ./O
Closely/O monitor/O patients/O for/O fever/O ./O
If/O Grade/O 3/O or/O 4/O neutropenia/O develops/O ,/O consider/O dose/O delays/O ,/O reductions/O ,/O discontinuation/O ,/O or/O G/O -/O CSF/O prophylaxis/O with/O subsequent/O doses/O (/O 5.3/O )/O ./O
Serious/B-Severity infections/B-AdverseReaction and/O opportunistic/B-AdverseReaction infections/I-AdverseReaction :/O Closely/O monitor/O patients/O for/O the/O emergence/O of/O bacterial/O ,/O fungal/O or/O viral/O infections/O (/O 5.4/O )/O ./O
Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction :/O Closely/O monitor/O patients/O with/O rapidly/O proliferating/O tumor/O or/O high/O tumor/O burden/O (/O 5.5/O )/O ./O
Hepatotoxicity/B-AdverseReaction :/O Monitor/O liver/O enzymes/O and/O bilirubin/O (/O 5.8/O )/O ./O
Pulmonary/B-AdverseReaction Toxicity/I-AdverseReaction :/O Monitor/O patients/O for/O new/O or/O worsening/O symptoms/O (/O 5.10/O )/O ./O
Serious/B-Severity dermatologic/B-AdverseReaction reactions/I-AdverseReaction :/O Discontinue/O if/O Stevens/O -/O Johnson/O syndrome/O or/O toxic/O epidermal/O necrolysis/O occurs/O (/O 5.10/O )/O ./O
Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O :/O Fetal/B-AdverseReaction harm/I-AdverseReaction can/B-Factor occur/O ./O
Advise/O pregnant/O women/O of/O the/O potential/O hazard/O to/O the/O fetus/O (/O 5.12/O )/O ./O
5.1/O Peripheral/O Neuropathy/O ADCETRIS/O treatment/O causes/O a/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction that/O is/O predominantly/O sensory/O ./O
Cases/O of/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction have/O also/O been/O reported/O ./O
ADCETRIS/O -/O induced/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction is/O cumulative/O ./O
In/O the/O relapsed/O classical/O HL/O and/O sALCL/O clinical/O trials/O ,/O 54/O %/O of/O patients/O experienced/O any/O grade/O of/O neuropathy/B-AdverseReaction ./O
Of/O these/O patients/O ,/O 49/O %/O had/O complete/O resolution/O ,/O 31/O %/O had/O partial/O improvement/O ,/O and/O 20/O %/O had/O no/O improvement/O ./O
Of/O the/O patients/O who/O reported/O neuropathy/B-AdverseReaction ,/O 51/O %/O had/O residual/B-AdverseReaction neuropathy/I-AdverseReaction at/O the/O time/O of/O their/O last/O evaluation/O ./O
Monitor/O patients/O for/O symptoms/O of/O neuropathy/O ,/O such/O as/O hypoesthesia/O ,/O hyperesthesia/O ,/O paresthesia/O ,/O discomfort/O ,/O a/O burning/O sensation/O ,/O neuropathic/O pain/O ,/O or/O weakness/O ./O
Patients/O experiencing/O new/O or/O worsening/O peripheral/O neuropathy/O may/O require/O a/O delay/O ,/O change/O in/O dose/O ,/O or/O discontinuation/O of/O ADCETRIS/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.2/O Anaphylaxis/O and/O Infusion/O Reactions/O Infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O ,/O including/O anaphylaxis/B-AdverseReaction ,/O have/O occurred/O with/O ADCETRIS/O ./O
Monitor/O patients/O during/O infusion/O ./O
If/O anaphylaxis/O occurs/O ,/O immediately/O and/O permanently/O discontinue/O administration/O of/O ADCETRIS/O and/O administer/O appropriate/O medical/O therapy/O ./O
If/O an/O infusion/O -/O related/O reaction/O occurs/O ,/O the/O infusion/O should/O be/O interrupted/O and/O appropriate/O medical/O management/O instituted/O ./O
Patients/O who/O have/O experienced/O a/O prior/O infusion/O -/O related/O reaction/O should/O be/O premedicated/O for/O subsequent/O infusions/O ./O
Premedication/O may/O include/O acetaminophen/O ,/O an/O antihistamine/O ,/O and/O a/O corticosteroid/O ./O
5.3/O Hematologic/O Toxicities/O Prolonged/O (/O 1/O week/O )/O severe/B-Severity neutropenia/B-AdverseReaction and/O Grade/B-Severity 3/I-Severity or/O Grade/B-Severity 4/I-Severity thrombocytopenia/B-AdverseReaction or/O anemia/B-AdverseReaction can/B-Factor occur/O with/O ADCETRIS/O ./O
Febrile/B-AdverseReaction neutropenia/I-AdverseReaction has/O been/O reported/O with/O treatment/O with/O ADCETRIS/O ./O
Complete/O blood/O counts/O should/O be/O monitored/O prior/O to/O each/O dose/O of/O ADCETRIS/O and/O more/O frequent/O monitoring/O should/O be/O considered/O for/O patients/O with/O Grade/O 3/O or/O 4/O neutropenia/O ./O
Monitor/O patients/O for/O fever/O ./O
If/O Grade/O 3/O or/O 4/O neutropenia/O develops/O ,/O consider/O dose/O delays/O ,/O reductions/O ,/O discontinuation/O ,/O or/O G/O -/O CSF/O prophylaxis/O with/O subsequent/O ADCETRIS/O doses/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.4/O Serious/O Infections/O and/O Opportunistic/O Infections/O Serious/B-Severity infections/B-AdverseReaction and/O opportunistic/B-AdverseReaction infections/I-AdverseReaction such/O as/O pneumonia/B-AdverseReaction ,/O bacteremia/B-AdverseReaction ,/O and/O sepsis/B-AdverseReaction or/O septic/B-AdverseReaction shock/I-AdverseReaction (/O including/O fatal/B-AdverseReaction outcomes/O )/O have/O been/O reported/O in/O patients/O treated/O with/O ADCETRIS/O ./O
Patients/O should/O be/O closely/O monitored/O during/O treatment/O for/O the/O emergence/O of/O possible/O bacterial/O ,/O fungal/O ,/O or/O viral/O infections/O ./O
5.5/O Tumor/O Lysis/O Syndrome/O Patients/O with/O rapidly/O proliferating/O tumor/O and/O high/O tumor/O burden/O may/B-Factor be/O at/O increased/O risk/O of/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction ./O
Monitor/O closely/O and/O take/O appropriate/O measures/O ./O
5.6/O Increased/O Toxicity/O in/O the/O Presence/O of/O Severe/O Renal/O Impairment/O The/O frequency/O of/O Grade/O 3/O adverse/O reactions/O and/O deaths/B-AdverseReaction was/O greater/O in/O patients/O with/O severe/O renal/O impairment/O compared/O to/O patients/O with/O normal/O renal/O function/O ./O
Due/O to/O higher/O MMAE/O exposure/O ,/O Grade/O 3/O adverse/O reactions/O may/O be/O more/O frequent/O in/O patients/O with/O severe/O renal/O impairment/O compared/O to/O patients/O with/O normal/O renal/O function/O ./O
Avoid/O the/O use/O of/O ADCETRIS/O in/O patients/O with/O severe/O renal/O impairment/O [/O creatinine/O clearance/O (/O CLcr/O )/O 30/O mL/O min/O ]/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
5.7/O Increased/O Toxicity/O in/O the/O Presence/O of/O Moderate/O or/O Severe/O Hepatic/O Impairment/O The/O frequency/O of/O Grade/O 3/O adverse/O reactions/O and/O deaths/B-AdverseReaction was/O greater/O in/O patients/O with/O moderate/O and/O severe/O hepatic/O impairment/O compared/O to/O patients/O with/O normal/O hepatic/O function/O ./O
Avoid/O the/O use/O of/O ADCETRIS/O in/O patients/O with/O moderate/O (/O Child/O -/O Pugh/O B/O )/O or/O severe/O (/O Child/O -/O Pugh/O C/O )/O hepatic/O impairment/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O ]/O ./O
5.8/O Hepatotoxicity/O Serious/B-Severity cases/O of/O hepatotoxicity/B-AdverseReaction ,/O including/O fatal/B-AdverseReaction outcomes/O ,/O have/O occurred/O in/O patients/O receiving/O ADCETRIS/O ./O
Cases/O were/O consistent/O with/O hepatocellular/B-AdverseReaction injury/I-AdverseReaction ,/O including/O elevations/B-AdverseReaction of/I-AdverseReaction transaminases/I-AdverseReaction and/or/O bilirubin/O ./O
Cases/O have/O occurred/O after/O the/O first/O dose/O of/O ADCETRIS/O or/O after/O ADCETRIS/O rechallenge/O ./O
Preexisting/O liver/O disease/O ,/O elevated/O baseline/O liver/O enzymes/O ,/O and/O concomitant/O medications/O may/O also/O increase/O the/O risk/O ./O
Monitor/O liver/O enzymes/O and/O bilirubin/O ./O
Patients/O experiencing/O new/O ,/O worsening/O ,/O or/O recurrent/O hepatotoxicity/O may/O require/O a/O delay/O ,/O change/O in/O dose/O ,/O or/O discontinuation/O of/O ADCETRIS/O ./O
5.9/O Progressive/O Multifocal/O Leukoencephalopathy/O JC/B-AdverseReaction virus/I-AdverseReaction infection/I-AdverseReaction resulting/O in/O PML/B-AdverseReaction and/O death/B-AdverseReaction has/O been/O reported/O in/O ADCETRIS/O -/O treated/O patients/O ./O
First/O onset/O of/O symptoms/O occurred/O at/O various/O times/O from/O initiation/O of/O ADCETRIS/O therapy/O ,/O with/O some/O cases/O occurring/O within/O 3/O months/O of/O initial/O exposure/O ./O
In/O addition/O to/O ADCETRIS/O therapy/O ,/O other/O possible/O contributory/O factors/O include/O prior/O therapies/O and/O underlying/O disease/O that/O may/O cause/O immunosuppression/O ./O
Consider/O the/O diagnosis/O of/O PML/O in/O any/O patient/O presenting/O with/O new/O -/O onset/O signs/O and/O symptoms/O of/O central/O nervous/O system/O abnormalities/O ./O
Hold/O ADCETRIS/O dosing/O for/O any/O suspected/O case/O of/O PML/O and/O discontinue/O ADCETRIS/O dosing/O if/O a/O diagnosis/O of/O PML/O is/O confirmed/O ./O
5.10/O Pulmonary/O Toxicity/O Events/O of/O noninfectious/B-AdverseReaction pulmonary/I-AdverseReaction toxicity/I-AdverseReaction including/O pneumonitis/B-AdverseReaction ,/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction ,/O and/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction (/O ARDS/B-AdverseReaction )/O ,/O some/O with/O fatal/B-AdverseReaction outcomes/O ,/O have/O been/O reported/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O pulmonary/O toxicity/O ,/O including/O cough/O and/O dyspnea/O ./O
In/O the/O event/O of/O new/O or/O worsening/O pulmonary/O symptoms/O ,/O hold/O ADCETRIS/O dosing/O during/O evaluation/O and/O until/O symptomatic/O improvement/O ./O
5.11/O Serious/O Dermatologic/O Reactions/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O (/O SJS/B-AdverseReaction )/O and/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction (/O TEN/B-AdverseReaction )/O ,/O including/O fatal/B-AdverseReaction outcomes/O ,/O have/O been/O reported/O with/O ADCETRIS/O ./O
If/O SJS/O or/O TEN/O occurs/O ,/O discontinue/O ADCETRIS/O and/O administer/O appropriate/O medical/O therapy/O ./O
5.12/O Embryo/O -/O Fetal/O Toxicity/O There/O are/O no/O adequate/O and/O well/O -/O controlled/O studies/O of/O ADCETRIS/O in/O pregnant/O women/O ./O
However/O ,/O based/O on/O its/O mechanism/O of/O action/O and/O findings/O in/O animals/O ,/O ADCETRIS/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Brentuximab/O vedotin/O caused/O embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicities/O ,/O including/O significantly/B-Severity decreased/B-AdverseReaction embryo/I-AdverseReaction viability/I-AdverseReaction and/O fetal/B-AdverseReaction malformations/I-AdverseReaction ,/O in/O animals/B-Animal at/O maternal/O exposures/O that/O were/O similar/O to/O human/O exposures/O at/O the/O recommended/O doses/O for/O patients/O with/O classical/O HL/O and/O sALCL/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O receiving/O the/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Serious/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O following/O AdreView/O administration/O ./O
The/O most/O common/O adverse/O reactions/O ,/O dizziness/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pruritis/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction occurred/O in/O 1.3/O %/O of/O patients/O ./O
(/O 6.1/O ,/O 6.2/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GE/O Healthcare/O at/O 1/O -/O 800/O -/O 654/O -/O 0118/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Study/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
During/O clinical/O development/O 1346/O patients/O were/O exposed/O to/O AdreView/O ,/O 251/O patients/O with/O known/O or/O suspected/O pheochromocytoma/O or/O neuroblastoma/O ,/O 985/O patients/O with/O heart/O failure/O ,/O and/O 110/O control/O patients/O ./O
All/O patients/O were/O monitored/O for/O adverse/O reactions/O over/O a/O 24/O hour/O period/O following/O AdreView/O administration/O ./O
Pheochromocytoma/O and/O Neuroblastoma/O Serious/O adverse/O reactions/O were/O not/O observed/O in/O the/O AdreView/O clinical/O study/O ./O
Adverse/O reactions/O were/O all/O mild/B-Severity to/O moderate/B-Severity in/O severity/O and/O were/O predominantly/O isolated/O occurrences/O (/O 2/O patients/O )/O of/O one/O of/O the/O following/O reactions/O :/O dizziness/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O flushing/B-AdverseReaction or/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ./O
Congestive/O Heart/O Failure/O No/O serious/O adverse/O reactions/O to/O AdreView/O were/O observed/O in/O clinical/O studies/O ./O
Adverse/O reactions/O that/O occurred/O with/O a/O frequency/O 1/O %/O were/O associated/O with/O the/O injection/O site/O (/O 1.3/O %/O )/O ,/O problems/O such/O as/O hematoma/O and/O bruising/O ./O
The/O other/O most/O common/O reactions/O were/O flushing/B-AdverseReaction (/O 0.3/O %/O )/O and/O headache/B-AdverseReaction (/O 0.4/O %/O )/O ./O
The/O adverse/O reactions/O were/O predominantly/O of/O mild/O to/O moderate/O intensity/O ./O
6.2/O Postmarketing/O Experience/O Because/O postmarketing/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O uncommonly/O been/O reported/O during/O the/O postmarketing/O use/O of/O AdreView/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O followed/O AdreView/O administration/O ./O
Have/O anaphylactic/O and/O hypersensitivity/O treatment/O measures/O available/O prior/O to/O AdreView/O administration/O ./O
(/O 5.1/O )/O Drugs/O which/O block/O norepinephrine/O uptake/O or/O deplete/O norepinephrine/O stores/O may/O decrease/O AdreView/O uptake/O ./O
When/O medically/O feasible/O ,/O stop/O these/O drugs/O before/O AdreView/O administration/O and/O monitor/O patients/O for/O withdrawal/O signs/O and/O symptoms/O ./O
(/O 5.2/O )/O AdreView/O contains/O benzyl/O alcohol/O (/O 10.3/O mg/O mL/O )/O which/O may/O cause/O serious/O reactions/O in/O premature/O or/O low/O birth/O -/O weight/O infants/O ./O
(/O 5.3/O )/O Patients/O with/O severe/O renal/O impairment/O may/O have/O increased/O radiation/O exposure/O and/O decreased/O quality/O of/O AdreView/O images/O ./O
(/O 5.4/O )/O Failure/O to/O block/O thyroid/O iodine/O uptake/O may/O result/O in/O iodine/O 123/O accumulation/O in/O the/O thyroid/O ./O
(/O 5.6/O )/O 5.1/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O following/O AdreView/O administration/O ./O
Prior/O to/O administration/O ,/O question/O the/O patient/O for/O a/O history/O of/O prior/O reactions/O to/O iodine/O ,/O an/O iodine/O -/O containing/O contrast/O agent/O or/O other/O products/O containing/O iodine/O ./O
If/O the/O patient/O is/O known/O or/O strongly/O suspected/O to/O have/O hypersensitivity/O to/O iodine/O ,/O an/O iodine/O -/O containing/O contrast/O agent/O or/O other/O products/O containing/O iodine/O ,/O the/O decision/O to/O administer/O AdreView/O should/O be/O based/O upon/O an/O assessment/O of/O the/O expected/O benefits/O compared/O to/O the/O potential/O hypersensitivity/O risks/O ./O
Have/O anaphylactic/O and/O hypersensitivity/O treatment/O measures/O available/O prior/O to/O AdreView/O administration/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.2/O Imaging/O Errors/O due/O to/O Concomitant/O Medications/O and/O Risks/O Associated/O with/O Withdrawal/O of/O Medications/O Many/O medications/O have/O the/O potential/O to/O interfere/O with/O AdreView/O imaging/O and/O review/O of/O the/O patient/O 's/O medications/O is/O required/O prior/O to/O AdreView/O dosing/O due/O to/O the/O risk/O for/O unreliable/O imaging/O results/O ./O
If/O the/O AdreView/O imaging/O information/O is/O essential/O for/O clinical/O care/O ,/O consider/O the/O withdrawal/O of/O the/O following/O categories/O of/O medications/O if/O the/O withdrawal/O can/O be/O accomplished/O safely/O :/O antihypertensives/O that/O deplete/O norepinephrine/O stores/O or/O inhibit/O reuptake/O (/O e.g./O ,/O reserpine/O ,/O labetalol/O )/O ,/O antidepressants/O that/O inhibit/O norepinephrine/O transporter/O function/O (/O e.g./O ,/O amitriptyline/O and/O derivatives/O ,/O imipramine/O and/O derivatives/O ,/O selective/O serotonin/O reuptake/O inhibitors/O )/O ,/O and/O sympathomimetic/O amines/O (/O e.g./O ,/O phenylephrine/O ,/O phenylpropanolamine/O ,/O pseudoephedrine/O and/O ephedrine/O )/O ./O
The/O period/O of/O time/O necessary/O to/O discontinue/O any/O specific/O medication/O prior/O to/O AdreView/O dosing/O has/O not/O been/O established/O [/O see/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
Pheochromocytoma/O and/O Neuroblastoma/O Drugs/O which/O interfere/O with/O norepinephrine/O uptake/O in/O neuroendocrine/O tumors/O may/O lead/O to/O false/O negative/O imaging/O results/O ./O
When/O medically/O feasible/O ,/O stop/O these/O drugs/O before/O AdreView/O administration/O and/O monitor/O patients/O for/O the/O occurrence/O of/O clinically/O significant/O withdrawal/O symptoms/O ,/O especially/O patients/O with/O elevated/O levels/O of/O circulating/O catecholamines/O and/O their/O metabolites/O ./O
Congestive/O Heart/O Failure/O Many/O commonly/O used/O cardiovascular/O ,/O pulmonary/O ,/O and/O neuropsychiatric/O medications/O interfere/O with/O AdreView/O imaging/O (/O see/O above/O )/O ./O
AdreView/O imaging/O should/O not/O be/O performed/O if/O discontinuation/O of/O these/O medications/O would/O involve/O risks/O which/O outweigh/O the/O value/O of/O AdreView/O imaging/O ./O
In/O clinical/O trials/O ,/O patients/O were/O not/O eligible/O for/O AdreView/O imaging/O if/O they/O were/O receiving/O medications/O in/O the/O above/O categories/O and/O the/O risks/O for/O medication/O withdrawal/O were/O unacceptable/O or/O if/O they/O were/O not/O clinically/O stable/O (/O e.g./O ,/O experiencing/O continuing/O chest/O pain/O ,/O hemodynamic/O instability/O ,/O or/O clinically/O significant/O arrhythmia/O )/O ./O
5.3/O Risks/O for/O Benzyl/O Alcohol/O Toxicity/O in/O Infants/O AdreView/O contains/O benzyl/O alcohol/O at/O a/O concentration/O of/O 10.3/O mg/O mL./O Benzyl/O alcohol/O has/O been/O associated/O with/O a/O fatal/B-AdverseReaction "/O Gasping/B-AdverseReaction Syndrome/I-AdverseReaction "/O in/O premature/O infants/O and/O infants/O of/O low/O birth/O weight/O ./O
Exposure/O to/O excessive/O amounts/O of/O benzyl/O alcohol/O has/O been/O associated/O with/O toxicity/O (/O hypotension/O ,/O metabolic/O acidosis/O )/O ,/O particularly/O in/O neonates/O ,/O and/O an/O increased/O incidence/O of/O kernicterus/O ,/O particularly/O in/O small/O preterm/O infants/O ./O
There/O have/O been/O rare/O reports/O of/O deaths/O ,/O primarily/O in/O preterm/O infants/O ,/O associated/O with/O exposure/O to/O excessive/O amounts/O of/O benzyl/O alcohol/O [/O see/O Description/O (/O 11/O )/O ]/O ./O
Observe/O infants/O for/O signs/O or/O symptoms/O of/O benzyl/O alcohol/O toxicity/O following/O AdreView/O administration/O ./O
AdreView/O safety/O and/O effectiveness/O have/O not/O been/O established/O in/O neonates/O (/O pediatric/O patients/O below/O the/O age/O of/O 1/O month/O )/O ./O
5.4/O Increased/O Radiation/O Exposure/O in/O Patients/O with/O Severe/O Renal/O Impairment/O AdreView/O is/O cleared/O by/O glomerular/O filtration/O and/O is/O not/O dialyzable/O ./O
The/O radiation/O dose/O to/O patients/O with/O severe/O renal/O impairment/O may/O be/O increased/O due/O to/O the/O delayed/O elimination/O of/O the/O drug/O ./O
Delayed/O AdreView/O clearance/O may/O also/O reduce/O the/O target/O to/O background/O ratios/O and/O decrease/O the/O quality/O of/O scintigraphic/O images/O ./O
These/O risks/O importantly/O may/O limit/O the/O role/O of/O AdreView/O in/O the/O diagnostic/O evaluation/O of/O patients/O with/O severe/O renal/O impairment/O ./O
AdreView/O safety/O and/O efficacy/O have/O not/O been/O established/O in/O these/O patients/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.5/O Imaging/O Errors/O due/O to/O Conditions/O that/O Affect/O the/O Sympathetic/O Nervous/O System/O Individuals/O with/O conditions/O that/O affect/O the/O sympathetic/O nervous/O system/O ,/O e.g./O ,/O Parkinsonian/O syndromes/O such/O as/O Parkinson/O 's/O disease/O or/O multiple/O system/O atrophy/O ,/O may/O show/O decreased/O cardiac/O uptake/O of/O AdreView/O independent/O of/O heart/O disease/O ./O
5.6/O Thyroid/O Accumulation/O Failure/O to/O block/O thyroid/O uptake/O of/O iodine/O 123/O may/O result/O in/O an/O increased/O long/O term/O risk/O for/O thyroid/O neoplasia/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.7/O Hypertension/O Assess/O the/O patient/O 's/O pulse/O and/O blood/O pressure/O before/O and/O intermittently/O for/O 30/O minutes/O after/O AdreView/O administration/O ./O
AdreView/O may/B-Factor increase/O release/O of/O norepinephrine/O from/O chromaffin/O granules/O and/O produce/O a/O transient/B-AdverseReaction episode/I-AdverseReaction of/I-AdverseReaction hypertension/I-AdverseReaction ,/O although/O this/O was/O not/O observed/O in/O the/O clinical/O studies/O ./O
Prior/O to/O AdreView/O administration/O ,/O ensure/O emergency/O cardiac/O and/O anti/O -/O hypertensive/O treatments/O are/O readily/O available/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O described/O in/O more/O detail/O in/O other/O sections/O of/O the/O prescribing/O information/O ./O
Hematologic/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Infection/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Gastrointestinal/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O The/O most/O common/O adverse/O reactions/O observed/O in/O the/O trial/O of/O patients/O with/O relapsed/O or/O refractory/O PTCL/O treated/O with/O Beleodaq/O were/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 25/O %/O )/O are/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Spectrum/O Pharmaceuticals/O ,/O Inc./O at/O 1/O -/O 888/O -/O 292/O -/O 9617/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O Beleodaq/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Adverse/O Reactions/O in/O Patients/O with/O Peripheral/O T/O -/O Cell/O Lymphoma/O The/O safety/O of/O Beleodaq/O was/O evaluated/O in/O 129/O patients/O with/O relapsed/O or/O refractory/O PTCL/O in/O the/O single/O arm/O clinical/O trial/O in/O which/O patients/O were/O administered/O Beleodaq/O at/O a/O dosage/O of/O 1,000/O mg/O m2/O administered/O over/O 30/O minutes/O by/O IV/O infusion/O once/O daily/O on/O Days/O 1/O -/O 5/O of/O a/O 21-day/O cycle/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O median/O duration/O of/O treatment/O was/O 2/O cycles/O (/O range/O 1/O -/O 33/O cycles/O )/O ./O
Table/O 2/O summarizes/O the/O adverse/O reactions/O regardless/O of/O causality/O from/O the/O trial/O in/O patients/O with/O relapsed/O or/O refractory/O PTCL/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Occurring/O in/O 10/O %/O of/O Patients/O by/O Preferred/O Term/O and/O Severity/O in/O Patients/O with/O Relapsed/O or/O Refractory/O PTCL/O (/O NCI/O -/O CTC/O Grade/O 1/O -/O 4/O )/O MedDRA/O Preferred/O Term/O Percentage/O of/O Patients/O (/O %/O )/O (/O N=129/O )/O All/O Grades/O Grade/O 3/O or/O 4/O All/O Adverse/O Reactions/O 97/O 61/O Nausea/B-AdverseReaction 42/O 1/O Fatigue/B-AdverseReaction 37/O 5/O Pyrexia/B-AdverseReaction 35/O 2/O Anemia/B-AdverseReaction 32/O 11/O Vomiting/B-AdverseReaction 29/O 1/O Constipation/B-AdverseReaction 23/O 1/O Diarrhea/B-AdverseReaction 23/O 2/O Dyspnea/B-AdverseReaction 22/O 6/O Rash/B-AdverseReaction 20/O 1/O Peripheral/B-AdverseReaction Edema/I-AdverseReaction 20/O 0/O Cough/B-AdverseReaction 19/O 0/O Thrombocytopenia/B-AdverseReaction 16/O 7/O Pruritus/B-AdverseReaction 16/O 3/O Chills/B-AdverseReaction 16/O 1/O Increased/B-AdverseReaction Blood/I-AdverseReaction Lactate/I-AdverseReaction Dehydrogenase/I-AdverseReaction 16/O 2/O Decreased/B-AdverseReaction Appetite/I-AdverseReaction 15/O 2/O Headache/B-AdverseReaction 15/O 0/O Infusion/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 14/O 0/O Hypokalemia/B-AdverseReaction 12/O 4/O Prolonged/B-AdverseReaction QT/I-AdverseReaction 11/O 4/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 11/O 1/O Hypotension/B-AdverseReaction 10/O 3/O Phlebitis/B-AdverseReaction 10/O 1/O Dizziness/B-AdverseReaction 10/O 0/O Note/O :/O Adverse/O reactions/O are/O listed/O by/O order/O of/O incidence/O in/O the/O "/O All/O Grades/O "/O category/O first/O ,/O then/O by/O incidence/O in/O "/O the/O Grade/O 3/O or/O 4/O "/O category/O ;/O MedDRA/O Medical/O Dictionary/O for/O Regulatory/O Activities/O ;/O Severity/O measured/O by/O National/O Cancer/O Institute/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O (/O NCI/O -/O CTCAE/O )/O version/O 3.0/O Serious/O Adverse/O Reactions/O Sixty/O -/O one/O patients/O (/O 47.3/O %/O )/O experienced/O serious/O adverse/O reactions/O while/O taking/O Beleodaq/O or/O within/O 30/O days/O after/O their/O last/O dose/O of/O Beleodaq/O ./O
The/O most/O common/O serious/O adverse/O reactions/O (/O 2/O %/O )/O were/O pneumonia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O infection/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O increased/B-AdverseReaction creatinine/I-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O and/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ./O
One/O treatment/O -/O related/O death/B-AdverseReaction associated/O with/O hepatic/B-AdverseReaction failure/I-AdverseReaction was/O reported/O in/O the/O trial/O ./O
One/O patient/O with/O baseline/O hyperuricemia/O and/O bulky/O disease/O experienced/O Grade/B-Severity 4/I-Severity tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction during/O the/O first/O cycle/O of/O treatment/O and/O died/B-AdverseReaction due/O to/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ./O
A/O treatment/O -/O related/O death/B-AdverseReaction from/O ventricular/B-AdverseReaction fibrillation/I-AdverseReaction was/O reported/O in/O another/O monotherapy/O clinical/O trial/O with/O Beleodaq/O ./O
ECG/O analysis/O did/B-Negation not/I-Negation identify/I-Negation QTc/B-AdverseReaction prolongation/I-AdverseReaction ./O
Discontinuations/O due/O to/O Adverse/O Reactions/O Twenty/O -/O five/O patients/O (/O 19.4/O %/O )/O discontinued/O treatment/O with/O Beleodaq/O due/O to/O adverse/O reactions/O ./O
The/O adverse/O reactions/O reported/O most/O frequently/O as/O the/O reason/O for/O discontinuation/O of/O treatment/O included/O anemia/B-AdverseReaction ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ./O
Dosage/O Modifications/O due/O to/O Adverse/O Reactions/O In/O the/O trial/O ,/O dosage/O adjustments/O due/O to/O adverse/O reactions/O occurred/O in/O 12/O %/O of/O Beleodaq/O -/O treated/O patients/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Thrombocytopenia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction (/O neutropenia/B-AdverseReaction and/O lymphopenia/B-AdverseReaction )/O ,/O and/O anemia/B-AdverseReaction :/O Monitor/O blood/O counts/O and/O modify/O dosage/O for/O hematologic/O toxicities/O ./O
(/O 2.2/O ,/O 5.1/O )/O Infection/B-AdverseReaction :/O Serious/B-Severity and/O fatal/B-AdverseReaction infections/B-AdverseReaction (/O e.g./O ,/O pneumonia/B-AdverseReaction and/O sepsis/B-AdverseReaction )/O ./O
(/O 5.2/O )/O Hepatotoxicity/B-AdverseReaction :/O Beleodaq/O may/B-Factor cause/O hepatic/B-AdverseReaction toxicity/I-AdverseReaction and/O liver/B-AdverseReaction function/I-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction ./O
Monitor/O liver/O function/O tests/O and/O omit/O or/O modify/O dosage/O for/O hepatic/O toxicities/O ./O
(/O 2.2/O ,/O 5.3/O )/O Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction :/O Monitor/O patients/O with/O advanced/O stage/O disease/O and/or/O high/O tumor/O burden/O and/O take/O appropriate/O precautions/O ./O
(/O 5.4/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O :/O Beleodaq/O may/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Advise/O women/O of/O potential/O harm/O to/O the/O fetus/O and/O to/O avoid/O pregnancy/O while/O receiving/O Beleodaq/O ./O
(/O 5.6/O )/O 5.1/O Hematologic/O Toxicity/O Beleodaq/O can/B-Factor cause/O thrombocytopenia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction (/O neutropenia/B-AdverseReaction and/O lymphopenia/B-AdverseReaction )/O ,/O and/or/O anemia/B-AdverseReaction ;/O monitor/O blood/O counts/O weekly/O during/O treatment/O ,/O and/O modify/O dosage/O as/O necessary/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.2/O Infections/O Serious/B-Severity and/O sometimes/O fatal/B-AdverseReaction infections/B-AdverseReaction ,/O including/O pneumonia/B-AdverseReaction and/O sepsis/B-AdverseReaction ,/O have/O occurred/O with/O Beleodaq/O ./O
Do/O not/O administer/O Beleodaq/O to/O patients/O with/O an/O active/O infection/O ./O
Patients/O with/O a/O history/O of/O extensive/O or/O intensive/O chemotherapy/O may/O be/O at/O higher/O risk/O of/O life/O threatening/O infections/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.3/O Hepatotoxicity/O Beleodaq/O can/B-Factor cause/O fatal/B-AdverseReaction hepatotoxicity/B-AdverseReaction and/O liver/B-AdverseReaction function/I-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O liver/O function/O tests/O before/O treatment/O and/O before/O the/O start/O of/O each/O cycle/O ./O
Interrupt/O or/O adjust/O dosage/O until/O recovery/O ,/O or/O permanently/O discontinue/O Beleodaq/O based/O on/O the/O severity/O of/O the/O hepatic/O toxicity/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.4/O Tumor/O Lysis/O Syndrome/O Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction has/O occurred/O in/O Beleodaq/O -/O treated/O patients/O in/O the/O clinical/O trial/O of/O patients/O with/O relapsed/O or/O refractory/O PTCL/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Monitor/O patients/O with/O advanced/O stage/O disease/O and/or/O high/O tumor/O burden/O and/O take/O appropriate/O precautions/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.5/O Gastrointestinal/O Toxicity/O Nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction and/O diarrhea/B-AdverseReaction occur/O with/O Beleodaq/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O and/O may/O require/O the/O use/O of/O antiemetic/O and/O antidiarrheal/O medications/O ./O
5.6/O Embryo/O -/O fetal/O Toxicity/O Beleodaq/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Beleodaq/O may/B-Factor cause/O teratogenicity/B-AdverseReaction and/or/O embryo/B-AdverseReaction -/I-AdverseReaction fetal/O lethality/O because/O it/O is/O genotoxic/B-AdverseReaction and/O targets/O actively/O dividing/O cells/O [/O see/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
Women/O of/O childbearing/O potential/O should/O be/O advised/O to/O avoid/O pregnancy/O while/O receiving/O Beleodaq/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O potential/O hazard/O to/O the/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O following/O have/O been/O observed/O with/O BENLYSTA/O and/O are/O discussed/O in/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O :/O Mortality/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Serious/B-Severity Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Malignancy/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction ,/O including/O Anaphylaxis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Depression/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O EXCERPT/O :/O Common/O adverse/O reactions/O (/O 5/O %/O )/O in/O clinical/O trials/O were/O :/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O depression/B-AdverseReaction ,/O migraine/B-AdverseReaction ,/O and/O pharyngitis/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 877/O -/O 423/O -/O 6597/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O The/O data/O described/O below/O reflect/O exposure/O to/O BENLYSTA/O plus/O standard/O of/O care/O compared/O with/O placebo/O plus/O standard/O of/O care/O in/O 2,133/O patients/O in/O 3/O controlled/O trials/O ./O
Patients/O received/O BENLYSTA/O at/O doses/O of/O 1/O mg/O kg/O (/O N/O 673/O )/O ,/O 4/O mg/O kg/O (/O N/O 111/O ;/O Trial/O 1/O only/O )/O ,/O or/O 10/O mg/O kg/O (/O N/O 674/O )/O or/O placebo/O (/O N/O 675/O )/O intravenously/O over/O a/O 1-hour/O period/O on/O Days/O 0/O ,/O 14/O ,/O 28/O ,/O and/O then/O every/O 28/O days/O ./O
In/O 2/O of/O the/O trials/O (/O Trial/O 1/O and/O Trial/O 3/O )/O ,/O treatment/O was/O given/O for/O 48/O weeks/O ,/O while/O in/O the/O other/O trial/O (/O Trial/O 2/O )/O treatment/O was/O given/O for/O 72/O weeks/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Because/O there/O was/O no/O apparent/O dose/O -/O related/O increase/O in/O the/O majority/O of/O adverse/O events/O observed/O with/O BENLYSTA/O ,/O the/O safety/O data/O summarized/O below/O are/O presented/O for/O the/O 3/O doses/O pooled/O ,/O unless/O otherwise/O indicated/O ;/O the/O adverse/O reaction/O table/O displays/O the/O results/O for/O the/O recommended/O dose/O of/O 10/O mg/O kg/O compared/O with/O placebo/O ./O
The/O population/O had/O a/O mean/O age/O of/O 39/O (/O range/O :/O 18/O to/O 75/O )/O ,/O 94/O %/O were/O female/O ,/O and/O 52/O %/O were/O Caucasian/O ./O
In/O these/O trials/O ,/O 93/O %/O of/O patients/O treated/O with/O BENLYSTA/O reported/O an/O adverse/O reaction/O compared/O with/O 92/O %/O treated/O with/O placebo/O ./O
The/O most/O common/O serious/O adverse/O reactions/O were/O serious/B-Severity infections/B-AdverseReaction (/O 6.0/O %/O and/O 5.2/O %/O in/O the/O groups/O receiving/O BENLYSTA/O and/O placebo/O ,/O respectively/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
The/O most/O commonly/O -/O reported/O adverse/O reactions/O ,/O occurring/O in/O 5/O %/O of/O patients/O in/O clinical/O trials/O were/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O depression/B-AdverseReaction ,/O migraine/B-AdverseReaction ,/O and/O pharyngitis/B-AdverseReaction ./O
The/O proportion/O of/O patients/O who/O discontinued/O treatment/O due/O to/O any/O adverse/O reaction/O during/O the/O controlled/O clinical/O trials/O was/O 6.2/O %/O for/O patients/O receiving/O BENLYSTA/O and/O 7.1/O %/O for/O patients/O receiving/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O resulting/O in/O discontinuation/O of/O treatment/O (/O 1/O %/O of/O patients/O receiving/O BENLYSTA/O or/O placebo/O )/O were/O infusion/B-AdverseReaction reactions/I-AdverseReaction (/O 1.6/O %/O BENLYSTA/O and/O 0.9/O %/O placebo/O )/O ,/O lupus/B-AdverseReaction nephritis/I-AdverseReaction (/O 0.7/O %/O BENLYSTA/O and/O 1.2/O %/O placebo/O )/O ,/O and/O infections/B-AdverseReaction (/O 0.7/O %/O BENLYSTA/O and/O 1.0/O %/O placebo/O )/O ./O
Table/O 1/O lists/O adverse/O reactions/O ,/O regardless/O of/O causality/O ,/O occurring/O in/O at/O least/O 3/O %/O of/O patients/O with/O SLE/O who/O received/O BENLYSTA/O 10/O mg/O kg/O and/O at/O an/O incidence/O at/O least/O 1/O %/O greater/O than/O that/O observed/O with/O placebo/O in/O the/O 3/O controlled/O studies/O ./O
Table/O 1/O ./O
Incidence/O of/O Adverse/O Reactions/O occurring/O in/O at/O Least/O 3/O %/O of/O Patients/O Treated/O with/O BENLYSTA/O 10/O mg/O kg/O plus/O Standard/O of/O Care/O and/O at/O Least/O 1/O %/O More/O Frequently/O than/O in/O Patients/O receiving/O Placebo/O plus/O Standard/O of/O Care/O in/O 3/O Controlled/O SLE/O Studies/O Preferred/O Term/O BENLYSTA/O 10/O mg/O kg/O +/O Standard/O of/O Care(n/O 674)%/O Placebo/O +/O Standard/O of/O Care(n/O 675)%/O Nausea/B-AdverseReaction 15/O 12/O Diarrhea/B-AdverseReaction 12/O 9/O Pyrexia/B-AdverseReaction 10/O 8/O Nasopharyngitis/B-AdverseReaction 9/O 7/O Bronchitis/B-AdverseReaction 9/O 5/O Insomnia/B-AdverseReaction 7/O 5/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 6/O 4/O Depression/B-AdverseReaction 5/O 4/O Migraine/B-AdverseReaction 5/O 4/O Pharyngitis/B-AdverseReaction 5/O 3/O Cystitis/B-AdverseReaction 4/O 3/O Leukopenia/B-AdverseReaction 4/O 2/O Gastroenteritis/B-AdverseReaction viral/I-AdverseReaction 3/O 1/O 6.2/O Immunogenicity/O In/O Trials/O 2/O and/O 3/O ,/O anti/O -/O belimumab/O antibodies/O were/O detected/O in/O 4/O of/O 563/O (/O 0.7/O %/O )/O patients/O receiving/O BENLYSTA/O 10/O mg/O kg/O and/O in/O 27/O of/O 559/O (/O 4.8/O %/O )/O patients/O receiving/O BENLYSTA/O 1/O mg/O kg/O ./O
The/O reported/O frequency/O for/O the/O group/O receiving/O 10/O mg/O kg/O may/O underestimate/O the/O actual/O frequency/O due/O to/O lower/O assay/O sensitivity/O in/O the/O presence/O of/O high/O drug/O concentrations/O ./O
Neutralizing/O antibodies/O were/O detected/O in/O 3/O patients/O receiving/O BENLYSTA/O 1/O mg/O kg/O ./O
Three/O patients/O with/O anti/O -/O belimumab/O antibodies/O experienced/O mild/B-Severity infusion/B-AdverseReaction reactions/I-AdverseReaction of/O nausea/B-AdverseReaction ,/O erythematous/B-AdverseReaction rash/I-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction ;/O none/O of/O the/O reactions/O was/O life/O -/O threatening/O ./O
The/O clinical/O relevance/O of/O the/O presence/O of/O anti/O -/O belimumab/O antibodies/O is/O not/O known/O ./O
The/O data/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O positive/O for/O antibodies/O to/O belimumab/O in/O specific/O assays/O ./O
The/O observed/O incidence/O of/O antibody/O positivity/O in/O an/O assay/O is/O highly/O dependent/O on/O several/O factors/O ,/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O belimumab/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O postapproval/O use/O of/O BENLYSTA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Fatal/B-AdverseReaction anaphylaxis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Mortality/B-AdverseReaction :/O There/O were/O more/O deaths/B-AdverseReaction reported/O with/O BENLYSTA/O than/O with/O placebo/O during/O the/O controlled/O period/O of/O clinical/O trials/O ./O
(/O 5.1/O )/O Serious/B-Severity Infections/B-AdverseReaction :/O Serious/B-Severity and/O sometimes/O fatal/B-AdverseReaction infections/B-AdverseReaction have/O been/O reported/O in/O patients/O receiving/O immunosuppressive/O agents/O ,/O including/O BENLYSTA/O ./O
Use/O with/O caution/O in/O patients/O with/O chronic/O infections/O ./O
Consider/O interrupting/O therapy/O with/O BENLYSTA/O if/O patients/O develop/O a/O new/O infection/O during/O treatment/O with/O BENLYSTA/O ./O
(/O 5.2/O )/O Progressive/B-AdverseReaction Multifocal/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O :/O Patients/O presenting/O with/O new/O -/O onset/O or/O deteriorating/O neurological/O signs/O and/O symptoms/O should/O be/O evaluated/O for/O PML/O by/O an/O appropriate/O specialist/O ./O
If/O PML/O is/O confirmed/O ,/O consider/O discontinuation/O of/O immunosuppressant/O therapy/O ,/O including/O BENLYSTA/O ./O
(/O 5.2/O )/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction ,/O including/O Anaphylaxis/B-AdverseReaction :/O Serious/B-Severity and/O fatal/B-AdverseReaction reactions/O have/O been/O reported/O ./O
BENLYSTA/O should/O be/O administered/O by/O healthcare/O providers/O prepared/O to/O manage/O anaphylaxis/O ./O
Monitor/O patients/O during/O and/O for/O an/O appropriate/O period/O of/O time/O after/O administration/O of/O BENLYSTA/O ./O
(/O 2.2/O ,/O 5.4/O )/O Depression/B-AdverseReaction :/O Depression/B-AdverseReaction and/O suicidality/B-AdverseReaction have/O been/O reported/O in/O trials/O with/O BENLYSTA/O ./O
Patients/O should/O be/O instructed/O to/O contact/O their/O healthcare/O provider/O if/O they/O experience/O new/O or/O worsening/O depression/O ,/O suicidal/O thoughts/O or/O other/O mood/O changes/O ./O
(/O 5.6/O )/O Immunization/O :/O Live/O vaccines/O should/O not/O be/O given/O concurrently/O with/O BENLYSTA/O ./O
(/O 5.7/O )/O 5.1/O Mortality/O There/O were/O more/O deaths/B-AdverseReaction reported/O with/O BENLYSTA/O than/O with/O placebo/O during/O the/O controlled/O period/O of/O the/O clinical/O trials/O ./O
Out/O of/O 2,133/O patients/O in/O 3/O clinical/O trials/O ,/O a/O total/O of/O 14/O deaths/B-AdverseReaction occurred/O during/O the/O placebo/O -/O controlled/O ,/O double/O -/O blind/O treatment/O periods/O :/O 3/675/O (/O 0.4/O %/O )/O ,/O 5/673/O (/O 0.7/O %/O )/O ,/O 0/111/O (/O 0/O %/O )/O ,/O and/O 6/674/O (/O 0.9/O %/O )/O deaths/B-AdverseReaction in/O the/O groups/O receiving/O placebo/O ,/O BENLYSTA/O 1/O mg/O kg/O ,/O BENLYSTA/O 4/O mg/O kg/O ,/O and/O BENLYSTA/O 10/O mg/O kg/O ,/O respectively/O ./O
No/O single/O cause/O of/O death/B-AdverseReaction predominated/O ./O
Etiologies/O included/O infection/B-AdverseReaction ,/O cardiovascular/B-AdverseReaction disease/I-AdverseReaction ,/O and/O suicide/B-AdverseReaction ./O
5.2/O Serious/O Infections/O Serious/B-Severity and/O sometimes/O fatal/B-AdverseReaction infections/B-AdverseReaction have/O been/O reported/O in/O patients/O receiving/O immunosuppressive/O agents/O ,/O including/O BENLYSTA/O ./O
Physicians/O should/O exercise/O caution/O when/O considering/O the/O use/O of/O BENLYSTA/O in/O patients/O with/O chronic/O infections/O ./O
Patients/O receiving/O any/O therapy/O for/O chronic/O infection/O should/O not/O begin/O therapy/O with/O BENLYSTA/O ./O
Consider/O interrupting/O therapy/O with/O BENLYSTA/O in/O patients/O who/O develop/O a/O new/O infection/O while/O undergoing/O treatment/O with/O BENLYSTA/O and/O monitor/O these/O patients/O closely/O ./O
In/O the/O controlled/O clinical/O trials/O ,/O the/O overall/O incidence/O of/O infections/B-AdverseReaction was/O 71/O %/O in/O patients/O treated/O with/O BENLYSTA/O compared/O with/O 67/O %/O in/O patients/O who/O received/O placebo/O ./O
The/O most/O frequent/O infections/B-AdverseReaction (/O 5/O %/O of/O patients/O receiving/O BENLYSTA/O )/O were/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O and/O influenza/B-AdverseReaction ./O
Serious/B-Severity infections/B-AdverseReaction occurred/O in/O 6.0/O %/O of/O patients/O treated/O with/O BENLYSTA/O and/O in/O 5.2/O %/O of/O patients/O who/O received/O placebo/O ./O
The/O most/O frequent/O serious/B-Severity infections/B-AdverseReaction included/O pneumonia/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O cellulitis/B-AdverseReaction ,/O and/O bronchitis/B-AdverseReaction ./O
Infections/B-AdverseReaction leading/O to/O discontinuation/O of/O treatment/O occurred/O in/O 0.7/O %/O of/O patients/O receiving/O BENLYSTA/O and/O 1.0/O %/O of/O patients/O receiving/O placebo/O ./O
Infections/B-AdverseReaction resulting/O in/O death/B-AdverseReaction occurred/O in/O 0.3/O %/O (/O 4/1,458/O )/O of/O patients/O treated/O with/O BENLYSTA/O and/O in/O 0.1/O %/O (/O 1/675/O )/O of/O patients/O receiving/O placebo/O ./O
Progressive/O Multifocal/O Leukoencephalopathy/O (/O PML/O )/O Cases/O of/O JC/B-AdverseReaction virus/I-AdverseReaction -/O associated/O PML/B-AdverseReaction resulting/O in/O neurological/B-AdverseReaction deficits/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O have/O been/O reported/O in/O patients/O with/O SLE/O receiving/O immunosuppressants/O ,/O including/O BENLYSTA/O ./O
Risk/O factors/O for/O PML/O include/O treatment/O with/O immunosuppressant/O therapies/O and/O impairment/O of/O immune/O function/O ./O
Consider/O the/O diagnosis/O of/O PML/O in/O any/O patient/O presenting/O with/O new/O -/O onset/O or/O deteriorating/O neurological/O signs/O and/O symptoms/O and/O consult/O with/O a/O neurologist/O or/O other/O appropriate/O specialist/O as/O clinically/O indicated/O ./O
In/O patients/O with/O confirmed/O PML/O ,/O consider/O stopping/O immunosuppressant/O therapy/O ,/O including/O BENLYSTA/O ./O
5.3/O Malignancy/O The/O impact/O of/O treatment/O with/O BENLYSTA/O on/O the/O development/O of/O malignancies/B-AdverseReaction is/O not/B-Factor known/I-Factor ./O
In/O the/O controlled/O clinical/O trials/O ,/O malignancies/B-AdverseReaction (/O including/O non/B-AdverseReaction -/I-AdverseReaction melanoma/I-AdverseReaction skin/O cancers/O )/O were/O reported/O in/O 0.4/O %/O of/O patients/O receiving/O BENLYSTA/O and/O 0.4/O %/O of/O patients/O receiving/O placebo/O ./O
In/O the/O controlled/O clinical/O trials/O ,/O malignancies/B-AdverseReaction ,/O excluding/O non/O -/O melanoma/O skin/O cancers/O ,/O were/O observed/O in/O 0.2/O %/O (/O 3/1,458/O )/O and/O 0.3/O %/O (/O 2/675/O )/O of/O patients/O receiving/O BENLYSTA/O and/O placebo/O ,/O respectively/O ./O
The/O mechanism/O of/O action/O of/O BENLYSTA/O could/O increase/O the/O risk/B-Factor for/O the/O development/O of/O malignancies/B-AdverseReaction ./O
5.4/O Hypersensitivity/O Reactions/O ,/O including/O Anaphylaxis/O Acute/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction and/O death/B-AdverseReaction ,/O have/O been/O reported/O in/O association/O with/O BENLYSTA/O ./O
These/O events/O generally/O occurred/O within/O hours/O of/O the/O infusion/O ;/O however/O ,/O they/O may/O occur/O later/O ./O
Non/O -/O acute/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction including/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O facial/B-AdverseReaction edema/I-AdverseReaction ,/O have/O been/O reported/O and/O typically/O occurred/O up/O to/O a/O week/O following/O the/O most/O recent/O infusion/O ./O
Hypersensitivity/B-AdverseReaction ,/O including/O serious/B-Severity reactions/O ,/O has/O occurred/O in/O patients/O who/O have/O previously/O tolerated/O infusions/O of/O BENLYSTA/O ./O
Limited/O data/O suggest/O that/O patients/O with/O a/O history/O of/O multiple/O drug/O allergies/O or/O significant/O hypersensitivity/O may/O be/O at/O increased/O risk/O ./O
In/O the/O controlled/O clinical/O trials/O ,/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O occurring/O on/O the/O same/O day/O of/O infusion/O )/O were/O reported/O in/O 13/O %/O (/O 191/1,458/O )/O of/O patients/O receiving/O BENLYSTA/O and/O 11/O %/O (/O 76/675/O )/O of/O patients/O receiving/O placebo/O ./O
Anaphylaxis/B-AdverseReaction was/O observed/O in/O 0.6/O %/O (/O 9/1,458/O )/O of/O patients/O receiving/O BENLYSTA/O and/O 0.4/O %/O (/O 3/675/O )/O of/O patients/O receiving/O placebo/O ./O
Manifestations/O included/O hypotension/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O urticaria/B-AdverseReaction or/O other/O rash/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction ./O
Due/O to/O overlap/O in/O signs/O and/O symptoms/O ,/O it/O was/O not/O possible/O to/O distinguish/O between/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction and/O infusion/B-AdverseReaction reactions/I-AdverseReaction in/O all/O cases/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Some/O patients/O (/O 13/O %/O )/O received/O premedication/O ,/O which/O may/O have/O mitigated/O or/O masked/O a/O hypersensitivity/O response/O ;/O however/O ,/O there/O is/O insufficient/O evidence/O to/O determine/O whether/O premedication/O diminishes/O the/O frequency/O or/O severity/O of/O hypersensitivity/O reactions/O ./O
BENLYSTA/O should/O be/O administered/O by/O healthcare/O providers/O prepared/O to/O manage/O anaphylaxis/O ./O
In/O the/O event/O of/O a/O serious/O reaction/O ,/O administration/O of/O BENLYSTA/O must/O be/O discontinued/O immediately/O and/O appropriate/O medical/O therapy/O administered/O ./O
Patients/O should/O be/O monitored/O during/O and/O for/O an/O appropriate/O period/O of/O time/O after/O administration/O of/O BENLYSTA/O ./O
Patients/O should/O be/O informed/O of/O the/O signs/O and/O symptoms/O of/O an/O acute/O hypersensitivity/O reaction/O and/O be/O instructed/O to/O seek/O immediate/O medical/O care/O should/O a/O reaction/O occur/O ./O
5.5/O Infusion/O Reactions/O In/O the/O controlled/O clinical/O trials/O ,/O adverse/B-AdverseReaction events/I-AdverseReaction associated/I-AdverseReaction with/I-AdverseReaction the/I-AdverseReaction infusion/I-AdverseReaction (/O occurring/O on/O the/O same/O day/O of/O the/O infusion/O )/O were/O reported/O in/O 17/O %/O (/O 251/1,458/O )/O of/O patients/O receiving/O BENLYSTA/O and/O 15/O %/O (/O 99/675/O )/O of/O patients/O receiving/O placebo/O ./O
Serious/B-Severity infusion/B-AdverseReaction reactions/I-AdverseReaction (/O excluding/B-Negation hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction )/O were/O reported/O in/O 0.5/O %/O of/O patients/O receiving/O BENLYSTA/O and/O 0.4/O %/O of/O patients/O receiving/O placebo/O and/O included/O bradycardia/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O and/O hypotension/B-AdverseReaction ./O
The/O most/O common/O infusion/B-AdverseReaction reactions/I-AdverseReaction (/O =3/O %/O of/O patients/O receiving/O BENLYSTA/O )/O were/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O skin/B-AdverseReaction reactions/I-AdverseReaction ./O
Due/O to/O overlap/O in/O signs/O and/O symptoms/O ,/O it/O was/O not/O possible/O to/O distinguish/O between/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction and/O infusion/B-AdverseReaction reactions/I-AdverseReaction in/O all/O cases/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Some/O patients/O (/O 13/O %/O )/O received/O premedication/O ,/O which/O may/O have/O mitigated/O or/O masked/O an/O infusion/O reaction/O ;/O however/O ,/O there/O is/O insufficient/O evidence/O to/O determine/O whether/O premedication/O diminishes/O the/O frequency/O or/O severity/O of/O infusion/O reactions/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
BENLYSTA/O should/O be/O administered/O by/O healthcare/O providers/O prepared/O to/O manage/O infusion/O reactions/O ./O
The/O infusion/O rate/O may/O be/O slowed/O or/O interrupted/O if/O the/O patient/O develops/O an/O infusion/O reaction/O ./O
Healthcare/O providers/O should/O be/O aware/O of/O the/O risk/O of/O hypersensitivity/O reactions/O ,/O which/O may/O present/O as/O infusion/O reactions/O ,/O and/O monitor/O patients/O closely/O ./O
5.6/O Depression/O In/O the/O controlled/O clinical/O trials/O ,/O psychiatric/B-AdverseReaction events/I-AdverseReaction were/O reported/O more/O frequently/O with/O BENLYSTA/O (/O 16/O %/O )/O than/O with/O placebo/O (/O 12/O %/O )/O ,/O related/O primarily/O to/O depression/B-AdverseReaction -/O related/O events/O (/O 6.3/O %/O BENLYSTA/O and/O 4.7/O %/O placebo/O )/O ,/O insomnia/B-AdverseReaction (/O 6.0/O %/O BENLYSTA/O and/O 5.3/O %/O placebo/O )/O ,/O and/O anxiety/B-AdverseReaction (/O 3.9/O %/O BENLYSTA/O and/O 2.8/O %/O placebo/O )/O ./O
Serious/B-Severity psychiatric/B-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 0.8/O %/O of/O patients/O receiving/O BENLYSTA/O (/O 0.6/O %/O and/O 1.2/O %/O with/O 1/O and/O 10/O mg/O kg/O ,/O respectively/O )/O and/O 0.4/O %/O of/O patients/O receiving/O placebo/O ./O
Serious/B-Severity depression/B-AdverseReaction was/O reported/O in/O 0.4/O %/O (/O 6/1,458/O )/O of/O patients/O receiving/O BENLYSTA/O and/O 0.1/O %/O (/O 1/675/O )/O of/O patients/O receiving/O placebo/O ./O
Two/O suicides/B-AdverseReaction (/O 0.1/O %/O )/O were/O reported/O in/O patients/O receiving/O BENLYSTA/O ./O
The/O majority/O of/O patients/O who/O reported/O serious/B-Severity depression/B-AdverseReaction or/O suicidal/B-AdverseReaction behavior/I-AdverseReaction had/O a/O history/O of/O depression/O or/O other/O serious/O psychiatric/O disorders/O and/O most/O were/O receiving/O psychoactive/O medications/O ./O
It/O is/O unknown/O if/O treatment/O with/O BENLYSTA/O is/O associated/O with/O increased/O risk/O for/O these/O events/O ./O
Patients/O receiving/O BENLYSTA/O should/O be/O instructed/O to/O contact/O their/O healthcare/O provider/O if/O they/O experience/O new/O or/O worsening/O depression/O ,/O suicidal/O thoughts/O ,/O or/O other/O mood/O changes/O ./O
5.7/O Immunization/O Live/O vaccines/O should/O not/O be/O given/O for/O 30/O days/O before/O or/O concurrently/O with/O BENLYSTA/O as/O clinical/O safety/O has/O not/O been/O established/O ./O
No/O data/O are/O available/O on/O the/O secondary/O transmission/O of/O infection/O from/O persons/O receiving/O live/O vaccines/O to/O patients/O receiving/O BENLYSTA/O or/O the/O effect/O of/O BENLYSTA/O on/O new/O immunizations/O ./O
Because/O of/O its/O mechanism/O of/O action/O ,/O BENLYSTA/O may/O interfere/O with/O the/O response/O to/O immunizations/O ./O
5.8/O Concomitant/O Use/O with/O Other/O Biologic/O Therapies/O or/O Intravenous/O Cyclophosphamide/O BENLYSTA/O has/O not/O been/O studied/O in/O combination/O with/O other/O biologic/O therapies/O ,/O including/O B/O -/O cell/O targeted/O therapies/O ,/O or/O intravenous/O cyclophosphamide/O ./O
Therefore/O ,/O use/O of/O BENLYSTA/O is/O not/O recommended/O in/O combination/O with/O biologic/O therapies/O or/O intravenous/O cyclophosphamide/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O in/O 13/O %/O of/O patients/O are/O :/O Infections/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O tonsilitis/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O ear/B-AdverseReaction infection/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Accredo/O Health/O Group/O Inc./O at/O 1/O -/O 888/O -/O 454/O -/O 8860,or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6/O ADVERSE/O REACTIONS/O 6.1/O Retrospective/O Case/O Series/O Experience/O The/O most/O common/O adverse/O reactions/O (/O occurring/O in/O 13/O %/O of/O patients/O )/O ,/O regardless/O of/O causality/O ,/O are/O :/O Infections/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O tonsilitis/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O ear/B-AdverseReaction infection/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
Table/O 1/O summarizes/O adverse/O reactions/O occurring/O in/O 2/O or/O more/O patients/O treated/O with/O Carbaglu/O in/O the/O retrospective/O case/O series/O ./O
Because/O these/O reactions/O were/O reported/O retrospectively/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Reported/O in/O 2/O Patients/O in/O the/O Retrospective/O Case/O Series/O treated/O with/O Carbaglu/O System/O Organ/O Class/O Preferred/O Term/O Number/O of/O Patients/O (/O N)(%/O )/O TOTAL/O 23/O (/O 100/O )/O Blood/O and/O lymphatic/O system/O disorders/O Anemia/B-AdverseReaction 3/O (/O 13/O )/O Ear/O and/O labyrinth/O disorders/O Ear/B-AdverseReaction infection/I-AdverseReaction 3/O (/O 13/O )/O Gastrointestinal/O disorders/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 4/O (/O 17/O )/O Diarrhea/B-AdverseReaction 3/O (/O 13/O )/O Vomiting/B-AdverseReaction 6/O (/O 26/O )/O Dysgeusia/B-AdverseReaction 2/O (/O 9/O )/O General/O disorders/O and/O administration/O site/O conditions/O Asthenia/B-AdverseReaction 2/O (/O 9/O )/O Hyperhidrosis/B-AdverseReaction 2/O (/O 9/O )/O Pyrexia/B-AdverseReaction 4/O (/O 17/O )/O Infections/O and/O infestations/O Infection/B-AdverseReaction 3/O (/O 13/O )/O Influenza/B-AdverseReaction 2/O (/O 9/O )/O Nasopharyngitis/B-AdverseReaction 3/O (/O 13/O )/O Pneumonia/B-AdverseReaction 2/O (/O 9/O )/O Tonsillitis/B-AdverseReaction 4/O (/O 17/O )/O Investigations/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 3/O (/O 13/O )/O Weight/B-AdverseReaction decreased/I-AdverseReaction 2/O (/O 9/O )/O Metabolism/O and/O nutrition/O disorders/O Anorexia/B-AdverseReaction 2/O (/O 9/O )/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 3/O (/O 13/O )/O Somnolence/B-AdverseReaction 2/O (/O 9/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 2/O (/O 9/O )/O EXCERPT/O :/O Hyperammonemia/B-AdverseReaction :/O Monitor/O plasma/O ammonia/O levels/O during/O treatment/O ./O
Prolonged/O exposure/O to/O elevated/O plasma/O ammonia/O levels/O can/O rapidly/O result/O in/O injury/O to/O the/O brain/O or/O death/O ./O
Prompt/O use/O of/O all/O therapies/O necessary/O to/O reduce/O plasma/O ammonia/O levels/O is/O essential/O ./O
(/O 5.1/O )/O Therapeutic/O Monitoring/O :/O Plasma/O ammonia/O levels/O should/O be/O maintained/O within/O normal/O range/O for/O age/O via/O individual/O dose/O adjustment/O ./O
(/O 5.2/O )/O Nutritional/O Management/O :/O In/O the/O initial/O treatment/O of/O NAGS/O deficiency/O ,/O protein/O restriction/O is/O recommended/O ./O
When/O plasma/O ammonia/O level/O is/O normalized/O ,/O dietary/O protein/O intake/O can/O usually/O be/O reintroduced/O ./O
(/O 5.3/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O 5.1/O Hyperammonemia/O Any/O episode/O of/O acute/O symptomatic/O hyperammonemia/O should/O be/O treated/O as/O a/O life/O -/O threatening/O emergency/O ./O
Treatment/O of/O hyperammonemia/O may/O require/O dialysis/O ,/O preferably/O hemodialysis/O ,/O to/O remove/O a/O large/O burden/O of/O ammonia/O ./O
Uncontrolled/O hyperammonemia/O can/O rapidly/O result/O in/O brain/O injury/O damage/O or/O death/O ,/O and/O prompt/O use/O of/O all/O therapies/O necessary/O to/O reduce/O plasma/O ammonia/O levels/O is/O essential/O ./O
Management/O of/O hyperammonemia/O due/O to/O NAGS/O deficiency/O should/O be/O done/O in/O coordination/O with/O medical/O personnel/O experienced/O in/O metabolic/O disorders/O ./O
Ongoing/O monitoring/O of/O plasma/O ammonia/O levels/O ,/O neurological/O status/O ,/O laboratory/O tests/O and/O clinical/O responses/O in/O patients/O receiving/O Carbaglu/O is/O crucial/O to/O assess/O patient/O response/O to/O treatment/O ./O
5.2/O Therapeutic/O Monitoring/O Plasma/O ammonia/O levels/O should/O be/O maintained/O within/O normal/O range/O for/O age/O via/O individual/O dose/O adjustment/O ./O
5.3/O Nutritional/O Management/O Since/O hyperammonemia/O is/O the/O result/O of/O protein/O catabolism/O ,/O complete/O protein/O restriction/O is/O recommended/O to/O be/O maintained/O for/O 24/O to/O 48/O hours/O and/O caloric/O supplementation/O should/O be/O maximized/O to/O reverse/O catabolism/O and/O nitrogen/O turnover/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O are/O :/O fatigue/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremities/I-AdverseReaction ,/O and/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Genzyme/O Corporation/O at/O 1/O -/O 800/O -/O 745/O -/O 4447/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O most/O common/O adverse/O reactions/O to/O CERDELGA/O (/O occurring/O in/O 10/O %/O of/O the/O 126/O GD1/O patients/O treated/O with/O CERDELGA/O across/O Trials/O 1/O and/O 2/O )/O were/O fatigue/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremities/I-AdverseReaction ,/O and/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction ./O
The/O adverse/O reaction/O profile/O of/O CERDELGA/O is/O based/O on/O two/O controlled/O studies/O ,/O Trials/O 1/O and/O 2/O ./O
Table/O 1/O presents/O the/O profile/O from/O the/O 9-month/O double/O -/O blind/O ,/O randomized/O ,/O placebo/O -/O controlled/O trial/O of/O 40/O treatment/O -/O naive/O patients/O (/O Trial/O 1/O )/O ./O
Patients/O were/O between/O the/O ages/O of/O 16/O and/O 63/O on/O the/O date/O of/O the/O first/O dose/O of/O study/O drug/O ,/O and/O included/O 20/O males/O and/O 20/O females/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Occurring/O in/O 10/O %/O of/O Treatment/O -/O Naive/O GD1/O Patients/O and/O More/O Frequently/O than/O Placebo/O (/O Trial/O 1/O )/O CERDELGA(N=20/O )/O Placebo(N=20/O )/O Adverse/O Reaction/O Patientsn/O (/O %/O )/O Patientsn/O (/O %/O )/O Arthralgia/B-AdverseReaction 9/O (/O 45/O )/O 2/O (/O 10/O )/O Headache/B-AdverseReaction 8/O (/O 40/O )/O 6/O (/O 30/O )/O Migraine/B-AdverseReaction 2/O (/O 10/O )/O 0/O (/O 0/O )/O Flatulence/B-AdverseReaction 2/O (/O 10/O )/O 1/O (/O 5/O )/O Nausea/B-AdverseReaction 2/O (/O 10/O )/O 1/O (/O 5/O )/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 2/O (/O 10/O )/O 1/O (/O 5/O )/O Table/O 2/O presents/O the/O profile/O from/O the/O 12-month/O open/O -/O label/O ,/O randomized/O ,/O imiglucerase/O -/O controlled/O trial/O of/O 159/O treated/O patients/O switching/O from/O enzyme/O replacement/O therapy/O (/O ERT/O )/O (/O Trial/O 2/O )/O ./O
Patients/O were/O between/O the/O ages/O of/O 18/O and/O 69/O on/O the/O date/O of/O the/O first/O dose/O of/O CERDELGA/O ,/O and/O included/O 87/O females/O and/O 72/O males/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Occurring/O in/O 5/O %/O of/O GD1/O Patients/O Switching/O from/O Enzyme/O Replacement/O Therapy/O to/O CERDELGA/O and/O More/O Frequently/O than/O Imiglucerase/O (/O Trial/O 2)Trial/O 2/O was/O not/O designed/O to/O support/O comparative/O claims/O for/O CERDELGA/O for/O the/O adverse/O reactions/O reported/O in/O this/O table/O ./O
CERDELGA(N=106/O )/O Imiglucerase(N=53/O )/O Adverse/O Reaction/O Patientsn/O (/O %/O )/O Patientsn/O (/O %/O )/O Fatigue/B-AdverseReaction 15/O (/O 14/O )/O 1/O (/O 2/O )/O Headache/B-AdverseReaction 14/O (/O 13/O )/O 1/O (/O 2/O )/O Nausea/B-AdverseReaction 13/O (/O 12/O )/O 0/O (/O 0/O )/O Diarrhea/B-AdverseReaction 13/O (/O 12/O )/O 2/O (/O 4/O )/O Back/B-AdverseReaction pain/I-AdverseReaction 13/O (/O 12/O )/O 3/O (/O 6/O )/O Pain/O in/O extremity/O 12/O (/O 11/O )/O 1/O (/O 2/O )/O Upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction 11/O (/O 10/O )/O 0/O (/O 0/O )/O Dizziness/B-AdverseReaction 9/O (/O 8)/O 0/O (/O 0/O )/O Asthenia/B-AdverseReaction 9/O (/O 8)/O 0/O (/O 0/O )/O Cough/B-AdverseReaction 7/O (/O 7/O )/O 2/O (/O 4/O )/O Dyspepsia/B-AdverseReaction 7/O (/O 7/O )/O 1/O (/O 2/O )/O Gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction 7/O (/O 7/O )/O 0/O (/O 0/O )/O Constipation/B-AdverseReaction 5/O (/O 5/O )/O 0/O (/O 0/O )/O Palpitations/B-AdverseReaction 5/O (/O 5/O )/O 0/O (/O 0/O )/O Rash/B-AdverseReaction 5/O (/O 5/O )/O 0/O (/O 0/O )/O In/O an/O uncontrolled/O study/O ,/O with/O up/O to/O 4/O years/O of/O treatment/O ,/O in/O 26/O patients/O ,/O the/O types/O and/O incidences/O of/O adverse/O reactions/O were/O similar/O to/O Trials/O 1/O and/O 2/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O ECG/B-AdverseReaction Changes/I-AdverseReaction and/O Potential/B-Factor for/O Cardiac/B-AdverseReaction Arrhythmias/I-AdverseReaction :/O Not/O recommended/O in/O patients/O with/O pre/O -/O existing/O cardiac/O disease/O ,/O long/O QT/O syndrome/O ,/O and/O concomitant/O use/O of/O Class/O IA/O and/O Class/O III/O antiarrhythmics/O (/O 5.2/O )/O 5.1/O Drug/O -/O Drug/O Interactions/O Eliglustat/O is/O a/O CYP2D6/O and/O CYP3A/O substrate/O ./O
Drugs/O that/O inhibit/O CYP2D6/O and/O CYP3A/O metabolism/O pathways/O may/O significantly/O increase/O the/O exposure/O to/O eliglustat/O and/O result/O in/O prolongation/O of/O the/O PR/O ,/O QTc/O ,/O and/or/O QRS/O cardiac/O intervals/O that/O could/B-Factor result/O in/O cardiac/B-AdverseReaction arrhythmias/I-AdverseReaction [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Some/O drugs/O that/O are/O inhibitors/O of/O CYP2D6/O and/O CYP3A/O are/O contraindicated/O with/O CERDELGA/O depending/O on/O the/O patient/O 's/O CYP2D6/O metabolizer/O status/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
See/O Table/O 3/O and/O Table/O 4/O for/O other/O potentially/O significant/O drug/O interactions/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
5.2/O ECG/O Changes/O and/O Potential/O for/O Cardiac/O Arrhythmias/O Use/O of/O CERDELGA/O in/O patients/O with/O pre/O -/O existing/O cardiac/O conditions/O has/O not/O been/O studied/O during/O clinical/O trials/O ./O
Because/O CERDELGA/O is/O predicted/O to/O cause/O increases/O in/O ECG/O intervals/O (/O PR/O ,/O QTc/O ,/O and/O QRS/O )/O at/O substantially/O elevated/O eliglustat/O plasma/O concentrations/O ,/O use/O of/O CERDELGA/O is/O not/O recommended/O in/O patients/O with/O pre/O -/O existing/O cardiac/O disease/O (/O congestive/O heart/O failure/O ,/O recent/O acute/O myocardial/O infarction/O ,/O bradycardia/O ,/O heart/O block/O ,/O ventricular/O arrhythmia/O )/O ,/O long/O QT/O syndrome/O ,/O and/O in/O combination/O with/O Class/O IA/O (/O e.g./O ,/O quinidine/O ,/O procainamide/O )/O and/O Class/O III/O (/O e.g./O ,/O amiodarone/O ,/O sotalol/O )/O antiarrhythmic/O medications/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O DALVANCE/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O rates/O observed/O in/O practice/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O in/O patients/O treated/O with/O DALVANCE/O were/O nausea/B-AdverseReaction (/O 5.5/O %/O )/O ,/O headache/B-AdverseReaction (/O 4.7/O %/O )/O ,/O and/O diarrhea/B-AdverseReaction (/O 4.4/O %/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Durata/O Therapeutics/O ,/O Inc./O at/O 1/O -/O 855/O -/O 387/O -/O 2825/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/O /medwatch/O ./O
6.1/O Adverse/O Reactions/O in/O Clinical/O Trials/O Adverse/O reactions/O were/O evaluated/O for/O 1778/O patients/O treated/O with/O DALVANCE/O and/O 1224/O patients/O treated/O with/O comparator/O antibacterial/O drugs/O in/O seven/O Phase/O 2/O and/O Phase/O 3/O clinical/O trials/O ./O
A/O causal/O relationship/O between/O study/O drug/O and/O adverse/O reactions/O was/O not/O always/O established/O ./O
The/O median/O age/O of/O patients/O treated/O with/O DALVANCE/O was/O 47/O years/O ,/O ranging/O between/O 16/O and/O 93/O years/O old/O ./O
Patients/O treated/O with/O DALVANCE/O were/O predominantly/O male/O (/O 60/O %/O )/O and/O Caucasian/O (/O 78/O %/O )/O ./O
Serious/O Adverse/O Reactions/O and/O Adverse/O Reactions/O Leading/O to/O Discontinuation/O Serious/O adverse/O reactions/O occurred/O in/O 109/1778/O (/O 6.1/O %/O )/O of/O patients/O treated/O with/O DALVANCE/O and/O in/O 80/1224/O (/O 6.5/O %/O )/O of/O patients/O treated/O with/O comparator/O ./O
DALVANCE/O was/O discontinued/O due/O to/O an/O adverse/O reaction/O in/O 53/1778/O (/O 3/O %/O )/O patients/O and/O the/O comparator/O was/O discontinued/O due/O to/O an/O adverse/O reaction/O in/O 35/1224/O (/O 2.8/O %/O )/O patients/O ./O
Most/O Common/O Adverse/O Reactions/O The/O most/O common/O adverse/O reactions/O in/O patients/O treated/O with/O DALVANCE/O were/O nausea/B-AdverseReaction (/O 5.5/O %/O )/O ,/O headache/B-AdverseReaction (/O 4.7/O %/O )/O ,/O and/O diarrhea/B-AdverseReaction (/O 4.4/O %/O )/O ./O
The/O median/O duration/O of/O adverse/O reactions/O was/O 4.0/O days/O in/O both/O treatment/O groups/O ./O
Table/O 1/O lists/O selected/O adverse/O reactions/O occurring/O in/O more/O than/O 2/O %/O of/O patients/O treated/O with/O DALVANCE/O in/O clinical/O trials/O ./O
Table1/O ./O
Selected/O Adverse/O Reactions/O in/O Phase/O 2/3/O Trials/O (/O Number/O (/O %/O )/O of/O Patients/O )/O Dalbavancin/O Comparator/O (/O N/O 1778/O )/O (/O N/O 1224/O )/O Nausea/B-AdverseReaction 98/O (/O 5.5/O )/O 78/O (/O 6.4/O )/O Vomiting/B-AdverseReaction 50/O (/O 2.8/O )/O 37/O (/O 3/O )/O Diarrhea/B-AdverseReaction 79/O (/O 4.4/O )/O 72/O (/O 5.9/O )/O Headache/B-AdverseReaction 83/O (/O 4.7/O )/O 59/O (/O 4.8/O )/O Rash/B-AdverseReaction 48/O (/O 2.7/O )/O 30/O (/O 2.4/O )/O Pruritus/B-AdverseReaction 38/O (/O 2.1/O )/O 41/O (/O 3.3/O )/O Comparators/O included/O linezolid/O ,/O cefazolin/O ,/O cephalexin/O ,/O and/O vancomycin/O ./O
The/O following/O selected/O adverse/O reactions/O were/O reported/O in/O DALVANCE/O treated/O patients/O at/O a/O rate/O of/O less/O than/O 2/O %/O in/O these/O clinical/O trials/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O anemia/B-AdverseReaction ,/O hemorrhagic/B-AdverseReaction anemia/I-AdverseReaction ,/O leucopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O petechiae/B-AdverseReaction ,/O eosinophilia/B-AdverseReaction ,/O thrombocytosis/B-AdverseReaction Gastrointestinal/O disorders/O :/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O melena/B-AdverseReaction ,/O hematochezia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O :/O infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O Hepatobiliary/O disorders/O :/O hepatotoxicity/B-AdverseReaction Immune/O system/O disorders/O :/O anaphylactoid/B-AdverseReaction reaction/I-AdverseReaction Infections/O and/O infestations/O :/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction colitis/O ,/O oral/B-AdverseReaction candidiasis/I-AdverseReaction ,/O vulvovaginal/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction Investigations/O :/O hepatic/B-AdverseReaction transaminases/I-AdverseReaction increased/I-AdverseReaction ,/O blood/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction ,/O international/B-AdverseReaction normalized/I-AdverseReaction ratio/I-AdverseReaction increased/I-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O hypoglycemia/B-AdverseReaction Nervous/O System/O disorders/O :/O dizziness/B-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O bronchospasm/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O disorders/O :/O urticaria/B-AdverseReaction Vascular/O disorders/O :/O flushing/B-AdverseReaction ,/O phlebitis/B-AdverseReaction ,/O wound/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O spontaneous/B-AdverseReaction hematoma/I-AdverseReaction Alanine/O Aminotransferase/O (/O ALT/O )/O Elevations/O Among/O patients/O with/O normal/O baseline/O ALT/O levels/O ,/O more/O DALVANCE-/O than/O comparator/O -/O treated/O patients/O had/O post/O -/O baseline/O ALT/B-AdverseReaction elevations/I-AdverseReaction greater/O than/O 3/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O ULN/O )/O ,/O 12/O (/O 0.8/O %/O )/O vs./O 2/O (/O 0.2/O %/O )/O ,/O respectively/O including/O three/O subjects/O with/O post/O -/O baseline/O ALT/B-AdverseReaction values/I-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 10/I-AdverseReaction times/I-AdverseReaction ULN/I-AdverseReaction ./O
Eight/O of/O 12/O patients/O treated/O with/O DALVANCE/O and/O one/O comparator/O patient/O had/O underlying/O conditions/O which/O could/O affect/O liver/O enzymes/O ,/O including/O chronic/O viral/O hepatitis/O and/O a/O history/O of/O alcohol/O abuse/O ./O
In/O addition/O ,/O one/O DALVANCE/O -/O treated/O subject/O in/O a/O Phase/O 1/O trial/O had/O post/O -/O baseline/O ALT/B-AdverseReaction elevations/I-AdverseReaction greater/O than/O 20/B-Severity times/I-Severity ULN/I-Severity ./O
ALT/B-AdverseReaction elevations/I-AdverseReaction were/O reversible/O in/O all/O subjects/O ./O
No/B-Negation comparator/O -/O treated/O subject/O with/O normal/O baseline/O transaminases/O had/O post/O -/O baseline/O ALT/B-AdverseReaction elevation/I-AdverseReaction greater/O than/O 10/B-Severity times/I-Severity ULN/I-Severity ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Serious/B-Severity hypersensitivity/O (/O anaphylactic/O )/O and/O skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O with/O glycopeptide/O antibacterial/O agents/O ,/O including/O DALVANCE/O ;/O exercise/O caution/O in/O patients/O with/O known/O hypersensitivity/O to/O glycopeptides/O ./O
(/O 5.1/O )/O Rapid/O intravenous/O infusion/O of/O glycopeptide/O antibacterial/O agents/O can/B-Factor cause/O reactions/O ./O
(/O 5.2/O )/O ALT/B-AdverseReaction elevations/I-AdverseReaction with/O DALVANCE/O treatment/O were/O reported/O in/O clinical/O trials/O ./O
(/O 5.3/O )/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/I-AdverseReaction (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O with/O nearly/O all/O systemic/O antibacterial/O agents/O ,/O including/O DALVANCE/O ./O
Evaluate/O if/O diarrhea/O occurs/O ./O
(/O 5.4/O )/O 5.1/O Hypersensitivity/O Reactions/O Serious/B-Severity hypersensitivity/O (/O anaphylactic/O )/O and/O skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O in/O patients/O treated/O with/O DALVANCE/O ./O
If/O an/O allergic/O reaction/O occurs/O ,/O treatment/O with/O DALVANCE/O should/O be/O discontinued/O ./O
Before/O using/O DALVANCE/O ,/O inquire/O carefully/O about/O previous/O hypersensitivity/O reactions/O to/O glycopeptides/O ,/O and/O due/O to/O the/O possibility/O of/O cross/O -/O sensitivity/O ,/O exercise/O caution/O in/O patients/O with/O a/O history/O of/O glycopeptide/O allergy/O [/O see/O Patient/O Counseling/O Information/O (/O 17/O )/O ]/O ./O
5.2/O Infusion/O -/O Related/O Reactions/O DALVANCE/O is/O administered/O via/O intravenous/O infusion/O ,/O using/O a/O total/O infusion/O time/O of/O 30/O minutes/O to/O minimize/O the/O risk/O of/O infusion/O -/O related/O reactions/O ./O
Rapid/O intravenous/O infusions/O of/O DALVANCE/O can/B-Factor cause/O reactions/O that/O resemble/O "/O Red/B-AdverseReaction -/I-AdverseReaction Man/O Syndrome/O ,/O "/O including/O flushing/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction upper/I-AdverseReaction body/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O and/or/O rash/B-AdverseReaction ./O
Stopping/O or/O slowing/O the/O infusion/O may/O result/O in/O cessation/O of/O these/O reactions/O ./O
5.3/O Hepatic/O Effects/O In/O Phase/O 2/O and/O 3/O clinical/O trials/O ,/O more/O DALVANCE-/O than/O comparator/O -/O treated/O subjects/O with/O normal/O baseline/O transaminase/O levels/O had/O post/O -/O baseline/O alanine/O aminotransferase/O (/O ALT/O )/O elevation/O greater/O than/O 3/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O ULN/O )/O ./O
Overall/O ,/O abnormalities/O in/O liver/O tests/O (/O ALT/O ,/O AST/O ,/O bilirubin/O )/O were/O reported/O with/O similar/O frequency/O in/O the/O DALVANCE/O and/O comparator/O arms/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.4/O Clostridium/O difficile/O -/O Associated/O Diarrhea/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/O (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O in/O users/O of/O nearly/O all/O systemic/O antibacterial/O drugs/O ,/O including/O DALVANCE/O ,/O with/O severity/O ranging/O from/O mild/B-Severity diarrhea/B-AdverseReaction to/O fatal/B-AdverseReaction colitis/B-AdverseReaction ./O
Treatment/O with/O antibacterial/O agents/O can/O alter/O the/O normal/O flora/O of/O the/O colon/O ,/O and/O may/O permit/O overgrowth/O of/O C./O difficile/O ./O
C./O difficile/O produces/O toxins/O A/O and/O B/O which/O contribute/O to/O the/O development/O of/O CDAD/O ./O
Hypertoxin/O -/O producing/O strains/O of/O C./O difficile/O cause/O increased/O morbidity/O and/O mortality/O ,/O as/O these/O infections/O can/O be/O refractory/O to/O antibacterial/O therapy/O and/O may/O require/O colectomy/O ./O
CDAD/O must/O be/O considered/O in/O all/O patients/O who/O present/O with/O diarrhea/O following/O antibacterial/O use/O ./O
Careful/O medical/O history/O is/O necessary/O because/O CDAD/O has/O been/O reported/O to/O occur/O more/O than/O 2/O months/O after/O the/O administration/O of/O antibacterial/O agents/O ./O
If/O CDAD/O is/O suspected/O or/O confirmed/O ,/O ongoing/O antibacterial/O use/O not/O directed/O against/O C./O difficile/O should/O be/O discontinued/O ,/O if/O possible/O ./O
Appropriate/O measures/O such/O as/O fluid/O and/O electrolyte/O management/O ,/O protein/O supplementation/O ,/O antibacterial/O treatment/O of/O C./O difficile/O ,/O and/O surgical/O evaluation/O should/O be/O instituted/O as/O clinically/O indicated/O ./O
5.5/O Development/O of/O Drug/O -/O Resistant/O Bacteria/O Prescribing/O DALVANCE/O in/O the/O absence/O of/O a/O proven/O or/O strongly/O suspected/O bacterial/O infection/O is/O unlikely/O to/O provide/O benefit/O to/O the/O patient/O and/O increases/O the/O risk/O of/O the/O development/O of/O drug/O -/O resistant/O bacteria/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O following/O DaTscan/O administration/O ./O
(/O 6.2/O )/O In/O clinical/O trials/O ,/O the/O most/O common/O adverse/O reactions/O ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction or/O dizziness/B-AdverseReaction occurred/O in/O 1/O %/O of/O subjects/O ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GE/O Healthcare/O at/O 1/O -/O 800/O -/O 654/O -/O 0118/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Study/O Experience/O The/O data/O from/O clinical/O studies/O reflect/O exposure/O to/O DaTscan/O in/O 942/O subjects/O with/O a/O mean/O age/O of/O 66/O years/O (/O range/O 25/O to/O 90/O years/O )/O ./O
Among/O these/O subjects/O ,/O 42/O %/O were/O women/O and/O 99/O %/O Caucasian/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O DaTscan/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O clinical/O trials/O ,/O no/O serious/O adverse/O reactions/O were/O reported/O ./O
Other/O adverse/O reactions/O occurred/O at/O a/O rate/O of/O 1/O %/O or/O less/O and/O the/O reported/O events/O consisted/O of/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction or/O dizziness/B-AdverseReaction ./O
These/O reactions/O were/O of/O mild/O to/O moderate/O severity/O ./O
6.2/O Postmarketing/O Experience/O Because/O postmarketing/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
In/O the/O postmarketing/O experience/O ,/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O ./O
The/O reactions/O generally/O related/O to/O rash/B-AdverseReaction and/O pruritis/B-AdverseReaction within/O minutes/O of/O DaTscan/O administration/O ./O
The/O reactions/O either/O resolved/O spontaneously/O or/O following/O the/O administration/O of/O corticosteroids/O and/O antihistamines/O ./O
Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction has/O also/O been/O reported/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O following/O DaTscan/O administration/O ./O
Have/O anaphylactic/O and/O hypersensitivity/O treatment/O measures/O available/O prior/O to/O DaTscan/O administration/O ./O
(/O 5.1/O )/O Administer/O a/O thyroid/O -/O blocking/O agent/O before/O DaTscan/O administration/O ./O
(/O 5.2/O )/O 5.1/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O following/O DaTscan/O administration/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
The/O reactions/O have/O generally/O consisted/O of/O skin/B-AdverseReaction erythema/I-AdverseReaction and/O pruritis/B-AdverseReaction and/O have/O either/O resolved/O spontaneously/O or/O following/O the/O administration/O of/O corticosteroids/O and/O anti/O -/O histamines/O ./O
Prior/O to/O administration/O ,/O question/O the/O patient/O for/O a/O history/O of/O prior/O reactions/O to/O DaTscan/O ./O
If/O the/O patient/O is/O known/O or/O strongly/O suspected/O of/O having/O had/O a/O hypersensitivity/O reaction/O to/O DaTscan/O ,/O the/O decision/O to/O administer/O DaTscan/O should/O be/O based/O upon/O an/O assessment/O of/O the/O expected/O benefits/O compared/O to/O the/O potential/O hypersensitivity/O risks/O ./O
Have/O anaphylactic/O and/O hypersensitivity/O treatment/O measures/O available/O prior/O to/O DaTscan/O administration/O and/O ,/O following/O administration/O ,/O observe/O patients/O for/O symptoms/O or/O signs/O of/O a/O hypersensitivity/O reaction/O ./O
5.2/O Thyroid/O Accumulation/O The/O DaTscan/O injection/O may/O contain/O up/O to/O 6/O %/O of/O free/O iodide/O (/O iodine/O 123/O )/O ./O
To/O decrease/O thyroid/O accumulation/O of/O iodine/O 123/O ,/O block/O the/O thyroid/O gland/O before/O administration/O of/O DaTscan/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Avoid/O the/O use/O of/O Potassium/O Iodide/O Oral/O Solution/O or/O Lugol/O 's/O Solution/O in/O patients/O who/O are/O sensitive/O to/O such/O products/O ./O
Failure/O to/O block/O thyroid/O uptake/O of/O iodine/O 123/O may/O result/O in/O an/O increased/O long/O term/O risk/O for/O thyroid/O neoplasia/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reaction/O in/O adults/O was/O diarrhea/B-AdverseReaction (/O 2/O %/O )/O ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Arbor/O Pharmaceuticals/O ,/O LLC/O at/O 1/O -/O 866/O -/O 516/O -/O 4950/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
A/O total/O of/O 4814/O patients/O were/O evaluated/O for/O safety/O when/O treated/O with/O Edarbi/O at/O doses/O of/O 20/O ,/O 40/O ,/O or/O 80/O mg/O in/O clinical/O trials/O ./O
This/O includes/O 1704/O patients/O treated/O for/O at/O least/O six/O months/O ;/O of/O these/O ,/O 588/O were/O treated/O for/O at/O least/O one/O year/O ./O
Treatment/O with/O Edarbi/O was/O well/O -/O tolerated/O with/O an/O overall/O incidence/O of/O adverse/O reactions/O similar/O to/O placebo/O ./O
The/O rate/O of/O withdrawals/O due/O to/O adverse/O events/O in/O placebo/O -/O controlled/O monotherapy/O and/O combination/O therapy/O trials/O was/O 2.4/O %/O (/O 19/801/O )/O for/O placebo/O ,/O 2.2/O %/O (/O 24/1072/O )/O for/O Edarbi/O 40/O mg/O ,/O and/O 2.7/O %/O (/O 29/1074/O )/O for/O Edarbi/O 80/O mg/O ./O
The/O most/O common/O adverse/O event/O leading/O to/O discontinuation/O ,/O hypotension/B-AdverseReaction orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O was/O reported/O by/O 0.4/O %/O (/O 8/2146/O )/O patients/O randomized/O to/O Edarbi/O 40/O mg/O or/O 80/O mg/O compared/O to/O 0/O %/O (/O 0/801/O )/O patients/O randomized/O to/O placebo/O ./O
Generally/O ,/O adverse/O reactions/O were/O mild/O ,/O not/O dose/O related/O ,/O and/O similar/O regardless/O of/O age/O ,/O gender/O ,/O and/O race/O ./O
In/O placebo/O -/O controlled/O monotherapy/O trials/O ,/O diarrhea/B-AdverseReaction was/O reported/O up/O to/O 2/O %/O in/O patients/O treated/O with/O Edarbi/O 80/O mg/O daily/O compared/O with/O 0.5/O %/O of/O patients/O on/O placebo/O ./O
Other/O adverse/O reactions/O with/O a/O plausible/O relationship/O to/O treatment/O that/O have/O been/O reported/O with/O an/O incidence/O of/O 0.3/O %/O and/O greater/O than/O placebo/O in/O more/O than/O 3300/O patients/O treated/O with/O Edarbi/O in/O controlled/O trials/O are/O listed/O below/O :/O Gastrointestinal/O Disorders/O :/O nausea/B-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O asthenia/B-AdverseReaction ,/O fatigue/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O muscle/B-AdverseReaction spasm/I-AdverseReaction Nervous/O System/O Disorders/O :/O dizziness/B-AdverseReaction ,/O dizziness/B-AdverseReaction postural/I-AdverseReaction Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O :/O cough/B-AdverseReaction 6.2/O Clinical/O Laboratory/O Findings/O In/O controlled/O clinical/O trials/O ,/O clinically/O relevant/O changes/O in/O standard/O laboratory/O parameters/O were/O uncommon/O with/O administration/O of/O Edarbi/O ./O
Serum/O creatinine/O Small/B-Severity reversible/B-Severity increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction are/O seen/O in/O patients/O receiving/O 80/O mg/O of/O Edarbi/O ./O
The/O increase/O may/O be/O larger/O when/O coadministered/O with/O chlorthalidone/O or/O hydrochlorothiazide/O ./O
In/O addition/O ,/O patients/O taking/O Edarbi/O who/O had/O moderate/O to/O severe/O renal/O impairment/O at/O baseline/O or/O who/O were/O 75/O years/O of/O age/O were/O more/O likely/O to/O report/O serum/B-AdverseReaction creatinine/I-AdverseReaction increases/I-AdverseReaction ./O
Hemoglobin/O Hematocrit/O Low/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O hematocrit/O ,/O and/O RBC/O counts/O were/O observed/O in/O 0.2/O %/O ,/O 0.4/O %/O ,/O and/O 0.3/O %/O of/O Edarbi/O -/O treated/O subjects/O ,/O respectively/O ./O
None/O of/O these/O abnormalities/O were/O reported/O in/O the/O placebo/O group/O ./O
Low/O and/O high/O markedly/B-Severity abnormal/O platelet/O and/O WBC/O counts/O were/O observed/O in/O 0.1/O %/O of/O subjects/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O the/O postmarketing/O use/O of/O EDARBI/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Nausea/B-AdverseReaction Muscle/B-AdverseReaction spasms/I-AdverseReaction Rash/B-AdverseReaction Pruritus/B-AdverseReaction Angioedema/B-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O FETAL/B-AdverseReaction TOXICITY/I-AdverseReaction WARNING/O :/O FETAL/B-AdverseReaction TOXICITY/I-AdverseReaction When/O pregnancy/O is/O detected/O ,/O discontinue/O Edarbi/O as/O soon/O as/O possible/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Drugs/B-DrugClass that/I-DrugClass act/I-DrugClass directly/I-DrugClass on/I-DrugClass the/I-DrugClass renin/I-DrugClass -/I-DrugClass angiotensin/O system/O can/O cause/O injury/O and/O death/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction developing/I-AdverseReaction fetus/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
WARNING/O :/O FETAL/B-AdverseReaction TOXICITY/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
When/O pregnancy/O is/O detected/O ,/O discontinue/O Edarbi/O as/O soon/O as/O possible/O ./O
(/O 5.1/O )/O Drugs/B-DrugClass that/I-DrugClass act/I-DrugClass directly/I-DrugClass on/I-DrugClass the/I-DrugClass renin/I-DrugClass -/I-DrugClass angiotensin/O system/O can/O cause/O injury/O and/O death/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction developing/I-AdverseReaction fetus/I-AdverseReaction ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Correct/O volume/O or/O salt/O depletion/O prior/O to/O administration/O of/O Edarbi/O ./O
(/O 5.2/O )/O Monitor/O for/O worsening/O renal/O function/O in/O patients/O with/O renal/O impairment/O ./O
(/O 5.3/O )/O 5.1/O Fetal/O Toxicity/O Use/O of/O drugs/B-DrugClass that/I-DrugClass act/I-DrugClass on/I-DrugClass the/I-DrugClass renin/I-DrugClass -/I-DrugClass angiotensin/O system/O during/O the/O second/O and/O third/O trimesters/O of/O pregnancy/O reduces/B-AdverseReaction fetal/I-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction and/O increases/O fetal/O and/O neonatal/B-AdverseReaction morbidity/I-AdverseReaction and/O death/O ./O
Resulting/O oligohydramnios/B-AdverseReaction can/B-Factor be/O associated/O with/O fetal/B-AdverseReaction lung/I-AdverseReaction hypoplasia/I-AdverseReaction and/O skeletal/O deformations/O ./O
Potential/B-Factor neonatal/B-AdverseReaction adverse/I-AdverseReaction effects/I-AdverseReaction include/O skull/O hypoplasia/O ,/O anuria/O ,/O hypotension/O ,/O renal/O failure/O ,/O and/O death/O ./O
When/O pregnancy/O is/O detected/O ,/O discontinue/O Edarbi/O as/O soon/O as/O possible/O [/O seeUse/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
5.2/O Hypotension/O in/O Volume-/O or/O Salt/O -/O Depleted/O Patients/O In/O patients/O with/O an/O activated/O renin/O -/O angiotensin/O system/O ,/O such/O as/O volume-/O and/or/O salt/O -/O depleted/O patients/O (/O e.g./O ,/O those/O being/O treated/O with/O high/O doses/O of/O diuretics/O )/O ,/O symptomatic/B-AdverseReaction hypotension/I-AdverseReaction may/B-Factor occur/O after/O initiation/O of/O treatment/O with/O Edarbi/O ./O
Correct/O volume/O or/O salt/O depletion/O prior/O to/O administration/O of/O Edarbi/O ,/O or/O start/O treatment/O at/O 40/O mg/O ./O
If/O hypotension/O does/O occur/O ,/O the/O patient/O should/O be/O placed/O in/O the/O supine/O position/O and/O ,/O if/O necessary/O ,/O given/O an/O intravenous/O infusion/O of/O normal/O saline/O ./O
A/O transient/O hypotensive/O response/O is/O not/O a/O contraindication/O to/O further/O treatment/O ,/O which/O usually/O can/O be/O continued/O without/O difficulty/O once/O the/O blood/O pressure/O has/O stabilized/O ./O
5.3/O Impaired/O Renal/O Function/O As/O a/O consequence/O of/O inhibiting/O the/O renin/O -/O angiotensin/O system/O ,/O changes/B-AdverseReaction in/I-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction may/B-Factor be/O anticipated/O in/O susceptible/O individuals/O treated/O with/O Edarbi/O ./O
In/O patients/O whose/O renal/O function/O may/O depend/O on/O the/O activity/O of/O the/O renin/O -/O angiotensin/O system/O (/O e.g./O ,/O patients/O with/O severe/O congestive/O heart/O failure/O ,/O renal/O artery/O stenosis/O ,/O or/O volume/O depletion/O )/O ,/O treatment/O with/O angiotensin/B-DrugClass -/I-DrugClass converting/I-DrugClass enzyme/O inhibitors/O and/O angiotensin/B-DrugClass receptor/I-DrugClass blockers/I-DrugClass has/O been/O associated/O with/O oliguria/B-AdverseReaction or/O progressive/B-AdverseReaction azotemia/I-AdverseReaction and/O rarely/O with/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O death/B-AdverseReaction ./O
Similar/O results/O may/O be/O anticipated/O in/O patients/O treated/O with/O Edarbi/O [/O seeDrug/O Interactions/O (/O 7),Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ,/O andClinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
In/O studies/O of/O ACE/B-DrugClass inhibitors/I-DrugClass in/O patients/O with/O unilateral/O or/O bilateral/O renal/O artery/O stenosis/O ,/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction or/O blood/O urea/O nitrogen/O have/O been/O reported/O ./O
There/O has/O been/O no/O long/O -/O term/O use/O of/O Edarbi/O in/O patients/O with/O unilateral/O or/O bilateral/O renal/O artery/O stenosis/O ,/O but/O similar/O results/O may/O be/O expected/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O prescribing/O information/O ./O
?/O Increased/O risk/B-Factor of/O thrombotic/B-AdverseReaction events/I-AdverseReaction after/O premature/O discontinuation/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ?/O Bleeding/B-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ?/O Spinal/O epidural/O anesthesia/O or/O puncture/O [/O seeWarnings/O and/O Precautions/O (/O 5.3/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 1/O %/O )/O are/O related/O to/O bleeding.(6.1/B-AdverseReaction )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bristol/O -/O Myers/O Squibb/O at/O 1/O -/O 800/O -/O 721/O -/O 5072/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Reduction/O of/O Risk/O of/O Stroke/O and/O Systemic/O Embolism/O in/O Patients/O with/O Nonvalvular/O Atrial/O Fibrillation/O The/O safety/O of/O ELIQUIS/O was/O evaluated/O in/O the/O ARISTOTLE/O and/O AVERROES/O studies/O [/O seeClinical/O Studies/O (/O 14/O )/O ]/O ,/O including/O 11,284/O patients/O exposed/O to/O ELIQUIS/O 5/O mg/O twice/O daily/O and/O 602/O patients/O exposed/O to/O ELIQUIS/O 2.5/O mg/O twice/O daily/O ./O
The/O duration/O of/O ELIQUIS/O exposure/O was/O 12/O months/O for/O 9375/O patients/O and/O 24/O months/O for/O 3369/O patients/O in/O the/O two/O studies/O ./O
In/O ARISTOTLE/O ,/O the/O mean/O duration/O of/O exposure/O was/O 89/O weeks/O (/O 15,000/O patient/O -/O years/O )/O ./O
In/O AVERROES/O ,/O the/O mean/O duration/O of/O exposure/O was/O approximately/O 59/O weeks/O (/O 3000/O patient/O -/O years/O )/O ./O
The/O most/O common/O reason/O for/O treatment/O discontinuation/O in/O both/O studies/O was/O for/O bleeding/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O ;/O in/O ARISTOTLE/O this/O occurred/O in/O 1.7/O %/O and/O 2.5/O %/O of/O patients/O treated/O with/O ELIQUIS/O and/O warfarin/O ,/O respectively/O ,/O and/O in/O AVERROES/O ,/O in/O 1.5/O %/O and/O 1.3/O %/O on/O ELIQUIS/O and/O aspirin/O ,/O respectively/O ./O
Bleeding/O in/O Patients/O with/O Nonvalvular/O Atrial/O Fibrillation/O in/O ARISTOTLE/O and/O AVERROES/O Tables/O 1/O and/O 2/O show/O the/O number/O of/O patients/O experiencing/O major/B-Severity bleeding/B-AdverseReaction during/O the/O treatment/O period/O and/O the/O bleeding/B-AdverseReaction rate/O (/O percentage/O of/O subjects/O with/O at/O least/O one/O bleeding/B-AdverseReaction event/O per/O 100/O patient/O -/O years/O )/O in/O ARISTOTLE/O and/O AVERROES/O ./O
Table/O 1/O :/O Bleeding/B-AdverseReaction Events/O in/O Patients/O with/O Nonvalvular/O Atrial/O Fibrillation/O in/O ARISTOTLE/O ELIQUISN=9088n/O (/O per/O 100/O pt/O -/O year/O )/O WarfarinN=9052n/O (/O per/O 100/O pt/O -/O year/O )/O Hazard/O Ratio(95/O %/O CI/O )/O P/O -/O value/O Bleeding/B-AdverseReaction events/O within/O each/O subcategory/O were/O counted/O once/O per/O subject/O ,/O but/O subjects/O may/O have/O contributed/O events/O to/O multiple/O endpoints/O ./O
Bleeding/B-AdverseReaction events/O were/O counted/O during/O treatment/O or/O within/O 2/O days/O of/O stopping/O study/O treatment/O (/O on/O -/O treatment/O period/O )/O ./O
Defined/O as/O clinically/O overt/O bleeding/B-AdverseReaction accompanied/O by/O one/O or/O more/O of/O the/O following/O :/O a/O decrease/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction of/O 2/B-Severity g/I-Severity dL/O ,/O a/O transfusion/O of/O 2/O or/O more/O units/O of/O packed/O red/O blood/O cells/O ,/O bleeding/B-AdverseReaction at/I-AdverseReaction a/I-AdverseReaction critical/I-AdverseReaction site/I-AdverseReaction :/O intracranial/O ,/O intraspinal/O ,/O intraocular/O ,/O pericardial/O ,/O intra/O -/O articular/O ,/O intramuscular/O with/O compartment/B-AdverseReaction syndrome/I-AdverseReaction ,/O retroperitoneal/O or/O with/O fatal/B-AdverseReaction outcome/I-AdverseReaction ./O
?/O Intracranial/B-AdverseReaction bleed/I-AdverseReaction includes/O intracerebral/O ,/O intraventricular/O ,/O subdural/O ,/O and/O subarachnoid/B-AdverseReaction bleeding/I-AdverseReaction ./O
Any/O type/O of/O hemorrhagic/B-AdverseReaction stroke/I-AdverseReaction was/O adjudicated/O and/O counted/O as/O an/O intracranial/O major/B-Severity bleed/O ./O
S/O On/O -/O treatment/O analysis/O based/O on/O the/O safety/O population/O ,/O compared/O to/O ITT/O analysis/O presented/O in/O Section/O 14/O ./O
GI/B-AdverseReaction bleed/I-AdverseReaction includes/O upper/O GI/O ,/O lower/O GI/O ,/O and/O rectal/B-AdverseReaction bleeding/I-AdverseReaction ./O
Fatal/B-AdverseReaction bleeding/B-AdverseReaction is/O an/O adjudicated/O death/B-AdverseReaction with/O the/O primary/O cause/O of/O death/B-AdverseReaction as/O intracranial/B-AdverseReaction bleeding/I-AdverseReaction or/O non/B-AdverseReaction -/I-AdverseReaction intracranial/O bleeding/O during/O the/O on/O -/O treatment/O period/O ./O
Major/O 327/O (/O 2.13/O )/O 462/O (/O 3.09/O )/O 0.69/O (/O 0.60/O ,/O 0.80/O )/O 0.0001/O Intracranial/O (/O ICH/B-AdverseReaction )/O ?/O 52/O (/O 0.33/O )/O 125/O (/O 0.82/O )/O 0.41/O (/O 0.30/O ,/O 0.57/O )/O -/O Hemorrhagic/B-AdverseReaction strokeS/I-AdverseReaction 38/O (/O 0.24/O )/O 74/O (/O 0.49/O )/O 0.51/O (/O 0.34/O ,/O 0.75/O )/O -/O Other/O ICH/B-AdverseReaction 15/O (/O 0.10/O )/O 51/O (/O 0.34/O )/O 0.29/O (/O 0.16/O ,/O 0.51/O )/O -/O Gastrointestinal/O (/O GI/O )/O 128/O (/O 0.83/O )/O 141/O (/O 0.93/O )/O 0.89/O (/O 0.70/O ,/O 1.14/O )/O -/O Fatal/B-AdverseReaction 10/O (/O 0.06/O )/O 37/O (/O 0.24/O )/O 0.27/O (/O 0.13/O ,/O 0.53/O )/O -/O Intracranial/O 4/O (/O 0.03/O )/O 30/O (/O 0.20/O )/O 0.13/O (/O 0.05/O ,/O 0.37/O )/O -/O Non/O -/O intracranial/O 6/O (/O 0.04/O )/O 7/O (/O 0.05/O )/O 0.84/O (/O 0.28/O ,/O 2.15/O )/O -/O In/O ARISTOTLE/O ,/O the/O results/O for/O major/B-Severity bleeding/B-AdverseReaction were/O generally/O consistent/O across/O most/O major/O subgroups/O including/O age/O ,/O weight/O ,/O CHADS2score/O (/O a/O scale/O from/O 0/O to/O 6/O used/O to/O estimate/O risk/O of/O stroke/O ,/O with/O higher/O scores/O predicting/O greater/O risk/O )/O ,/O prior/O warfarin/O use/O ,/O geographic/O region/O ,/O and/O aspirin/O use/O at/O randomization/O (/O Figure/O 1/O )/O ./O
Subjects/O treated/O with/O apixaban/O with/O diabetes/O bled/B-AdverseReaction more/O (/O 3.0/O %/O per/O year/O )/O than/O did/O subjects/O without/O diabetes/O (/O 1.9/O %/O per/O year/O )/O ./O
Figure/O 1/O :/O Major/B-Severity Bleeding/B-AdverseReaction Hazard/O Ratios/O by/O Baseline/O Characteristics/O -/O ARISTOTLE/O Study/O Note/O :/O The/O figure/O above/O presents/O effects/O in/O various/O subgroups/O ,/O all/O of/O which/O are/O baseline/O characteristics/O and/O all/O of/O which/O were/O pre/O -/O specified/O ,/O if/O not/O the/O groupings/O ./O
The/O 95/O %/O confidence/O limits/O that/O are/O shown/O do/O not/O take/O into/O account/O how/O many/O comparisons/O were/O made/O ,/O nor/O do/O they/O reflect/O the/O effect/O of/O a/O particular/O factor/O after/O adjustment/O for/O all/O other/O factors/O ./O
Apparent/O homogeneity/O or/O heterogeneity/O among/O groups/O should/O not/O be/O over/O -/O interpreted/O ./O
Table/O 2/O :/O Bleeding/B-AdverseReaction Events/O in/O Patients/O with/O Nonvalvular/O Atrial/O Fibrillation/O in/O AVERROES/O ELIQUISN=2798n/O (/O %/O /year/O )/O AspirinN=2780n/O (/O %/O /year/O )/O Hazard/O Ratio(95/O %/O CI/O )/O P/O -/O value/O Events/O associated/O with/O each/O endpoint/O were/O counted/O once/O per/O subject/O ,/O but/O subjects/O may/O have/O contributed/O events/O to/O multiple/O endpoints/O ./O
Major/O 45/O (/O 1.41/O )/O 29/O (/O 0.92/O )/O 1.54/O (/O 0.96/O ,/O 2.45/O )/O 0.07/O Fatal/B-AdverseReaction 5/O (/O 0.16/O )/O 5/O (/O 0.16/O )/O 0.99/O (/O 0.23/O ,/O 4.29/O )/O -/O Intracranial/O 11/O (/O 0.34/O )/O 11/O (/O 0.35/O )/O 0.99/O (/O 0.39/O ,/O 2.51/O )/O -/O ARISTOTLE/O Major/B-Severity Bleeding/B-AdverseReaction Forest/O Plot/O Other/O Adverse/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O including/O drug/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O such/O as/O skin/B-AdverseReaction rash/I-AdverseReaction ,/O and/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction ,/O such/O as/O allergic/B-AdverseReaction edema/I-AdverseReaction )/O and/O syncope/B-AdverseReaction were/O reported/O in/O 1/O %/O of/O patients/O receiving/O ELIQUIS/O ./O
Prophylaxis/O of/O Deep/O Vein/O Thrombosis/O Following/O Hip/O or/O Knee/O Replacement/O Surgery/O The/O safety/O of/O ELIQUIS/O has/O been/O evaluated/O in/O 1/O Phase/O II/O and/O 3/O Phase/O III/O studies/O including/O 5924/O patients/O exposed/O to/O ELIQUIS/O 2.5/O mg/O twice/O daily/O undergoing/O major/O orthopedic/O surgery/O of/O the/O lower/O limbs/O (/O elective/O hip/O replacement/O or/O elective/O knee/O replacement/O )/O treated/O for/O up/O to/O 38/O days/O ./O
In/O total/O ,/O 11/O %/O of/O the/O patients/O treated/O with/O ELIQUIS/O 2.5/O mg/O twice/O daily/O experienced/O adverse/O reactions/O ./O
Bleeding/B-AdverseReaction results/O during/O the/O treatment/O period/O in/O the/O Phase/O III/O studies/O are/O shown/O in/O Table/O 3/O ./O
Bleeding/B-AdverseReaction was/O assessed/O in/O each/O study/O beginning/O with/O the/O first/O dose/O of/O double/O -/O blind/O study/O drug/O ./O
Table/O 3/O :/O Bleeding/B-AdverseReaction During/O the/O Treatment/O Period/O in/O Patients/O Undergoing/O Elective/O Hip/O or/O Knee/O Replacement/O Surgery/O Bleeding/O Endpoint/O ADVANCE-3Hip/O Replacement/O Surgery/O ADVANCE-2Knee/O Replacement/O Surgery/O ADVANCE-1Knee/O Replacement/O Surgery/O All/O bleeding/B-AdverseReaction criteria/O included/O surgical/B-AdverseReaction site/I-AdverseReaction bleeding/I-AdverseReaction ./O
Includes/O 13/O subjects/O with/O major/B-Severity bleeding/B-AdverseReaction events/O that/O occurred/O before/B-Negation the/I-Negation first/I-Negation dose/I-Negation of/O apixaban/O (/O administered/O 12/O to/O 24/O hours/O post/O surgery/O )/O ./O
?/O Includes/O 5/O subjects/O with/O major/B-Severity bleeding/B-AdverseReaction events/O that/O occurred/O before/B-Negation the/I-Negation first/I-Negation dose/I-Negation of/O apixaban/O (/O administered/O 12/O to/O 24/O hours/O post/O surgery/O )/O ./O
S/O Intracranial/O ,/O intraspinal/O ,/O intraocular/O ,/O pericardial/O ,/O an/O operated/O joint/O requiring/O re/O -/O operation/O or/O intervention/O ,/O intramuscular/O with/O compartment/O syndrome/O ,/O or/O retroperitoneal/O ./O
Bleeding/B-AdverseReaction into/I-AdverseReaction an/I-AdverseReaction operated/I-AdverseReaction joint/I-AdverseReaction requiring/O re/O -/O operation/O or/O intervention/O was/O present/O in/O all/O patients/O with/O this/O category/O of/O bleeding/B-AdverseReaction ./O
Events/O and/O event/O rates/O include/O one/O enoxaparin/O -/O treated/O patient/O in/O ADVANCE-1/O who/O also/O had/O intracranial/B-AdverseReaction hemorrhage/I-AdverseReaction ./O
CRNM/O clinically/O relevant/O nonmajor/O ./O
ELIQUIS2.5/O mg/O po/O bid35+/-3/O days/O Enoxaparin/O 40/O mg/O sc/O qd/O 35+/-3/O days/O ELIQUIS/O 2.5/O mg/O po/O bid/O 12+/-2/O days/O Enoxaparin/O 40/O mg/O sc/O qd/O 12+/-2/O days/O ELIQUIS/O 2.5/O mg/O po/O bid/O 12+/-2/O days/O Enoxaparin/O 30/O mg/O sc/O q12h/O 12+/-2/O days/O First/O dose/O 12/O to/O 24/O hours/O post/O surgery/O First/O dose/O 9/O to/O 15/O hours/O prior/O to/O surgery/O First/O dose/O 12/O to/O 24/O hours/O post/O surgery/O First/O dose/O 9/O to/O 15/O hours/O prior/O to/O surgery/O First/O dose/O 12/O to/O 24/O hours/O post/O surgery/O First/O dose/O 12/O to/O 24/O hours/O post/O surgery/O All/O treated/O N=2673/O N=2659/O N=1501/O N=1508/O N=1596/O N=1588/O Major/O (/O including/O surgical/O site/O )/O 22/O (/O 0.82/O %/O )/O 18/O (/O 0.68/O %/O )/O 9/O (/O 0.60/O %/O )/O ?/O 14/O (/O 0.93/O %/O )/O 11/O (/O 0.69/O %/O )/O 22/O (/O 1.39/O %/O )/O Fatal/B-AdverseReaction 0/O 0/O 0/O 0/O 0/O 1/O (/O 0.06/O %/O )/O Hgb/B-AdverseReaction decrease/I-AdverseReaction 2/B-Severity g/I-Severity dL/O 13/O (/O 0.49/O %/O )/O 10/O (/O 0.38/O %/O )/O 8/O (/O 0.53/O %/O )/O 9/O (/O 0.60/O %/O )/O 10/O (/O 0.63/O %/O )/O 16/O (/O 1.01/O %/O )/O Transfusion/O of/O 2/O units/O RBC/O 16/O (/O 0.60/O %/O )/O 14/O (/O 0.53/O %/O )/O 5/O (/O 0.33/O %/O )/O 9/O (/O 0.60/O %/O )/O 9/O (/O 0.56/O %/O )/O 18/O (/O 1.13/O %/O )/O Bleed/B-AdverseReaction at/I-AdverseReaction critical/I-AdverseReaction siteS/I-AdverseReaction 1/O (/O 0.04/O %/O )/O 1/O (/O 0.04/O %/O )/O 1/O (/O 0.07/O %/O )/O 2/O (/O 0.13/O %/O )/O 1/O (/O 0.06/O %/O )/O 4/O (/O 0.25/O %/O )/O Major+/O CRNM/O 129/O (/O 4.83/O %/O )/O 134/O (/O 5.04/O %/O )/O 53/O (/O 3.53/O %/O )/O 72/O (/O 4.77/O %/O )/O 46/O (/O 2.88/O %/O )/O 68/O (/O 4.28/O %/O )/O All/O 313/O (/O 11.71/O %/O )/O 334/O (/O 12.56/O %/O )/O 104/O (/O 6.93/O %/O )/O 126/O (/O 8.36/O %/O )/O 85/O (/O 5.33/O %/O )/O 108/O (/O 6.80/O %/O )/O Adverse/O reactions/O occurring/O in/O 1/O %/O of/O patients/O undergoing/O hip/O or/O knee/O replacement/O surgery/O in/O the/O 1/O Phase/O II/O study/O and/O the/O 3/O Phase/O III/O studies/O are/O listed/O in/O Table/O 4/O ./O
Table/O 4/O :/O Adverse/O Reactions/O Occurring/O in/O 1/O %/O of/O Patients/O in/O Either/O Group/O Undergoing/O Hip/O or/O Knee/O Replacement/O Surgery/O ELIQUIS/O ,/O n/O (/O %/O )/O 2.5/O mg/O po/O bidN=5924/O Enoxaparin/O ,/O n/O (/O %/O )/O 40/O mg/O sc/O qd/O or30/O mg/O sc/O q12hN=5904/O Nausea/B-AdverseReaction 153/O (/O 2.6/O )/O 159/O (/O 2.7/O )/O Anemia/B-AdverseReaction (/O including/O postoperative/O and/O hemorrhagic/B-AdverseReaction anemia/I-AdverseReaction ,/O and/O respective/O laboratory/O parameters/O )/O 153/O (/O 2.6/O )/O 178/O (/O 3.0/O )/O Contusion/B-AdverseReaction 83/O (/O 1.4/O )/O 115/O (/O 1.9/O )/O Hemorrhage/B-AdverseReaction (/O including/O hematoma/B-AdverseReaction ,/O and/O vaginal/O and/O urethral/B-AdverseReaction hemorrhage/I-AdverseReaction )/O 67/O (/O 1.1/O )/O 81/O (/O 1.4/O )/O Postprocedural/B-AdverseReaction hemorrhage/I-AdverseReaction (/O including/O postprocedural/B-AdverseReaction hematoma/I-AdverseReaction ,/O wound/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O vessel/B-AdverseReaction puncture/I-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction and/O catheter/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction )/O 54/O (/O 0.9/O )/O 60/O (/O 1.0/O )/O Transaminases/B-AdverseReaction increased/I-AdverseReaction (/O including/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction and/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction abnormal/I-AdverseReaction )/O 50/O (/O 0.8/O )/O 71/O (/O 1.2/O )/O Aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction 47/O (/O 0.8/O )/O 69/O (/O 1.2/O )/O Gamma/B-AdverseReaction -/I-AdverseReaction glutamyltransferase/O increased/O 38/O (/O 0.6/O )/O 65/O (/O 1.1/O )/O Less/O common/O adverse/O reactions/O in/O apixaban/O -/O treated/O patients/O undergoing/O hip/O or/O knee/O replacement/O surgery/O occurring/O at/O a/O frequency/O of/O 0.1/O %/O to/O 1/O %/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O thrombocytopenia/B-AdverseReaction (/O including/O platelet/B-AdverseReaction count/I-AdverseReaction decreases/I-AdverseReaction )/O Vascular/O disorders/O :/O hypotension/B-AdverseReaction (/O including/O procedural/B-AdverseReaction hypotension/I-AdverseReaction )/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O :/O epistaxis/B-AdverseReaction Gastrointestinal/O disorders/O :/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction (/O including/O hematemesis/B-AdverseReaction and/O melena/B-AdverseReaction )/O ,/O hematochezia/B-AdverseReaction Hepatobiliary/O disorders/O :/O liver/B-AdverseReaction function/I-AdverseReaction test/I-AdverseReaction abnormal/I-AdverseReaction ,/O blood/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction ,/O blood/B-AdverseReaction bilirubin/I-AdverseReaction increased/I-AdverseReaction Renal/O and/O urinary/O disorders/O :/O hematuria/B-AdverseReaction (/O including/O respective/O laboratory/O parameters/O )/O Injury/O ,/O poisoning/O ,/O and/O procedural/O complications/O :/O wound/B-AdverseReaction secretion/I-AdverseReaction ,/O incision/B-AdverseReaction -/I-AdverseReaction site/O hemorrhage/O (/O including/O incision/B-AdverseReaction -/I-AdverseReaction site/O hematoma/O )/O ,/O operative/B-AdverseReaction hemorrhage/I-AdverseReaction Less/O common/O adverse/O reactions/O in/O apixaban/O -/O treated/O patients/O undergoing/O hip/O or/O knee/O replacement/O surgery/O occurring/O at/O a/O frequency/O of/O 0.1/O %/O :/O Gingival/B-AdverseReaction bleeding/I-AdverseReaction ,/O hemoptysis/B-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ,/O muscle/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O ocular/B-AdverseReaction hemorrhage/I-AdverseReaction (/O including/O conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction )/O ,/O rectal/B-AdverseReaction hemorrhage/I-AdverseReaction Treatment/O of/O DVT/O and/O PE/O and/O Reduction/O in/O the/O Risk/O of/O Recurrence/O of/O DVT/O or/O PE/O The/O safety/O of/O ELIQUIS/O has/O been/O evaluated/O in/O the/O AMPLIFY/O and/O AMPLIFY/O -/O EXT/O studies/O ,/O including/O 2676/O patients/O exposed/O to/O ELIQUIS/O 10/O mg/O twice/O daily/O ,/O 3359/O patients/O exposed/O to/O ELIQUIS/O 5/O mg/O twice/O daily/O ,/O and/O 840/O patients/O exposed/O to/O ELIQUIS/O 2.5/O mg/O twice/O daily/O ./O
Common/O adverse/O reactions/O (/O 1/O %/O )/O were/O gingival/B-AdverseReaction bleeding/I-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O contusion/B-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O rectal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hematoma/B-AdverseReaction ,/O menorrhagia/B-AdverseReaction ,/O and/O hemoptysis/B-AdverseReaction ./O
AMPLIFY/O Study/O The/O mean/O duration/O of/O exposure/O to/O ELIQUIS/O was/O 154/O days/O and/O to/O enoxaparin/O warfarin/O was/O 152/O days/O in/O the/O AMPLIFY/O study/O ./O
Adverse/O reactions/O related/O to/O bleeding/B-AdverseReaction occurred/O in/O 417/O (/O 15.6/O %/O )/O ELIQUIS/O -/O treated/O patients/O compared/O to/O 661/O (/O 24.6/O %/O )/O enoxaparin/O warfarin/O -/O treated/O patients/O ./O
The/O discontinuation/O rate/O due/O to/O bleeding/B-AdverseReaction events/O was/O 0.7/O %/O in/O the/O ELIQUIS/O -/O treated/O patients/O compared/O to/O 1.7/O %/O in/O enoxaparin/O warfarin/O -/O treated/O patients/O in/O the/O AMPLIFY/O study/O ./O
In/O the/O AMPLIFY/O study/O ,/O ELIQUIS/O was/O statistically/O superior/O to/O enoxaparin/O warfarin/O in/O the/O primary/O safety/O endpoint/O of/O major/B-Severity bleeding/B-AdverseReaction (/O relative/O risk/O 0.31/O ,/O 95/O %/O CI/O [/O 0.17/O ,/O 0.55/O ]/O ,/O P/O -/O value/O 0.0001/O )/O ./O
Bleeding/B-AdverseReaction results/O from/O the/O AMPLIFY/O study/O are/O summarized/O in/O Table/O 5/O ./O
Table/O 5/O :/O Bleeding/B-AdverseReaction Results/O in/O the/O AMPLIFY/O Study/O ELIQUISN=2676n/O (/O %/O )/O Enoxaparin/O WarfarinN=2689n/O (/O %/O )/O Relative/O Risk/O (/O 95/O %/O CI/O )/O CRNM/B-AdverseReaction clinically/B-AdverseReaction relevant/I-AdverseReaction nonmajor/I-AdverseReaction bleeding/I-AdverseReaction ./O
Events/O associated/O with/O each/O endpoint/O were/O counted/O once/O per/O subject/O ,/O but/O subjects/O may/O have/O contributed/O events/O to/O multiple/O endpoints/O ./O
Major/O 15/O (/O 0.6/O )/O 49/O (/O 1.8/O )/O 0.31/O (/O 0.17/O ,/O 0.55)p<0.0001/O CRNM/B-AdverseReaction 103/O (/O 3.9/O )/O 215/O (/O 8.0/O )/O Major/O +/O CRNM/B-AdverseReaction 115/O (/O 4.3/O )/O 261/O (/O 9.7/O )/O Minor/O 313/O (/O 11.7/O )/O 505/O (/O 18.8/O )/O All/O 402/O (/O 15.0/O )/O 676/O (/O 25.1/O )/O Adverse/O reactions/O occurring/O in/O 1/O %/O of/O patients/O in/O the/O AMPLIFY/O study/O are/O listed/O in/O Table/O 6/O ./O
Table/O 6/O :/O Adverse/O Reactions/O Occurring/O in/O 1/O %/O of/O Patients/O Treated/O for/O DVT/O and/O PE/O in/O the/O AMPLIFY/O Study/O ELIQUISN=2676n/O (/O %/O )/O Enoxaparin/O WarfarinN=2689n/O (/O %/O )/O Epistaxis/B-AdverseReaction 77/O (/O 2.9/O )/O 146/O (/O 5.4/O )/O Contusion/B-AdverseReaction 49/O (/O 1.8/O )/O 97/O (/O 3.6/O )/O Hematuria/B-AdverseReaction 46/O (/O 1.7/O )/O 102/O (/O 3.8/O )/O Menorrhagia/B-AdverseReaction 38/O (/O 1.4/O )/O 30/O (/O 1.1/O )/O Hematoma/B-AdverseReaction 35/O (/O 1.3/O )/O 76/O (/O 2.8/O )/O Hemoptysis/B-AdverseReaction 32/O (/O 1.2/O )/O 31/O (/O 1.2/O )/O Rectal/B-AdverseReaction hemorrhage/I-AdverseReaction 26/O (/O 1.0/O )/O 39/O (/O 1.5/O )/O Gingival/B-AdverseReaction bleeding/I-AdverseReaction 26/O (/O 1.0/O )/O 50/O (/O 1.9/O )/O AMPLIFY/O -/O EXT/O Study/O The/O mean/O duration/O of/O exposure/O to/O ELIQUIS/O was/O approximately/O 330/O days/O and/O to/O placebo/O was/O 312/O days/O in/O the/O AMPLIFY/O -/O EXT/O study/O ./O
Adverse/O reactions/O related/O to/O bleeding/B-AdverseReaction occurred/O in/O 219/O (/O 13.3/O %/O )/O ELIQUIS/O -/O treated/O patients/O compared/O to/O 72/O (/O 8.7/O %/O )/O placebo/O -/O treated/O patients/O ./O
The/O discontinuation/O rate/O due/O to/O bleeding/B-AdverseReaction events/O was/O approximately/O 1/O %/O in/O the/O ELIQUIS/O -/O treated/O patients/O compared/O to/O 0.4/O %/O in/O those/O patients/O in/O the/O placebo/O group/O in/O the/O AMPLIFY/O -/O EXT/O study/O ./O
Bleeding/B-AdverseReaction results/O from/O the/O AMPLIFY/O -/O EXT/O study/O are/O summarized/O in/O Table/O 7/O ./O
Table/O 7/O :/O Bleeding/B-AdverseReaction Results/O in/O the/O AMPLIFY/O -/O EXT/O Study/O ELIQUIS/O 2.5/O mg/O bidN=840n/O (/O %/O )/O ELIQUIS/O 5/O mg/O bidN=811n/O (/O %/O )/O PlaceboN=826n/O (/O %/O )/O CRNM/B-AdverseReaction clinically/B-AdverseReaction relevant/I-AdverseReaction nonmajor/I-AdverseReaction bleeding/I-AdverseReaction ./O
Events/O associated/O with/O each/O endpoint/O were/O counted/O once/O per/O subject/O ,/O but/O subjects/O may/O have/O contributed/O events/O to/O multiple/O endpoints/O ./O
Major/O 2/O (/O 0.2/O )/O 1/O (/O 0.1/O )/O 4/O (/O 0.5/O )/O CRNM/B-AdverseReaction 25/O (/O 3.0/O )/O 34/O (/O 4.2/O )/O 19/O (/O 2.3/O )/O Major/O +/O CRNM/B-AdverseReaction 27/O (/O 3.2/O )/O 35/O (/O 4.3/O )/O 22/O (/O 2.7/O )/O Minor/O 75/O (/O 8.9/O )/O 98/O (/O 12.1/O )/O 58/O (/O 7.0/O )/O All/O 94/O (/O 11.2/O )/O 121/O (/O 14.9/O )/O 74/O (/O 9.0/O )/O Adverse/O reactions/O occurring/O in/O 1/O %/O of/O patients/O in/O the/O AMPLIFY/O -/O EXT/O study/O are/O listed/O in/O Table/O 8/O ./O
Table/O 8/O :/O Adverse/O Reactions/O Occurring/O in/O 1/O %/O of/O Patients/O Undergoing/O Extended/O Treatment/O for/O DVT/O and/O PE/O in/O the/O AMPLIFY/O -/O EXT/O Study/O ELIQUIS/O 2.5/O mg/O bidN=840n/O (/O %/O )/O ELIQUIS/O 5/O mg/O bidN=811n/O (/O %/O )/O PlaceboN=826n/O (/O %/O )/O Epistaxis/B-AdverseReaction 13/O (/O 1.5/O )/O 29/O (/O 3.6/O )/O 9/O (/O 1.1/O )/O Hematuria/B-AdverseReaction 12/O (/O 1.4/O )/O 17/O (/O 2.1/O )/O 9/O (/O 1.1/O )/O Hematoma/B-AdverseReaction 13/O (/O 1.5/O )/O 16/O (/O 2.0/O )/O 10/O (/O 1.2/O )/O Contusion/B-AdverseReaction 18/O (/O 2.1/O )/O 18/O (/O 2.2/O )/O 18/O (/O 2.2/O )/O Gingival/B-AdverseReaction bleeding/I-AdverseReaction 12/O (/O 1.4/O )/O 9/O (/O 1.1/O )/O 3/O (/O 0.4/O )/O Other/O Adverse/O Reactions/O Less/O common/O adverse/O reactions/O in/O ELIQUIS/O -/O treated/O patients/O in/O the/O AMPLIFY/O or/O AMPLIFY/O -/O EXT/O studies/O occurring/O at/O a/O frequency/O of/O 0.1/O %/O to/O 1/O %/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O hemorrhagic/B-AdverseReaction anemia/I-AdverseReaction Gastrointestinal/O disorders/O :/O hematochezia/B-AdverseReaction ,/O hemorrhoidal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hematemesis/B-AdverseReaction ,/O melena/B-AdverseReaction ,/O anal/B-AdverseReaction hemorrhage/I-AdverseReaction Injury/O ,/O poisoning/O ,/O and/O procedural/O complications/O :/O wound/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O postprocedural/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O traumatic/B-AdverseReaction hematoma/I-AdverseReaction ,/O periorbital/B-AdverseReaction hematoma/I-AdverseReaction Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O muscle/B-AdverseReaction hemorrhage/I-AdverseReaction Reproductive/O system/O and/O breast/O disorders/O :/O vaginal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O metrorrhagia/B-AdverseReaction ,/O menometrorrhagia/B-AdverseReaction ,/O genital/B-AdverseReaction hemorrhage/I-AdverseReaction Vascular/O disorders/O :/O hemorrhage/B-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O ecchymosis/B-AdverseReaction ,/O skin/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O petechiae/B-AdverseReaction Eye/O disorders/O :/O conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O retinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O eye/B-AdverseReaction hemorrhage/I-AdverseReaction Investigations/O :/O blood/B-AdverseReaction urine/I-AdverseReaction present/I-AdverseReaction ,/O occult/B-AdverseReaction blood/I-AdverseReaction positive/I-AdverseReaction ,/O occult/B-AdverseReaction blood/I-AdverseReaction ,/O red/B-AdverseReaction blood/I-AdverseReaction cells/I-AdverseReaction urine/I-AdverseReaction positive/I-AdverseReaction General/O disorders/O and/O administration/O -/O site/O conditions/O :/O injection/B-AdverseReaction -/I-AdverseReaction site/O hematoma/O ,/O vessel/B-AdverseReaction puncture/I-AdverseReaction -/I-AdverseReaction site/O hematoma/O BOXED/O WARNING/O :/O WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O ELIQUIS/O INCREASES/O THE/O RISK/B-Factor OF/O THROMBOTIC/B-AdverseReaction EVENTS(B/I-AdverseReaction )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/I-AdverseReaction WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O ELIQUIS/O INCREASES/O THE/O RISK/B-Factor OF/O THROMBOTIC/B-AdverseReaction EVENTS(B/I-AdverseReaction )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/I-AdverseReaction (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O ELIQUIS/O INCREASES/O THE/O RISK/B-Factor OF/O THROMBOTIC/B-AdverseReaction EVENTS/I-AdverseReaction Premature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O ELIQUIS/O ,/O increases/O the/O risk/B-Factor of/O thrombotic/B-AdverseReaction events/I-AdverseReaction ./O
If/O anticoagulation/O with/O ELIQUIS/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O ,/O consider/O coverage/O with/O another/O anticoagulant/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O and/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
(/O B/O )/O SPINAL/O EPIDURAL/O HEMATOMA/O Epidural/O or/O spinal/B-AdverseReaction hematomas/I-AdverseReaction may/B-Factor occur/O in/O patients/O treated/O with/O ELIQUIS/O who/O are/O receiving/O neuraxial/O anesthesia/O or/O undergoing/O spinal/O puncture/O ./O
These/O hematomas/B-AdverseReaction may/B-Factor result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/I-AdverseReaction ./O
Consider/O these/O risks/O when/O scheduling/O patients/O for/O spinal/O procedures/O ./O
Factors/O that/O can/O increase/O the/O risk/B-Factor of/O developing/O epidural/O or/O spinal/B-AdverseReaction hematomas/I-AdverseReaction in/O these/O patients/O include/O :/O ?/O use/O of/O indwelling/O epidural/O catheters/O ?/O concomitant/O use/O of/O other/O drugs/O that/O affect/O hemostasis/O ,/O such/O as/O nonsteroidal/O anti/O -/O inflammatory/O drugs/O (/O NSAIDs/O )/O ,/O platelet/O inhibitors/O ,/O other/O anticoagulants/O ?/O a/O history/O of/O traumatic/O or/O repeated/O epidural/O or/O spinal/O punctures/O ?/O a/O history/O of/O spinal/O deformity/O or/O spinal/O surgery/O ?/O optimal/O timing/O between/O the/O administration/O of/O ELIQUIS/O and/O neuraxial/O procedures/O is/O not/O known/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Monitor/O patients/O frequently/O for/O signs/O and/O symptoms/O of/O neurological/O impairment/O ./O
If/O neurological/O compromise/O is/O noted/O ,/O urgent/O treatment/O is/O necessary/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Consider/O the/O benefits/O and/O risks/O before/O neuraxial/O intervention/O in/O patients/O anticoagulated/O or/O to/O be/O anticoagulated/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O ELIQUIS/O INCREASES/O THE/O RISK/B-Factor OF/O THROMBOTIC/B-AdverseReaction EVENTS(B/I-AdverseReaction )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
(/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O ELIQUIS/O INCREASES/O THE/O RISK/B-Factor OF/O THROMBOTIC/B-AdverseReaction EVENTS/I-AdverseReaction :/O Premature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O ELIQUIS/O ,/O increases/O the/O risk/B-Factor of/O thrombotic/B-AdverseReaction events/I-AdverseReaction ./O
To/O reduce/O this/O risk/O ,/O consider/O coverage/O with/O another/O anticoagulant/O if/O ELIQUIS/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O ./O
(/O 2.4/O ,/O 5.1/O ,/O 14.1/O )/O (/O B/O )/O SPINAL/O EPIDURAL/O HEMATOMA/O :/O Epidural/O or/O spinal/B-AdverseReaction hematomas/I-AdverseReaction may/B-Factor occur/O in/O patients/O treated/O with/O ELIQUIS/O who/O are/O receiving/O neuraxial/O anesthesia/O or/O undergoing/O spinal/O puncture/O ./O
These/O hematomas/B-AdverseReaction may/B-Factor result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/I-AdverseReaction ./O
Consider/O these/O risks/O when/O scheduling/O patients/O for/O spinal/O procedures/O ./O
(/O 5.3/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O ?/O ELIQUIS/O can/B-Factor cause/O serious/B-Severity ,/O potentially/B-Factor fatal/B-AdverseReaction bleeding/B-AdverseReaction ./O
Promptly/O evaluate/O signs/O and/O symptoms/O of/O blood/O loss.(5.2/O )/O ?/O Prosthetic/O heart/O valves/O :/O ELIQUIS/O use/O not/O recommended.(5.4/O )/O 5.1/O Increased/O Risk/O of/O Thrombotic/O Events/O after/O Premature/O Discontinuation/O Premature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O ELIQUIS/O ,/O in/O the/O absence/O of/O adequate/O alternative/O anticoagulation/O increases/O the/O risk/B-Factor of/O thrombotic/B-AdverseReaction events/I-AdverseReaction ./O
An/O increased/O rate/O of/O stroke/B-AdverseReaction was/O observed/O during/O the/O transition/O from/O ELIQUIS/O to/O warfarin/O in/O clinical/O trials/O in/O atrial/O fibrillation/O patients/O ./O
If/O ELIQUIS/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O ,/O consider/O coverage/O with/O another/O anticoagulant/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O andClinical/O Studies/O (/O 14.1/O )/O ]/O ./O
5.2/O Bleeding/O ELIQUIS/O increases/O the/O risk/B-Factor of/O bleeding/B-AdverseReaction and/O can/B-Factor cause/O serious/B-Severity ,/O potentially/B-Factor fatal/B-AdverseReaction ,/O bleeding/B-AdverseReaction [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O andAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Concomitant/O use/O of/O drugs/O affecting/O hemostasis/O increases/O the/O risk/B-Factor of/O bleeding/B-AdverseReaction ./O
These/O include/O aspirin/O and/O other/O antiplatelet/O agents/O ,/O other/O anticoagulants/O ,/O heparin/O ,/O thrombolytic/O agents/O ,/O selective/O serotonin/O reuptake/O inhibitors/O ,/O serotonin/O norepinephrine/O reuptake/O inhibitors/O ,/O and/O nonsteroidal/O anti/O -/O inflammatory/O drugs/O (/O NSAIDs/O )/O [/O seeDrug/O Interactions/O (/O 7.3/O )/O ]/O ./O
Advise/O patients/O of/O signs/O and/O symptoms/O of/O blood/O loss/O and/O to/O report/O them/O immediately/O or/O go/O to/O an/O emergency/O room/O ./O
Discontinue/O ELIQUIS/O in/O patients/O with/O active/O pathological/O hemorrhage/O ./O
There/O is/O no/O established/O way/O to/O reverse/O the/O anticoagulant/O effect/O of/O apixaban/O ,/O which/O can/O be/O expected/O to/O persist/O for/O at/O least/O 24/O hours/O after/O the/O last/O dose/O ,/O i.e./O ,/O for/O about/O two/O drug/O half/O -/O lives/O ./O
A/O specific/O antidote/O for/O ELIQUIS/O is/O not/O available/O ./O
Hemodialysis/O does/O not/O appear/O to/O have/O a/O substantial/O impact/O on/O apixaban/O exposure/O [/O seeClinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Protamine/O sulfate/O and/O vitamin/O K/O are/O not/O expected/O to/O affect/O the/O anticoagulant/O activity/O of/O apixaban/O ./O
There/O is/O no/O experience/O with/O antifibrinolytic/O agents/O (/O tranexamic/O acid/O ,/O aminocaproic/O acid/O )/O in/O individuals/O receiving/O apixaban/O ./O
There/O is/O neither/O scientific/O rationale/O for/O reversal/O nor/O experience/O with/O systemic/O hemostatics/O (/O desmopressin/O and/O aprotinin/O )/O in/O individuals/O receiving/O apixaban/O ./O
Use/O of/O procoagulant/O reversal/O agents/O such/O as/O prothrombin/O complex/O concentrate/O ,/O activated/O prothrombin/O complex/O concentrate/O ,/O or/O recombinant/O factor/O VIIa/O may/O be/O considered/O but/O has/O not/O been/O evaluated/O in/O clinical/O studies/O ./O
Activated/O oral/O charcoal/O reduces/O absorption/O of/O apixaban/O ,/O thereby/O lowering/O apixaban/O plasma/O concentration/O [/O seeOverdosage/O (/O 10/O )/O ]/O ./O
5.3/O Spinal/O Epidural/O Anesthesia/O or/O Puncture/O When/O neuraxial/O anesthesia/O (/O spinal/O epidural/O anesthesia/O )/O or/O spinal/O epidural/O puncture/O is/O employed/O ,/O patients/O treated/O with/O antithrombotic/O agents/O for/O prevention/O of/O thromboembolic/O complications/O are/O at/O risk/B-Factor of/O developing/O an/O epidural/O or/O spinal/B-AdverseReaction hematoma/I-AdverseReaction which/O can/B-Factor result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/I-AdverseReaction ./O
The/O risk/O of/O these/O events/O may/O be/O increased/O by/O the/O postoperative/O use/O of/O indwelling/O epidural/O catheters/O or/O the/O concomitant/O use/O of/O medicinal/O products/O affecting/O hemostasis/O ./O
Indwelling/O epidural/O or/O intrathecal/O catheters/O should/O not/O be/O removed/O earlier/O than/O 24/O hours/O after/O the/O last/O administration/O of/O ELIQUIS/O ./O
The/O next/O dose/O of/O ELIQUIS/O should/O not/O be/O administered/O earlier/O than/O 5/O hours/O after/O the/O removal/O of/O the/O catheter/O ./O
The/O risk/O may/O also/O be/O increased/O by/O traumatic/O or/O repeated/O epidural/O or/O spinal/O puncture/O ./O
If/O traumatic/O puncture/O occurs/O ,/O delay/O the/O administration/O of/O ELIQUIS/O for/O 48/O hours/O ./O
Monitor/O patients/O frequently/O for/O signs/O and/O symptoms/O of/O neurological/O impairment/O (/O e.g./O ,/O numbness/O or/O weakness/O of/O the/O legs/O ,/O bowel/O ,/O or/O bladder/O dysfunction/O )/O ./O
If/O neurological/O compromise/O is/O noted/O ,/O urgent/O diagnosis/O and/O treatment/O is/O necessary/O ./O
Prior/O to/O neuraxial/O intervention/O the/O physician/O should/O consider/O the/O potential/O benefit/O versus/O the/O risk/O in/O anticoagulated/O patients/O or/O in/O patients/O to/O be/O anticoagulated/O for/O thromboprophylaxis/O ./O
5.4/O Patients/O with/O Prosthetic/O Heart/O Valves/O The/O safety/O and/O efficacy/O of/O ELIQUIS/O have/O not/O been/O studied/O in/O patients/O with/O prosthetic/O heart/O valves/O ./O
Therefore/O ,/O use/O of/O ELIQUIS/O is/O not/O recommended/O in/O these/O patients/O ./O
5.5/O Acute/O PE/O in/O Hemodynamically/O Unstable/O Patients/O or/O Patients/O who/O Require/O Thrombolysis/O or/O Pulmonary/O Embolectomy/O Initiation/O of/O ELIQUIS/O is/O not/O recommended/O as/O an/O alternative/O to/O unfractionated/O heparin/O for/O the/O initial/O treatment/O of/O patients/O with/O PE/O who/O present/O with/O hemodynamic/O instability/O or/O who/O may/O receive/O thrombolysis/O or/O pulmonary/O embolectomy/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Commonly/O observed/O adverse/O reactions/O (/O incidence/O 5/O %/O and/O 2-fold/O greater/O than/O placebo/O )/O were/O :/O dizziness/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O and/O weight/B-AdverseReaction increased/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trial/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O information/O below/O is/O derived/O from/O a/O clinical/O trial/O database/O for/O FANAPT/O consisting/O of/O 2070/O patients/O exposed/O to/O FANAPT/O at/O doses/O of/O 10/O mg/O day/O or/O greater/O ,/O for/O the/O treatment/O of/O schizophrenia/O ./O
Of/O these/O ,/O 806/O received/O FANAPT/O for/O at/O least/O 6/O months/O ,/O with/O 463/O exposed/O to/O FANAPT/O for/O at/O least/O 12/O months/O ./O
All/O of/O these/O patients/O who/O received/O FANAPT/O were/O participating/O in/O multiple/O -/O dose/O clinical/O trials/O ./O
The/O conditions/O and/O duration/O of/O treatment/O with/O FANAPT/O varied/O greatly/O and/O included/O (/O in/O overlapping/O categories/O )/O ,/O open/O -/O label/O and/O double/O -/O blind/O phases/O of/O studies/O ,/O inpatients/O and/O outpatients/O ,/O fixed/O -/O dose/O and/O flexible/O -/O dose/O studies/O ,/O and/O short/O -/O term/O and/O longer/O -/O term/O exposure/O ./O
Adverse/O reactions/O during/O exposure/O were/O obtained/O by/O general/O inquiry/O and/O recorded/O by/O clinical/O investigators/O using/O their/O own/O terminology/O ./O
Consequently/O ,/O to/O provide/O a/O meaningful/O estimate/O of/O the/O proportion/O of/O individuals/O experiencing/O adverse/O reactions/O ,/O reactions/O were/O grouped/O in/O standardized/O categories/O using/O MedDRA/O terminology/O ./O
The/O stated/O frequencies/O of/O adverse/O reactions/O represent/O the/O proportions/O of/O individuals/O who/O experienced/O a/O treatment/O -/O emergent/O adverse/O reaction/O of/O the/O type/O listed/O ./O
A/O reaction/O was/O considered/O treatment/O -/O emergent/O if/O it/O occurred/O for/O the/O first/O time/O or/O worsened/O while/O receiving/O therapy/O following/O baseline/O evaluation/O ./O
The/O information/O presented/O in/O these/O sections/O was/O derived/O from/O pooled/O data/O from/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O in/O patients/O who/O received/O FANAPT/O at/O daily/O doses/O within/O a/O range/O of/O 10/O to/O 24/O mg/O (/O n=874/O )/O ./O
Adverse/O Reactions/O Occurring/O at/O an/O Incidence/O of/O 2/O %/O or/O More/O among/O FANAPT/O -Treated/O Patients/O and/O More/O Frequent/O than/O Placebo/O Table/O 7/O enumerates/O the/O pooled/O incidences/O of/O treatment/O -/O emergent/O adverse/O reactions/O that/O were/O spontaneously/O reported/O in/O four/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O ,/O listing/O those/O reactions/O that/O occurred/O in/O 2/O %/O or/O more/O of/O patients/O treated/O with/O FANAPT/O in/O any/O of/O the/O dose/O groups/O ,/O and/O for/O which/O the/O incidence/O in/O FANAPT/O -/O treated/O patients/O in/O any/O dose/O group/O was/O greater/O than/O the/O incidence/O in/O patients/O treated/O with/O placebo/O ./O
Table/O 7/O :/O Percentage/O of/O Treatment/O -/O Emergent/O Adverse/O Reactions/O in/O Short/O -/O Term/O ,/O Fixed-/O or/O Flexible/O -/O Dose/O ,/O Placebo/O -/O Controlled/O Trials/O in/O Adult/O Patients/O Body/O System/O or/O Organ/O Class/O Placebo(%/O )/O FANAPT/O 10/O -/O 16/O mg/O day(%/O )/O FANAPT/O 20/O -/O 24/O mg/O day(%/O )/O Dictionary/O -/O derived/O Term/O (/O N=587/O )/O (/O N=483/O )/O (/O N=391/O )/O Body/O as/O a/O Whole/O Arthralgia/B-AdverseReaction 2/O 3/O 3/O Fatigue/B-AdverseReaction 3/O 4/O 6/O Musculoskeletal/B-AdverseReaction Stiffness/I-AdverseReaction 1/O 1/O 3/O Weight/B-AdverseReaction Increased/I-AdverseReaction 1/O 1/O 9/O Cardiac/O Disorders/O Tachycardia/B-AdverseReaction 1/O 3/O 12/O Eye/O Disorders/O Vision/B-AdverseReaction Blurred/I-AdverseReaction 2/O 3/O 1/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 8/O 7/O 10/O Dry/B-AdverseReaction Mouth/I-AdverseReaction 1/O 8/O 10/O Diarrhea/B-AdverseReaction 4/O 5/O 7/O Abdominal/B-AdverseReaction Discomfort/I-AdverseReaction 1/O 1/O 3/O Infections/O Nasopharyngitis/B-AdverseReaction 3/O 4/O 3/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 1/O 2/O 3/O Nervous/O System/O Disorders/O Dizziness/B-AdverseReaction 7/O 10/O 20/O Somnolence/B-AdverseReaction 5/O 9/O 15/O Extrapyramidal/B-AdverseReaction Disorder/I-AdverseReaction 4/O 5/O 4/O Tremor/B-AdverseReaction 2/O 3/O 3/O Lethargy/B-AdverseReaction 1/O 3/O 1/O Reproductive/O System/O Ejaculation/B-AdverseReaction Failure/I-AdverseReaction 1/O 2/O 2/O Respiratory/O Nasal/B-AdverseReaction Congestion/I-AdverseReaction 2/O 5/O 8/O Dyspnea/B-AdverseReaction 1/O 2/O 2/O Skin/O Rash/B-AdverseReaction 2/O 3/O 2/O Vascular/O Disorders/O Orthostatic/B-AdverseReaction Hypotension/I-AdverseReaction 1/O 3/O 5/O Hypotension/B-AdverseReaction 1/O 1/O 3/O Table/O includes/O adverse/O reactions/O that/O were/O reported/O in/O 2/O %/O or/O more/O of/O patients/O in/O any/O of/O the/O FANAPT/O dose/O groups/O and/O which/O occurred/O at/O greater/O incidence/O than/O in/O the/O placebo/O -/O group/O ./O
Figures/O rounded/O to/O the/O nearest/O integer/O ./O
Dose/O -/O Related/O Adverse/O Reactions/O in/O Clinical/O Trials/O Based/O on/O the/O pooled/O data/O from/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O ,/O adverse/O reactions/O that/O occurred/O with/O a/O greater/O than/O 2/O %/O incidence/O in/O the/O patients/O treated/O with/O FANAPT/O ,/O and/O for/O which/O the/O incidence/O in/O patients/O treated/O with/O FANAPT/O 20/O to/O 24/O mg/O day/O were/O twice/O than/O the/O incidence/O in/O patients/O treated/O with/O FANAPT/O 10/O to/O 16/O mg/O day/O were/O :/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction stiffness/I-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O and/O weight/B-AdverseReaction increased/I-AdverseReaction ./O
Common/O and/O Drug/O -/O Related/O Adverse/O Reactions/O in/O Clinical/O Trials/O Based/O on/O the/O pooled/O data/O from/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O ,/O the/O following/O adverse/O reactions/O occurred/O in/O 5/O %/O incidence/O in/O the/O patients/O treated/O with/O FANAPT/O and/O at/O least/O twice/O the/O placebo/O rate/O for/O at/O least/O 1/O dose/O :/O dizziness/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O and/O weight/B-AdverseReaction increased/I-AdverseReaction ./O
Dizziness/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O and/O weight/B-AdverseReaction increased/I-AdverseReaction were/O at/O least/O twice/O as/O common/O on/O 20/O to/O 24/O mg/O day/O as/O on/O 10/O to/O 16/O mg/O day/O ./O
Extrapyramidal/O Symptoms/O (/O EPS/O )/O in/O Clinical/O Trials/O Pooled/O data/O from/O the/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O provided/O information/O regarding/O treatment/O -/O emergent/O EPS/B-AdverseReaction ./O
Adverse/O event/O data/O collected/O from/O those/O trials/O showed/O the/O following/O rates/O of/O EPS/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O events/O as/O shown/O in/O Table/O 8/O ./O
Table/O 8/O :/O Percentage/O of/O EPS/B-AdverseReaction Compared/O to/O Placebo/O Placebo(%/O )/O FANAPT/O 10/O -/O 16/O mg/O day(%/O )/O FANAPT/O 20/O -/O 24/O mg/O day(%/O )/O Adverse/O Event/O Term/O (/O N=587/O )/O (/O N=483/O )/O (/O N=391/O )/O All/O EPS/O events/O 11.6/O 13.5/O 15.1/O Akathisia/B-AdverseReaction 2.7/O 1.7/O 2.3/O Bradykinesia/B-AdverseReaction 0/O 0.6/O 0.5/O Dyskinesia/B-AdverseReaction 1.5/O 1.7/O 1.0/O Dystonia/B-AdverseReaction 0.7/O 1.0/O 0.8/O Parkinsonism/B-AdverseReaction 0/O 0.2/O 0.3/O Tremor/B-AdverseReaction 1.9/O 2.5/O 3.1/O Adverse/O Reactions/O Associated/O with/O Discontinuation/O of/O Treatment/O in/O Clinical/O Trials/O Based/O on/O the/O pooled/O data/O from/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O ,/O there/O was/O no/O difference/O in/O the/O incidence/O of/O discontinuation/O due/O to/O adverse/O events/O between/O FANAPT/O -/O treated/O (/O 5/O %/O )/O and/O placebo/O -/O treated/O (/O 5/O %/O )/O patients/O ./O
The/O types/O of/O adverse/O events/O that/O led/O to/O discontinuation/O were/O similar/O for/O the/O FANAPT-/O and/O placebo/O -/O treated/O patients/O ./O
Demographic/O Differences/O in/O Adverse/O Reactions/O in/O Clinical/O Trials/O An/O examination/O of/O population/O subgroups/O in/O the/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O did/O not/O reveal/O any/O evidence/O of/O differences/O in/O safety/O on/O the/O basis/O of/O age/O ,/O gender/O or/O race/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Laboratory/O Test/O Abnormalities/O in/O Clinical/O Trials/O There/O were/O no/O differences/O between/O FANAPT/O and/O placebo/O in/O the/O incidence/O of/O discontinuation/O due/O to/O changes/O in/O hematology/O ,/O urinalysis/O ,/O or/O serum/O chemistry/O ./O
In/O short/O -/O term/O placebo/O -/O controlled/O trials/O (/O 4-/O to/O 6-weeks/O )/O ,/O there/O were/O 1.0/O %/O (/O 13/1342/O )/O iloperidone/O -/O treated/O patients/O with/O hematocrit/O at/O least/O one/O time/O below/O the/O extended/O normal/O range/O during/O post/O -/O randomization/O treatment/O ,/O compared/O to/O 0.3/O %/O (/O 2/585/O )/O on/O placebo/O ./O
The/O extended/O normal/O range/O for/O lowered/O hematocrit/O was/O defined/O in/O each/O of/O these/O trials/O as/O the/O value/O 15/O %/O below/O the/O normal/O range/O for/O the/O centralized/O laboratory/O that/O was/O used/O in/O the/O trial/O ./O
Other/O Reactions/O During/O the/O Premarketing/O Evaluation/O of/O FANAPT/O The/O following/O is/O a/O list/O of/O MedDRA/O terms/O that/O reflect/O treatment/O -/O emergent/O adverse/O reactions/O in/O patients/O treated/O with/O FANAPT/O at/O multiple/O doses/O 4/O mg/O day/O during/O any/O phase/O of/O a/O trial/O with/O the/O database/O of/O 3210/O FANAPT/O -/O treated/O patients/O ./O
All/O reported/O reactions/O are/O included/O except/O those/O already/O listed/O in/O Table/O 7/O ,/O or/O other/O parts/O of/O the/O Adverse/O Reactions/O (/O 6/O )/O section/O ,/O those/O considered/O in/O the/O Warnings/O and/O Precautions/O (/O 5/O )/O ,/O those/O reaction/O terms/O which/O were/O so/O general/O as/O to/O be/O uninformative/O ,/O reactions/O reported/O in/O fewer/O than/O 3/O patients/O and/O which/O were/O neither/O serious/O nor/O life/O -/O threatening/O ,/O reactions/O that/O are/O otherwise/O common/O as/O background/O reactions/O ,/O and/O reactions/O considered/O unlikely/O to/O be/O drug/O related/O ./O
It/O is/O important/O to/O emphasize/O that/O ,/O although/O the/O reactions/O reported/O occurred/O during/O treatment/O with/O FANAPT/O ,/O they/O were/O not/O necessarily/O caused/O by/O it/O ./O
Reactions/O are/O further/O categorized/O by/O MedDRA/O system/O organ/O class/O and/O listed/O in/O order/O of/O decreasing/O frequency/O according/O to/O the/O following/O definitions/O :/O frequent/O adverse/O events/O are/O those/O occurring/O in/O at/O least/O 1/100/O patients/O (/O only/O those/O not/O listed/O in/O Table/O 7/O appear/O in/O this/O listing/O )/O ;/O infrequent/O adverse/O reactions/O are/O those/O occurring/O in/O 1/100/O to/O 1/1000/O patients/O ;/O rare/O events/O are/O those/O occurring/O in/O fewer/O than/O 1/1000/O patients/O ./O
Blood/O and/O Lymphatic/O Disorders/O :/O Infrequent/O -/O anemia/B-AdverseReaction ,/O iron/B-AdverseReaction deficiency/I-AdverseReaction anemia/I-AdverseReaction ;/O Rare/O -/O leukopenia/B-AdverseReaction Cardiac/O Disorders/O :/O Frequent/O -/O palpitations/B-AdverseReaction ;/O Rare/O -/O arrhythmia/B-AdverseReaction ,/O atrioventricular/B-AdverseReaction block/I-AdverseReaction first/B-Severity degree/I-Severity ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction (/O including/O congestive/O and/O acute/O )/O Ear/O and/O Labyrinth/O Disorders/O :/O Infrequent/O -/O vertigo/B-AdverseReaction ,/O tinnitus/B-AdverseReaction Endocrine/O Disorders/O :/O Infrequent/O -/O hypothyroidism/B-AdverseReaction Eye/O Disorders/O :/O Frequent/O -/O conjunctivitis/B-AdverseReaction (/O including/O allergic/O )/O ;/O Infrequent/O -/O dry/B-AdverseReaction eye/I-AdverseReaction ,/O blepharitis/B-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eye/B-AdverseReaction swelling/I-AdverseReaction ,/O lenticular/B-AdverseReaction opacities/I-AdverseReaction ,/O cataract/B-AdverseReaction ,/O hyperemia/B-AdverseReaction (/O including/O conjunctival/O )/O Gastrointestinal/O Disorders/O :/O Infrequent/O -/O gastritis/B-AdverseReaction ,/O salivary/B-AdverseReaction hypersecretion/I-AdverseReaction ,/O fecal/B-AdverseReaction incontinence/I-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ;/O Rare/O -/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction ,/O duodenal/B-AdverseReaction ulcer/I-AdverseReaction ,/O hiatus/B-AdverseReaction hernia/I-AdverseReaction ,/O hyperchlorhydria/B-AdverseReaction ,/O lip/B-AdverseReaction ulceration/I-AdverseReaction ,/O reflux/B-AdverseReaction esophagitis/I-AdverseReaction ,/O stomatitis/B-AdverseReaction General/O Disorders/O and/O Administrative/O Site/O Conditions/O :/O Infrequent/O -/O edema/B-AdverseReaction (/O general/O ,/O pitting/O ,/O due/O to/O cardiac/O disease/O )/O ,/O difficulty/B-AdverseReaction in/I-AdverseReaction walking/I-AdverseReaction ,/O thirst/B-AdverseReaction ;/O Rare/O -/O hyperthermia/B-AdverseReaction Hepatobiliary/O Disorders/O :/O Infrequent/O -/O cholelithiasis/B-AdverseReaction Investigations/O :/O Frequent/O -/O weight/B-AdverseReaction decreased/I-AdverseReaction ;/O Infrequent/O -/O hemoglobin/B-AdverseReaction decreased/I-AdverseReaction ,/O neutrophil/B-AdverseReaction count/I-AdverseReaction increased/I-AdverseReaction ,/O hematocrit/B-AdverseReaction decreased/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O Infrequent/O -/O increased/B-AdverseReaction appetite/I-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O fluid/B-AdverseReaction retention/I-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O Frequent/O -/O myalgia/B-AdverseReaction ,/O muscle/B-AdverseReaction spasms/I-AdverseReaction ;/O Rare/O -/O torticollis/B-AdverseReaction Nervous/O System/O Disorders/O :/O Infrequent/O -/O paresthesia/B-AdverseReaction ,/O psychomotor/B-AdverseReaction hyperactivity/I-AdverseReaction ,/O restlessness/B-AdverseReaction ,/O amnesia/B-AdverseReaction ,/O nystagmus/B-AdverseReaction ;/O Rare/O -/O restless/B-AdverseReaction legs/I-AdverseReaction syndrome/I-AdverseReaction Psychiatric/O Disorders/O :/O Frequent/O -/O restlessness/B-AdverseReaction ,/O aggression/B-AdverseReaction ,/O delusion/B-AdverseReaction ;/O Infrequent/O -/O hostility/B-AdverseReaction ,/O libido/B-AdverseReaction decreased/I-AdverseReaction ,/O paranoia/B-AdverseReaction ,/O anorgasmia/B-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O mania/B-AdverseReaction ,/O catatonia/B-AdverseReaction ,/O mood/B-AdverseReaction swings/I-AdverseReaction ,/O panic/B-AdverseReaction attack/I-AdverseReaction ,/O obsessive/B-AdverseReaction -/I-AdverseReaction compulsive/O disorder/O ,/O bulimia/B-AdverseReaction nervosa/I-AdverseReaction ,/O delirium/B-AdverseReaction ,/O polydipsia/B-AdverseReaction psychogenic/I-AdverseReaction ,/O impulse/B-AdverseReaction -/I-AdverseReaction control/O disorder/O ,/O major/B-AdverseReaction depression/I-AdverseReaction Renal/O and/O Urinary/O Disorders/O :/O Frequent/O -/O urinary/B-AdverseReaction incontinence/I-AdverseReaction ;/O Infrequent/O -/O dysuria/B-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O enuresis/B-AdverseReaction ,/O nephrolithiasis/B-AdverseReaction ;/O Rare/O -/O urinary/B-AdverseReaction retention/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction acute/I-AdverseReaction Reproductive/O System/O and/O Breast/O Disorders/O :/O Frequent/O -/O erectile/B-AdverseReaction dysfunction/I-AdverseReaction ;/O Infrequent/O -/O testicular/B-AdverseReaction pain/I-AdverseReaction ,/O amenorrhea/B-AdverseReaction ,/O breast/B-AdverseReaction pain/I-AdverseReaction ;/O Rare/O -/O menstruation/B-AdverseReaction irregular/I-AdverseReaction ,/O gynecomastia/B-AdverseReaction ,/O menorrhagia/B-AdverseReaction ,/O metrorrhagia/B-AdverseReaction ,/O postmenopausal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O prostatitis/B-AdverseReaction ./O
Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O Infrequent/O -/O epistaxis/B-AdverseReaction ,/O asthma/B-AdverseReaction ,/O rhinorrhea/B-AdverseReaction ,/O sinus/B-AdverseReaction congestion/I-AdverseReaction ,/O nasal/B-AdverseReaction dryness/I-AdverseReaction ;/O Rare/O -/O dry/B-AdverseReaction throat/I-AdverseReaction ,/O sleep/B-AdverseReaction apnea/I-AdverseReaction syndrome/I-AdverseReaction ,/O dyspnea/B-AdverseReaction exertional/I-AdverseReaction 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O FANAPT/O :/O retrograde/B-AdverseReaction ejaculation/I-AdverseReaction ./O
Because/O these/O reactions/O were/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O INCREASED/O MORTALITY/B-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O WARNING/O :/O INCREASED/O MORTALITY/B-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction ./O
Analysis/O of/O seventeen/O placebo/O -/O controlled/O trials/O (/O modal/O duration/O 10/O weeks/O )/O ,/O largely/O in/O patients/O taking/O atypical/O antipsychotic/O drugs/O ,/O revealed/O a/O risk/B-Factor of/O death/B-AdverseReaction in/O the/O drug/O -/O treated/O patients/O of/O between/O 1.6/O to/O 1.7/O times/O the/O risk/O of/O death/O in/O placebo/O -/O treated/O patients/O ./O
Over/O the/O course/O of/O a/O typical/O 10-week/O controlled/O trial/O ,/O the/O rate/O of/O death/B-AdverseReaction in/O drug/O -/O treated/O patients/O was/O about/O 4.5/O %/O ,/O compared/O to/O a/O rate/O of/O about/O 2.6/O %/O in/O the/O placebo/O group/O ./O
Although/O the/O causes/O of/O death/B-AdverseReaction were/O varied/O ,/O most/O of/O the/O deaths/B-AdverseReaction appeared/O to/O be/O either/O cardiovascular/O (/O e.g./O ,/O heart/B-AdverseReaction failure/I-AdverseReaction ,/O sudden/B-AdverseReaction death/I-AdverseReaction )/O or/O infectious/O (/O e.g./O ,/O pneumonia/B-AdverseReaction )/O in/O nature/O ./O
Observational/O studies/O suggest/O that/O ,/O similar/O to/O atypical/O antipsychotic/O drugs/O ,/O treatment/O with/O conventional/O antipsychotic/O drugs/O may/O increase/O mortality/O ./O
The/O extent/O to/O which/O the/O findings/O of/O increased/O mortality/O in/O observational/O studies/O may/O be/O attributed/O to/O the/O antipsychotic/O drug/O as/O opposed/O to/O some/O characteristic(s/O )/O of/O the/O patients/O is/O not/O clear/O ./O
FANAPT/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O Dementia/O -/O Related/O Psychosis/O ./O
[/O See/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O EXCERPT/O :/O WARNING/O :/O INCREASED/O MORTALITY/B-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction ./O
FANAPT/O is/O not/O approved/O for/O use/O in/O patients/O with/O dementia/O -/O related/O psychosis/O ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O who/O are/O treated/O with/O atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction and/O cerebrovascular/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O events/O ,/O including/O stroke/B-AdverseReaction ./O
(/O 5.1/O )/O QT/B-AdverseReaction prolongation/I-AdverseReaction :/O Prolongs/B-AdverseReaction QT/I-AdverseReaction interval/I-AdverseReaction and/O may/B-Factor be/O associated/O with/O arrhythmia/B-AdverseReaction and/O sudden/B-AdverseReaction death/I-AdverseReaction -/O consider/O using/O other/O antipsychotics/O first/O ./O
Avoid/O use/O of/O FANAPT/O in/O combination/O with/O other/O drugs/O that/O are/O known/O to/O prolong/O QTc/O ;/O use/O caution/O and/O consider/O dose/O modification/O when/O prescribing/O FANAPT/O with/O other/O drugs/O that/O inhibit/O FANAPT/O metabolism/O ./O
Monitor/O serum/O potassium/O and/O magnesium/O in/O patients/O at/O risk/O for/O electrolyte/O disturbances/O ./O
(/O 1/O ,/O 5.2/O ,/O 7.1/O ,/O 7.3/O ,/O 12.3/O )/O Neuroleptic/B-AdverseReaction Malignant/I-AdverseReaction Syndrome/I-AdverseReaction :/O Manage/O with/O immediate/O discontinuation/O of/O drug/O and/O close/O monitoring/O ./O
(/O 5.3/O )/O Tardive/B-AdverseReaction dyskinesia/I-AdverseReaction :/O Discontinue/O if/O clinically/O appropriate/O ./O
(/O 5.4/O )/O Hyperglycemia/B-AdverseReaction and/O diabetes/B-AdverseReaction mellitus/I-AdverseReaction :/O Monitor/O patients/O for/O symptoms/O of/O hyperglycemia/O including/O polydipsia/O ,/O polyuria/O ,/O polyphagia/O ,/O and/O weakness/O ./O
Monitor/O glucose/O regularly/O in/O patients/O at/O risk/O for/O diabetes/O ./O
(/O 5.5/O )/O Dyslipidemia/B-AdverseReaction :/O Undesirable/O alterations/O have/O been/O observed/O in/O patients/O treated/O with/O atypical/O antipsychotics/O ./O
(/O 5.5/O )/O Weight/B-AdverseReaction Gain/I-AdverseReaction :/O Weight/O gain/O has/O been/O reported/O ./O
Monitor/O weight/O ./O
(/O 5.5/O )/O Metabolic/B-AdverseReaction Changes/I-AdverseReaction :/O Atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass have/O been/O associated/O with/O metabolic/O changes/O that/O may/O increase/O cardiovascular/O cerebrovascular/B-AdverseReaction risk/I-AdverseReaction ./O
These/O metabolic/B-AdverseReaction changes/I-AdverseReaction include/O hyperglycemia/B-AdverseReaction ,/O dyslipidemia/B-AdverseReaction ,/O and/O weight/B-AdverseReaction gain/I-AdverseReaction ./O
(/O 5.5/O )/O Seizures/B-AdverseReaction :/O Use/O cautiously/O in/O patients/O with/O a/O history/O of/O seizures/O or/O with/O conditions/O that/O lower/O seizure/O threshold/O ./O
(/O 5.6/O )/O Orthostatic/B-AdverseReaction hypotension/I-AdverseReaction :/O Dizziness/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O and/O syncope/B-AdverseReaction can/B-Factor occur/O with/O standing/O ./O
(/O 5.7/O )/O Leukopenia/B-AdverseReaction ,/O Neutropenia/B-AdverseReaction ,/O and/O Agranulocytosis/B-AdverseReaction have/O been/O reported/O with/O antipsychotics/B-DrugClass ./O
Patients/O with/O a/O pre/O -/O existing/O low/O white/O blood/O cell/O count/O (/O WBC/O )/O or/O a/O history/O of/O leukopenia/O neutropenia/O should/O have/O their/O complete/O blood/O count/O (/O CBC/O )/O monitored/O frequently/O during/O the/O first/O few/O months/O of/O therapy/O and/O should/O discontinue/O FANAPT/O at/O the/O first/O sign/O of/O a/O decline/O in/O WBC/O in/O the/O absence/O of/O other/O causative/O factors/O ./O
(/O 5.8/O )/O Suicide/B-AdverseReaction :/O Close/O supervision/O of/O high/O risk/O patients/O ./O
(/O 5.12/O )/O Priapism/B-AdverseReaction :/O Cases/O have/O been/O reported/O in/O association/O with/O FANAPT/O treatment/O ./O
(/O 5.13/O )/O Potential/B-Factor for/O cognitive/O and/O motor/B-AdverseReaction impairment/I-AdverseReaction :/O Use/O caution/O when/O operating/O machinery/O ./O
(/O 5.14/O )/O See/O Full/O Prescribing/O Information/O for/O additional/O WARNINGS/O and/O PRECAUTIONS/O ./O
5.1/O Increased/O Risks/O in/O Elderly/O Patients/O with/O Dementia/O -/O Related/O Psychosis/O Increased/O Mortality/O Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction compared/O to/O placebo/O ./O
FANAPT/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O [/O s/O ee/O Boxed/O Warning/O ]/O ./O
Cerebrovascular/O Adverse/O Events/O ,/O Including/O Stroke/O In/O placebo/O -/O controlled/O trials/O with/O risperidone/O ,/O aripiprazole/O ,/O and/O olanzapine/O in/O elderly/O patients/O with/O dementia/O ,/O there/O was/O a/O higher/O incidence/O of/O cerebrovascular/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O cerebrovascular/B-AdverseReaction accidents/I-AdverseReaction and/O transient/B-AdverseReaction ischemic/I-AdverseReaction attacks/I-AdverseReaction )/O including/O fatalities/B-AdverseReaction compared/O to/O placebo/O -/O treated/O patients/O ./O
FANAPT/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O [/O s/O ee/O Boxed/O Warning/O ]/O ./O
5.2/O QT/O Prolongation/O In/O an/O open/O -/O label/O QTc/O study/O in/O patients/O with/O schizophrenia/O or/O schizoaffective/O disorder/O (/O n=160/O )/O ,/O FANAPT/O was/O associated/O with/O QTc/B-AdverseReaction prolongation/I-AdverseReaction of/O 9/O msec/O at/O an/O iloperidone/O dose/O of/O 12/O mg/O twice/O daily/O ./O
The/O effect/O of/O FANAPT/O on/O the/O QT/O interval/O was/O augmented/O by/O the/O presence/O of/O CYP450/O 2D6/O or/O 3A4/O metabolic/O inhibition/O (/O paroxetine/O 20/O mg/O once/O daily/O and/O ketoconazole/O 200/O mg/O twice/O daily/O ,/O respectively/O )/O ./O
Under/O conditions/O of/O metabolic/O inhibition/O for/O both/O 2D6/O and/O 3A4/O ,/O FANAPT/O 12/O mg/O twice/O daily/O was/O associated/O with/O a/O mean/O QTcF/B-AdverseReaction increase/I-AdverseReaction from/O baseline/O of/O about/O 19/O msec/O ./O
No/B-Negation cases/O of/O torsade/B-AdverseReaction de/I-AdverseReaction pointes/I-AdverseReaction or/O other/O severe/B-Severity cardiac/B-AdverseReaction arrhythmias/I-AdverseReaction were/O observed/O during/O the/O pre/O -/O marketing/O clinical/O program/O ./O
The/O use/O of/O FANAPT/O should/O be/O avoided/O in/O combination/O with/O other/O drugs/O that/O are/O known/O to/O prolong/O QTc/O including/O Class/O 1A/O (/O e.g./O ,/O quinidine/O ,/O procainamide/O )/O or/O Class/O III/O (/O e.g./O ,/O amiodarone/O ,/O sotalol/O )/O antiarrhythmic/O medications/O ,/O antipsychotic/O medications/O (/O e.g./O ,/O chlorpromazine/O ,/O thioridazine/O )/O ,/O antibiotics/O (/O e.g./O ,/O gatifloxacin/O ,/O moxifloxacin/O )/O ,/O or/O any/O other/O class/O of/O medications/O known/O to/O prolong/O the/O QTc/O interval/O (/O e.g./O ,/O pentamidine/O ,/O levomethadyl/O acetate/O ,/O methadone/O )/O ./O
FANAPT/O should/O also/O be/O avoided/O in/O patients/O with/O congenital/O long/O QT/O syndrome/O and/O in/O patients/O with/O a/O history/O of/O cardiac/O arrhythmias/O ./O
Certain/O circumstances/O may/O increase/O the/O risk/O of/O torsade/O de/O pointes/O and/or/O sudden/O death/O in/O association/O with/O the/O use/O of/O drugs/O that/O prolong/O the/O QTc/O interval/O ,/O including/O (/O 1/O )/O bradycardia/O ;/O (/O 2/O )/O hypokalemia/O or/O hypomagnesemia/O ;/O (/O 3/O )/O concomitant/O use/O of/O other/O drugs/O that/O prolong/O the/O QTc/O interval/O ;/O and/O (/O 4/O )/O presence/O of/O congenital/O prolongation/O of/O the/O QT/O interval/O ;/O (/O 5/O )/O recent/O acute/O myocardial/O infarction/O ;/O and/or/O (/O 6/O )/O uncompensated/O heart/O failure/O ./O
Caution/O is/O warranted/O when/O prescribing/O FANAPT/O with/O drugs/O that/O inhibit/O FANAPT/O metabolism/O [/O see/O Drug/O Interaction/O s/O (/O 7.1/O )/O ]/O ,/O and/O in/O patients/O with/O reduced/O activity/O of/O CYP2D6/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
It/O is/O recommended/O that/O patients/O being/O considered/O for/O FANAPT/O treatment/O who/O are/O at/O risk/O for/O significant/O electrolyte/O disturbances/O have/O baseline/O serum/O potassium/O and/O magnesium/O measurements/O with/O periodic/O monitoring/O ./O
Hypokalemia/O (/O and/or/O hypomagnesemia/O )/O may/O increase/O the/O risk/O of/O QT/O prolongation/O and/O arrhythmia/O ./O
FANAPT/O should/O be/O avoided/O in/O patients/O with/O histories/O of/O significant/O cardiovascular/O illness/O ,/O e.g./O ,/O QT/O prolongation/O ,/O recent/O acute/O myocardial/O infarction/O ,/O uncompensated/O heart/O failure/O ,/O or/O cardiac/O arrhythmia/O ./O
FANAPT/O should/O be/O discontinued/O in/O patients/O who/O are/O found/O to/O have/O persistent/O QTc/O measurements/O 500/O msec/O ./O
If/O patients/O taking/O FANAPT/O experience/O symptoms/O that/O could/O indicate/O the/O occurrence/O of/O cardiac/O arrhythmias/O ,/O e.g./O ,/O dizziness/O ,/O palpitations/O ,/O or/O syncope/O ,/O the/O prescriber/O should/O initiate/O further/O evaluation/O ,/O including/O cardiac/O monitoring/O ./O
5.3/O Neuroleptic/O Malignant/O Syndrome/O (/O NMS/O )/O A/O potentially/O fatal/O symptom/O complex/O sometimes/O referred/O to/O as/O Neuroleptic/B-AdverseReaction Malignant/I-AdverseReaction Syndrome/I-AdverseReaction (/O NMS/B-AdverseReaction )/O has/O been/O reported/O in/O association/O with/O administration/O of/O antipsychotic/O drugs/O ,/O including/O FANAPT/O ./O
Clinical/O manifestations/O include/O hyperpyrexia/B-AdverseReaction ,/O muscle/B-AdverseReaction rigidity/I-AdverseReaction ,/O altered/B-AdverseReaction mental/I-AdverseReaction status/I-AdverseReaction (/O including/O catatonic/B-AdverseReaction signs/I-AdverseReaction )/O and/O evidence/O of/O autonomic/B-AdverseReaction instability/I-AdverseReaction (/O irregular/B-AdverseReaction pulse/I-AdverseReaction or/O blood/O pressure/O ,/O tachycardia/B-AdverseReaction ,/O diaphoresis/B-AdverseReaction ,/O and/O cardiac/B-AdverseReaction dysrhythmia/I-AdverseReaction )/O ./O
Additional/O signs/O may/B-Factor include/O elevated/B-AdverseReaction creatine/I-AdverseReaction phosphokinase/I-AdverseReaction ,/O myoglobinuria/B-AdverseReaction (/O rhabdomyolysis/B-AdverseReaction )/O ,/O and/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ./O
The/O diagnostic/O evaluation/O of/O patients/O with/O this/O syndrome/O is/O complicated/O ./O
In/O arriving/O at/O a/O diagnosis/O ,/O it/O is/O important/O to/O identify/O cases/O in/O which/O the/O clinical/O presentation/O includes/O both/O serious/O medical/O illness/O (/O e.g./O ,/O pneumonia/O ,/O systemic/O infection/O ,/O etc/O ./O
)/O and/O untreated/O or/O inadequately/O treated/O extrapyramidal/O signs/O and/O symptoms/O (/O EPS/O )/O ./O
Other/O important/O considerations/O in/O the/O differential/O diagnosis/O include/O central/O anticholinergic/O toxicity/O ,/O heat/O stroke/O ,/O drug/O fever/O ,/O and/O primary/O central/O nervous/O system/O (/O CNS/O )/O pathology/O ./O
The/O management/O of/O this/O syndrome/O should/O include/O :/O (/O 1/O )/O immediate/O discontinuation/O of/O the/O antipsychotic/O drugs/O and/O other/O drugs/O not/O essential/O to/O concurrent/O therapy/O ,/O (/O 2/O )/O intensive/O symptomatic/O treatment/O and/O medical/O monitoring/O ,/O and/O (/O 3/O )/O treatment/O of/O any/O concomitant/O serious/O medical/O problems/O for/O which/O specific/O treatments/O are/O available/O ./O
There/O is/O no/O general/O agreement/O about/O specific/O pharmacological/O treatment/O regimens/O for/O NMS/O ./O
If/O a/O patient/O requires/O antipsychotic/O drug/O treatment/O after/O recovery/O from/O NMS/O ,/O the/O potential/O reintroduction/O of/O drug/O therapy/O should/O be/O carefully/O considered/O ./O
The/O patient/O should/O be/O carefully/O monitored/O ,/O since/O recurrences/O of/O NMS/O have/O been/O reported/O ./O
5.4/O Tardive/O Dyskinesia/O Tardive/B-AdverseReaction dyskinesia/I-AdverseReaction is/O a/O syndrome/O consisting/O of/O potentially/O irreversible/O ,/O involuntary/B-AdverseReaction ,/I-AdverseReaction dyskinetic/I-AdverseReaction movements/O ,/O which/O may/O develop/O in/O patients/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass ./O
Although/O the/O prevalence/O of/O the/O syndrome/O appears/O to/O be/O highest/O among/O the/O elderly/O ,/O especially/O elderly/O women/O ,/O it/O is/O impossible/O to/O rely/O on/O prevalence/O estimates/O to/O predict/O ,/O at/O the/O inception/O of/O antipsychotic/O treatment/O ,/O which/O patients/O are/O likely/O to/O develop/O the/O syndrome/O ./O
Whether/O antipsychotic/O drug/O products/O differ/O in/O their/O potential/O to/O cause/O tardive/O dyskinesia/O is/O unknown/O ./O
The/O risk/O of/O developing/O tardive/O dyskinesia/O and/O the/O likelihood/O that/O it/O will/O become/O irreversible/O are/O believed/O to/O increase/O as/O the/O duration/O of/O treatment/O and/O the/O total/O cumulative/O dose/O of/O antipsychotic/O administered/O increases/O ./O
However/O ,/O the/O syndrome/O can/O develop/O ,/O although/O much/O less/O commonly/O ,/O after/O relatively/O brief/O treatment/O periods/O at/O low/O doses/O ./O
There/O is/O no/O known/O treatment/O for/O established/O cases/O of/O tardive/O dyskinesia/O ,/O although/O the/O syndrome/O may/O remit/O ,/O partially/O or/O completely/O ,/O if/O antipsychotic/O treatment/O is/O withdrawn/O ./O
Antipsychotic/O treatment/O itself/O ,/O however/O ,/O may/O suppress/O (/O or/O partially/O suppress/O )/O the/O signs/O and/O symptoms/O of/O the/O syndrome/O and/O thereby/O may/O possibly/O mask/O the/O underlying/O process/O ./O
The/O effect/O that/O symptomatic/O suppression/O has/O upon/O the/O long/O -/O term/O course/O of/O the/O syndrome/O is/O unknown/O ./O
Given/O these/O considerations/O ,/O FANAPT/O should/O be/O prescribed/O in/O a/O manner/O that/O is/O most/O likely/O to/O minimize/O the/O occurrence/O of/O tardive/O dyskinesia/O ./O
Chronic/O antipsychotic/O treatment/O should/O generally/O be/O reserved/O for/O patients/O who/O suffer/O from/O a/O chronic/O illness/O that/O (/O 1/O )/O is/O known/O to/O respond/O to/O antipsychotic/O drugs/O ,/O and/O (/O 2/O )/O for/O whom/O alternative/O ,/O equally/O effective/O ,/O but/O potentially/O less/O harmful/O treatments/O are/O not/O available/O or/O appropriate/O ./O
In/O patients/O who/O do/O require/O chronic/O treatment/O ,/O the/O smallest/O dose/O and/O the/O shortest/O duration/O of/O treatment/O producing/O a/O satisfactory/O clinical/O response/O should/O be/O sought/O ./O
The/O need/O for/O continued/O treatment/O should/O be/O reassessed/O periodically/O ./O
If/O signs/O and/O symptoms/O of/O tardive/O dyskinesia/O appear/O in/O a/O patient/O on/O FANAPT/O ,/O drug/O discontinuation/O should/O be/O considered/O ./O
However/O ,/O some/O patients/O may/O require/O treatment/O with/O FANAPT/O despite/O the/O presence/O of/O the/O syndrome/O ./O
5.5/O Metabolic/O Changes/O Atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass have/O been/O associated/O with/O metabolic/O changes/O that/O may/O increase/O cardiovascular/O cerebrovascular/O risk/O ./O
These/O metabolic/O changes/O include/O hyperglycemia/B-AdverseReaction ,/O dyslipidemia/B-AdverseReaction ,/O and/O body/B-AdverseReaction weight/I-AdverseReaction gain/I-AdverseReaction [/O see/O Patient/O Counseling/O Information/O (/O 17.3/O )/O ]/O ./O
While/O all/O atypical/O antipsychotic/O drugs/O have/O been/O shown/O to/O produce/O some/O metabolic/O changes/O ,/O each/O drug/O in/O the/O class/O has/O its/O own/O specific/O risk/O profile/O ./O
Hyperglycemia/O and/O Diabetes/O Mellitus/O Hyperglycemia/B-AdverseReaction ,/O in/O some/O cases/O extreme/B-Severity and/O associated/O with/O ketoacidosis/B-AdverseReaction or/O hyperosmolar/B-AdverseReaction coma/I-AdverseReaction or/O death/B-AdverseReaction ,/O has/O been/O reported/O in/O patients/O treated/O with/O atypical/O antipsychotics/O including/O FANAPT/O ./O
Assessment/O of/O the/O relationship/O between/O atypical/O antipsychotic/O use/O and/O glucose/O abnormalities/O is/O complicated/O by/O the/O possibility/O of/O an/O increased/O background/O risk/O of/O diabetes/O mellitus/O in/O patients/O with/O schizophrenia/O and/O the/O increasing/O incidence/O of/O diabetes/O mellitus/O in/O the/O general/O population/O ./O
Given/O these/O confounders/O ,/O the/O relationship/O between/O atypical/O antipsychotic/O use/O and/O hyperglycemia/O -/O related/O adverse/O events/O is/O not/O completely/O understood/O ./O
However/O ,/O epidemiological/O studies/O suggest/O an/O increased/O risk/O of/O treatment/O -/O emergent/O hyperglycemia/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O events/O in/O patients/O treated/O with/O the/O atypical/B-DrugClass antipsychotics/I-DrugClass included/O in/O these/O studies/O ./O
Because/O FANAPT/O was/O not/O marketed/O at/O the/O time/O these/O studies/O were/O performed/O ,/O it/O is/O not/O known/O if/O FANAPT/O is/O associated/O with/O this/O increased/O risk/O ./O
Patients/O with/O an/O established/O diagnosis/O of/O diabetes/O mellitus/O who/O are/O started/O on/O atypical/O antipsychotics/O should/O be/O monitored/O regularly/O for/O worsening/O of/O glucose/O control/O ./O
Patients/O with/O risk/O factors/O for/O diabetes/O mellitus/O (/O e.g./O ,/O obesity/O ,/O family/O history/O of/O diabetes/O )/O who/O are/O starting/O treatment/O with/O atypical/O antipsychotics/O should/O undergo/O fasting/O blood/O glucose/O testing/O at/O the/O beginning/O of/O treatment/O and/O periodically/O during/O treatment/O ./O
Any/O patient/O treated/O with/O atypical/O antipsychotics/O should/O be/O monitored/O for/O symptoms/O of/O hyperglycemia/O including/O polydipsia/O ,/O polyuria/O ,/O polyphagia/O ,/O and/O weakness/O ./O
Patients/O who/O develop/O symptoms/O of/O hyperglycemia/O during/O treatment/O with/O atypical/O antipsychotics/O should/O undergo/O fasting/O blood/O glucose/O testing/O ./O
In/O some/O cases/O ,/O hyperglycemia/O has/O resolved/O when/O the/O atypical/O antipsychotic/O was/O discontinued/O ;/O however/O ,/O some/O patients/O required/O continuation/O of/O antidiabetic/O treatment/O despite/O discontinuation/O of/O the/O suspect/O drug/O ./O
Data/O from/O a/O 4-week/O ,/O fixed/O -/O dose/O study/O in/O adult/O subjects/O with/O schizophrenia/O ,/O in/O which/O fasting/O blood/O samples/O were/O drawn/O ,/O are/O presented/O in/O Table/O 1/O ./O
Table/O 1/O :/O Change/O in/O Fasting/O Glucose/O FANAPT/O Placebo/O 24/O mg/O day/O Mean/O Change/O from/O Baseline(mg/O dL/O )/O n=114/O n=228/O Serum/O Glucose/O Change/O from/O Baseline/O -0.5/O 6.6/O Proportion/O of/O Patients/O with/O Shifts/O Serum/O Glucose/O Normal/O to/O High/O 2.5/O %/O 10.7/O %/O (/O 100/O mg/O dL/O to/O 126/O mg/O dL/O )/O (/O 2/80/O )/O (/O 18/169/O )/O Pooled/O analyses/O of/O glucose/O data/O from/O clinical/O studies/O including/O longer/O term/O trials/O are/O shown/O in/O Table/O 2/O ./O
Table/O 2/O :/O Change/O in/O Glucose/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O 3/O -/O 6/O months/O 6/O -/O 12/O months/O 12/O months/O FANAPT/O 10/O -/O 16/O mg/O day/O 1.8/O (/O N=773/O )/O 5.4/O (/O N=723/O )/O 5.4/O (/O N=425/O )/O FANAPT/O 20/O -/O 24/O mg/O day/O -3.6/O (/O N=34/O )/O -9.0/O (/O N=31/O )/O -18.0/O (/O N=20/O )/O Dyslipidemia/O Undesirable/B-AdverseReaction alterations/I-AdverseReaction in/I-AdverseReaction lipids/I-AdverseReaction have/O been/O observed/O in/O patients/O treated/O with/O atypical/B-DrugClass antipsychotics/I-DrugClass ./O
Data/O from/O a/O placebo/O -/O controlled/O ,/O 4-week/O ,/O fixed/O -/O dose/O study/O ,/O in/O which/O fasting/O blood/O samples/O were/O drawn/O ,/O in/O adult/O subjects/O with/O schizophrenia/O are/O presented/O in/O Table/O 3/O ./O
Table/O 3/O :/O Change/O in/O Fasting/O Lipids/O FANAPT/O Placebo/O 24/O mg/O day/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O Cholesterol/O n=114/O n=228/O Change/O from/O baseline/O -2.17/O 8.18/O LDL/O n=109/O n=217/O Change/O from/O baseline/O -1.41/O 9.03/O HDL/O n=114/O n=228/O Change/O from/O baseline/O -3.35/O 0.55/O Triglycerides/O n=114/O n=228/O Change/O from/O baseline/O 16.47/O -0.83/O Proportion/O of/O Patients/O with/O Shifts/O Cholesterol/O Normal/O to/O High/O 1.4/O %/O 3.6/O %/O (/O 200/O mg/O dL/O to/O 240/O mg/O dL/O )/O (/O 1/72/O )/O (/O 5/141/O )/O LDL/O Normal/O to/O High/O 2.4/O %/O 1.1/O %/O (/O 100/O mg/O dL/O to/O 160/O mg/O dL/O )/O (/O 1/42/O )/O (/O 1/90/O )/O HDL/O Normal/O to/O Low/O 23.8/O %/O 12.1/O %/O (/O 40/O mg/O dL/O to/O 40/O mg/O dL/O )/O (/O 19/80/O )/O (/O 20/166/O )/O Triglycerides/O Normal/O to/O High/O 8.3/O %/O 10.1/O %/O (/O 150/O mg/O dL/O to/O 200/O mg/O dL/O )/O (/O 6/72/O )/O (/O 15/148/O )/O Pooled/O analyses/O of/O cholesterol/O and/O triglyceride/O data/O from/O clinical/O studies/O including/O longer/O term/O trials/O are/O shown/O in/O Tables/O 4/O and/O 5/O ./O
Table/O 4/O :/O Change/O in/O Cholesterol/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O 3/O -/O 6/O months/O 6/O -/O 12/O months/O 12/O months/O FANAPT/O 10/O -/O 16/O mg/O day/O -3.9/O (/O N=783/O )/O -3.9/O (/O N=726/O )/O -7.7/O (/O N=428/O )/O FANAPT/O 20/O -/O 24/O mg/O day/O -19.4/O (/O N=34/O )/O -23.2/O (/O N=31/O )/O -19.4/O (/O N=20/O )/O Table/O 5/O :/O Change/O in/O Triglycerides/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O 3/O -/O 6/O months/O 6/O -/O 12/O months/O 12/O months/O FANAPT/O 10/O -/O 16/O mg/O day/O -8.9/O (/O N=783/O )/O -8.9/O (/O N=726/O )/O -17.7/O (/O N=428/O )/O FANAPT/O 20/O -/O 24/O mg/O day/O -26.6/O (/O N=34/O )/O -35.4/O (/O N=31/O )/O -17.7/O (/O N=20/O )/O Weight/O Gain/O Weight/B-AdverseReaction gain/I-AdverseReaction has/O been/O observed/O with/O atypical/B-DrugClass antipsychotic/I-DrugClass use/O ./O
Clinical/O monitoring/O of/O weight/O is/O recommended/O ./O
Across/O all/O short-/O and/O long/O -/O term/O studies/O ,/O the/O overall/O mean/O change/O from/O baseline/O at/O endpoint/O was/O 2.1/O kg/O ./O
Changes/O in/O body/O weight/O (/O kg/O )/O and/O the/O proportion/O of/O subjects/O with/O 7/O %/O gain/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction from/O 4/O placebo/O -/O controlled/O ,/O 4-/O or/O 6-week/O ,/O fixed-/O or/O flexible/O -/O dose/O studies/O in/O adult/O subjects/O are/O presented/O in/O Table/O 6/O ./O
Table/O 6/O :/O Change/O in/O Body/O Weight/O FANAPT/O FANAPT/O Placebo/O 10/O -/O 16/O mg/O day/O 20/O -/O 24/O mg/O day/O n=576/O n=481/O n=391/O Weight/O (/O kg/O )/O Change/O from/O Baseline/O -0.1/O 2.0/O 2.7/O Weight/O Gain/O 7/O %/O increase/O from/O Baseline/O 4/O %/O 12/O %/O 18/O %/O 5.6/O Seizures/O In/O short/O -/O term/O placebo/O -/O controlled/O trials/O (/O 4-/O to/O 6-weeks/O )/O ,/O seizures/B-AdverseReaction occurred/O in/O 0.1/O %/O (/O 1/1344/O )/O of/O patients/O treated/O with/O FANAPT/O compared/O to/O 0.3/O %/O (/O 2/587/O )/O on/O placebo/O ./O
As/O with/O other/O antipsychotics/O ,/O FANAPT/O should/O be/O used/O cautiously/O in/O patients/O with/O a/O history/O of/O seizures/O or/O with/O conditions/O that/O potentially/O lower/O the/O seizure/O threshold/O ,/O e.g./O ,/O Alzheimer/O 's/O dementia/O ./O
Conditions/O that/O lower/O the/O seizure/O threshold/O may/O be/O more/O prevalent/O in/O a/O population/O of/O 65/O years/O or/O older/O ./O
5.7/O Orthostatic/O Hypotension/O and/O Syncope/O FANAPT/O can/B-Factor induce/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction associated/O with/O dizziness/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O and/O syncope/B-AdverseReaction ./O
This/O reflects/O its/O alpha1-adrenergic/O antagonist/O properties/O ./O
In/O double/O -/O blind/O placebo/O -/O controlled/O short/O -/O term/O studies/O ,/O where/O the/O dose/O was/O increased/O slowly/O ,/O as/O recommended/O above/O ,/O syncope/B-AdverseReaction was/O reported/O in/O 0.4/O %/O (/O 5/1344/O )/O of/O patients/O treated/O with/O FANAPT/O ,/O compared/O with/O 0.2/O %/O (/O 1/587/O )/O on/O placebo/O ./O
Orthostatic/B-AdverseReaction hypotension/I-AdverseReaction was/O reported/O in/O 5/O %/O of/O patients/O given/O 20/O to/O 24/O mg/O day/O ,/O 3/O %/O of/O patients/O given/O 10/O to/O 16/O mg/O day/O ,/O and/O 1/O %/O of/O patients/O given/O placebo/O ./O
More/O rapid/O titration/O would/O be/O expected/O to/O increase/O the/O rate/O of/O orthostatic/O hypotension/O and/O syncope/O ./O
FANAPT/O should/O be/O used/O with/O caution/O in/O patients/O with/O known/O cardiovascular/O disease/O (/O e.g./O ,/O heart/O failure/O ,/O history/O of/O myocardial/O infarction/O ,/O ischemia/O ,/O or/O conduction/O abnormalities/O )/O ,/O cerebrovascular/O disease/O ,/O or/O conditions/O that/O predispose/O the/O patient/O to/O hypotension/O (/O dehydration/O ,/O hypovolemia/O ,/O and/O treatment/O with/O antihypertensive/O medications/O )/O ./O
Monitoring/O of/O orthostatic/O vital/O signs/O should/O be/O considered/O in/O patients/O who/O are/O vulnerable/O to/O hypotension/O ./O
5.8/O Leukopenia/O ,/O Neutropenia/O and/O Agranulocytosis/O In/O clinical/O trial/O and/O postmarketing/O experience/O ,/O events/O of/O leukopenia/B-AdverseReaction neutropenia/B-AdverseReaction have/O been/O reported/O temporally/O related/O to/O antipsychotic/B-DrugClass agents/I-DrugClass ./O
Agranulocytosis/B-AdverseReaction (/O including/O fatal/B-AdverseReaction cases/O )/O has/O also/O been/O reported/O ./O
Possible/O risk/O factors/O for/O leukopenia/B-AdverseReaction neutropenia/B-AdverseReaction include/O preexisting/O low/O white/O blood/O cell/O count/O (/O WBC/O )/O and/O history/O of/O drug/O induced/O leukopenia/O neutropenia/O ./O
Patients/O with/O a/O pre/O -/O existing/O low/O WBC/O or/O a/O history/O of/O drug/O induced/O leukopenia/O neutropenia/O should/O have/O their/O complete/O blood/O count/O (/O CBC/O )/O monitored/O frequently/O during/O the/O first/O few/O months/O of/O therapy/O and/O should/O discontinue/O FANAPT/O at/O the/O first/O sign/O of/O a/O decline/O in/O WBC/O in/O the/O absence/O of/O other/O causative/O factors/O ./O
Patients/O with/O neutropenia/O should/O be/O carefully/O monitored/O for/O fever/O or/O other/O symptoms/O or/O signs/O of/O infection/O and/O treated/O promptly/O if/O such/O symptoms/O or/O signs/O occur/O ./O
Patients/O with/O severe/O neutropenia/O (/O absolute/O neutrophil/O count/O 1000/O mm/O 3/O )/O should/O discontinue/O FANAPT/O and/O have/O their/O WBC/O followed/O until/O recovery/O ./O
5.9/O Hyperprolactinemia/O As/O with/O other/O drugs/O that/O antagonize/O dopamine/O D2/O receptors/O ,/O FANAPT/O elevates/B-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction ./O
Hyperprolactinemia/B-AdverseReaction may/B-Factor suppress/B-AdverseReaction hypothalamic/I-AdverseReaction GnRH/I-AdverseReaction ,/O resulting/O in/O reduced/B-AdverseReaction pituitary/I-AdverseReaction gonadotropin/I-AdverseReaction secretion/I-AdverseReaction ./O
This/O ,/O in/O turn/O ,/O may/B-Factor inhibit/B-AdverseReaction reproductive/I-AdverseReaction function/I-AdverseReaction by/O impairing/B-AdverseReaction gonadalsteroidogenesis/I-AdverseReaction in/O both/O female/O and/O male/O patients/O ./O
Galactorrhea/B-AdverseReaction ,/O amenorrhea/B-AdverseReaction ,/O gynecomastia/B-AdverseReaction ,/O and/O impotence/B-AdverseReaction have/O been/O reported/O with/O prolactin/B-DrugClass -/I-DrugClass elevating/O compounds/O ./O
Long/B-AdverseReaction -/I-AdverseReaction standing/O hyperprolactinemia/O when/O associated/O with/O hypogonadism/B-AdverseReaction may/B-Factor lead/O to/O decreased/B-AdverseReaction bone/I-AdverseReaction density/I-AdverseReaction in/O both/O female/O and/O male/O patients/O ./O
Tissue/O culture/O experiments/O indicate/O that/O approximately/O one/O -/O third/O of/O human/O breast/O cancers/O are/O prolactin/O -/O dependent/O in/O vitro/O ,/O a/O factor/O of/O potential/O importance/O if/O the/O prescription/O of/O these/O drugs/O is/O contemplated/O in/O a/O patient/O with/O previously/O detected/O breast/O cancer/O ./O
Mammary/B-AdverseReaction gland/I-AdverseReaction proliferative/I-AdverseReaction changes/I-AdverseReaction and/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction prolactin/I-AdverseReaction were/O seen/O in/O mice/B-Animal and/O rats/B-Animal treated/O with/O FANAPT/O [/O see/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
Neither/O clinical/O studies/O nor/O epidemiologic/O studies/O conducted/O to/O date/O have/O shown/O an/O association/O between/O chronic/O administration/O of/O this/O class/O of/O drugs/O and/O tumorigenesis/O in/O humans/O ;/O the/O available/O evidence/O is/O considered/O too/O limited/O to/O be/O conclusive/O at/O this/O time/O ./O
In/O a/O short/O -/O term/O placebo/O -/O controlled/O trial/O (/O 4-weeks/O )/O ,/O the/O mean/O change/O from/O baseline/O to/O endpoint/O in/O plasma/O prolactin/O levels/O for/O the/O FANAPT/O 24/O mg/O day/O -/O treated/O group/O was/O an/O increase/O of/O 2.6/B-Severity ng/I-Severity mL/O compared/O to/O a/O decrease/O of/O 6.3/O ng/O mL/O in/O the/O placebo/O -/O group/O ./O
In/O this/O trial/O ,/O elevated/B-AdverseReaction plasma/I-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction were/O observed/O in/O 26/O %/O of/O adults/O treated/O with/O FANAPT/O compared/O to/O 12/O %/O in/O the/O placebo/O -/O group/O ./O
In/O the/O short/O -/O term/O trials/O ,/O FANAPT/O was/O associated/O with/O modest/B-Severity levels/I-Severity of/O prolactin/B-AdverseReaction elevation/I-AdverseReaction compared/O to/O greater/B-Severity prolactin/B-AdverseReaction elevations/I-AdverseReaction observed/O with/O some/O other/B-DrugClass antipsychotic/I-DrugClass agents/I-DrugClass ./O
In/O pooled/O analysis/O from/O clinical/O studies/O including/O longer/O term/O trials/O ,/O in/O 3210/O adults/O treated/O with/O iloperidone/O ,/O gynecomastia/B-AdverseReaction was/O reported/O in/O 2/O male/O subjects/O (/O 0.1/O %/O )/O compared/O to/O 0/O %/O in/O placebo/O -/O treated/O patients/O ,/O and/O galactorrhea/B-AdverseReaction was/O reported/O in/O 8/O female/O subjects/O (/O 0.2/O %/O )/O compared/O to/O 3/O female/O subjects/O (/O 0.5/O %/O )/O in/O placebo/O -/O treated/O patients/O ./O
5.10/O Body/O Temperature/O Regulation/O Disruption/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction body/I-AdverseReaction 's/I-AdverseReaction ability/I-AdverseReaction to/I-AdverseReaction reduce/I-AdverseReaction core/I-AdverseReaction body/I-AdverseReaction temperature/O has/O been/O attributed/O to/O antipsychotic/B-DrugClass agents/I-DrugClass ./O
Appropriate/O care/O is/O advised/O when/O prescribing/O FANAPT/O for/O patients/O who/O will/O be/O experiencing/O conditions/O which/O may/O contribute/O to/O an/O elevation/O in/O core/O body/O temperature/O ,/O e.g./O ,/O exercising/O strenuously/O ,/O exposure/O to/O extreme/O heat/O ,/O receiving/O concomitant/O medication/O with/O anticholinergic/O activity/O ,/O or/O being/O subject/O to/O dehydration/O ./O
5.11/O Dysphagia/O Esophageal/B-AdverseReaction dysmotility/I-AdverseReaction and/O aspiration/B-AdverseReaction have/O been/O associated/O with/O antipsychotic/B-DrugClass drug/I-DrugClass use/O ./O
Aspiration/O pneumonia/O is/O a/O common/O cause/O of/O morbidity/O and/O mortality/O in/O elderly/O patients/O ,/O in/O particular/O those/O with/O advanced/O Alzheimer/O 's/O dementia/O ./O
FANAPT/O and/O other/O antipsychotic/O drugs/O should/O be/O used/O cautiously/O in/O patients/O at/O risk/O for/O aspiration/O pneumonia/O [/O see/O Boxed/O Warning/O ]/O ./O
5.12/O Suicide/O The/O possibility/O of/O a/O suicide/O attempt/O is/O inherent/O in/O psychotic/O illness/O ,/O and/O close/O supervision/O of/O high/O -/O risk/O patients/O should/O accompany/O drug/O therapy/O ./O
Prescriptions/O for/O FANAPT/O should/O be/O written/O for/O the/O smallest/O quantity/O of/O tablets/O consistent/O with/O good/O patient/O management/O in/O order/O to/O reduce/O the/O risk/O of/O overdose/O ./O
5.13/O Priapism/O Three/O cases/O of/O priapism/B-AdverseReaction were/O reported/O in/O the/O premarketing/O FANAPT/O program/O ./O
Drugs/B-DrugClass with/I-DrugClass alpha/I-DrugClass -/I-DrugClass adrenergic/I-DrugClass blocking/O effects/O have/O been/O reported/O to/O induce/O priapism/B-AdverseReaction ./O
FANAPT/O shares/O this/O pharmacologic/O activity/O ./O
Severe/B-Severity priapism/B-AdverseReaction may/O require/O surgical/O intervention/O ./O
5.14/O Potential/O for/O Cognitive/O and/O Motor/O Impairment/O FANAPT/O ,/O like/O other/O antipsychotics/O ,/O has/O the/O potential/B-Factor to/O impair/B-AdverseReaction judgment/I-AdverseReaction ,/O thinking/O or/O motor/O skills/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O trials/O ,/O somnolence/B-AdverseReaction (/O including/O sedation/B-AdverseReaction )/O was/O reported/O in/O 11.9/O %/O (/O 104/874/O )/O of/O adult/O patients/O treated/O with/O FANAPT/O at/O doses/O of/O 10/O mg/O day/O or/O greater/O versus/O 5.3/O %/O (/O 31/587/O )/O treated/O with/O placebo/O ./O
Patients/O should/O be/O cautioned/O about/O operating/O hazardous/O machinery/O ,/O including/O automobiles/O ,/O until/O they/O are/O reasonably/O certain/O that/O therapy/O with/O FANAPT/O does/O not/O affect/O them/O adversely/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O important/O adverse/O reactions/O are/O described/O below/O and/O elsewhere/O in/O the/O labeling/O :/O Hypotension/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Impairment/B-AdverseReaction in/I-AdverseReaction Renal/I-AdverseReaction Function/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hypoglycemia/B-AdverseReaction with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Genital/B-AdverseReaction Mycotic/I-AdverseReaction Infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Increases/B-AdverseReaction in/I-AdverseReaction Low/I-AdverseReaction -/I-AdverseReaction Density/I-AdverseReaction Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Bladder/B-AdverseReaction Cancer/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O The/O most/O common/O adverse/O reactions/O associated/O with/O FARXIGA/O (/O 5/O %/O or/O greater/O incidence/O )/O were/O female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O AstraZeneca/O at/O 1/O -/O 800-/O 236/O -/O 9933/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Pool/O of/O 12/O Placebo/O -/O Controlled/O Studies/O for/O FARXIGA/O 5/O and/O 10/O mg/O The/O data/O in/O Table/O 1/O is/O derived/O from/O 12/O placebo/O -/O controlled/O studies/O ranging/O from/O 12/O to/O 24/O weeks/O ./O
In/O 4/O studies/O FARXIGA/O was/O used/O as/O monotherapy/O ,/O and/O in/O 8/O studies/O FARXIGA/O was/O used/O as/O add/O -/O on/O to/O background/O antidiabetic/O therapy/O or/O as/O combination/O therapy/O with/O metformin/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O data/O reflect/O exposure/O of/O 2338/O patients/O to/O FARXIGA/O with/O a/O mean/O exposure/O duration/O of/O 21/O weeks/O ./O
Patients/O received/O placebo/O (/O N=1393/O )/O ,/O FARXIGA/O 5/O mg/O (/O N=1145/O )/O ,/O or/O FARXIGA/O 10/O mg/O (/O N=1193/O )/O once/O daily/O ./O
The/O mean/O age/O of/O the/O population/O was/O 55/O years/O and/O 2/O %/O were/O older/O than/O 75/O years/O of/O age/O ./O
Fifty/O percent/O (/O 50/O %/O )/O of/O the/O population/O were/O male/O ;/O 81/O %/O were/O White/O ,/O 14/O %/O were/O Asian/O ,/O and/O 3/O %/O were/O Black/O or/O African/O American/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 6/O years/O ,/O had/O a/O mean/O hemoglobin/O A1c/O (/O HbA1c/O )/O of/O 8.3/O %/O ,/O and/O 21/O %/O had/O established/O microvascular/O complications/O of/O diabetes/O ./O
Baseline/O renal/O function/O was/O normal/O or/O mildly/O impaired/O in/O 92/O %/O of/O patients/O and/O moderately/O impaired/O in/O 8/O %/O of/O patients/O (/O mean/O eGFR/O 86/O mL/O min/1.73/O m/O 2/O )/O ./O
Table/O 1/O shows/O common/O adverse/O reactions/O associated/O with/O the/O use/O of/O FARXIGA/O ./O
These/O adverse/O reactions/O were/O not/O present/O at/O baseline/O ,/O occurred/O more/O commonly/O on/O FARXIGA/O than/O on/O placebo/O ,/O and/O occurred/O in/O at/O least/O 2/O %/O of/O patients/O treated/O with/O either/O FARXIGA/O 5/O mg/O or/O FARXIGA/O 10/O mg/O ./O
Table/O 1/O :/O Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O Studies/O Reported/O in/O 2/O %/O of/O Patients/O Treated/O with/O FARXIGA/O Adverse/O Reaction/O %/O of/O Patients/O Pool/O of/O 12/O Placebo/O -/O Controlled/O Studies/O Placebo/O N=1393/O FARXIGA/O 5/O mg/O N=1145/O FARXIGA/O 10/O mg/O N=1193/O Female/O genital/O mycotic/O infectionsGenital/O mycotic/O infections/O include/O the/O following/O adverse/O reactions/O ,/O listed/O in/O order/O of/O frequency/O reported/O for/O females/O :/O vulvovaginal/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction ,/O vaginal/B-AdverseReaction infection/I-AdverseReaction ,/O vulvovaginal/B-AdverseReaction candidiasis/I-AdverseReaction ,/O vulvovaginitis/B-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction ,/O genital/B-AdverseReaction candidiasis/I-AdverseReaction ,/O fungal/B-AdverseReaction genital/I-AdverseReaction infection/I-AdverseReaction ,/O vulvitis/B-AdverseReaction ,/O genitourinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O vulval/B-AdverseReaction abscess/I-AdverseReaction ,/O and/O vaginitis/B-AdverseReaction bacterial/I-AdverseReaction ./O
(/O N/O for/O females/O :/O Placebo=677/O ,/O FARXIGA/O 5/O mg=581/O ,/O FARXIGA/O 10/O mg=598/O )/O ./O
1.5/O 8.4/O 6.9/O Nasopharyngitis/B-AdverseReaction 6.2/O 6.6/O 6.3/O Urinary/O tract/O infectionsUrinary/O tract/O infections/O include/O the/O following/O adverse/O reactions/O ,/O listed/O in/O order/O of/O frequency/O reported/O :/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O cystitis/B-AdverseReaction ,/O Escherichia/B-AdverseReaction urinary/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O genitourinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O pyelonephritis/B-AdverseReaction ,/O trigonitis/B-AdverseReaction ,/O urethritis/B-AdverseReaction ,/O kidney/B-AdverseReaction infection/I-AdverseReaction ,/O and/O prostatitis/B-AdverseReaction ./O
3.7/O 5.7/O 4.3/O Back/B-AdverseReaction pain/I-AdverseReaction 3.2/O 3.1/O 4.2/O Increased/O urinationIncreased/O urination/O includes/O the/O following/O adverse/O reactions/O ,/O listed/O in/O order/O of/O frequency/O reported/O :/O pollakiuria/B-AdverseReaction ,/O polyuria/B-AdverseReaction ,/O and/O urine/B-AdverseReaction output/I-AdverseReaction increased/I-AdverseReaction ./O
1.7/O 2.9/O 3.8/O Male/O genital/O mycotic/O infectionsGenital/O mycotic/O infections/O include/O the/O following/O adverse/O reactions/O ,/O listed/O in/O order/O of/O frequency/O reported/O for/O males/O :/O balanitis/B-AdverseReaction ,/O fungal/B-AdverseReaction genital/I-AdverseReaction infection/I-AdverseReaction ,/O balanitis/B-AdverseReaction candida/I-AdverseReaction ,/O genital/B-AdverseReaction candidiasis/I-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction male/I-AdverseReaction ,/O penile/B-AdverseReaction infection/I-AdverseReaction ,/O balanoposthitis/B-AdverseReaction ,/O balanoposthitis/B-AdverseReaction infective/I-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction ,/O posthitis/B-AdverseReaction ./O
(/O N/O for/O males/O :/O Placebo=716/O ,/O FARXIGA/O 5/O mg=564/O ,/O FARXIGA/O 10/O mg=595/O )/O ./O
0.3/O 2.8/O 2.7/O Nausea/B-AdverseReaction 2.4/O 2.8/O 2.5/O Influenza/B-AdverseReaction 2.3/O 2.7/O 2.3/O Dyslipidemia/B-AdverseReaction 1.5/O 2.1/O 2.5/O Constipation/B-AdverseReaction 1.5/O 2.2/O 1.9/O Discomfort/B-AdverseReaction with/I-AdverseReaction urination/I-AdverseReaction 0.7/O 1.6/O 2.1/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 1.4/O 2.0/O 1.7/O Pool/O of/O 13/O Placebo/O -/O Controlled/O Studies/O for/O FARXIGA/O 10/O mg/O The/O safety/O and/O tolerability/O of/O FARXIGA/O 10/O mg/O was/O also/O evaluated/O in/O a/O larger/O placebo/O -/O controlled/O study/O pool/O ./O
This/O pool/O combined/O 13/O placebo/O -/O controlled/O studies/O ,/O including/O 3/O monotherapy/O studies/O ,/O 9/O add/O -/O on/O to/O background/O antidiabetic/O therapy/O studies/O ,/O and/O an/O initial/O combination/O with/O metformin/O study/O ./O
Across/O these/O 13/O studies/O ,/O 2360/O patients/O were/O treated/O once/O daily/O with/O FARXIGA/O 10/O mg/O for/O a/O mean/O duration/O of/O exposure/O of/O 22/O weeks/O ./O
The/O mean/O age/O of/O the/O population/O was/O 59/O years/O and/O 4/O %/O were/O older/O than/O 75/O years/O ./O
Fifty/O -/O eight/O percent/O (/O 58/O %/O )/O of/O the/O population/O were/O male/O ;/O 84/O %/O were/O White/O ,/O 9/O %/O were/O Asian/O ,/O and/O 3/O %/O were/O Black/O or/O African/O American/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 9/O years/O ,/O had/O a/O mean/O HbA1c/O of/O 8.2/O %/O ,/O and/O 30/O %/O had/O established/O microvascular/O disease/O ./O
Baseline/O renal/O function/O was/O normal/O or/O mildly/O impaired/O in/O 88/O %/O of/O patients/O and/O moderately/O impaired/O in/O 11/O %/O of/O patients/O (/O mean/O eGFR/O 82/O mL/O min/1.73/O m/O 2/O )/O ./O
Volume/O Depletion/O FARXIGA/O causes/O an/O osmotic/B-AdverseReaction diuresis/I-AdverseReaction ,/O which/O may/B-Factor lead/O to/O reductions/B-AdverseReaction in/I-AdverseReaction intravascular/I-AdverseReaction volume/I-AdverseReaction ./O
Adverse/O reactions/O related/O to/O volume/B-AdverseReaction depletion/I-AdverseReaction (/O including/O reports/O of/O dehydration/B-AdverseReaction ,/O hypovolemia/B-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O or/O hypotension/B-AdverseReaction )/O are/O shown/O in/O Table/O 2/O for/O the/O 12-study/O and/O 13-study/O ,/O short/O -/O term/O ,/O placebo/O -/O controlled/O pools/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Table/O 2/O :/O Adverse/O Reactions/O of/O Volume/B-AdverseReaction DepletionVolume/I-AdverseReaction depletion/O includes/O reports/O of/O dehydration/B-AdverseReaction ,/O hypovolemia/B-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O or/O hypotension/B-AdverseReaction ./O
in/O Clinical/O Studies/O with/O FARXIGA/O Pool/O of/O 12/O Placebo/O -/O Controlled/O Studies/O Pool/O of/O 13/O Placebo/O -/O Controlled/O Studies/O Placebo/O FARXIGA/O 5/O mg/O FARXIGA/O 10/O mg/O Placebo/O FARXIGA/O 10/O mg/O Overall/O population/O N/O (/O %/O )/O N=1393/O 5/O (/O 0.4/O %/O )/O N=1145/O 7/O (/O 0.6/O %/O )/O N=1193/O 9/O (/O 0.8/O %/O )/O N=2295/O 17/O (/O 0.7/O %/O )/O N=2360/O 27/O (/O 1.1/O %/O )/O Patient/O Subgroup/O n/O (/O %/O )/O Patients/O on/O loop/O diuretics/O n=551/O (/O 1.8/O %/O )/O n=400/O n=313/O (/O 9.7/O %/O )/O n=2674/O (/O 1.5/O %/O )/O n=2366/O (/O 2.5/O %/O )/O Patients/O with/O moderate/O renal/O impairment/O with/O eGFR/O 30/O and/O 60/O mL/O min/1.73/O m2/O n=1072/O (/O 1.9/O %/O )/O n=1071/O (/O 0.9/O %/O )/O n=891/O (/O 1.1/O %/O )/O n=2684/O (/O 1.5/O %/O )/O n=2655/O (/O 1.9/O %/O )/O Patients/O 65/O years/O of/O age/O n=2761/O (/O 0.4/O %/O )/O n=2161/O (/O 0.5/O %/O )/O n=2043/O (/O 1.5/O %/O )/O n=7116/O (/O 0.8/O %/O )/O n=66511/O (/O 1.7/O %/O )/O Impairment/O of/O Renal/O Function/O Use/O of/O FARXIGA/O was/O associated/O with/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction in/I-AdverseReaction eGFR/I-AdverseReaction (/O see/O Table/O 3/O )/O ./O
In/O patients/O with/O normal/O or/O mildly/O impaired/O renal/O function/O at/O baseline/O ,/O serum/O creatinine/O and/O eGFR/O returned/O to/O baseline/O values/O at/O Week/O 24/O ./O
Renal/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O ,/O including/O renal/B-AdverseReaction failure/I-AdverseReaction and/O blood/B-AdverseReaction creatinine/I-AdverseReaction increase/I-AdverseReaction ,/O were/O more/O frequent/O in/O patients/O treated/O with/O FARXIGA/O (/O see/O Table/O 4/O )/O ./O
Elderly/O patients/O and/O patients/O with/O impaired/O renal/O function/O were/O more/O susceptible/O to/O these/O adverse/O reactions/O (/O see/O Table/O 4/O )/O ./O
Sustained/O decreases/O in/O eGFR/O were/O seen/O in/O patients/O with/O moderate/O renal/O impairment/O (/O eGFR/O 30/O to/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O ./O
Table/O 3/O :/O Changes/O in/O Serum/O Creatinine/O and/O eGFR/O Associated/O with/O FARXIGA/O in/O the/O Pool/O of/O 12/O Placebo/O -/O Controlled/O Studies/O and/O Moderate/O Renal/O Impairment/O Study/O Pool/O of/O 12/O Placebo/O -/O Controlled/O Studies/O PlaceboN=1393/O FARXIGA/O 5/O mgN=1145/O FARXIGA/O 10/O mgN=1193/O Baseline/O Mean/O Serum/O Creatinine/O (/O mg/O dL/O )/O 0.853/O 0.860/O 0.847/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 86.0/O 85.3/O 86.7/O Week/O 1/O Change/O Serum/O Creatinine/O (/O mg/O dL/O )/O -0.003/O 0.029/O 0.041/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 0.4/O -2.9/O -4.1/O Week/O 24/O Change/O Serum/O Creatinine/O (/O mg/O dL/O )/O -0.005/O -0.001/O 0.001/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 0.8/O 0.8/O 0.3/O Moderate/O Renal/O Impairment/O Study/O PlaceboN=84/O FARXIGA/O 5/O mgN=83/O FARXIGA/O 10/O mgN=85/O Baseline/O Mean/O Serum/O Creatinine/O (/O mg/O dL/O )/O 1.46/O 1.53/O 1.52/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 45.6/O 44.2/O 43.9/O Week/O 1/O Change/O Serum/O Creatinine/O (/O mg/O dL/O )/O 0.01/O 0.13/O 0.18/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 0.5/O -3.8/O -5.5/O Week/O 24/O Change/O Serum/O Creatinine/O (/O mg/O dL/O )/O 0.02/O 0.08/O 0.16/O eGFR/O (/O mL/O min/1.73/O m2/O )/O 0.03/O -4.0/O -7.4/O Week/O 52/O Change/O Serum/O Creatinine/O (/O mg/O dL/O )/O 0.10/O 0.06/O 0.15/O eGFR/O (/O mL/O min/1.73/O m2/O )/O -2.6/O -4.2/O -7.3/O Table/O 4/O :/O Proportion/O of/O Patients/O with/O at/O Least/O One/O Renal/B-AdverseReaction Impairment/I-AdverseReaction -/I-AdverseReaction Related/I-AdverseReaction Adverse/O Reaction/O Pool/O of/O 6/O Placebo/O -/O Controlled/O Studies/O (/O up/O to/O 104/O weeks/O )/O Pool/O of/O 9/O Placebo/O -/O Controlled/O Studies/O (/O up/O to/O 104/O weeks/O )/O Baseline/O Characteristic/O Placebo/O FARXIGA/O 5/O mg/O FARXIGA/O 10/O mg/O Placebo/O FARXIGA/O 10/O mg/O Overall/O populationPatients/O (/O %/O )/O with/O at/O least/O one/O event/O n=78513/O (/O 1.7/O %/O )/O n=76714/O (/O 1.8/O %/O )/O n=85916/O (/O 1.9/O %/O )/O n=195682/O (/O 4.2/O %/O )/O n=2026136/O (/O 6.7/O %/O )/O 65/O years/O of/O age/O and/O older/O Patients/O (/O %/O )/O with/O at/O least/O one/O event/O n=1904/O (/O 2.1/O %/O )/O n=1625/O (/O 3.1/O %/O )/O n=1596/O (/O 3.8/O %/O )/O n=65552/O (/O 7.9/O %/O )/O n=62087/O (/O 14.0/O %/O )/O eGFR/O 30/O and/O 60/O mL/O min/1.73/O m2Patients/O (/O %/O )/O with/O at/O least/O one/O event/O n=775/O (/O 6.5/O %/O )/O n=887/O (/O 8.0/O %/O )/O n=75/O 9/O (/O 12.0/O %/O )/O n=24940/O (/O 16.1/O %/O )/O n=25171/O (/O 28.3/O %/O )/O 65/O years/O of/O age/O and/O older/O and/O eGFR/O 30/O and/O 60/O mL/O min/1.73/O m2Patients/O (/O %/O )/O with/O at/O least/O one/O event/O n=412/O (/O 4.9/O %/O )/O n=433/O (/O 7.0/O %/O )/O n=354/O (/O 11.4/O %/O )/O n=14127/O (/O 19.1/O %/O )/O n=13447/O (/O 35.1/O %/O )/O The/O safety/O of/O FARXIGA/O was/O evaluated/O in/O a/O study/O of/O patients/O with/O moderate/O renal/O impairment/O (/O eGFR/O 30/O to/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
In/O this/O study/O 13/O patients/O experienced/O bone/B-AdverseReaction fractures/I-AdverseReaction for/O treatment/O durations/O up/O to/O 104/O weeks/O ./O
No/O fractures/B-AdverseReaction occurred/O in/O the/O placebo/O group/O ,/O 5/O occurred/O in/O the/O FARXIGA/O 5/O mg/O group/O ,/O and/O 8/O occurred/O in/O the/O FARXIGA/O 10/O mg/O group/O ./O
Eight/O of/O these/O 13/O fractures/B-AdverseReaction were/O in/O patients/O who/O had/O a/O baseline/O eGFR/O of/O 30/O to/O 45/O mL/O min/1.73/O m/O 2/O ./O
Eleven/O of/O the/O 13/O fractures/B-AdverseReaction were/O reported/O within/O the/O first/O 52/O weeks/O ./O
There/O was/O no/O apparent/O pattern/O with/O respect/O to/O the/O anatomic/O site/O of/O fracture/B-AdverseReaction ./O
Hypoglycemia/O The/O frequency/O of/O hypoglycemia/B-AdverseReaction by/O study/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O is/O shown/O in/O Table/O 5/O ./O
Hypoglycemia/B-AdverseReaction was/O more/O frequent/O when/O FARXIGA/O was/O added/O to/O sulfonylurea/O or/O insulin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Table/O 5/O :/O Incidence/O of/O MajorMajor/O episodes/O of/O hypoglycemia/B-AdverseReaction were/O defined/O as/O symptomatic/O episodes/O requiring/O external/O (/O third/O party/O )/O assistance/O due/O to/O severe/B-Severity impairment/B-AdverseReaction in/I-AdverseReaction consciousness/I-AdverseReaction or/O behavior/O with/O a/O capillary/O or/O plasma/B-AdverseReaction glucose/I-AdverseReaction value/I-AdverseReaction 54/I-AdverseReaction mg/O dL/O and/O prompt/O recovery/O after/O glucose/O or/O glucagon/O administration/O ./O
and/O MinorMinor/O episodes/O of/O hypoglycemia/B-AdverseReaction were/O defined/O as/O either/O a/O symptomatic/O episode/O with/O a/O capillary/O or/O plasma/B-AdverseReaction glucose/I-AdverseReaction measurement/I-AdverseReaction 63/I-AdverseReaction mg/O dL/O regardless/O of/O need/O for/O external/O assistance/O ,/O or/O an/O asymptomatic/O capillary/O or/O plasma/B-AdverseReaction glucose/I-AdverseReaction measurement/I-AdverseReaction 63/I-AdverseReaction mg/O dL/O that/O does/O not/O qualify/O as/O a/O major/O episode/O ./O
Hypoglycemia/B-AdverseReaction in/O Controlled/O Clinical/O Studies/O Placebo/O Active/O Control/O FARXIGA/O 5/O mg/O FARXIGA/O 10/O mg/O Monotherapy/O (/O 24/O weeks/O )/O N=75/O N=64/O N=70/O Major/O [/O n/O (/O %/O )/O ]/O 0/O 0/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 0/O 0/O 0/O Add/O -/O on/O to/O Metformin/O (/O 24/O weeks/O )/O N=137/O N=137/O N=135/O Major/O [/O n/O (/O %/O )/O ]/O 0/O 0/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 0/O 2/O (/O 1.5/O )/O 1/O (/O 0.7/O )/O Active/O Control/O Add/O -/O on/O to/O Metformin/O versus/O Glipizide/O (/O 52/O weeks/O )/O N=408/O -/O N=406/O Major/O [/O n/O (/O %/O )/O ]/O 3/O (/O 0.7/O )/O -/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 147/O (/O 36.0/O )/O -/O 7/O (/O 1.7/O )/O Add/O -/O on/O to/O Glimepiride/O (/O 24/O weeks/O )/O N=146/O N=145/O N=151/O Major/O [/O n/O (/O %/O )/O ]/O 0/O 0/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 3/O (/O 2.1/O )/O 8/O (/O 5.5/O )/O 9/O (/O 6.0/O )/O Add/O -/O on/O to/O Metformin/O and/O a/O Sulfonylurea/O (/O 24/O Weeks/O )/O N=109/O -/O N=109/O Major/O [/O n/O (/O %/O )/O ]/O 0/O -/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 4/O (/O 3.7/O )/O -/O 14/O (/O 12.8/O )/O Add/O -/O on/O to/O Pioglitazone/O (/O 24/O weeks/O )/O N=139/O N=141/O N=140/O Major/O [/O n/O (/O %/O )/O ]/O 0/O 0/O 0/O Minor/O [/O n/O (/O %/O )/O ]/O 0/O 3/O (/O 2.1/O )/O 0/O Add/O -/O on/O to/O DPP4/O inhibitor/O (/O 24/O weeks/O )/O N=226/O -/O N=225/O Major/O [/O n/O (/O %/O )/O ]/O 0/O -/O 1/O (/O 0.4/O )/O Minor/O [/O n/O (/O %/O )/O ]/O 3/O (/O 1.3/O )/O -/O 4/O (/O 1.8/O )/O Add/O -/O on/O to/O Insulin/O with/O or/O without/O other/O OADsOAD/O oral/O antidiabetic/O therapy/O ./O
(/O 24/O weeks/O )/O N=197/O N=212/O N=196/O Major/O [/O n/O (/O %/O )/O ]/O 1/O (/O 0.5/O )/O 1/O (/O 0.5/O )/O 1/O (/O 0.5/O )/O Minor/O [/O n/O (/O %/O )/O ]/O 67/O (/O 34.0/O )/O 92/O (/O 43.4/O )/O 79/O (/O 40.3/O )/O Genital/O Mycotic/O Infections/O Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction were/O more/O frequent/O with/O FARXIGA/O treatment/O ./O
Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction were/O reported/O in/O 0.9/O %/O of/O patients/O on/O placebo/O ,/O 5.7/O %/O on/O FARXIGA/O 5/O mg/O ,/O and/O 4.8/O %/O on/O FARXIGA/O 10/O mg/O ,/O in/O the/O 12-study/O placebo/O -/O controlled/O pool/O ./O
Discontinuation/O from/O study/O due/O to/O genital/B-AdverseReaction infection/I-AdverseReaction occurred/O in/O 0/O %/O of/O placebo/O -/O treated/O patients/O and/O 0.2/O %/O of/O patients/O treated/O with/O FARXIGA/O 10/O mg/O ./O
Infections/B-AdverseReaction were/O more/O frequently/O reported/O in/O females/O than/O in/O males/O (/O see/O Table/O 1/O )/O ./O
The/O most/O frequently/O reported/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction were/O vulvovaginal/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction in/O females/O and/O balanitis/B-AdverseReaction in/O males/O ./O
Patients/O with/O a/O history/O of/O genital/O mycotic/O infections/O were/O more/O likely/O to/O have/O a/O genital/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction during/O the/O study/O than/O those/O with/O no/O prior/O history/O (/O 10.0/O %/O ,/O 23.1/O %/O ,/O and/O 25.0/O %/O versus/O 0.8/O %/O ,/O 5.9/O %/O ,/O and/O 5.0/O %/O on/O placebo/O ,/O FARXIGA/O 5/O mg/O ,/O and/O FARXIGA/O 10/O mg/O ,/O respectively/O )/O ./O
Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O e.g./O ,/O angioedema/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O hypersensitivity/B-AdverseReaction )/O were/O reported/O with/O FARXIGA/O treatment/O ./O
Across/O the/O clinical/O program/O ,/O serious/B-Severity anaphylactic/B-AdverseReaction reactions/I-AdverseReaction and/O severe/B-Severity cutaneous/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction and/O angioedema/B-AdverseReaction were/O reported/O in/O 0.2/O %/O of/O comparator/O -/O treated/O patients/O and/O 0.3/O %/O of/O FARXIGA/O -/O treated/O patients/O ./O
If/O hypersensitivity/O reactions/O occur/O ,/O discontinue/O use/O of/O FARXIGA/O ;/O treat/O per/O standard/O of/O care/O and/O monitor/O until/O signs/O and/O symptoms/O resolve/O ./O
Laboratory/O Tests/O Increase/O in/O Hematocrit/O In/O the/O pool/O of/O 13/O placebo/O -/O controlled/O studies/O ,/O increases/O from/O baseline/O in/O mean/O hematocrit/O values/O were/O observed/O in/O FARXIGA/O -/O treated/O patients/O starting/O at/O Week/O 1/O and/O continuing/O up/O to/O Week/O 16/O ,/O when/O the/O maximum/O mean/O difference/O from/O baseline/O was/O observed/O ./O
At/O Week/O 24/O ,/O the/O mean/O changes/O from/O baseline/O in/O hematocrit/O were/O -0.33/O %/O in/O the/O placebo/O group/O and/O 2.30/O %/O in/O the/O FARXIGA/O 10/O mg/O group/O ./O
By/O Week/O 24/O ,/O hematocrit/B-AdverseReaction values/I-AdverseReaction 55/O %/O were/O reported/O in/O 0.4/O %/O of/O placebo/O -/O treated/O patients/O and/O 1.3/O %/O of/O FARXIGA/O 10/O mg/O -/O treated/O patients/O ./O
Increase/O in/O Serum/O Inorganic/O Phosphorus/O In/O the/O pool/O of/O 13/O placebo/O -/O controlled/O studies/O ,/O increases/O from/O baseline/O in/O mean/O serum/O phosphorus/O levels/O were/O reported/O at/O Week/O 24/O in/O FARXIGA/O -/O treated/O patients/O compared/O with/O placebo/O -/O treated/O patients/O (/O mean/O increase/O of/O 0.13/O versus/O -0.04/O mg/O dL/O ,/O respectively/O )/O ./O
Higher/O proportions/O of/O patients/O with/O marked/O laboratory/O abnormalities/O of/O hyperphosphatemia/B-AdverseReaction (/O 5.6/O mg/O dL/O for/O age/O 17/O -/O 65/O years/O or/O 5.1/O mg/O dL/O for/O age/O 66/O years/O )/O were/O reported/O on/O FARXIGA/O at/O Week/O 24/O (/O 0.9/O %/O versus/O 1.7/O %/O for/O placebo/O and/O FARXIGA/O 10/O mg/O ,/O respectively/O )/O ./O
Increase/O in/O Low/O -/O Density/O Lipoprotein/O Cholesterol/O In/O the/O pool/O of/O 13/O placebo/O -/O controlled/O studies/O ,/O changes/O from/O baseline/O in/O mean/O lipid/O values/O were/O reported/O in/O FARXIGA/O -/O treated/O patients/O compared/O to/O placebo/O -/O treated/O patients/O ./O
Mean/O percent/O changes/O from/O baseline/O at/O Week/O 24/O ,/O were/O 0.0/O %/O versus/O 2.5/O %/O for/O total/O cholesterol/O and/O -1.0/O %/O versus/O 2.9/O %/O for/O LDL/O cholesterol/O ,/O in/O the/O placebo/O and/O FARXIGA/O 10/O mg/O groups/O ,/O respectively/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypotension/B-AdverseReaction :/O Before/O initiating/O FARXIGA/O ,/O assess/O volume/O status/O and/O correct/O hypovolemia/O in/O the/O elderly/O ,/O in/O patients/O with/O renal/O impairment/O or/O low/O systolic/O blood/O pressure/O ,/O and/O in/O patients/O on/O diuretics/O ./O
Monitor/O for/O signs/O and/O symptoms/O during/O therapy/O ./O
(/O 5.1/O ,/O 6.1/O )/O Impairment/B-AdverseReaction in/I-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction :/O Monitor/O renal/O function/O during/O therapy/O ./O
(/O 5.2/O )/O Hypoglycemia/B-AdverseReaction :/O In/O patients/O taking/O insulin/O or/O an/O insulin/O secretagogue/O with/O FARXIGA/O ,/O consider/O a/O lower/O dose/O of/O insulin/O or/O the/O insulin/O secretagogue/O to/O reduce/O the/O risk/O of/O hypoglycemia/O ./O
(/O 5.3/O )/O Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction :/O Monitor/O and/O treat/O if/O indicated/O ./O
(/O 5.4/O )/O Increased/B-AdverseReaction LDL/I-AdverseReaction -/O C/O :/O Monitor/O and/O treat/O per/O standard/O of/O care/O ./O
(/O 5.5/O )/O Bladder/B-AdverseReaction Cancer/I-AdverseReaction :/O An/O imbalance/O in/O bladder/B-AdverseReaction cancers/I-AdverseReaction was/O observed/O in/O clinical/O trials/O ./O
FARXIGA/O should/O not/O be/O used/O in/O patients/O with/O active/O bladder/O cancer/O and/O should/O be/O used/O with/O caution/O in/O patients/O with/O a/O prior/O history/O of/O bladder/O cancer/O ./O
(/O 5.6/O )/O Macrovascular/O outcomes/O :/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O FARXIGA/O or/O any/O other/O antidiabetic/O drug/O ./O
(/O 5.7/O )/O 5.1/O Hypotension/O FARXIGA/O causes/O intravascular/B-AdverseReaction volume/I-AdverseReaction contraction/I-AdverseReaction ./O
Symptomatic/B-AdverseReaction hypotension/I-AdverseReaction can/B-Factor occur/O after/O initiating/O FARXIGA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O particularly/O in/O patients/O with/O impaired/O renal/O function/O (/O eGFR/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O ,/O elderly/O patients/O ,/O or/O patients/O on/O loop/O diuretics/O ./O
Before/O initiating/O FARXIGA/O in/O patients/O with/O one/O or/O more/O of/O these/O characteristics/O ,/O volume/O status/O should/O be/O assessed/O and/O corrected/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O hypotension/O after/O initiating/O therapy/O ./O
5.2/O Impairment/O in/O Renal/O Function/O FARXIGA/O increases/B-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction eGFR/I-AdverseReaction ./O
Elderly/O patients/O and/O patients/O with/O impaired/O renal/O function/O may/O be/O more/O susceptible/O to/O these/O changes/O ./O
Adverse/O reactions/O related/O to/O renal/O function/O can/B-Factor occur/O after/O initiating/O FARXIGA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Renal/O function/O should/O be/O evaluated/O prior/O to/O initiation/O of/O FARXIGA/O and/O monitored/O periodically/O thereafter/O ./O
5.3/O Hypoglycemia/O with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O Insulin/O and/O insulin/O secretagogues/O are/O known/O to/O cause/O hypoglycemia/O ./O
FARXIGA/O can/B-Factor increase/O the/O risk/O of/O hypoglycemia/B-AdverseReaction when/O combined/O with/O insulin/O or/O an/O insulin/O secretagogue/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Therefore/O ,/O a/O lower/O dose/O of/O insulin/O or/O insulin/O secretagogue/O may/O be/O required/O to/O minimize/O the/O risk/O of/O hypoglycemia/O when/O these/O agents/O are/O used/O in/O combination/O with/O FARXIGA/O ./O
5.4/O Genital/O Mycotic/O Infections/O FARXIGA/O increases/O the/O risk/B-Factor of/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction ./O
Patients/O with/O a/O history/O of/O genital/O mycotic/O infections/O were/O more/O likely/O to/O develop/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O and/O treat/O appropriately/O ./O
5.5/O Increases/O in/O Low/O -/O Density/O Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O Increases/B-AdverseReaction in/I-AdverseReaction LDL/I-AdverseReaction -/O C/O occur/O with/O FARXIGA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O LDL/O -/O C/O and/O treat/O per/O standard/O of/O care/O after/O initiating/O FARXIGA/O ./O
5.6/O Bladder/O Cancer/O Across/O 22/O clinical/O studies/O ,/O newly/O diagnosed/O cases/O of/O bladder/B-AdverseReaction cancer/I-AdverseReaction were/O reported/O in/O 10/6045/O patients/O (/O 0.17/O %/O )/O treated/O with/O FARXIGA/O and/O 1/3512/O patient/O (/O 0.03/O %/O )/O treated/O with/O placebo/O comparator/O ./O
After/O excluding/O patients/O in/O whom/O exposure/O to/O study/O drug/O was/O less/O than/O one/O year/O at/O the/O time/O of/O diagnosis/O of/O bladder/B-AdverseReaction cancer/I-AdverseReaction ,/O there/O were/O 4/O cases/O with/O FARXIGA/O and/O no/O cases/O with/O placebo/O comparator/O ./O
Bladder/O cancer/O risk/O factors/O and/O hematuria/O (/O a/O potential/O indicator/O of/O pre/O -/O existing/O tumors/O )/O were/O balanced/O between/O treatment/O arms/O at/O baseline/O ./O
There/O were/O too/O few/O cases/O to/O determine/O whether/O the/O emergence/O of/O these/O events/O is/O related/O to/O FARXIGA/O ./O
There/O are/O insufficient/O data/O to/O determine/O whether/O FARXIGA/O has/O an/O effect/O on/O pre/O -/O existing/O bladder/O tumors/O ./O
Consequently/O ,/O FARXIGA/O should/O not/O be/O used/O in/O patients/O with/O active/O bladder/O cancer/O ./O
In/O patients/O with/O prior/O history/O of/O bladder/O cancer/O ,/O the/O benefits/O of/O glycemic/O control/O versus/O unknown/O risks/O for/O cancer/O recurrence/O with/O FARXIGA/O should/O be/O considered/O ./O
5.7/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O FARXIGA/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O elsewhere/O in/O labeling/O :/O Nephrogenic/B-AdverseReaction Systemic/I-AdverseReaction Fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O [/O see/O Boxed/O Warning/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 0.5/O %/O )/O are/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O dizziness/B-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bayer/O HealthCare/O Pharmaceuticals/O Inc./O at/O 1/O -/O 888/O -/O 842/O -/O 2937/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O adverse/O reactions/O described/O in/O this/O section/O reflect/O Gadavist/O exposure/O in/O 6,330/O subjects/O (/O including/O 184/O pediatric/O patients/O ,/O ages/O 0/O to/O 17/O years/O )/O with/O the/O majority/O receiving/O the/O recommended/O dose/O ./O
Approximately/O 50/O %/O of/O the/O subjects/O were/O male/O and/O the/O ethnic/O distribution/O was/O 60/O %/O Caucasian/O ,/O 30/O %/O Asian/O ,/O 6/O %/O Hispanic/O ,/O 2/O %/O Black/O ,/O and/O 3/O %/O patients/O of/O other/O ethnic/O groups/O ./O
The/O average/O age/O was/O 55/O years/O (/O range/O from1/O week/O to/O 93/O years/O )/O ./O
Overall/O ,/O approximately/O 4/O %/O of/O subjects/O reported/O one/O or/O more/O adverse/O reactions/O during/O a/O follow/O -/O up/O period/O that/O ranged/O from/O 24/O hours/O to/O 7/O days/O after/O Gadavist/O administration/O ./O
Adverse/O reactions/O associated/O with/O the/O use/O of/O Gadavist/O were/O usually/O mild/O to/O moderate/O in/O severity/O and/O transient/O in/O nature/O ./O
Table/O 2/O lists/O adverse/O reactions/O that/O occurred/O in/O 0.1/O %/O subjects/O who/O received/O Gadavist/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reaction/O Rate/O (/O %/O )/O n=6330/O Headache/B-AdverseReaction 1.5/O Nausea/B-AdverseReaction 1.2/O Dizziness/B-AdverseReaction 0.5/O Dysgeusia/B-AdverseReaction 0.4/O Feeling/B-AdverseReaction Hot/I-AdverseReaction 0.4/O Injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction 0.4/O Vomiting/B-AdverseReaction 0.4/O Rash/B-AdverseReaction (/O includes/O generalized/O ,/O macular/O ,/O papular/O ,/O pruritic/O )/O 0.3/O Pruritus/B-AdverseReaction (/O includes/O generalized/O )/O 0.2/O Erythema/B-AdverseReaction 0.2/O Hypersensitivity/B-AdverseReaction Anaphylactoid/B-AdverseReaction 0.1/O Dyspnea/B-AdverseReaction 0.1/O Paresthesia/B-AdverseReaction 0.1/O Hypersensitivity/B-AdverseReaction anaphylactoid/B-AdverseReaction reaction/I-AdverseReaction may/O occur/O with/O one/O or/O more/O of/O the/O following/O adverse/O reactions/O :/O for/O example/O ,/O hypotension/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O face/B-AdverseReaction edema/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O flushing/B-AdverseReaction Adverse/O reactions/O that/O occurred/O with/O a/O frequency/O of/O 0.1/O %/O in/O subjects/O who/O received/O Gadavist/O include/O :/O loss/B-AdverseReaction of/I-AdverseReaction consciousness/I-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O parosmia/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O palpitation/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O malaise/B-AdverseReaction and/O feeling/B-AdverseReaction cold/I-AdverseReaction ./O
6.2/O Postmarketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O reported/O during/O postmarketing/O use/O of/O Gadavist/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Cardiac/B-AdverseReaction arrest/I-AdverseReaction Nephrogenic/B-AdverseReaction Systemic/I-AdverseReaction Fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction ,/O circulatory/B-AdverseReaction collapse/I-AdverseReaction ,/O respiratory/B-AdverseReaction arrest/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction swelling/I-AdverseReaction ,/O laryngeal/B-AdverseReaction edema/I-AdverseReaction ,/O blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction ,/O chest/B-AdverseReaction pain/I-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O conjunctivitis/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O sneezing/B-AdverseReaction ,/O burning/B-AdverseReaction sensation/I-AdverseReaction ,/O and/O pallor/B-AdverseReaction )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O BOXED/O WARNING/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/B-Factor for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O Chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73m2/O )/O ,/O orAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O hypertension/O or/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O Gadavist/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O from/O the/O body/O prior/O to/O any/O re/O -/O administration/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O Chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73m2/O )/O ,/O orAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O hypertension/O or/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Nephrogenic/B-AdverseReaction Systemic/I-AdverseReaction Fibrosis/I-AdverseReaction has/O occurred/O in/O patients/O with/O impaired/O elimination/O of/O GBCAs/O ./O
Higher/O than/O recommended/O dosing/O or/O repeated/O dosing/O appears/O to/O increase/O the/O risk/O (/O 5.1/O )/O Anaphylactic/O and/O other/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction with/O cardiovascular/O ,/O respiratory/O or/O cutaneous/B-AdverseReaction manifestations/I-AdverseReaction ,/O ranging/O from/O mild/B-Severity to/O severe/B-Severity ,/O including/O death/B-AdverseReaction ,/O have/O occurred/O ./O
Monitor/O patients/O closely/O during/O and/O after/O administration/O of/O Gadavist/O (/O 5.2/O )/O 5.1/O Nephrogenic/O Systemic/O Fibrosis/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O nephrogenic/B-AdverseReaction systemic/I-AdverseReaction fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O among/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrast/O MRI/O or/O other/O modalities/O ./O
The/O GBCA/B-DrugClass -/O associated/O NSF/B-AdverseReaction risk/O appears/O highest/O for/O patients/O with/O chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73/O m/O 2/O )/O as/O well/O as/O patients/O with/O acute/O kidney/O injury/O ./O
The/O risk/O appears/O lower/O for/O patients/O with/O chronic/O ,/O moderate/O kidney/O disease/O (/O GFR/O 30/O to/O 59/O mL/O min/1.73/O m/O 2/O )/O and/O little/O ,/O if/O any/O ,/O for/O patients/O with/O chronic/O ,/O mild/O kidney/O disease/O (/O GFR/O 60/O to/O 89/O mL/O min/1.73/O m/O 2/O )/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
Report/O any/O diagnosis/O of/O NSF/O following/O Gadavist/O administration/O to/O Bayer/O Healthcare/O (/O 1/O -/O 888/O -/O 842/O -/O 2937/O )/O or/O FDA/O (/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O )/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
Features/O of/O acute/O kidney/O injury/O consist/O of/O rapid/O (/O over/O hours/O to/O days/O )/O and/O usually/O reversible/O decrease/O in/O kidney/O function/O ,/O commonly/O in/O the/O setting/O of/O surgery/O ,/O severe/O infection/O ,/O injury/O or/O drug/O -/O induced/O kidney/O toxicity/O ./O
Serum/O creatinine/O levels/O and/O estimated/O GFR/O may/O not/O reliably/O assess/O renal/O function/O in/O the/O setting/O of/O acute/O kidney/O injury/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O diabetes/O mellitus/O or/O chronic/O hypertension/O )/O ,/O estimate/O the/O GFR/O through/O laboratory/O testing/O ./O
Among/O the/O factors/O that/O may/O increase/O the/O risk/O for/O NSF/O are/O repeated/O or/O higher/O than/O recommended/O doses/O of/O a/O GBCA/O and/O degree/O of/O renal/O impairment/O at/O the/O time/O of/O exposure/O ./O
Record/O the/O specific/O GBCA/O and/O the/O dose/O administered/O to/O a/O patient/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O Gadavist/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O prior/O to/O re/O -/O administration/O ./O
For/O patients/O receiving/O hemodialysis/O ,/O consider/O the/O prompt/O initiation/O of/O hemodialysis/O following/O the/O administration/O of/O a/O GBCA/O in/O order/O to/O enhance/O the/O contrast/O agent/O 's/O elimination/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
The/O usefulness/O of/O hemodialysis/O in/O the/O prevention/O of/O NSF/O is/O unknown/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.2/O Hypersensitivity/O Reactions/O Anaphylactic/O and/O other/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction with/O cardiovascular/O ,/O respiratory/O or/O cutaneous/O manifestations/O ,/O ranging/O from/O mild/B-Severity to/O severe/B-Severity ,/O including/O death/B-AdverseReaction ,/O have/O uncommonly/O occurred/O following/O Gadavist/O administration/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Before/O Gadavist/O administration/O ,/O assess/O all/O patients/O for/O any/O history/O of/O a/O reaction/O to/O contrast/O media/O ,/O bronchial/O asthma/O and/or/O allergic/O disorders/O ./O
These/O patients/O may/O have/O an/O increased/O risk/O for/O a/O hypersensitivity/O reaction/O to/O Gadavist/O ./O
Administer/O Gadavist/O only/O in/O situations/O where/O trained/O personnel/O and/O therapies/O are/O promptly/O available/O for/O the/O treatment/O of/O hypersensitivity/O reactions/O ,/O including/O personnel/O trained/O in/O resuscitation/O ./O
Most/O hypersensitivity/O reactions/O to/O Gadavist/O have/O occurred/O within/O half/O an/O hour/O after/O administration/O ./O
Delayed/O reactions/O can/O occur/O up/O to/O several/O days/O after/O administration/O ./O
Observe/O patients/O for/O signs/O and/O symptoms/O of/O hypersensitivity/O reactions/O during/O and/O following/O Gadavist/O administration/O ./O
5.3/O Acute/O Kidney/O Injury/O In/O patients/O with/O chronic/O renal/O impairment/O ,/O acute/B-AdverseReaction kidney/I-AdverseReaction injury/I-AdverseReaction sometimes/O requiring/O dialysis/O has/O been/O observed/O with/O the/O use/O of/O some/O GBCAs/B-DrugClass ./O
Do/O not/O exceed/O the/O recommended/O dose/O ;/O the/O risk/O of/O acute/O kidney/O injury/O may/O increase/O with/O higher/O than/O recommended/O doses/O ./O
5.4/O Extravasation/O and/O Injection/O Site/O Reactions/O Ensure/O catheter/O and/O venous/O patency/O before/O the/O injection/O of/O Gadavist/O ./O
Extravasation/O into/O tissues/O during/O Gadavist/O administration/O may/B-Factor result/O in/O moderate/B-Severity irritation/O [/O see/O Nonclinical/O Toxicology/O (/O 13.2/O )/O ]/O ./O
5.5/O Overestimation/O of/O Extent/O of/O Malignant/O Disease/O in/O MRI/O of/O the/O Breast/O Gadavist/O MRI/O of/O the/O breast/O overestimated/O the/O histologically/O confirmed/O extent/O of/O malignancy/O in/O the/O diseased/O breast/O in/O up/O to/O 50/O %/O of/O the/O patients/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O incidence/O 25/O %/O )/O were/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O asthenia/B-AdverseReaction fatigue/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O constipation/B-AdverseReaction (/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Eisai/O Inc./O at/O (/O 1/O -/O 877/O -/O 873/O -/O 4724/O )/O or/O contact/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O the/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O other/O clinical/O trials/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O following/O adverse/O reactions/O are/O discussed/O in/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Neutropenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
QT/B-AdverseReaction interval/I-AdverseReaction prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
The/O most/O common/O adverse/O reactions/O (/O 25/O %/O )/O reported/O in/O patients/O receiving/O HALAVEN/O were/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O asthenia/B-AdverseReaction fatigue/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
The/O most/O common/O serious/O adverse/O reactions/O reported/O in/O patients/O receiving/O HALAVEN/O were/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction (/O 4/O %/O )/O and/O neutropenia/B-AdverseReaction (/O 2/O %/O )/O ./O
The/O most/O common/O adverse/O reaction/O resulting/O in/O discontinuation/O of/O HALAVEN/O was/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction (/O 5/O %/O )/O ./O
In/O clinical/O trials/O ,/O HALAVEN/O has/O been/O administered/O to/O 1,222/O patients/O with/O multiple/O tumor/O types/O ,/O including/O 240/O patients/O exposed/O to/O HALAVEN/O for/O 6/O months/O or/O longer/O ./O
The/O majority/O of/O the/O 1,222/O patients/O were/O women/O (/O 82/O %/O )/O with/O a/O median/O age/O of/O 58/O years/O (/O range/O :/O 26/O to/O 91/O years/O )/O ./O
The/O racial/O and/O ethnic/O distribution/O was/O Caucasian/O (/O 83/O %/O )/O ,/O Black/O (/O 5/O %/O )/O ,/O Asian/O (/O 2/O %/O )/O ,/O and/O other/O (/O 5/O %/O )/O ./O
The/O adverse/O reactions/O described/O in/O Table/O 2/O were/O identified/O in/O 750/O patients/O treated/O in/O Study/O 1/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
In/O Study/O 1/O ,/O patients/O were/O randomized/O (/O 2:1/O )/O to/O receive/O either/O HALAVEN/O (/O 1.4/O mg/O m/O 2/O on/O Days/O 1/O and/O 8/O of/O a/O 21-day/O cycle/O )/O or/O single/O agent/O treatment/O chosen/O by/O their/O physician/O (/O control/O group/O )/O ./O
A/O total/O of/O 503/O patients/O received/O HALAVEN/O ,/O and/O 247/O patients/O in/O the/O control/O group/O received/O therapy/O consisting/O of/O chemotherapy/O [/O total/O 97/O %/O (/O anthracyclines/O 10/O %/O ,/O capecitabine/O 18/O %/O ,/O gemcitabine/O 19/O %/O ,/O taxanes/O 15/O %/O ,/O vinorelbine/O 25/O %/O ,/O other/O chemotherapies/O 10/O %/O )/O ]/O or/O hormonal/O therapy/O (/O 3/O %/O )/O ./O
The/O median/O duration/O of/O exposure/O was/O 118/O days/O for/O patients/O receiving/O HALAVEN/O and/O 63/O days/O for/O patients/O receiving/O control/O therapy/O ./O
Table/O 2/O reports/O the/O most/O common/O adverse/O reactions/O occurring/O in/O at/O least/O 10/O %/O of/O patients/O in/O either/O group/O ./O
Table/O 2/O Adverse/O Reactions/O with/O a/O Per/O -/O Patient/O Incidence/O of/O at/O Least/O 10/O %/O in/O Study/O 1/O MedDRA/O ver/O 10.0/O HALAVEN/O n=503/O Control/O Group/O n=247/O All/O Grades/O Grade/O 3/O All/O Grades/O Grade/O 3/O Blood/O and/O Lymphatic/O System/O Disorders/O a/O Neutropenia/B-AdverseReaction 82/O %/O 57/O %/O 53/O %/O 23/O %/O Anemia/B-AdverseReaction 58/O %/O 2/O %/O 55/O %/O 4/O %/O Nervous/O system/O disorders/O Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction b/O 35/O %/O 8/O %/O 16/O %/O 2/O %/O Headache/B-AdverseReaction 19/O %/O 1/O %/O 12/O %/O 1/O %/O General/O disorders/O and/O administrative/O site/O conditions/O Asthenia/B-AdverseReaction Fatigue/B-AdverseReaction 54/O %/O 10/O %/O 40/O %/O 11/O %/O Mucosal/B-AdverseReaction inflammation/I-AdverseReaction 9/O %/O 1/O %/O 10/O %/O 2/O %/O Pyrexia/B-AdverseReaction 21/O %/O 1/O %/O 13/O %/O 1/O %/O Gastrointestinal/O disorders/O Constipation/B-AdverseReaction 25/O %/O 1/O %/O 21/O %/O 1/O %/O Diarrhea/B-AdverseReaction 18/O %/O 0/O 18/O %/O 0/O Nausea/B-AdverseReaction 35/O %/O 1/O %/O 28/O %/O 3/O %/O Vomiting/B-AdverseReaction 18/O %/O 1/O %/O 18/O %/O 1/O %/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction Myalgia/B-AdverseReaction 22/O %/O 1/O %/O 12/O %/O 1/O %/O Back/B-AdverseReaction pain/I-AdverseReaction 16/O %/O 1/O %/O 7/O %/O 2/O %/O Bone/B-AdverseReaction pain/I-AdverseReaction 12/O %/O 2/O %/O 9/O %/O 2/O %/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 11/O %/O 1/O %/O 10/O %/O 1/O %/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 21/O %/O 1/O %/O 14/O %/O 1/O %/O Metabolism/O and/O nutrition/O disorders/O Anorexia/B-AdverseReaction 20/O %/O 1/O %/O 13/O %/O 1/O %/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 14/O %/O 0/O 9/O %/O 0/O Dyspnea/B-AdverseReaction 16/O %/O 4/O %/O 13/O %/O 4/O %/O Skin/O and/O subcutaneous/O tissue/O disorders/O Alopecia/B-AdverseReaction 45/O %/O NA/O c/O 10/O %/O NA/O c/O Infections/O and/O Infestations/O Urinary/B-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 10/O %/O 1/O %/O 5/O %/O 0/O a./O based/O upon/O laboratory/O data/O ./O
b/O includes/O neuropathy/B-AdverseReaction peripheral/I-AdverseReaction ,/O neuropathy/B-AdverseReaction ,/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction ,/O polyneuropathy/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensoryneuropathy/I-AdverseReaction ,/O and/O paraesthesia/B-AdverseReaction ./O
c/O not/O applicable/O ;/O (/O grading/O system/O does/O not/O specify/O Grade/O 2/O for/O alopecia/B-AdverseReaction )/O ./O
Cytopenias/O :/O Grade/B-Severity 3/I-Severity neutropenia/B-AdverseReaction occurred/O in/O 28/O %/O (/O 143/503/O )/O of/O patients/O who/O received/O HALAVEN/O in/O Study/O 1/O ,/O and/O 29/O %/O (/O 144/503/O )/O of/O patients/O experienced/O Grade/B-Severity 4/I-Severity neutropenia/B-AdverseReaction ./O
Febrile/B-AdverseReaction neutropenia/I-AdverseReaction occurred/O in/O 5/O %/O (/O 23/503/O )/O of/O patients/O ;/O two/O patients/O (/O 0.4/O %/O )/O died/B-AdverseReaction from/O complications/O of/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ./O
Dose/O reduction/O due/O to/O neutropenia/B-AdverseReaction was/O required/O in/O 12/O %/O (/O 62/503/O )/O of/O patients/O and/O discontinuation/O was/O required/O in/O 1/O %/O of/O patients/O ./O
The/O mean/O time/O to/O nadir/O was/O 13/O days/O and/O the/O mean/O time/O to/O recovery/O from/O severe/B-Severity neutropenia/B-AdverseReaction (/O 500/O mm/O 3/O )/O was/O 8/O days/O ./O
Grade/B-Severity 3/I-Severity or/O greater/O thrombocytopenia/B-AdverseReaction occurred/O in/O 1/O %/O (/O 7/503/O )/O of/O patients/O ./O
G/O -/O CSF/O (/O granulocyte/O colony/O -/O stimulating/O factor/O )/O or/O GM/O -/O CSF/O (/O granulocyte/O -/O macrophage/O colony/O -/O stimulating/O factor/O )/O was/O used/O in/O 19/O %/O of/O patients/O who/O received/O HALAVEN/O ./O
Peripheral/O Neuropathy/O :/O In/O Study/O 1/O ,/O 17/O %/O of/O enrolled/O patients/O had/O Grade/B-Severity 1/I-Severity peripheral/B-AdverseReaction neuropathy/I-AdverseReaction and/O 3/O %/O of/O patients/O had/O Grade/B-Severity 2/I-Severity peripheral/B-AdverseReaction neuropathy/I-AdverseReaction at/O baseline/O ./O
Dose/O reduction/O due/O to/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction was/O required/O by/O 3/O %/O (/O 14/503/O )/O of/O patients/O who/O received/O HALAVEN/O ./O
Four/O percent/O (/O 20/503/O )/O of/O patients/O experienced/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction of/O any/O grade/O and/O 2/O %/O (/O 8/503/O )/O of/O patients/O developed/O Grade/B-Severity 3/I-Severity peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction ./O
Liver/O Function/O Test/O Abnormalities/O :/O Among/O patients/O with/O Grade/O 0/O or/O 1/O ALT/O levels/O at/O baseline/O ,/O 18/O %/O of/O HALAVEN/O -/O treated/O patients/O experienced/O Grade/B-Severity 2/I-Severity or/O greater/O ALT/B-AdverseReaction elevation/I-AdverseReaction ./O
One/O HALAVEN/O -/O treated/O patient/O without/O documented/O liver/O metastases/O had/O concomitant/O Grade/B-Severity 2/I-Severity elevations/B-AdverseReaction in/I-AdverseReaction bilirubin/I-AdverseReaction and/O ALT/O ;/O these/O abnormalities/O resolved/O and/O did/O not/O recur/O with/O re/O -/O exposure/O to/O HALAVEN/O ./O
Less/O Common/O Adverse/O Reactions/O :/O The/O following/O additional/O adverse/O reactions/O were/O reported/O in/O 5/O %/O to/O 10/O %/O of/O the/O HALAVEN/O -/O treated/O group/O :/O Eye/O Disorders/O :/O increased/B-AdverseReaction lacrimation/I-AdverseReaction Gastrointestinal/O Disorders/O :/O dyspepsia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O peripheral/B-AdverseReaction edema/I-AdverseReaction Infections/O and/O Infestations/O :/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O hypokalemia/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O muscle/B-AdverseReaction spasms/I-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction Nervous/O System/O Disorders/O :/O dysgeusia/B-AdverseReaction ,/O dizziness/B-AdverseReaction Psychiatric/O Disorders/O :/O insomnia/B-AdverseReaction ,/O depression/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O rash/B-AdverseReaction 6/O ./O
2/O Postmarketing/O Experience/O The/O following/O adverse/O drug/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O of/O HALAVEN/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Blood/O and/O Lymphatic/O System/O Disorders/O :/O lymphopenia/B-AdverseReaction Gastrointestinal/O Disorders/O :/O pancreatitis/B-AdverseReaction Hepatobiliary/O Disorders/O :/O hepatotoxicity/B-AdverseReaction Immune/O System/O Disorders/O :/O drug/O hypersensitivity/B-AdverseReaction Infections/O and/O Infestations/O :/O pneumonia/B-AdverseReaction ,/O sepsis/B-AdverseReaction neutropenic/B-AdverseReaction sepsis/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O hypomagnesemia/B-AdverseReaction ,/O dehydration/B-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O pruritus/B-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Neutropenia/B-AdverseReaction :/O Monitor/O peripheral/O blood/O cell/O counts/O and/O adjust/O dose/O as/O appropriate/O (/O 2.2/O ,/O 5.1/O ,/O 6/O )/O Peripheral/B-AdverseReaction Neuropathy/I-AdverseReaction :/O Monitor/O for/O signs/O of/O neuropathy/O ./O
Manage/O with/O dose/O delay/O and/O adjustment/O (/O 2.2/O ,/O 5.2/O ,/O 6/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction Fetal/O Toxicity/O :/O Fetal/B-AdverseReaction harm/I-AdverseReaction can/B-Factor occur/O when/O administered/O to/O a/O pregnant/O woman/O (/O 5.3/O )/O (/O 8.1/O )/O QT/B-AdverseReaction Prolongation/I-AdverseReaction :/O Monitor/O for/O prolonged/O QT/O intervals/O in/O patients/O with/O congestive/O heart/O failure/O ,/O bradyarrhythmias/O ,/O drugs/O known/O to/O prolong/O the/O QT/O interval/O ,/O and/O electrolyte/O abnormalities/O ./O
Avoid/O in/O patients/O with/O congenital/O long/O QT/O syndrome/O (/O 5.4/O )/O 5.1/O Neutropenia/O Severe/B-Severity neutropenia/B-AdverseReaction (/O ANC/O 500/O mm/O 3/O )/O lasting/O more/O than/O one/O week/O occurred/O in/O 12/O %/O (/O 62/503/O )/O of/O patients/O in/O Study/O 1/O ,/O leading/O to/O discontinuation/O in/O 1/O %/O of/O patients/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Patients/O with/O alanine/O aminotransferase/O or/O aspartate/O aminotransferase/O 3/O ULN/O (/O upper/O limit/O of/O normal/O )/O experienced/O a/O higher/O incidence/O of/O Grade/B-Severity 4/I-Severity neutropenia/B-AdverseReaction and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction than/O patients/O with/O normal/O aminotransferase/O levels/O ./O
Patients/O with/O bilirubin/O 1.5/O ULN/O also/O had/O a/O higher/O incidence/O of/O Grade/B-Severity 4/I-Severity neutropenia/B-AdverseReaction and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ./O
Monitor/O complete/O blood/O counts/O prior/O to/O each/O dose/O ;/O increase/O the/O frequency/O of/O monitoring/O in/O patients/O who/O develop/O Grade/O 3/O or/O 4/O cytopenias/O ./O
Delay/O administration/O of/O HALAVEN/O and/O reduce/O subsequent/O doses/O in/O patients/O who/O experience/O febrile/O neutropenia/O or/O Grade/O 4/O neutropenia/O lasting/O longer/O than/O 7/O days/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Clinical/O studies/O of/O HALAVEN/O did/O not/O include/O patients/O with/O baseline/O neutrophil/O counts/O below/O 1,500/O mm/O 3/O ./O
5.2/O Peripheral/O Neuropathy/O Grade/B-Severity 3/I-Severity peripheral/B-AdverseReaction neuropathy/I-AdverseReaction occurred/O in/O 8/O %/O (/O 40/503/O )/O of/O patients/O ,/O and/O Grade/B-Severity 4/I-Severity in/O 0.4/O %/O (/O 2/503/O )/O of/O patients/O in/O Study/O 1/O ./O
Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction was/O the/O most/O common/O toxicity/O leading/O to/O discontinuation/O of/O HALAVEN/O (/O 5/O %/O of/O patients/O ;/O 24/503/O )/O ./O
Neuropathy/B-AdverseReaction lasting/O more/O than/O one/O year/O occurred/O in/O 5/O %/O (/O 26/503/O )/O of/O patients/O ./O
Twenty/O -/O two/O percent/O (/O 109/503/O )/O of/O patients/O developed/O a/O new/O or/O worsening/O neuropathy/B-AdverseReaction that/O had/O not/O recovered/O within/O a/O median/O follow/O -/O up/O duration/O of/O 269/O days/O (/O range/O 25/O -/O 662/O days/O )/O ./O
Monitor/O patients/O closely/O for/O signs/O of/O peripheral/O motor/O and/O sensory/O neuropathy/O ./O
Withhold/O HALAVEN/O in/O patients/O who/O experience/O Grade/O 3/O or/O 4/O peripheral/O neuropathy/O until/O resolution/O to/O Grade/O 2/O or/O less/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.3/O Embryo/O -/O Fetal/O Toxicity/O There/O are/O no/O adequate/O and/O well/O -/O controlled/O studies/O of/O HALAVEN/O in/O pregnant/O women/O ./O
HALAVEN/O is/O a/O microtubule/B-DrugClass inhibitor/I-DrugClass ;/O therefore/O ,/O it/O is/O expected/O to/O cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O and/O teratogenicity/B-AdverseReaction occurred/O in/O rats/B-Animal that/O received/O eribulin/O mesylate/O at/O approximately/O half/O of/O the/O recommended/O human/O dose/O based/O on/O body/O surface/O area/O ./O
If/B-Factor this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O a/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O she/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/B-Factor [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
5.4/O QT/O Prolongation/O In/O an/O uncontrolled/O open/O -/O label/O ECG/O study/O in/O 26/O patients/O ,/O QT/B-AdverseReaction prolongation/I-AdverseReaction was/O observed/O on/O Day/O 8/O ,/O independent/O of/O eribulin/O concentration/O ,/O with/O no/B-Negation QT/B-AdverseReaction prolongation/I-AdverseReaction observed/O on/O Day/O 1/O ./O
ECG/O monitoring/O is/O recommended/O if/O therapy/O is/O initiated/O in/O patients/O with/O congestive/O heart/O failure/O ,/O bradyarrhythmias/O ,/O drugs/O known/O to/O prolong/O the/O QT/O interval/O ,/O including/O Class/O Ia/O and/O III/O antiarrhythmics/O ,/O and/O electrolyte/O abnormalities/O ./O
Correct/O hypokalemia/O or/O hypomagnesemia/O prior/O to/O initiating/O HALAVEN/O and/O monitor/O these/O electrolytes/O periodically/O during/O therapy/O ./O
Avoid/O HALAVEN/O in/O patients/O with/O congenital/O long/O QT/O syndrome/O ./O
6/O ADVERSE/O REACTIONS/O Three/O hundred/O ninety/O -/O five/O patients/O ,/O including/O approximately/O 250/O children/O (/O aged/O 2/O to/O 17/O years/O )/O have/O been/O treated/O with/O ILARIS/O in/O interventional/O trials/O in/O CAPS/O or/O SJIA/O ./O
The/O most/O frequently/O reported/O adverse/O drug/O reactions/O were/O infections/B-AdverseReaction predominantly/O of/O the/O upper/O respiratory/O tract/O ./O
The/O majority/O of/O the/O events/O were/O mild/B-Severity to/I-Severity moderate/B-Severity although/O serious/B-Severity infections/B-AdverseReaction were/O observed/O ./O
The/O type/O and/O frequency/O of/O adverse/O drug/O reactions/O appeared/O to/O be/O consistent/O over/O time/O ./O
Opportunistic/B-AdverseReaction infections/I-AdverseReaction have/O also/O been/O reported/O in/O patients/O treated/O with/O ILARIS/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O CAPS/O :/O The/O most/O common/O adverse/O reactions/O greater/O than/O 10/O %/O reported/O by/O patients/O with/O CAPS/O treated/O with/O ILARIS/O are/O nasopharyngitis/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O headache/B-AdverseReaction and/O nausea/B-AdverseReaction ./O
(/O 6/O )/O SJIA/O :/O The/O most/O common/O adverse/O drug/O reactions/O greater/O than/O 10/O %/O reported/O by/O patients/O with/O SJIA/O treated/O with/O ILARIS/O are/O infections/B-AdverseReaction (/O nasopharyngitis/B-AdverseReaction and/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Treatment/O of/O CAPS/O The/O data/O described/O herein/O reflect/O exposure/O to/O ILARIS/O in/O 104/O adult/O and/O pediatric/O CAPS/O patients/O ,/O including/O 20/O FCAS/O ,/O 72/O MWS/O ,/O 10/O MWS/O NOMID/O (/O Neonatal/O Onset/O Multisystem/O Inflammatory/O Disorder/O )/O overlap/O ,/O 1/O non/O -/O FCAS/O non/O -/O MWS/O ,/O and/O 1/O misdiagnosed/O in/O placebo/O -/O controlled/O (/O 35/O patients/O )/O and/O uncontrolled/O trials/O ./O
Sixty/O -/O two/O patients/O were/O exposed/O to/O ILARIS/O for/O at/O least/O 6/O months/O ,/O 56/O for/O at/O least/O 1/O year/O and/O 4/O for/O at/O least/O 3/O years/O ./O
A/O total/O of/O 9/O serious/O adverse/O reactions/O were/O reported/O for/O CAPS/O patients/O ./O
Among/O these/O were/O vertigo/B-AdverseReaction (/O 2/O patients/O )/O ,/O infections/B-AdverseReaction (/O 3/O patients/O )/O ,/O including/O intra/B-AdverseReaction -/I-AdverseReaction abdominal/O abscess/O following/O appendectomy/O (/O 1/O patient/O )/O ./O
The/O most/O commonly/O reported/O adverse/O reactions/O associated/O with/O ILARIS/O treatment/O in/O the/O CAPS/O patients/O were/O nasopharyngitis/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
One/O patient/O discontinued/O treatment/O due/O to/O potential/B-Factor infection/B-AdverseReaction ./O
CAPS/O Study/O 1/O investigated/O the/O safety/O of/O ILARIS/O in/O an/O 8-week/O ,/O open/O -/O label/O period/O (/O Part/O 1/O )/O ,/O followed/O by/O a/O 24-week/O ,/O randomized/O withdrawal/O period/O (/O Part/O 2/O )/O ,/O followed/O by/O a/O 16-week/O ,/O open/O -/O label/O period/O (/O Part/O 3/O )/O ./O
All/O patients/O were/O treated/O with/O ILARIS/O 150/O mg/O subcutaneously/O or/O 2/O mg/O kg/O if/O body/O weight/O was/O greater/O than/O or/O equal/O to/O 15/O kg/O and/O less/O than/O or/O equal/O to/O 40/O kg/O (/O see/O Table/O 1/O )/O ./O
Since/O all/O CAPS/O patients/O received/O ILARIS/O in/O Part/O 1/O ,/O there/O are/O no/O controlled/O data/O on/O adverse/O events/O (/O AEs/O )/O ./O
Data/O in/O Table/O 1/O are/O for/O all/O AEs/O for/O all/O CAPS/O patients/O receiving/O canakinumab/O ./O
In/O CAPS/O Study/O 1/O ,/O no/O pattern/O was/O observed/O for/O any/O type/O or/O frequency/O of/O adverse/O events/O throughout/O the/O three/O study/O periods/O ./O
Table/O 1/O Number/O (/O %/O )/O of/O Patients/O with/O AEs/O by/O Preferred/O Terms/O ,/O in/O 10/O %/O of/O Patients/O in/O Parts/O 1/O to/O 3/O of/O the/O Phase/O 3/O Trial/O for/O CAPS/O Patients/O Preferred/O Term/O ILARISN=35n/O (/O %/O )/O n/O %/O of/O Patients/O with/O Adverse/O Events/O 35/O (/O 100/O )/O Nasopharyngitis/B-AdverseReaction 12/O (/O 34/O )/O Diarrhea/B-AdverseReaction 7/O (/O 20/O )/O Influenza/B-AdverseReaction 6/O (/O 17/O )/O Rhinitis/B-AdverseReaction 6/O (/O 17/O )/O Nausea/B-AdverseReaction 5/O (/O 14/O )/O Headache/B-AdverseReaction 5/O (/O 14/O )/O Bronchitis/B-AdverseReaction 4/O (/O 11/O )/O Gastroenteritis/B-AdverseReaction 4/O (/O 11/O )/O Pharyngitis/B-AdverseReaction 4/O (/O 11/O )/O Weight/B-AdverseReaction increased/I-AdverseReaction 4/O (/O 11/O )/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 4/O (/O 11/O )/O Vertigo/B-AdverseReaction 4/O (/O 11/O )/O Vertigo/O Vertigo/B-AdverseReaction has/O been/O reported/O in/O 9/O %/O to/O 14/O %/O of/O patients/O in/O CAPS/O studies/O ,/O exclusively/O in/O MWS/O patients/O ,/O and/O reported/O as/O a/O serious/B-Severity adverse/O event/O in/O two/O cases/O ./O
All/O events/O resolved/O with/O continued/O treatment/O with/O ILARIS/O ./O
Injection/O Site/O Reactions/O In/O CAPS/O Study/O 1/O ,/O subcutaneous/B-AdverseReaction injection/I-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction were/O observed/O in/O 9/O %/O of/O patients/O in/O Part/O 1/O with/O mild/O tolerability/O reactions/O ;/O in/O Part/O 2/O ,/O one/O patient/O each/O (/O 7/O %/O )/O had/O a/O mild/O or/O a/O moderate/O tolerability/O reaction/O and/O ,/O in/O Part/O 3/O ,/O one/O patient/O had/O a/O mild/B-Severity local/B-AdverseReaction tolerability/I-AdverseReaction reaction/I-AdverseReaction ./O
No/B-Negation severe/B-Severity injection/B-AdverseReaction -/I-AdverseReaction site/O reactions/O were/O reported/O and/O none/O led/O to/O discontinuation/O of/O treatment/O ./O
Treatment/O of/O SJIA/O A/O total/O of/O 201/O SJIA/O patients/O aged/O 2/O to/O less/O than/O 20/O years/O have/O received/O ILARIS/O in/O clinical/O trials/O ./O
The/O safety/O of/O ILARIS/O compared/O to/O placebo/O was/O investigated/O in/O two/O phase/O 3/O studies/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
Patients/O in/O SJIA/O Study/O 1/O received/O a/O single/O dose/O of/O ILARIS/O 4/O mg/O kg/O (/O n=43/O )/O or/O placebo/O (/O n=41/O )/O via/O subcutaneous/O injection/O and/O were/O assessed/O at/O Day/O 15/O for/O the/O efficacy/O endpoints/O and/O had/O a/O safety/O analysis/O up/O to/O Day/O 29/O ./O
SJIA/O Study/O 2/O was/O a/O two/O -/O part/O study/O with/O an/O open/O -/O label/O ,/O single/O -/O arm/O active/O treatment/O period/O (/O Part/O I/O )/O followed/O by/O a/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O event/O -/O driven/O withdrawal/O design/O (/O Part/O II/O )/O ./O
Overall/O ,/O 177/O patients/O were/O enrolled/O into/O the/O study/O and/O received/O ILARIS/O 4/O mg/O kg/O (/O up/O to/O 300/O mg/O maximum/O )/O in/O Part/O I/O ,/O and/O 100/O patients/O received/O ILARIS/O 4/O mg/O kg/O (/O up/O to/O 300/O mg/O maximum/O )/O every/O 4/O weeks/O or/O placebo/O in/O Part/O II/O ./O
Adverse/O drug/O reactions/O listed/O in/O Table/O 2/O showed/O higher/O rates/O than/O placebo/O from/O both/O trials/O ./O
The/O adverse/O drug/O reactions/O associated/O with/O ILARIS/O treatment/O in/O SJIA/O patients/O were/O infections/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ./O
Serious/B-Severity infections/B-AdverseReaction (/O e.g./O ,/O pneumonia/B-AdverseReaction ,/O varicella/B-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O measles/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O otitis/B-AdverseReaction media/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O adenovirus/B-AdverseReaction ,/O lymph/B-AdverseReaction node/I-AdverseReaction abscess/I-AdverseReaction ,/O pharyngitis/B-AdverseReaction )/O were/O observed/O in/O approximately/O 4/O %/O to/O 5/O %/O (/O 0.02/O to/O 0.17/O per/O 100/O patient/O -/O days/O )/O of/O patients/O receiving/O ILARIS/O in/O both/O studies/O ./O
Adverse/O reactions/O are/O listed/O according/O to/O MedDRA/O version/O 15.0/O system/O organ/O class/O ./O
Table/O 2/O Tabulated/O Summary/O of/O Adverse/O Drug/O Reactions/O from/O Pivotal/O SJIA/O Clinical/O Trials/O n=/O number/O of/O patients^/O IR/O Exposure/O adjusted/O incidence/O rate/O per/O 100/O patient/O -/O days/O No/O injection/O site/O reaction/O led/O to/O study/O discontinuation/O SJIA/O Study/O 2/O SJIA/O Study/O 1/O Part/O I/O Part/O II/O ILARISN=177n/O (/O %/O )/O (/O IR)^/O ILARISN=50n/O (/O %/O )/O (/O IR/O )/O PlaceboN=50n/O (/O %/O )/O (/O IR/O )/O ILARISN=43n/O (/O %/O )/O (/O IR/O )/O PlaceboN=41n/O (/O %/O )/O (/O IR/O )/O Infections/O and/O infestations/O All/O Infections/B-AdverseReaction (/O e.g./O ,/O nasopharyngitis/B-AdverseReaction ,/O (/O viral/O )/O upper/O respiratory/O tract/O infection/O ,/O pneumonia/B-AdverseReaction ,/O rhinitis/B-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O tonsillitis/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O viral/B-AdverseReaction infection/I-AdverseReaction )/O 97/O (/O 54.8%)(0.91/O )/O 27/O (/O 54%)(0.59/O )/O 19/O (/O 38%)(0.63/O )/O 13/O (/O 30.2%)(1.26/O )/O 5/O (/O 12.2%)(1.37/O )/O Gastrointestinal/O disorders/O Abdominal/O pain/O (/O upper/O )/O 25/O (/O 14.1%)(0.16/O )/O 8/O (/O 16%)(0.15/O )/O 6/O (/O 12%)(0.08/O )/O 3/O (/O 7%)(0.25/O )/O 1/O (/O 2.4%)(0.23/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction mild/O 19/O (/O 10.7/O %/O )/O 6/O (/O 12.0/O %/O )/O 2/O (/O 4.0/O %/O )/O 0/O 3/O (/O 7.3/O %/O )/O moderate/O 2/O (/O 1.1/O %/O )/O 1/O (/O 2.0/O %/O )/O 0/O 0/O 0/O 6.2/O Hypersensitivity/O During/O clinical/O trials/O ,/O no/B-Negation anaphylactic/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O ./O
In/O CAPS/O trials/O one/O patient/O discontinued/O and/O in/O SJIA/O trials/O no/O patients/O discontinued/O due/O to/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ./O
ILARIS/O should/O not/O be/O administered/O to/O any/O patients/O with/O known/O clinical/O hypersensitivity/O to/O ILARIS/O [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
6.3/O Immunogenicity/O A/O biosensor/O binding/O assay/O or/O a/O bridging/O immunoassay/O was/O used/O to/O detect/O antibodies/O directed/O against/O canakinumab/O in/O patients/O who/O received/O ILARIS/O ./O
Antibodies/O against/O ILARIS/O were/O observed/O in/O approximately/O 1.5/O %/O and/O 3.1/O %/O of/O the/O patients/O treated/O with/O ILARIS/O for/O CAPS/O and/O SJIA/O ,/O respectively/O ./O
No/O neutralizing/O antibodies/O were/O detected/O ./O
No/O apparent/O correlation/O of/O antibody/O development/O to/O clinical/O response/O or/O adverse/O events/O was/O observed/O ./O
The/O CAPS/O clinical/O studies/O employed/O the/O biosensor/O binding/O assay/O ,/O and/O most/O of/O the/O SJIA/O clinical/O studies/O employed/O the/O bridging/O assay/O ./O
The/O data/O obtained/O in/O an/O assay/O are/O highly/O dependent/O on/O several/O factors/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O underlying/O disease/O ,/O and/O the/O number/O of/O patients/O tested/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O canakinumab/O between/O the/O CAPS/O and/O SJIA/O clinical/O studies/O or/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
6.4/O Laboratory/O Findings/O Hematology/O During/O clinical/O trials/O with/O ILARIS/O ,/O mean/O values/O decreased/O for/O white/O blood/O cells/O ,/O neutrophils/O and/O platelets/O ./O
In/O the/O randomized/O ,/O placebo/O -/O controlled/O portion/O of/O SJIA/O Study/O 2/O decreased/B-AdverseReaction white/I-AdverseReaction blood/I-AdverseReaction cell/I-AdverseReaction counts/I-AdverseReaction (/O WBC/O )/O less/O than/O or/O equal/O to/O 0.8/B-Severity times/I-Severity lower/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O LLN/O )/O were/O reported/O in/O 5/O patients/O (/O 10.4%)in/O the/O ILARIS/O group/O compared/O to/O 2/O (/O 4.0/O %/O )/O in/O the/O placebo/O group/O ./O
Transient/B-Severity decreases/B-AdverseReaction in/I-AdverseReaction absolute/I-AdverseReaction neutrophil/I-AdverseReaction count/I-AdverseReaction (/O ANC/O )/O to/O less/O than/O 1x10/B-Severity 9/I-Severity /L/O were/O reported/O in/O 3/O patients/O (/O 6.0/O %/O )/O in/O the/O ILARIS/O group/O compared/O to1/O patient/O (/O 2.0/O %/O )/O in/O the/O placebo/O group/O ./O
One/O case/O of/O ANC/B-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 0.5x10/I-AdverseReaction 9/I-AdverseReaction /L/O was/O observed/O in/O the/O ILARIS/O group/O and/O none/O in/O the/O placebo/O group/O ./O
Mild/B-Severity (/O less/O than/O LLN/B-Severity and/O greater/O than/O 75x10/B-Severity 9/I-Severity /L/O )/O and/O transient/B-Severity decreases/B-AdverseReaction in/I-AdverseReaction platelet/I-AdverseReaction counts/I-AdverseReaction were/O observed/O in/O 3/O (/O 6.3/O %/O )/O ILARIS/O treated/O patients/O versus/O 1/O (/O 2.0/O %/O )/O placebo/O -/O treated/O patient/O ./O
Hepatic/O Transaminases/O Elevations/B-AdverseReaction of/I-AdverseReaction transaminases/I-AdverseReaction have/O been/O observed/O in/O patients/O treated/O with/O ILARIS/O ./O
In/O the/O randomized/O ,/O placebo/O -/O controlled/O portion/O of/O SJIA/O Study/O 2/O ,/O high/B-AdverseReaction ALT/I-AdverseReaction and/or/O AST/O greater/O than/O or/O equal/O to/O 3/B-Severity times/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O ULN/O )/O were/O reported/O in/O 2/O (/O 4.1/O %/O )/O ILARIS/O -/O treated/O patients/O and/O 1/O (/O 2.0/O %/O )/O placebo/O patient/O ./O
All/O patients/O had/O normal/O values/O at/O the/O next/O visit/O ./O
Bilirubin/O Asymptomatic/O and/O mild/B-Severity elevations/B-AdverseReaction of/I-AdverseReaction serum/I-AdverseReaction bilirubin/I-AdverseReaction have/O been/O observed/O in/O patients/O treated/O with/O ILARIS/O without/B-Negation concomitant/O elevations/B-AdverseReaction of/I-AdverseReaction transaminases/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Interleukin-1/O blockade/O may/O interfere/O with/O immune/O response/O to/O infections/O ./O
Treatment/O with/O medications/B-DrugClass that/I-DrugClass work/I-DrugClass through/I-DrugClass inhibition/I-DrugClass of/I-DrugClass IL-1/I-DrugClass has/O been/O associated/O with/O an/O increased/O risk/O of/O serious/B-Severity infections/B-AdverseReaction ./O
ILARIS/O has/O been/O associated/O with/O an/O increased/O incidence/O of/O serious/B-Severity infections/B-AdverseReaction ./O
Physicians/O should/O exercise/O caution/O when/O administering/O ILARIS/O to/O patients/O with/O infections/O ,/O a/O history/O of/O recurring/O infections/O or/O underlying/O conditions/O which/O may/O predispose/O them/O to/O infections/O ./O
Discontinue/O treatment/O with/O ILARIS/O if/O a/O patient/O develops/O a/O serious/O infection/O ./O
Do/O not/O administer/O ILARIS/O to/O patients/O during/O an/O active/O infection/O requiring/O medical/O intervention/O ./O
(/O 5.1/O )/O Live/O vaccines/O should/O not/O be/O given/O concurrently/O with/O ILARIS/O ./O
Prior/O to/O initiation/O of/O therapy/O with/O ILARIS/O ,/O patients/O should/O receive/O all/O recommended/O vaccinations/O ./O
(/O 5.4/O )/O 5.1/O Serious/O Infections/O ILARIS/O has/O been/O associated/O with/O an/O increased/O risk/B-Factor of/O serious/B-Severity infections/B-AdverseReaction ./O
Physicians/O should/O exercise/O caution/O when/O administering/O ILARIS/O to/O patients/O with/O infections/O ,/O a/O history/O of/O recurring/O infections/O or/O underlying/O conditions/O which/O may/O predispose/O them/O to/O infections/O ./O
ILARIS/O should/O not/O be/O administered/O to/O patients/O during/O an/O active/O infection/O requiring/O medical/O intervention/O ./O
Administration/O of/O ILARIS/O should/O be/O discontinued/O if/O a/O patient/O develops/O a/O serious/O infection/O ./O
Infections/B-AdverseReaction ,/O predominantly/O of/O the/O upper/O respiratory/O tract/O ,/O in/O some/O instances/O serious/B-Severity ,/O have/O been/O reported/O with/O ILARIS/O ./O
Generally/O ,/O the/O observed/O infections/B-AdverseReaction responded/O to/O standard/O therapy/O ./O
Isolated/O cases/O of/O unusual/O or/O opportunistic/B-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O aspergillosis/B-AdverseReaction ,/O atypical/B-AdverseReaction mycobacterial/I-AdverseReaction infections/I-AdverseReaction ,/O cytomegalovirus/O ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction )/O were/O reported/O during/O ILARIS/O treatment/O ./O
A/O causal/O relationship/O of/O ILARIS/O to/O these/O events/O can/O not/O be/O excluded/O ./O
In/O clinical/O trials/O ,/O ILARIS/O has/O not/O been/O administered/O concomitantly/O with/O tumor/O necrosis/O factor/O (/O TNF/O )/O inhibitors/O ./O
An/O increased/O incidence/O of/O serious/B-Severity infections/B-AdverseReaction has/O been/O associated/O with/O administration/O of/O another/O IL-1/B-DrugClass blocker/I-DrugClass in/O combination/O with/O TNF/O inhibitors/O ./O
Coadministration/O of/O ILARIS/O with/O TNF/O inhibitors/O is/O not/O recommended/O because/O this/O may/O increase/O the/O risk/O of/O serious/O infections/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
Drugs/O that/O affect/O the/O immune/O system/O by/O blocking/O TNF/O have/O been/O associated/O with/O an/O increased/O risk/O of/O new/O tuberculosis/O and/O reactivation/O of/O latent/O tuberculosis/O (/O TB/O )/O ./O
It/O is/O possible/O that/O use/O of/O IL-1/O inhibitors/O such/O as/O ILARIS/O increases/O the/O risk/B-Factor of/O reactivation/B-AdverseReaction of/I-AdverseReaction tuberculosis/I-AdverseReaction or/O of/O opportunistic/B-AdverseReaction infections/I-AdverseReaction ./O
Prior/O to/O initiating/O immunomodulatory/O therapies/O ,/O including/O ILARIS/O ,/O patients/O should/O be/O evaluated/O for/O active/O and/O latent/O tuberculosis/O infection/O ./O
Appropriate/O screening/O tests/O should/O be/O performed/O in/O all/O patients/O ./O
ILARIS/O has/O not/O been/O studied/O in/O patients/O with/O a/O positive/O tuberculosis/O screen/O ,/O and/O the/O safety/O of/O ILARIS/O in/O individuals/O with/O latent/O tuberculosis/O infection/O is/O unknown/O ./O
Patients/O testing/O positive/O in/O tuberculosis/O screening/O should/O be/O treated/O according/O to/O standard/O medical/O practice/O prior/O to/O therapy/O with/O ILARIS/O ./O
All/O patients/O should/O be/O instructed/O to/O seek/O medical/O advice/O if/O signs/O ,/O symptoms/O ,/O or/O high/O risk/O exposure/O suggestive/O of/O tuberculosis/O (/O e.g./O ,/O persistent/O cough/O ,/O weight/O loss/O ,/O subfebrile/O temperature/O )/O appear/O during/O or/O after/O ILARIS/O therapy/O ./O
Healthcare/O providers/O should/O follow/O current/O CDC/O guidelines/O both/O to/O evaluate/O for/O and/O to/O treat/O possible/O latent/O tuberculosis/O infections/O before/O initiating/O therapy/O with/O ILARIS/O ./O
5.2/O Immunosuppression/O The/O impact/O of/O treatment/O with/O anti/O -/O interleukin-1/O (/O IL-1/O )/O therapy/O on/O the/O development/O of/O malignancies/O is/O not/O known/O ./O
However/O ,/O treatment/O with/O immunosuppressants/O ,/O including/O ILARIS/O ,/O may/O result/O in/O an/O increase/O in/O the/O risk/B-Factor of/O malignancies/B-AdverseReaction ./O
5.3/O Hypersensitivity/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O with/O ILARIS/O therapy/O ./O
During/O clinical/O trials/O ,/O no/B-Negation anaphylactic/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O ./O
It/O should/O be/O recognized/O that/O symptoms/O of/O the/O underlying/O disease/O being/O treated/O may/O be/O similar/O to/O symptoms/O of/O hypersensitivity/O ./O
ILARIS/O should/O not/O be/O administered/O to/O any/O patients/O with/O known/O clinical/O hypersensitivity/O to/O ILARIS/O [/O see/O Contraindications/O (/O 4/O )/O and/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.4/O Immunizations/O Live/O vaccines/O should/O not/O be/O given/O concurrently/O with/O ILARIS/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
Since/O no/O data/O are/O available/O on/O either/O the/O efficacy/O or/O on/O the/O risks/O of/O secondary/O transmission/O of/O infection/O by/O live/O vaccines/O in/O patients/O receiving/O ILARIS/O ,/O live/O vaccines/O should/O not/O be/O given/O concurrently/O with/O ILARIS/O ./O
In/O addition/O ,/O because/O ILARIS/O may/B-Factor interfere/B-AdverseReaction with/I-AdverseReaction normal/I-AdverseReaction immune/I-AdverseReaction response/I-AdverseReaction to/O new/O antigens/O ,/O vaccinations/O may/O not/O be/O effective/O in/O patients/O receiving/O ILARIS/O ./O
No/O data/O are/O available/O on/O the/O effectiveness/O of/O vaccinations/O with/O inactivated/O (/O killed/O )/O antigens/O in/O patients/O receiving/O ILARIS/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
Because/O IL-1/O blockade/O may/O interfere/O with/O immune/O response/O to/O infections/O ,/O it/O is/O recommended/O that/O prior/O to/O initiation/O of/O therapy/O with/O ILARIS/O ,/O adult/O and/O pediatric/O patients/O receive/O all/O recommended/O vaccinations/O ,/O as/O appropriate/O ,/O including/O pneumococcal/O vaccine/O and/O inactivated/O influenza/O vaccine/O ./O
(/O See/O current/O recommended/O immunization/O schedules/O at/O the/O website/O of/O the/O Centers/O for/O Disease/O Control/O ,/O http://www.cdc.gov/vaccines/schedules/index.html/O )/O ./O
5.5/O Macrophage/O Activation/O Syndrome/O Macrophage/O activation/O syndrome/O (/O MAS/O )/O is/O a/O known/O ,/O life/O -/O threatening/O disorder/O that/O may/O develop/O in/O patients/O with/O rheumatic/O conditions/O ,/O in/O particular/O SJIA/O ,/O and/O should/O be/O aggressively/O treated/O ./O
Physicians/O should/O be/O attentive/O to/O symptoms/O of/O infection/O or/O worsening/O of/O SJIA/O ,/O as/O these/O are/O known/O triggers/O for/O MAS/O ./O
Eleven/O cases/O of/O MAS/B-AdverseReaction were/O observed/O in/O 201/O SJIA/O patients/O treated/O with/O canakinumab/O in/O clinical/O trials/O ./O
Based/O on/O the/O clinical/O trial/O experience/O ,/O ILARIS/O does/O not/O appear/O to/O increase/O the/O incidence/O of/O MAS/B-AdverseReaction in/O SJIA/O patients/O ,/O but/O no/B-Factor definitive/I-Factor conclusion/I-Factor can/O be/O made/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Hemorrhage/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Cytopenias/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Atrial/B-AdverseReaction Fibrillation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Second/B-AdverseReaction Primary/I-AdverseReaction Malignancies/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O variable/O conditions/O ,/O adverse/O event/O rates/O observed/O in/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O of/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 25/O %/O )/O in/O patients/O with/O B/O -/O cell/O malignancies/O (/O MCL/O ,/O CLL/O ,/O WM/O )/O were/O thrombocytopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O bruising/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pharmacyclics/O at/O 1/O -/O 877/O -/O 877/O -/O 3536/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Mantle/O Cell/O Lymphoma/O The/O data/O described/O below/O reflect/O exposure/O to/O IMBRUVICA/O in/O a/O clinical/O trial/O that/O included/O 111/O patients/O with/O previously/O treated/O MCL/O treated/O with/O 560/O mg/O daily/O with/O a/O median/O treatment/O duration/O of/O 8.3/O months/O ./O
The/O most/O commonly/O occurring/O adverse/O reactions/O (/O 20/O %/O )/O were/O thrombocytopenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O bruising/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O vomiting/B-AdverseReaction and/O decreased/B-AdverseReaction appetite/I-AdverseReaction (/O see/O Tables/O 1/O and/O 2/O )/O ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity or/O 4/O non/O -/O hematological/O adverse/O reactions/O (/O 5/O %/O )/O were/O pneumonia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O skin/B-AdverseReaction infections/I-AdverseReaction ./O
Fatal/B-AdverseReaction and/O serious/B-Severity cases/O of/O renal/B-AdverseReaction failure/I-AdverseReaction have/O occurred/O with/O IMBRUVICA/O therapy/O ./O
Increases/B-AdverseReaction in/I-AdverseReaction creatinine/I-AdverseReaction 1.5/B-Severity to/I-Severity 3/I-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity occurred/O in/O 9/O %/O of/O patients/O ./O
Adverse/O reactions/O from/O the/O MCL/O trial/O (/O N=111/O )/O using/O single/O agent/O IMBRUVICA/O 560/O mg/O daily/O occurring/O at/O a/O rate/O of/O 10/O %/O are/O presented/O in/O Table/O 1/O ./O
Table/O 1/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O in/O 10/O %/O of/O Patients/O with/O MCL/O (/O N=111/O )/O System/O Organ/O Class/O Preferred/O Term/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 51/O 5/O Nausea/B-AdverseReaction 31/O 0/O Constipation/B-AdverseReaction 25/O 0/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 24/O 5/O Vomiting/B-AdverseReaction 23/O 0/O Stomatitis/B-AdverseReaction 17/O 1/O Dyspepsia/B-AdverseReaction 11/O 0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 34/O 0/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 14/O 3/O Pneumonia/B-AdverseReaction 14/O 7/O Skin/B-AdverseReaction infections/I-AdverseReaction 14/O 5/O Sinusitis/B-AdverseReaction 13/O 1/O General/O disorders/O and/O administrative/O site/O conditions/O Fatigue/B-AdverseReaction 41/O 5/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 35/O 3/O Pyrexia/B-AdverseReaction 18/O 1/O Asthenia/B-AdverseReaction 14/O 3/O Skin/O and/O subcutaneous/O tissue/O disorders/O Bruising/B-AdverseReaction 30/O 0/O Rash/B-AdverseReaction 25/O 3/O Petechiae/B-AdverseReaction 11/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 37/O 1/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 14/O 0/O Arthralgia/B-AdverseReaction 11/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Dyspnea/B-AdverseReaction 27/O 4/O Cough/B-AdverseReaction 19/O 0/O Epistaxis/B-AdverseReaction 11/O 0/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 21/O 2/O Dehydration/B-AdverseReaction 12/O 4/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 14/O 0/O Headache/B-AdverseReaction 13/O 0/O Table/O 2/O :/O Treatment/O -/O EmergentBased/O on/O laboratory/O measurements/O and/O adverse/O reactions/O Decrease/B-AdverseReaction of/I-AdverseReaction Hemoglobin/I-AdverseReaction ,/O Platelets/O ,/O or/O Neutrophils/O in/O Patients/O with/O MCL/O (/O N=111/O )/O Percent/O of/O Patients/O (/O N=111/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 57/O 17/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 47/O 29/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 41/O 9/O Ten/O patients/O (/O 9/O %/O )/O discontinued/O treatment/O due/O to/O adverse/O reactions/O in/O the/O trial/O (/O N=111/O )/O ./O
The/O most/O frequent/O adverse/O reaction/O leading/O to/O treatment/O discontinuation/O was/O subdural/B-AdverseReaction hematoma/I-AdverseReaction (/O 1.8/O %/O )/O ./O
Adverse/O reactions/O leading/O to/O dose/O reduction/O occurred/O in/O 14/O %/O of/O patients/O ./O
Patients/O with/O MCL/O who/O develop/O lymphocytosis/O greater/O than/O 400,000/O mcL/O have/O developed/O intracranial/O hemorrhage/O ,/O lethargy/O ,/O gait/O instability/O ,/O and/O headache/O ./O
However/O ,/O some/O of/O these/O cases/O were/O in/O the/O setting/O of/O disease/O progression/O ./O
Forty/O percent/O of/O patients/O had/O elevated/B-AdverseReaction uric/I-AdverseReaction acid/I-AdverseReaction levels/I-AdverseReaction on/O study/O including/O 13/O %/O with/O values/O above/B-Severity 10/I-Severity mg/I-Severity dL./O Adverse/O reaction/O of/O hyperuricemia/B-AdverseReaction was/O reported/O for/O 15/O %/O of/O patients/O ./O
Chronic/O Lymphocytic/O Leukemia/O The/O data/O described/O below/O reflect/O exposure/O to/O IMBRUVICA/O in/O an/O open/O label/O clinical/O trial/O (/O Study/O 1/O )/O that/O included/O 48/O patients/O with/O previously/O treated/O CLL/O and/O a/O randomized/O clinical/O trial/O (/O Study/O 2/O )/O that/O included/O 391/O randomized/O patients/O with/O previously/O treated/O CLL/O or/O SLL/O ./O
The/O most/O commonly/O occurring/O adverse/O reactions/O in/O Study/O 1/O and/O Study/O 2/O (/O 20/O %/O )/O were/O thrombocytopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O pyrexia/B-AdverseReaction ./O
Approximately/O five/O percent/O of/O patients/O receiving/O IMBRUVICA/O in/O Study/O 1/O and/O Study/O 2/O discontinued/O treatment/O due/O to/O adverse/O events/O ./O
These/O included/O infections/B-AdverseReaction ,/O subdural/B-AdverseReaction hematomas/I-AdverseReaction and/O diarrhea/B-AdverseReaction ./O
Adverse/O events/O leading/O to/O dose/O reduction/O occurred/O in/O approximately/O 6/O %/O of/O patients/O ./O
Study/O 1/O Adverse/O reactions/O and/O laboratory/O abnormalities/O from/O the/O CLL/O trial/O (/O N=48/O )/O using/O single/O agent/O IMBRUVICA/O 420/O mg/O daily/O occurring/O at/O a/O rate/O of/O 10/O %/O are/O presented/O in/O Tables/O 3/O and/O 4/O ./O
Table/O 3/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O in/O 10/O %/O of/O Patients/O with/O CLL/O (/O N=48/O )/O in/O Study/O 1/O System/O Organ/O Class/O Preferred/O Term/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 63/O 4/O Constipation/B-AdverseReaction 23/O 2/O Nausea/B-AdverseReaction 21/O 2/O Stomatitis/B-AdverseReaction 21/O 0/O Vomiting/B-AdverseReaction 19/O 2/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 15/O 0/O Dyspepsia/B-AdverseReaction 13/O 0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 48/O 2/O Sinusitis/B-AdverseReaction 21/O 6/O Skin/B-AdverseReaction infection/I-AdverseReaction 17/O 6/O Pneumonia/B-AdverseReaction 10/O 8/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 10/O 0/O General/O disorders/O and/O administrative/O site/O conditions/O Fatigue/B-AdverseReaction 31/O 4/O Pyrexia/B-AdverseReaction 25/O 2/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 23/O 0/O Asthenia/B-AdverseReaction 13/O 4/O Chills/B-AdverseReaction 13/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Bruising/B-AdverseReaction 54/O 2/O Rash/B-AdverseReaction 27/O 0/O Petechiae/B-AdverseReaction 17/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 19/O 0/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 15/O 0/O Dyspnea/B-AdverseReaction 10/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 27/O 6/O Arthralgia/B-AdverseReaction 23/O 0/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 19/O 2/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 21/O 0/O Headache/B-AdverseReaction 19/O 2/O Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction 10/O 0/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 17/O 2/O Neoplasms/O benign/O ,/O malignant/O ,/O unspecified/O Second/B-AdverseReaction malignancies/I-AdverseReaction 10/O 0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Laceration/B-AdverseReaction 10/O 2/O Psychiatric/O disorders/O Anxiety/B-AdverseReaction 10/O 0/O Insomnia/B-AdverseReaction 10/O 0/O Vascular/O disorders/O Hypertension/B-AdverseReaction 17/O 8/O Table/O 4/O :/O Treatment/O -/O EmergentBased/O on/O laboratory/O measurements/O per/O IWCLL/O criteria/O and/O adverse/O reactions/O Decrease/B-AdverseReaction of/I-AdverseReaction Hemoglobin/I-AdverseReaction ,/O Platelets/O ,/O or/O Neutrophils/O in/O Patients/O with/O CLL/O (/O N=48/O )/O in/O Study/O 1/O Percent/O of/O Patients/O (/O N=48/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 71/O 10/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 54/O 27/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 44/O 0/O Study/O 2/O Adverse/O reactions/O and/O laboratory/O abnormalities/O described/O below/O in/O Tables/O 5/O and/O 6/O reflect/O exposure/O to/O IMBRUVICA/O with/O a/O median/O duration/O of/O 8.6/O months/O and/O exposure/O to/O ofatumumab/O with/O a/O median/O of/O 5.3/O months/O in/O Study/O 2/O ./O
Table/O 5/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O 10/O %/O Reported/O in/O Study/O 2/O IMBRUVICA(N=195/O )/O Ofatumumab(N=191/O )/O System/O Organ/O Class/O ADR/O Term/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Subjects/O with/O multiple/O events/O for/O a/O given/O ADR/O term/O are/O counted/O once/O only/O for/O each/O ADR/O term/O ./O
The/O system/O organ/O class/O and/O individual/O ADR/O terms/O are/O sorted/O in/O descending/O frequency/O order/O in/O the/O IMBRUVICA/O arm/O ./O
Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 48/O 4/O 18/O 2/O Nausea/B-AdverseReaction 26/O 2/O 18/O 0/O Stomatitis/B-AdverseReaction 17/O 1/O 6/O 1/O Constipation/B-AdverseReaction 15/O 0/O 9/O 0/O Vomiting/B-AdverseReaction 14/O 0/O 6/O 1/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 28/O 2/O 30/O 2/O Pyrexia/B-AdverseReaction 24/O 2/O 15/O 1/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 16/O 1/O 11/O 2/O Pneumonia/B-AdverseReaction 15/O 10/O 13/O 9/O Sinusitis/B-AdverseReaction 11/O 1/O 6/O 0/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 10/O 4/O 5/O 1/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 24/O 3/O 13/O 0/O Petechiae/B-AdverseReaction 14/O 0/O 1/O 0/O Bruising/B-AdverseReaction 12/O 0/O 1/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Musculoskeletal/B-AdverseReaction Pain/I-AdverseReaction 28/O 2/O 18/O 1/O Arthralgia/B-AdverseReaction 17/O 1/O 7/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 14/O 1/O 6/O 0/O Dizziness/B-AdverseReaction 11/O 0/O 5/O 0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Contusion/B-AdverseReaction 11/O 0/O 3/O 0/O Eye/O disorders/O Vision/B-AdverseReaction blurred/I-AdverseReaction 10/O 0/O 3/O 0/O Table/O 6/O :/O Treatment/O -/O EmergentBased/O on/O laboratory/O measurements/O per/O IWCLL/O criteria/O Decrease/B-AdverseReaction of/I-AdverseReaction Hemoglobin/I-AdverseReaction ,/O Platelets/O ,/O or/O Neutrophils/O in/O Study/O 2/O IMBRUVICA(N=195/O )/O Ofatumumab(N=191/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 51/O 23/O 57/O 26/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 52/O 5/O 45/O 10/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 36/O 0/O 21/O 0/O Waldenstrom/O 's/O Macroglobulinemia/O The/O data/O described/O below/O reflect/O exposure/O to/O IMBRUVICA/O in/O an/O open/O label/O clinical/O trial/O that/O included/O 63/O patients/O with/O previously/O treated/O WM/O ./O
The/O most/O commonly/O occurring/O adverse/O reactions/O in/O the/O WM/O trial/O (/O 20/O %/O )/O were/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O muscle/B-AdverseReaction spasms/I-AdverseReaction ,/O and/O fatigue/B-AdverseReaction ./O
Six/O percent/O of/O patients/O receiving/O IMBRUVICA/O in/O the/O WM/O trial/O discontinued/O treatment/O due/O to/O adverse/O events/O ./O
Adverse/O events/O leading/O to/O dose/O reduction/O occurred/O in/O 11/O %/O of/O patients/O ./O
Adverse/O reactions/O and/O laboratory/O abnormalities/O described/O below/O in/O Tables/O 7/O and/O 8/O reflect/O exposure/O to/O IMBRUVICA/O with/O a/O median/O duration/O of/O 11.7/O months/O in/O the/O WM/O trial/O ./O
Table/O 7/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O in/O 10/O %/O of/O Patients/O with/O Waldenstrom/O 's/O Macroglobulinemia/O (/O N=63/O )/O System/O Organ/O Class/O Preferred/O Term/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O The/O system/O organ/O class/O and/O individual/O ADR/O terms/O are/O sorted/O in/O descending/O frequency/O order/O ./O
Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 37/O 0/O Nausea/B-AdverseReaction 21/O 0/O Stomatitis/B-AdverseReaction 16/O 0/O Gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction 13/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 22/O 0/O Bruising/B-AdverseReaction 16/O 0/O Pruritus/B-AdverseReaction 11/O 0/O General/O disorders/O and/O administrative/O site/O conditions/O Fatigue/B-AdverseReaction 21/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 21/O 0/O Arthropathy/B-AdverseReaction 13/O 0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 19/O 0/O Sinusitis/B-AdverseReaction 19/O 0/O Pneumonia/B-AdverseReaction 14/O 6/O Skin/B-AdverseReaction infection/I-AdverseReaction 14/O 2/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Epistaxis/B-AdverseReaction 19/O 0/O Cough/B-AdverseReaction 13/O 0/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 14/O 0/O Headache/B-AdverseReaction 13/O 0/O Neoplasms/O benign/O ,/O malignant/O ,/O and/O unspecified/O (/O including/O cysts/O and/O polyps/O )/O Skin/B-AdverseReaction cancer/I-AdverseReaction 11/O 0/O Table/O 8/O :/O Treatment/O -/O EmergentBased/O on/O laboratory/O measurements/O ./O
Decrease/B-AdverseReaction of/I-AdverseReaction Hemoglobin/I-AdverseReaction ,/O Platelets/O ,/O or/O Neutrophils/O in/O Patients/O with/O WM/O (/O N=63/O )/O Percent/O of/O Patients/O (/O N=63/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O or/O 4/O (/O %/O )/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 43/O 13/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 44/O 19/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 13/O 8/O 6/O ./O
2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O IMBRUVICA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction including/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction (/O fatal/B-AdverseReaction )/O ,/O urticaria/B-AdverseReaction ,/O and/O angioedema/B-AdverseReaction have/O been/O reported/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hemorrhage/B-AdverseReaction :/O Monitor/O for/O bleeding/O (/O 5.1/O )/O ./O
Infections/B-AdverseReaction :/O Monitor/O patients/O for/O fever/O and/O infections/O and/O evaluate/O promptly/O (/O 5.2/O )/O ./O
Cytopenias/B-AdverseReaction :/O Check/O complete/O blood/O counts/O monthly/O (/O 5.3/O )/O ./O
Atrial/B-AdverseReaction Fibrillation/I-AdverseReaction :/O Monitor/O patients/O for/O atrial/O fibrillation/O (/O 5.4/O )/O ./O
Second/B-AdverseReaction Primary/I-AdverseReaction Malignancies/I-AdverseReaction :/O Other/O malignancies/B-AdverseReaction have/O occurred/O in/O patients/O ,/O including/O skin/B-AdverseReaction cancers/I-AdverseReaction ,/O and/O other/O carcinomas/B-AdverseReaction (/O 5.5/O )/O ./O
Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction (/O TLS/B-AdverseReaction )/O :/O Monitor/O patients/O at/O risk/O for/O TLS/O (/O e.g./O high/O tumor/O burden/O )/O (/O 5.6/O )/O ./O
Embryo/B-AdverseReaction -/I-AdverseReaction Fetal/O Toxicity/O :/O Can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O women/O of/O the/O potential/O risk/O to/O a/O fetus/O and/O to/O avoid/O pregnancy/O while/O taking/O the/O drug/O (/O 5.7/O )/O ./O
5.1/O Hemorrhage/O Fatal/B-AdverseReaction bleeding/B-AdverseReaction events/I-AdverseReaction have/O occurred/O in/O patients/O treated/O with/O IMBRUVICA/O ./O
Grade/B-Severity 3/I-Severity or/O higher/O bleeding/B-AdverseReaction events/I-AdverseReaction (/O subdural/B-AdverseReaction hematoma/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction bleeding/I-AdverseReaction ,/O hematuria/B-AdverseReaction and/O post/B-AdverseReaction procedural/I-AdverseReaction hemorrhage/I-AdverseReaction )/O have/O occurred/O in/O up/O to/O 6/O %/O of/O patients/O ./O
Bleeding/B-AdverseReaction events/O of/O any/O grade/O ,/O including/O bruising/B-AdverseReaction and/O petechiae/B-AdverseReaction ,/O occurred/O in/O approximately/O half/O of/O patients/O treated/O with/O IMBRUVICA/O ./O
The/O mechanism/O for/O the/O bleeding/O events/O is/O not/O well/O understood/O ./O
IMBRUVICA/O may/B-Factor increase/O the/O risk/O of/O hemorrhage/B-AdverseReaction in/O patients/O receiving/O antiplatelet/O or/O anticoagulant/O therapies/O ./O
Consider/O the/O benefit/O -/O risk/O of/O withholding/O IMBRUVICA/O for/O at/O least/O 3/O to/O 7/O days/O pre/O and/O post/O -/O surgery/O depending/O upon/O the/O type/O of/O surgery/O and/O the/O risk/O of/O bleeding/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
5.2/O Infections/O Fatal/B-AdverseReaction and/O non/B-Severity -/O fatal/O infections/B-AdverseReaction have/O occurred/O with/O IMBRUVICA/O therapy/O ./O
Grade/B-Severity 3/I-Severity or/O greater/O infections/B-AdverseReaction occurred/O in/O 14/O %/O to/O 26/O %/O of/O patients/O ./O
[/O See/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Cases/O of/O progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O have/O occurred/O in/O patients/O treated/O with/O IMBRUVICA/O ./O
Monitor/O patients/O for/O fever/O and/O infections/O and/O evaluate/O promptly/O ./O
5.3/O Cytopenias/O Treatment/O -/O emergent/O Grade/B-Severity 3/I-Severity or/O 4/O cytopenias/B-AdverseReaction including/O neutropenia/B-AdverseReaction (/O range/O ,/O 19/O to/O 29/O %/O )/O ,/O thrombocytopenia/B-AdverseReaction (/O range/O ,/O 5/O to/O 17/O %/O )/O ,/O and/O anemia/B-AdverseReaction (/O range/O ,/O 0/O to/O 9/O %/O )/O occurred/O in/O patients/O treated/O with/O IMBRUVICA/O ./O
Monitor/O complete/O blood/O counts/O monthly/O ./O
5.4/O Atrial/O Fibrillation/O Atrial/B-AdverseReaction fibrillation/I-AdverseReaction and/O atrial/B-AdverseReaction flutter/I-AdverseReaction (/O range/O ,/O 6/O to/O 9/O %/O )/O have/O occurred/O in/O patients/O treated/O with/O IMBRUVICA/O ,/O particularly/O in/O patients/O with/O cardiac/O risk/O factors/O ,/O acute/O infections/O ,/O and/O a/O previous/O history/O of/O atrial/O fibrillation/O ./O
Periodically/O monitor/O patients/O clinically/O for/O atrial/O fibrillation/O ./O
Patients/O who/O develop/O arrhythmic/O symptoms/O (/O e.g./O ,/O palpitations/O ,/O lightheadedness/O )/O or/O new/O onset/O dyspnea/O should/O have/O an/O ECG/O performed/O ./O
If/O atrial/O fibrillation/O persists/O ,/O consider/O the/O risks/O and/O benefits/O of/O IMBRUVICA/O treatment/O and/O dose/O modification/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.5/O Second/O Primary/O Malignancies/O Other/O malignancies/B-AdverseReaction (/O range/O ,/O 5/O to/O 14/O %/O )/O including/O non/B-AdverseReaction -/I-AdverseReaction skin/O carcinomas/O (/O range/O ,/O 1/O to/O 3/O %/O )/O have/O occurred/O in/O patients/O treated/O with/O IMBRUVICA/O ./O
The/O most/O frequent/O second/B-AdverseReaction primary/I-AdverseReaction malignancy/I-AdverseReaction was/O non/B-AdverseReaction -/I-AdverseReaction melanoma/I-AdverseReaction skin/O cancer/O (/O range/O ,/O 4/O to/O 11/O %/O )/O ./O
5.6/O Tumor/O Lysis/O Syndrome/O Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O with/O IMBRUVICA/O therapy/O ./O
Monitor/O patients/O closely/O and/O take/O appropriate/O precautions/O in/O patients/O at/O risk/O for/O tumor/O lysis/O syndrome/O (/O e.g./O high/O tumor/O burden/O )/O ./O
5.7/O Embryo/O -/O Fetal/O Toxicity/O Based/O on/O findings/O in/O animals/B-Animal ,/O IMBRUVICA/O can/O cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Ibrutinib/O caused/O malformations/B-AdverseReaction in/O rats/B-Animal at/O exposures/O 14/O times/O those/O reported/O in/O patients/O with/O MCL/O and/O 20/O times/O those/O reported/O in/O patients/O with/O CLL/O or/O WM/O ,/O receiving/O the/O ibrutinib/O dose/O of/O 560/O mg/O per/O day/O and/O 420/O mg/O per/O day/O ,/O respectively/O ./O
Reduced/B-AdverseReaction fetal/I-AdverseReaction weights/I-AdverseReaction were/O observed/O at/O lower/O exposures/O ./O
Advise/O women/O to/O avoid/O becoming/O pregnant/O while/O taking/O IMBRUVICA/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O a/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O important/O adverse/O reactions/O are/O described/O below/O and/O elsewhere/O in/O the/O labeling/O :/O Hypotension/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Impairment/B-AdverseReaction in/I-AdverseReaction Renal/I-AdverseReaction Function/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hypoglycemia/B-AdverseReaction with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Genital/B-AdverseReaction Mycotic/I-AdverseReaction Infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Urinary/B-AdverseReaction Tract/I-AdverseReaction Infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Increased/B-AdverseReaction Low/I-AdverseReaction -/I-AdverseReaction Density/I-AdverseReaction Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O The/O most/O common/O adverse/O reactions/O associated/O with/O JARDIANCE/O (/O 5/O %/O or/O greater/O incidence/O )/O were/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction and/O female/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction (/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Boehringer/O Ingelheim/O Pharmaceuticals/O ,/O Inc./O at/O 1/O -/O 800/O -/O 542/O -/O 6257/O or/O 1/O -/O 800/O -/O 459/O -/O 9906/O TTY/O ,/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Pool/O of/O Placebo/O -/O Controlled/O Trials/O evaluating/O JARDIANCE/O 10/O and/O 25/O mg/O The/O data/O in/O Table/O 1/O are/O derived/O from/O a/O pool/O of/O four/O 24-week/O placebo/O -/O controlled/O trials/O and/O 18-week/O data/O from/O a/O placebo/O -/O controlled/O trial/O with/O insulin/O ./O
JARDIANCE/O was/O used/O as/O monotherapy/O in/O one/O trial/O and/O as/O add/O -/O on/O therapy/O in/O four/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O data/O reflect/O exposure/O of/O 1976/O patients/O to/O JARDIANCE/O with/O a/O mean/O exposure/O duration/O of/O approximately/O 23/O weeks/O ./O
Patients/O received/O placebo/O (/O N=995/O )/O ,/O JARDIANCE/O 10/O mg/O (/O N=999/O )/O ,/O or/O JARDIANCE/O 25/O mg/O (/O N=977/O )/O once/O daily/O ./O
The/O mean/O age/O of/O the/O population/O was/O 56/O years/O and/O 3/O %/O were/O older/O than/O 75/O years/O of/O age/O ./O
More/O than/O half/O (/O 55/O %/O )/O of/O the/O population/O was/O male/O ;/O 46/O %/O were/O White/O ,/O 50/O %/O were/O Asian/O ,/O and/O 3/O %/O were/O Black/O or/O African/O American/O ./O
At/O baseline/O ,/O 57/O %/O of/O the/O population/O had/O diabetes/O more/O than/O 5/O years/O and/O had/O a/O mean/O hemoglobin/O A1c/O (/O HbA1c/O )/O of/O 8/O %/O ./O
Established/O microvascular/O complications/O of/O diabetes/O at/O baseline/O included/O diabetic/O nephropathy/O (/O 7/O %/O )/O ,/O retinopathy/O (/O 8/O %/O )/O ,/O or/O neuropathy/O (/O 16/O %/O )/O ./O
Baseline/O renal/O function/O was/O normal/O or/O mildly/O impaired/O in/O 91/O %/O of/O patients/O and/O moderately/O impaired/O in/O 9/O %/O of/O patients/O (/O mean/O eGFR/O 86.8/O mL/O min/1.73/O m/O 2/O )/O ./O
Table/O 1/O shows/O common/O adverse/O reactions/O (/O excluding/O hypoglycemia/B-AdverseReaction )/O associated/O with/O the/O use/O of/O JARDIANCE/O ./O
The/O adverse/O reactions/O were/O not/O present/O at/O baseline/O ,/O occurred/O more/O commonly/O on/O JARDIANCE/O than/O on/O placebo/O and/O occurred/O in/O greater/O than/O or/O equal/O to/O 2/O %/O of/O patients/O treated/O with/O JARDIANCE/O 10/O mg/O or/O JARDIANCE/O 25/O mg/O ./O
Table/O 1/O Adverse/O Reactions/O Reported/O in/O 2/O %/O of/O Patients/O Treated/O with/O JARDIANCE/O and/O Greater/O than/O Placebo/O in/O Pooled/O Placebo/O -/O Controlled/O Clinical/O Studies/O of/O JARDIANCE/O Monotherapy/O or/O Combination/O Therapy/O a/O Predefined/O adverse/O event/O grouping/O ,/O including/O ,/O but/O not/O limited/O to/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O asymptomatic/B-AdverseReaction bacteriuria/I-AdverseReaction ,/O cystitis/B-AdverseReaction b/O Female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction include/O the/O following/O adverse/O reactions/O :/O vulvovaginal/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction ,/O vaginal/B-AdverseReaction infection/I-AdverseReaction ,/O vulvitis/B-AdverseReaction ,/O vulvovaginal/B-AdverseReaction candidiasis/I-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction ,/O genital/B-AdverseReaction candidiasis/I-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction fungal/I-AdverseReaction ,/O genitourinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O vulvovaginitis/B-AdverseReaction ,/O cervicitis/B-AdverseReaction ,/O urogenital/B-AdverseReaction infection/I-AdverseReaction fungal/I-AdverseReaction ,/O vaginitis/B-AdverseReaction bacterial/I-AdverseReaction ./O
Percentages/O calculated/O with/O the/O number/O of/O female/O subjects/O in/O each/O group/O as/O denominator/O :/O placebo/O (/O N=481/O )/O ,/O JARDIANCE/O 10/O mg/O (/O N=443/O )/O ,/O JARDIANCE/O 25/O mg/O (/O N=420/O )/O ./O
c/O Predefined/O adverse/O event/O grouping/O ,/O including/O ,/O but/O not/O limited/O to/O ,/O polyuria/B-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O and/O nocturia/B-AdverseReaction d/O Male/O genital/O mycotic/O infections/O include/O the/O following/O adverse/O reactions/O :/O balanoposthitis/B-AdverseReaction ,/O balanitis/B-AdverseReaction ,/O genital/B-AdverseReaction infections/I-AdverseReaction fungal/I-AdverseReaction ,/O genitourinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O balanitis/B-AdverseReaction candida/I-AdverseReaction ,/O scrotal/B-AdverseReaction abscess/I-AdverseReaction ,/O penile/B-AdverseReaction infection/I-AdverseReaction ./O
Percentages/O calculated/O with/O the/O number/O of/O male/O subjects/O in/O each/O group/O as/O denominator/O :/O placebo/O (/O N=514/O )/O ,/O JARDIANCE/O 10/O mg/O (/O N=556/O )/O ,/O JARDIANCE/O 25/O mg/O (/O N=557/O )/O ./O
Number/O (/O %/O )/O of/O Patients/O PlaceboN=995/O JARDIANCE/O 10/O mgN=999/O JARDIANCE/O 25/O mgN=977/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction a/O 7.6/O %/O 9.3/O %/O 7.6/O %/O Female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction b/O 1.5/O %/O 5.4/O %/O 6.4/O %/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 3.8/O %/O 3.1/O %/O 4.0/O %/O Increased/B-AdverseReaction urination/I-AdverseReaction c/O 1.0/O %/O 3.4/O %/O 3.2/O %/O Dyslipidemia/B-AdverseReaction 3.4/O %/O 3.9/O %/O 2.9/O %/O Arthralgia/B-AdverseReaction 2.2/O %/O 2.4/O %/O 2.3/O %/O Male/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction d/O 0.4/O %/O 3.1/O %/O 1.6/O %/O Nausea/B-AdverseReaction 1.4/O %/O 2.3/O %/O 1.1/O %/O Thirst/B-AdverseReaction (/O including/O polydipsia/B-AdverseReaction )/O was/O reported/O in/O 0/O %/O ,/O 1.7/O %/O ,/O and/O 1.5/O %/O for/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O ./O
Volume/O Depletion/O JARDIANCE/O causes/O an/O osmotic/B-AdverseReaction diuresis/I-AdverseReaction ,/O which/O may/B-Factor lead/O to/O intravascular/B-AdverseReaction volume/I-AdverseReaction contraction/I-AdverseReaction and/O adverse/O reactions/O related/O to/O volume/B-AdverseReaction depletion/I-AdverseReaction ./O
In/O the/O pool/O of/O five/O placebo/O -/O controlled/O clinical/O trials/O ,/O adverse/O reactions/O related/O to/O volume/B-AdverseReaction depletion/I-AdverseReaction (/O e.g./O ,/O blood/O pressure/O (/O ambulatory/O )/O decreased/O ,/O blood/B-AdverseReaction pressure/I-AdverseReaction systolic/I-AdverseReaction decreased/I-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O hypovolemia/B-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O and/O syncope/B-AdverseReaction )/O were/O reported/O by/O 0.3/O %/O ,/O 0.5/O %/O ,/O and/O 0.3/O %/O of/O patients/O treated/O with/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O respectively/O ./O
JARDIANCE/O may/O increase/O the/O risk/B-Factor of/O hypotension/B-AdverseReaction in/O patients/O at/O risk/O for/O volume/O contraction/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.5/O ,/O 8.6/O )/O ]/O ./O
Increased/B-AdverseReaction Urination/I-AdverseReaction In/O the/O pool/O of/O five/O placebo/O -/O controlled/O clinical/O trials/O ,/O adverse/O reactions/O of/O increased/B-AdverseReaction urination/I-AdverseReaction (/O e.g./O ,/O polyuria/B-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O and/O nocturia/B-AdverseReaction )/O occurred/O more/O frequently/O on/O JARDIANCE/O than/O on/O placebo/O (/O see/O Table/O 1/O )/O ./O
Specifically/O ,/O nocturia/B-AdverseReaction was/O reported/O by/O 0.4/O %/O ,/O 0.3/O %/O ,/O and/O 0.8/O %/O of/O patients/O treated/O with/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O ./O
Impairment/B-AdverseReaction in/I-AdverseReaction Renal/I-AdverseReaction Function/I-AdverseReaction Use/O of/O JARDIANCE/O was/O associated/O with/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction in/I-AdverseReaction eGFR/I-AdverseReaction (/O see/O Table/O 2/O )/O ./O
Patients/O with/O moderate/O renal/O impairment/O at/O baseline/O had/O larger/O mean/O changes/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.5/O ,/O 8.6/O )/O ]/O ./O
Table/O 2/O Changes/O from/O Baseline/O in/O Serum/O Creatinine/O and/O eGFR/O in/O the/O Pool/O of/O Four/O 24-week/O Placebo/O -/O Controlled/O Studies/O and/O Renal/O Impairment/O Study/O a/O Subset/O of/O patients/O from/O renal/O impairment/O study/O with/O eGFR/B-AdverseReaction 30/I-AdverseReaction to/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 60/I-AdverseReaction mL/I-AdverseReaction min/1.73/I-AdverseReaction m/O 2/O Pool/O of/O 24-Week/O Placebo/O -/O Controlled/O Studies/O Placebo/O JARDIANCE/O 10/O mg/O JARDIANCE/O 25/O mg/O Baseline/O Mean/O N/O 825/O 830/O 822/O Creatinine/O (/O mg/O dL/O )/O 0.84/O 0.85/O 0.85/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 87.3/O 87.1/O 87.8/O Week/O 12/O Change/O N/O 771/O 797/O 783/O Creatinine/O (/O mg/O dL/O )/O 0.00/O 0.02/O 0.01/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -0.3/O -1.3/O -1.4/O Week/O 24/O Change/O N/O 708/O 769/O 754/O Creatinine/O (/O mg/O dL/O )/O 0.00/O 0.01/O 0.01/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -0.3/O -0.6/O -1.4/O Moderate/O Renal/O Impairment/O a/O Placebo/O JARDIANCE/O 25/O mg/O Baseline/O N/O 187/O --/O 187/O Creatinine/O (/O mg/O dL/O )/O 1.49/O --/O 1.46/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 44.3/O --/O 45.4/O Week/O 12/O Change/O N/O 176/O --/O 179/O Creatinine/O (/O mg/O dL/O )/O 0.01/O --/O 0.12/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 0.1/O --/O -3.8/O Week/O 24/O Change/O N/O 170/O --/O 171/O Creatinine/O (/O mg/O dL/O )/O 0.01/O --/O 0.10/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 0.2/O --/O -3.2/O Week/O 52/O Change/O N/O 164/O --/O 162/O Creatinine/O (/O mg/O dL/O )/O 0.02/O --/O 0.11/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -0.3/O --/O -2.8/O Hypoglycemia/B-AdverseReaction The/O incidence/O of/O hypoglycemia/B-AdverseReaction by/O study/O is/O shown/O in/O Table/O 3/O ./O
The/O incidence/O of/O hypoglycemia/B-AdverseReaction increased/O when/O JARDIANCE/O was/O administered/O with/O insulin/O or/O sulfonylurea/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Table/O 3/O Incidence/O of/O Overalla/O and/O Severeb/B-Severity Hypoglycemic/B-AdverseReaction Events/I-AdverseReaction in/O Placebo/O -/O Controlled/O Clinical/O Studies/O a/O Overall/O hypoglycemic/B-AdverseReaction events/I-AdverseReaction :/O plasma/O or/O capillary/B-AdverseReaction glucose/I-AdverseReaction of/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction or/I-AdverseReaction equal/I-AdverseReaction to/I-AdverseReaction 70/I-AdverseReaction mg/I-AdverseReaction dL/O b/O Severe/B-Severity hypoglycemic/B-AdverseReaction events/I-AdverseReaction :/O requiring/O assistance/O regardless/O of/O blood/O glucose/O c/O Insulin/O dose/O could/O not/O be/O adjusted/O during/O the/O initial/O 18/O week/O treatment/O period/O Monotherapy(24/O weeks/O )/O Placebo(n=229/O )/O JARDIANCE/O 10/O mg(n=224/O )/O JARDIANCE/O 25/O mg(n=223/O )/O Overall/O (/O %/O )/O 0.4/O %/O 0.4/O %/O 0.4/O %/O Severe/O (/O %/O )/O 0/O %/O 0/O %/O 0/O %/O In/O Combination/O withMetformin(24/O weeks/O )/O Placebo/O +/O Metformin(n=206/O )/O JARDIANCE/O 10/O mg/O +/O Metformin(n=217/O )/O JARDIANCE/O 25/O mg/O +/O Metformin(n=214/O )/O Overall/O (/O %/O )/O 0.5/O %/O 1.8/O %/O 1.4/O %/O Severe/O (/O %/O )/O 0/O %/O 0/O %/O 0/O %/O In/O Combination/O withMetformin/O +/O Sulfonylurea(24/O weeks/O )/O Placebo(n=225/O )/O JARDIANCE/O 10/O mg/O +/O Metformin/O +/O Sulfonylurea(n=224/O )/O JARDIANCE/O 25/O mg/O +/O Metformin/O +/O Sulfonylurea(n=217/O )/O Overall/O (/O %/O )/O 8.4/O %/O 16.1/O %/O 11.5/O %/O Severe/O (/O %/O )/O 0/O %/O 0/O %/O 0/O %/O In/O Combination/O withPioglitazone/O +/O /-/O Metformin(24/O weeks/O )/O Placebo(n=165/O )/O JARDIANCE/O 10/O mg/O +/O Pioglitazone/O +/O /-/O Metformin(n=165/O )/O JARDIANCE/O 25/O mg/O +/O Pioglitazone/O +/O /-/O Metformin(n=168/O )/O Overall/O (/O %/O )/O 1.8/O %/O 1.2/O %/O 2.4/O %/O Severe/O (/O %/O )/O 0/O %/O 0/O %/O 0/O %/O In/O Combination/O with/O Basal/O Insulin(18/O weeks/O c/O )/O Placebo(n=170/O )/O JARDIANCE/O 10/O mg(n=169/O )/O JARDIANCE/O 25/O mg(n=155/O )/O Overall/O (/O %/O )/O 20.6/O %/O 19.5/O %/O 28.4/O %/O Severe/O (/O %/O )/O 0/O %/O 0/O %/O 1.3/O %/O In/O Combination/O with/O MDI/O Insulin/O +/O /-/O Metformin(18/O weeks/O c/O )/O Placebo(n=188/O )/O JARDIANCE/O 10/O mg(n=186/O )/O JARDIANCE/O 25/O mg(n=189/O )/O Overall/O (/O %/O )/O 37.2/O %/O 39.8/O %/O 41.3/O %/O Severe/O (/O %/O )/O 0.5/O %/O 0.5/O %/O 0.5/O %/O Genital/B-AdverseReaction Mycotic/I-AdverseReaction Infections/I-AdverseReaction In/O the/O pool/O of/O five/O placebo/O -/O controlled/O clinical/O trials/O ,/O the/O incidence/O of/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O vaginal/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction ,/O vaginal/B-AdverseReaction infection/I-AdverseReaction ,/O genital/B-AdverseReaction infection/I-AdverseReaction fungal/I-AdverseReaction ,/O vulvovaginal/B-AdverseReaction candidiasis/I-AdverseReaction ,/O and/O vulvitis/B-AdverseReaction )/O was/O increased/O in/O patients/O treated/O with/O JARDIANCE/O compared/O to/O placebo/O ,/O occurring/O in/O 0.9/O %/O ,/O 4.1/O %/O ,/O and/O 3.7/O %/O of/O patients/O randomized/O to/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O ./O
Discontinuation/O from/O study/O due/O to/O genital/B-AdverseReaction infection/I-AdverseReaction occurred/O in/O 0/O %/O of/O placebo/O -/O treated/O patients/O and/O 0.2/O %/O of/O patients/O treated/O with/O either/O JARDIANCE/O 10/O or/O 25/O mg/O ./O
Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction occurred/O more/O frequently/O in/O female/O than/O male/O patients/O (/O see/O Table/O 1/O )/O ./O
Phimosis/B-AdverseReaction occurred/O more/O frequently/O in/O male/O patients/O treated/O with/O JARDIANCE/O 10/O mg/O (/O less/O than/O 0.1/O %/O )/O and/O JARDIANCE/O 25/O mg/O (/O 0.1/O %/O )/O than/O placebo/O (/O 0/O %/O )/O ./O
Urinary/B-AdverseReaction Tract/I-AdverseReaction Infections/I-AdverseReaction In/O the/O pool/O of/O five/O placebo/O -/O controlled/O clinical/O trials/O ,/O the/O incidence/O of/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O asymptomatic/B-AdverseReaction bacteriuria/I-AdverseReaction ,/O and/O cystitis/B-AdverseReaction )/O was/O increased/O in/O patients/O treated/O with/O JARDIANCE/O compared/O to/O placebo/O (/O see/O Table/O 1/O )/O ./O
Patients/O with/O a/O history/O of/O chronic/O or/O recurrent/O urinary/O tract/O infections/O were/O more/O likely/O to/O experience/O a/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
The/O rate/O of/O treatment/O discontinuation/O due/O to/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction was/O 0.1/O %/O ,/O 0.2/O %/O ,/O and/O 0.1/O %/O for/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O ./O
Urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction occurred/O more/O frequently/O in/O female/O patients/O ./O
The/O incidence/O of/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction in/O female/O patients/O randomized/O to/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O was/O 16.6/O %/O ,/O 18.4/O %/O ,/O and/O 17.0/O %/O ,/O respectively/O ./O
The/O incidence/O of/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction in/O male/O patients/O randomized/O to/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O was/O 3.2/O %/O ,/O 3.6/O %/O ,/O and/O 4.1/O %/O ,/O respectively/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O ]/O ./O
Laboratory/O Tests/O Increase/B-AdverseReaction in/I-AdverseReaction Low/I-AdverseReaction -/I-AdverseReaction Density/I-AdverseReaction Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O Dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction low/I-AdverseReaction -/I-AdverseReaction density/I-AdverseReaction lipoprotein/O cholesterol/O (/O LDL/O -/O C/O )/O were/O observed/O in/O patients/O treated/O with/O JARDIANCE/O ./O
LDL/B-AdverseReaction -/I-AdverseReaction C/O increased/O by/O 2.3/O %/O ,/O 4.6/O %/O ,/O and/O 6.5/O %/O in/O patients/O treated/O with/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
The/O range/O of/O mean/O baseline/O LDL/O -/O C/O levels/O was/O 90.3/O to/O 90.6/O mg/O dL/O across/O treatment/O groups/O ./O
Increase/B-AdverseReaction in/I-AdverseReaction Hematocrit/I-AdverseReaction In/O a/O pool/O of/O four/O placebo/O -/O controlled/O studies/O ,/O median/O hematocrit/B-AdverseReaction decreased/I-AdverseReaction by/O 1.3/O %/O in/O placebo/B-Factor and/O increased/O by/O 2.8/O %/O in/O JARDIANCE/O 10/O mg/O and/O 2.8/O %/O in/O JARDIANCE/O 25/O mg/O treated/O patients/O ./O
At/O the/O end/O of/O treatment/O ,/O 0.6/O %/O ,/O 2.7/O %/O ,/O and/O 3.5/O %/O of/O patients/O with/O hematocrits/O initially/O within/O the/O reference/O range/O had/O values/O above/O the/O upper/O limit/O of/O the/O reference/O range/O with/O placebo/O ,/O JARDIANCE/O 10/O mg/O ,/O and/O JARDIANCE/O 25/O mg/O ,/O respectively/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypotension/B-AdverseReaction :/O Before/O initiating/O JARDIANCE/O assess/O and/O correct/O volume/O status/O in/O patients/O with/O renal/O impairment/O ,/O the/O elderly/O ,/O in/O patients/O with/O low/O systolic/O blood/O pressure/O ,/O and/O in/O patients/O on/O diuretics/O ./O
Monitor/O for/O signs/O and/O symptoms/O during/O therapy/O ./O
(/O 5.1/O )/O Impairment/B-AdverseReaction in/I-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction :/O Monitor/O renal/O function/O during/O therapy/O ./O
More/O frequent/O monitoring/O is/O recommended/O in/O patients/O with/O eGFR/O below/O 60/O mL/O min/1.73/O m/O 2/O (/O 5.2/O )/O Hypoglycemia/B-AdverseReaction :/O Consider/O lowering/O the/O dose/O of/O insulin/O secretagogue/O or/O insulin/O to/O reduce/O the/O risk/O of/O hypoglycemia/O when/O initiating/O JARDIANCE/O (/O 5.3/O )/O Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction :/O Monitor/O and/O treat/O as/O appropriate/O (/O 5.4/O )/O Urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction :/O Monitor/O and/O treat/O as/O appropriate/O (/O 5.5/O )/O Increased/B-AdverseReaction LDL/I-AdverseReaction -/O C/O :/O Monitor/O and/O treat/O as/O appropriate/O (/O 5.6/O )/O Macrovascular/O outcomes/O :/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O JARDIANCE/O (/O 5.7/O )/O 5.1/O Hypotension/O JARDIANCE/O causes/O intravascular/B-AdverseReaction volume/I-AdverseReaction contraction/I-AdverseReaction ./O
Symptomatic/B-AdverseReaction hypotension/I-AdverseReaction may/B-Factor occur/O after/O initiating/O JARDIANCE/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O particularly/O in/O patients/O with/O renal/O impairment/O ,/O the/O elderly/O ,/O in/O patients/O with/O low/O systolic/O blood/O pressure/O ,/O and/O in/O patients/O on/O diuretics/O ./O
Before/O initiating/O JARDIANCE/O ,/O assess/O for/O volume/O contraction/O and/O correct/O volume/O status/O if/O indicated/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O hypotension/O after/O initiating/O therapy/O and/O increase/O monitoring/O in/O clinical/O situations/O where/O volume/O contraction/O is/O expected/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O ]/O ./O
5.2/O Impairment/O in/O Renal/O Function/O JARDIANCE/O increases/B-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction eGFR/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
The/O risk/B-Factor of/O impaired/B-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction with/O JARDIANCE/O is/O increased/O in/O elderly/O patients/O and/O patients/O with/O moderate/O renal/O impairment/O ./O
More/O frequent/O monitoring/O of/O renal/O function/O is/O recommended/O in/O these/O patients/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.5/O ,/O 8.6/O )/O ]/O ./O
Renal/O function/O should/O be/O evaluated/O prior/O to/O initiating/O JARDIANCE/O and/O periodically/O thereafter/O ./O
5.3/O Hypoglycemia/O with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O Insulin/O and/O insulin/O secretagogues/O are/O known/O to/O cause/O hypoglycemia/O ./O
The/O risk/B-Factor of/O hypoglycemia/B-AdverseReaction is/O increased/O when/O JARDIANCE/O is/O used/O in/O combination/O with/O insulin/O secretagogues/O (/O e.g./O ,/O sulfonylurea/O )/O or/O insulin/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Therefore/O ,/O a/O lower/O dose/O of/O the/O insulin/O secretagogue/O or/O insulin/O may/O be/O required/O to/O reduce/O the/O risk/O of/O hypoglycemia/O when/O used/O in/O combination/O with/O JARDIANCE/O ./O
5.4/O Genital/O Mycotic/O Infections/O JARDIANCE/O increases/O the/O risk/B-Factor for/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Patients/O with/O a/O history/O of/O chronic/O or/O recurrent/O genital/O mycotic/O infections/O were/O more/O likely/O to/O develop/O mycotic/B-AdverseReaction genital/I-AdverseReaction infections/I-AdverseReaction ./O
Monitor/O and/O treat/O as/O appropriate/O ./O
5.5/O Urinary/O Tract/O Infections/O JARDIANCE/O increases/O the/O risk/B-Factor for/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O and/O treat/O as/O appropriate/O ./O
5.6/O Increased/O Low/O -/O Density/O Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O Increases/B-AdverseReaction in/I-AdverseReaction LDL/I-AdverseReaction -/O C/O can/B-Factor occur/O with/O JARDIANCE/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O and/O treat/O as/O appropriate/O ./O
5.7/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O JARDIANCE/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O Hypersensitivity/B-AdverseReaction reactions/O ,/O including/O anaphylaxis/B-AdverseReaction ,/O have/O occurred/O in/O patients/O treated/O with/O KALBITOR/O [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O occurring/O in/O =3/O %/O of/O KALBITOR/O -/O treated/O patients/O and/O greater/O than/O placebo/O are/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O and/O nasopharyngitis/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Dyax/O Corp./O at/O 1/O -/O 888/O -/O 452/O -/O 5248/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O data/O described/O below/O reflect/O exposure/O to/O KALBITOR/O in/O 255/O patients/O with/O HAE/O treated/O with/O either/O intravenous/O or/O subcutaneous/O KALBITOR/O ./O
Of/O the/O 255/O patients/O ,/O 66/O %/O of/O patients/O were/O female/O and/O 86/O %/O were/O Caucasian/O ./O
Patients/O treated/O with/O KALBITOR/O were/O between/O the/O ages/O of/O 10/O and/O 78/O years/O ./O
Overall/O ,/O the/O most/O common/O adverse/O reactions/O in/O 255/O patients/O with/O HAE/O were/O headache/B-AdverseReaction (/O 16/O %/O )/O ,/O nausea/B-AdverseReaction (/O 13/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 12/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 11/O %/O )/O ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 8/O %/O )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction (/O 7/O %/O )/O ,/O nasopharyngitis/B-AdverseReaction (/O 6/O %/O )/O ,/O vomiting/B-AdverseReaction (/O 6/O %/O )/O ,/O pruritus/B-AdverseReaction (/O 5/O %/O )/O ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction (/O 5/O %/O )/O ,/O and/O pyrexia/B-AdverseReaction (/O 5/O %/O )/O ./O
Anaphylaxis/B-AdverseReaction was/O reported/O in/O 4/O %/O of/O patients/O with/O HAE/O ./O
Injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction were/O characterized/O by/O local/O pruritus/O ,/O erythema/O ,/O pain/O ,/O irritation/O ,/O urticaria/O ,/O and/or/O bruising/O ./O
The/O incidence/O of/O adverse/O reactions/O below/O is/O based/O upon/O 2/O placebo/O -/O controlled/O ,/O clinical/O trials/O (/O EDEMA3/O (/O r/O )/O and/O EDEMA4/O (/O r/O )/O )/O in/O a/O total/O of/O 143/O unique/O patients/O with/O HAE/O ./O
Patients/O were/O treated/O with/O KALBITOR/O 30/O mg/O subcutaneous/O or/O placebo/O ./O
Patients/O were/O permitted/O to/O participate/O sequentially/O in/O both/O placebo/O -/O controlled/O trials/O ;/O safety/O data/O collected/O during/O exposure/O to/O KALBITOR/O was/O attributed/O to/O treatment/O with/O KALBITOR/O ,/O and/O safety/O data/O collected/O during/O exposure/O to/O placebo/O was/O attributed/O to/O treatment/O with/O placebo/O ./O
Table/O 1/O shows/O adverse/O reactions/O occurring/O in/O =3/O %/O of/O KALBITOR/O -/O treated/O patients/O that/O also/O occurred/O at/O a/O higher/O rate/O than/O in/O the/O placebo/O -/O treated/O patients/O in/O the/O two/O controlled/O trials/O (/O EDEMA3/O and/O EDEMA4/O )/O of/O the/O 30/O mg/O subcutaneous/O dose/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Occurring/O at/O =3/O %/O and/O Higher/O than/O Placebo/O in/O 2/O Placebo/O Controlled/O Clinical/O Trials/O in/O Patients/O with/O HAE/O Treated/O with/O KALBITOR/O a/O Patients/O experiencing/O more/O than/O 1/O event/O with/O the/O same/O preferred/O term/O are/O counted/O only/O once/O for/O that/O preferred/O term/O ./O
KALIBITORN=100/O PlaceboN=81/O Adverse/O Reactions/O n/O (/O %/O )/O a/O n/O (/O %/O )/O a/O Headache/B-AdverseReaction 8/O (/O 8/O %/O )/O 6/O (/O 7/O %/O )/O Nausea/B-AdverseReaction 5/O (/O 5/O %/O )/O 1/O (/O 1/O %/O )/O Diarrhea/B-AdverseReaction 4/O (/O 4/O %/O )/O 3/O (/O 4/O %/O )/O Pyrexia/B-AdverseReaction 4/O (/O 4/O %/O )/O 0/O Injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction 3/O (/O 3/O %/O )/O 1/O (/O 1/O %/O )/O Nasopharyngitis/B-AdverseReaction 3/O (/O 3/O %/O )/O 0/O Some/O patients/O in/O EDEMA3/O and/O EDEMA4/O received/O a/O second/O ,/O open/O -/O label/O 30/O mg/O subcutaneous/O dose/O of/O KALBITOR/O within/O 24/O hours/O following/O the/O initial/O dose/O ./O
Adverse/O reactions/O reported/O by/O these/O patients/O who/O received/O the/O additional/O 30/O mg/O subcutaneous/O dose/O of/O KALBITOR/O were/O consistent/O with/O those/O reported/O in/O the/O patients/O receiving/O a/O single/O dose/O ./O
6.2/O Immunogenicity/O In/O the/O KALBITOR/O HAE/O program/O ,/O patients/O developed/O antibodies/O to/O KALBITOR/O ./O
Rates/O of/O seroconversion/O increased/O with/O exposure/O to/O KALBITOR/O over/O time/O ./O
Overall/O ,/O 20.2/O %/O of/O patients/O seroconverted/O to/O anti/O -/O ecallantide/O antibodies/O ./O
Neutralizing/O antibodies/O to/O ecallantide/O were/O determined/O in/O vitro/O to/O be/O present/O in/O 8.8/O %/O of/O patients/O and/O were/O not/O associated/O with/O loss/O of/O efficacy/O ./O
Anti/O -/O ecallantide/O IgE/O antibodies/O were/O detected/O at/O a/O rate/O of/O 4.7/O %/O for/O tested/O patients/O ,/O and/O anti-/O P./O pastoris/O IgE/O antibodies/O were/O also/O detected/O at/O a/O rate/O of/O 20.2/O %/O ./O
Patients/O who/O seroconvert/O may/O be/O at/O a/O higher/O risk/O of/O a/O hypersensitivity/O reaction/O ./O
The/O long/O -/O term/O effects/O of/O antibodies/O to/O KALBITOR/O are/O not/O known/O ./O
The/O test/O results/O for/O the/O ecallantide/O program/O were/O determined/O using/O one/O of/O two/O assay/O formats/O :/O ELISA/O and/O bridging/O electrochemiluminescence/O (/O ECL/O )/O ./O
As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O a/O potential/O for/O immunogenicity/O with/O the/O use/O of/O KALBITOR/O ./O
The/O incidence/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O ,/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O KALBITOR/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
6.3/O Postmarketing/O Experience/O Similar/O adverse/O reactions/O have/O been/O observed/O postmarketing/O as/O described/O for/O clinical/O trial/O experience/O ./O
Because/O these/O events/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O frequency/O or/O to/O establish/O a/O causal/O relationship/O with/O drug/O exposure/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O ANAPHYLAXIS/B-AdverseReaction WARNING/O :/O ANAPHYLAXIS/B-AdverseReaction Anaphylaxis/B-AdverseReaction has/O been/O reported/O after/O administration/O of/O KALBITOR/O ./O
Because/O of/O the/O risk/O of/O anaphylaxis/O ,/O KALBITOR/O should/O only/O be/O administered/O by/O a/O healthcare/O professional/O with/O appropriate/O medical/O support/O to/O manage/O anaphylaxis/O and/O hereditary/O angioedema/O ./O
Healthcare/O professionals/O should/O be/O aware/O of/O the/O similarity/O of/O symptoms/O between/O hypersensitivity/O reactions/O and/O hereditary/O angioedema/O and/O patients/O should/O be/O monitored/O closely/O ./O
Do/O not/O administer/O KALBITOR/O to/O patients/O with/O known/O clinical/O hypersensitivity/O to/O KALBITOR/O ./O
[/O see/O Contraindications/O (/O 4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O EXCERPT/O :/O WARNING/O :/O ANAPHYLAXIS/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O Anaphylaxis/B-AdverseReaction has/O been/O reported/O after/O administration/O of/O KALBITOR/O (/O r/O )/O ./O
Because/O of/O the/O risk/O of/O anaphylaxis/O ,/O KALBITOR/O should/O only/O be/O administered/O by/O a/O healthcare/O professional/O with/O appropriate/O medical/O support/O to/O manage/O anaphylaxis/O and/O hereditary/O angioedema/O ./O
Healthcare/O professionals/O should/O be/O aware/O of/O the/O similarity/O of/O symptoms/O between/O hypersensitivity/O reactions/O and/O hereditary/O angioedema/O and/O patients/O should/O be/O monitored/O closely/O ./O
Do/O not/O administer/O KALBITOR/O to/O patients/O with/O known/O clinical/O hypersensitivity/O to/O KALBITOR/O [/O see/O Contraindications/O (/O 4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction Including/O Anaphylaxis/B-AdverseReaction :/O Anaphylaxis/B-AdverseReaction has/O occurred/O in/O 4/O %/O of/O treated/O patients/O ./O
Administer/O KALBITOR/O in/O a/O setting/O equipped/O to/O manage/O anaphylaxis/O and/O hereditary/O angioedema/O ./O
Given/O the/O similarity/O in/O hypersensitivity/O symptoms/O and/O acute/O HAE/O symptoms/O ,/O monitor/O patients/O closely/O for/O hypersensitivity/O reactions/O (/O 5/O )/O ./O
5.1/O Hypersensitivity/O Reactions/O ,/O Including/O Anaphylaxis/O Potentially/B-Factor serious/B-Severity hypersensitivity/B-AdverseReaction reactions/O ,/O including/O anaphylaxis/B-AdverseReaction ,/O have/O occurred/O in/O patients/O treated/O with/O KALBITOR/O ./O
In/O 255/O HAE/O patients/O treated/O with/O intravenous/O or/O subcutaneous/O KALBITOR/O in/O clinical/O studies/O ,/O 10/O patients/O (/O 4/O %/O )/O experienced/O anaphylaxis/B-AdverseReaction ./O
For/O the/O subgroup/O of/O 187/O patients/O treated/O with/O subcutaneous/O KALBITOR/O ,/O 5/O patients/O (/O 3/O %/O )/O experienced/O anaphylaxis/B-AdverseReaction ./O
Symptoms/O associated/O with/O these/O reactions/O have/O included/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O flushing/B-AdverseReaction ,/O pharyngeal/B-AdverseReaction edema/I-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rhinorrhea/B-AdverseReaction ,/O sneezing/B-AdverseReaction ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction ,/O throat/B-AdverseReaction irritation/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O wheezing/B-AdverseReaction ,/O and/O hypotension/B-AdverseReaction ./O
These/O reactions/O occurred/O within/O the/O first/O hour/O after/O dosing/O ./O
Other/O adverse/O reactions/O indicative/O of/O hypersensitivity/B-AdverseReaction reactions/O included/O the/O following/O :/O pruritus/B-AdverseReaction (/O 5/O %/O )/O ,/O rash/B-AdverseReaction (/O 3/O %/O )/O ,/O and/O urticaria/B-AdverseReaction (/O 2/O %/O )/O ./O
Patients/O should/O be/O observed/O for/O an/O appropriate/O period/O of/O time/O after/O administration/O of/O KALBITOR/O ,/O taking/O into/O account/O the/O time/O to/O onset/O of/O anaphylaxis/O seen/O in/O clinical/O trials/O ./O
Given/O the/O similarity/O in/O hypersensitivity/O symptoms/O and/O acute/O HAE/O symptoms/O ,/O patients/O should/O be/O monitored/O closely/O in/O the/O event/O of/O a/O hypersensitivity/O reaction/O ./O
KALBITOR/O should/O not/O be/O administered/O to/O any/O patients/O with/O known/O clinical/O hypersensitivity/O to/O KALBITOR/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O with/O the/O use/O of/O COCs/O are/O discussed/O elsewhere/O in/O the/O labeling/O :/O Serious/B-Severity cardiovascular/B-AdverseReaction events/I-AdverseReaction and/O stroke/B-AdverseReaction [/O see/O Boxed/O Warning/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Vascular/B-AdverseReaction events/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Liver/B-AdverseReaction disease/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Adverse/O reactions/O commonly/O reported/O by/O COC/O users/O are/O :/O Irregular/B-AdverseReaction uterine/I-AdverseReaction bleeding/I-AdverseReaction Nausea/B-AdverseReaction Breast/B-AdverseReaction tenderness/I-AdverseReaction Headache/B-AdverseReaction EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 2/O %/O )/O in/O clinical/O trials/O for/O Natazia/O are/O headaches/B-AdverseReaction ,/O irregular/B-AdverseReaction uterine/I-AdverseReaction bleeding/I-AdverseReaction ,/O headache/B-AdverseReaction (/O including/O migraines/B-AdverseReaction )/O 13/O %/O ,/O breast/B-AdverseReaction tenderness/I-AdverseReaction ,/O pain/O 7/O %/O ,/O menstrual/B-AdverseReaction disorders/I-AdverseReaction 7/O %/O ,/O nausea//B-AdverseReaction or/O vomiting/B-AdverseReaction ,/O 6/O %/O ,/O acne/B-AdverseReaction 4/O %/O ,/O mood/B-AdverseReaction changes/I-AdverseReaction (/O 3/O %/O )/O and/O increased/B-AdverseReaction weight/I-AdverseReaction ./O
3/O %/O ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bayer/O HealthCare/O Pharmaceuticals/O Inc./O at/O 1/O -/O 888/O -/O 842/O -/O 2937/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Contraception/O and/O Heavy/O Menstrual/O Bleeding/O Studies/O A/O total/O of/O 2,131/O women/O ,/O 18/O to/O 54/O years/O of/O age/O ,/O who/O took/O at/O least/O one/O dose/O of/O Natazia/O were/O enrolled/O in/O four/O clinical/O phase/O 3/O trials/O ./O
A/O total/O of/O 1,867/O subjects/O were/O included/O in/O two/O clinical/O phase/O 3/O studies/O with/O a/O treatment/O duration/O up/O to/O 28/O cycles/O with/O Natazia/O as/O an/O oral/O contraceptive/O and/O 264/O subjects/O in/O the/O two/O phase/O 3/O clinical/O trials/O with/O a/O treatment/O duration/O of/O 7/O cycles/O evaluating/O Natazia/O in/O the/O treatment/O of/O heavy/O ,/O prolonged/O ,/O and/or/O frequent/O menstrual/O bleeding/O in/O women/O without/O organic/O pathology/O ./O
[/O See/O Clinical/O Studies/O (/O 14.1/O ,/O 14.2/O ./O
)/O ]/O Adverse/O Reactions/O Leading/O to/O Study/O Discontinuation/O :/O 11.4/O %/O of/O the/O women/O discontinued/O from/O the/O clinical/O trials/O due/O to/O an/O adverse/O reaction/O ;/O the/O most/O frequent/O adverse/O reactions/O leading/O to/O discontinuation/O were/O menstrual/B-AdverseReaction disorder/I-AdverseReaction (/O metrorrhagia/B-AdverseReaction ,/O menorrhagia/B-AdverseReaction ,/O menstruation/B-AdverseReaction irregular/I-AdverseReaction ,/O genital/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O vaginal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O dysfunctional/B-AdverseReaction uterine/I-AdverseReaction bleeding/I-AdverseReaction )/O (/O 2.3/O %/O )/O ;/O mood/B-AdverseReaction changes/I-AdverseReaction (/O depression/B-AdverseReaction ,/O mood/B-AdverseReaction swings/I-AdverseReaction ,/O mood/B-AdverseReaction altered/I-AdverseReaction ,/O depressed/B-AdverseReaction mood/I-AdverseReaction ,/O dysthymic/B-AdverseReaction disorder/I-AdverseReaction ,/O crying/B-AdverseReaction )/O (/O 1.2/O %/O )/O ;/O acne/B-AdverseReaction (/O 1.1/O %/O )/O ,/O headache/B-AdverseReaction (/O including/O migraines/B-AdverseReaction )/O (/O 1.1/O %/O )/O ,/O and/O weight/B-AdverseReaction increased/I-AdverseReaction (/O 0.7/O %/O )/O ./O
Common/O Adverse/O Reactions/O (/O 2/O %/O )/O :/O headache/B-AdverseReaction (/O including/O migraines/B-AdverseReaction )/O (/O 12.7/O %/O )/O ,/O breast/B-AdverseReaction pain/I-AdverseReaction ,/O discomfort/O or/O tenderness/O (/O 7.0/O %/O )/O ,/O menstrual/B-AdverseReaction disorders/I-AdverseReaction (/O metrorrhagia/B-AdverseReaction ,/O menstruation/B-AdverseReaction irregular/I-AdverseReaction ,/O menorrhagia/B-AdverseReaction ,/O vaginal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O dysfunctional/B-AdverseReaction uterine/I-AdverseReaction bleeding/I-AdverseReaction ,/O genital/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O abnormal/B-AdverseReaction withdrawal/I-AdverseReaction bleeding/I-AdverseReaction ,/O uterine/B-AdverseReaction hemorrhage/I-AdverseReaction )/O (/O 6.9/O %/O )/O ,/O nausea/B-AdverseReaction or/O vomiting/B-AdverseReaction (/O 6.0/O %/O )/O ,/O acne/B-AdverseReaction (/O 3.9/O %/O )/O ,/O mood/B-AdverseReaction changes/I-AdverseReaction (/O depression/B-AdverseReaction ,/O mood/B-AdverseReaction swings/I-AdverseReaction ,/O depressed/B-AdverseReaction mood/I-AdverseReaction ,/O mood/B-AdverseReaction altered/I-AdverseReaction ,/O affect/B-AdverseReaction lability/I-AdverseReaction ,/O dysthymic/B-AdverseReaction disorder/I-AdverseReaction ,/O crying/B-AdverseReaction )/O (/O 3.0/O %/O )/O and/O increased/B-AdverseReaction weight/I-AdverseReaction (/O 2.9/O %/O )/O ./O
Serious/O Adverse/O Reactions/O :/O myocardial/B-AdverseReaction infarction/I-AdverseReaction (/O 2/O cases/O )/O ,/O ruptured/B-AdverseReaction ovarian/I-AdverseReaction cyst/I-AdverseReaction (/O 2/O cases/O )/O ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction ,/O focal/B-AdverseReaction nodular/I-AdverseReaction hyperplasia/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction liver/I-AdverseReaction ,/O uterine/B-AdverseReaction leiomyoma/I-AdverseReaction ,/O acute/B-AdverseReaction cholecystitis/I-AdverseReaction ,/O and/O chronic/B-AdverseReaction acalculous/I-AdverseReaction cholecystitis/I-AdverseReaction ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O Natazia/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Vascular/O disorders/O :/O Venous/O and/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction (/O including/O pulmonary/B-AdverseReaction emboli/I-AdverseReaction ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction ,/O cerebral/B-AdverseReaction thrombosis/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction and/O stroke/B-AdverseReaction )/O ,/O hypertension/B-AdverseReaction Hepatobiliary/O disorders/O :/O Gallbladder/B-AdverseReaction disease/I-AdverseReaction ,/O hepatitis/B-AdverseReaction Immune/O system/O disorders/O :/O Hypersensitivity/B-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O Fluid/B-AdverseReaction retention/I-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction Nervous/O system/O disorders/O :/O Dizziness/B-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Chloasma/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O erythema/B-AdverseReaction nodosum/I-AdverseReaction ,/O erythema/B-AdverseReaction multiforme/I-AdverseReaction Gastrointestinal/O disorders/O :/O Gastrointestinal/B-AdverseReaction symptoms/I-AdverseReaction (/O for/O example/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction )/O Infections/O and/O infestations/O :/O Vulvovaginal/B-AdverseReaction candidiasis/I-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O CIGARETTE/O SMOKING/O AND/O SERIOUS/B-Severity CARDIOVASCULAR/B-AdverseReaction EVENTS/I-AdverseReaction WARNING/O :/O CIGARETTE/O SMOKING/O AND/O SERIOUS/B-Severity CARDIOVASCULAR/B-AdverseReaction EVENTS/I-AdverseReaction Cigarette/O smoking/O increases/O the/O risk/O of/O serious/O cardiovascular/B-AdverseReaction events/I-AdverseReaction from/O combination/B-DrugClass oral/I-DrugClass contraceptives/I-DrugClass (/O COC/O )/O use/O ./O
This/O risk/O increases/O with/O age/O ,/O particularly/O in/O women/O over/O 35/O years/O of/O age/O ,/O and/O with/O the/O number/O of/O cigarettes/O smoked/O ./O
For/O this/O reason/O ,/O COCs/O should/O not/O be/O used/O by/O women/O who/O are/O over/O 35/O years/O of/O age/O and/O smoke/O ./O
[/O See/O Contraindications/O (/O 4/O )/O ./O
]/O EXCERPT/O :/O WARNING/O :/O CIGARETTE/O SMOKING/O AND/O SERIOUS/B-Severity CARDIOVASCULAR/B-AdverseReaction EVENTS/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Women/O over/O 35/O years/O old/O who/O smoke/O should/O not/O use/O Natazia/O ./O
(/O 4/O )/O Cigarette/O smoking/O increases/O the/O risk/O of/O serious/O cardiovascular/B-AdverseReaction events/I-AdverseReaction from/O combination/B-DrugClass oral/I-DrugClass contraceptive/I-DrugClass (/O COC/O )/O use/O ./O
(/O 4/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Vascular/O risks/O :/O Stop/O Natazia/O if/O a/O thrombotic/O event/O occurs/O ./O
Stop/O Natazia/O at/O least/O 4/O weeks/O before/O and/O through/O 2/O weeks/O after/O major/O surgery/O ./O
Start/O Natazia/O no/O earlier/O than/O 4/O weeks/O after/O delivery/O ,/O in/O women/O who/O are/O not/O breastfeeding/O ./O
(/O 5.1/O )/O Liver/B-AdverseReaction disease/I-AdverseReaction :/O Discontinue/O Natazia/O if/O jaundice/O occurs/O ./O
(/O 5.3/O )/O High/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction :/O Do/O not/O prescribe/O Natazia/O for/O women/O with/O uncontrolled/O hypertension/O or/O hypertension/O with/O vascular/O disease/O ./O
(/O 5.4/O )/O Carbohydrate/O and/O lipid/B-AdverseReaction metabolic/I-AdverseReaction effects/I-AdverseReaction :/O Monitor/O prediabetic/O and/O diabetic/O women/O taking/O Natazia/O ./O
Consider/O an/O alternate/O contraceptive/O method/O for/O women/O with/O uncontrolled/O dyslipidemia/O ./O
(/O 5.6/O )/O Headache/B-AdverseReaction :/O Evaluate/O significant/O change/O in/O headaches/O and/O discontinue/O Natazia/O if/O indicated/O ./O
(/O 5.7/O )/O Uterine/B-AdverseReaction bleeding/I-AdverseReaction :/O Evaluate/O irregular/O bleeding/O or/O amenorrhea/O ./O
(/O 5.8/O )/O CYP3A4/O induction/O :/O Women/O taking/O strong/O CYP3A4/O inducers/O (/O for/O example/O ,/O carbamazepine/O ,/O phenytoin/O ,/O rifampicin/O ,/O and/O St./O John/O 's/O wort/O )/O should/O not/O choose/O Natazia/O as/O their/O oral/O contraceptive/O due/O to/O the/O possibility/O of/O decreased/O contraceptive/O efficacy/O ./O
(/O 5.13/O ,/O 7.1/O )/O 5.1/O Thromboembolic/O Disorders/O and/O Other/O Vascular/O Problems/O Stop/O Natazia/O if/O an/O arterial/O or/O venous/O thrombotic/O event/O (/O VTE/O )/O occurs/O ./O
The/O use/O of/O COCs/B-DrugClass increases/O the/O risk/O of/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction ./O
However/O ,/O pregnancy/B-Factor increases/O the/O risk/O of/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction as/O much/O or/O more/O than/O the/O use/O of/O COCs/O ./O
The/O risk/O of/O VTE/B-AdverseReaction in/O women/O using/O COCs/B-DrugClass has/O been/O estimated/O to/O be/O 3/O to/O 9/O per/O 10,000/O woman/O -/O years/O ./O
The/O risk/B-Factor of/O VTE/B-AdverseReaction is/O highest/O during/O the/O first/O year/O of/O use/O ./O
Data/O from/O a/O large/O ,/O prospective/O cohort/O safety/O study/O of/O various/O COCs/O suggest/O that/O this/O increased/O risk/O ,/O as/O compared/O to/O that/O in/O non/O -/O COC/O users/O ,/O is/O greatest/O during/O the/O first/O 6/O months/O of/O COC/O use/O ./O
Data/O from/O this/O safety/O study/O indicate/O that/O the/O greatest/O risk/O of/O VTE/B-AdverseReaction is/O present/O after/O initially/O starting/O a/O COC/B-DrugClass or/O restarting/O (/O following/O a/O 4/O week/O or/O greater/O pill/O -/O free/O interval/O )/O the/O same/O or/O a/O different/O COC/O ./O
Use/O of/O COCs/B-DrugClass also/O increases/O the/O risk/O of/O arterial/B-AdverseReaction thromboses/I-AdverseReaction such/O as/O strokes/B-AdverseReaction and/O myocardial/B-AdverseReaction infarctions/I-AdverseReaction ,/O especially/O in/O women/O with/O other/O risk/O factors/O for/O these/O events/O ./O
The/O risk/O of/O thromboembolic/B-AdverseReaction disease/I-AdverseReaction due/O to/O oral/B-DrugClass contraceptives/I-DrugClass gradually/O disappears/O after/O COC/O use/O is/O discontinued/O ./O
If/O feasible/O ,/O stop/O Natazia/O at/O least/O 4/O weeks/O before/O and/O through/O 2/O weeks/O after/O major/O surgery/O or/O other/O surgeries/O known/O to/O have/O an/O elevated/O risk/O of/O thromboembolism/O ./O
Start/O Natazia/O no/O earlier/O than/O 4/O weeks/O after/O delivery/O ,/O in/O women/O who/O are/O not/O breastfeeding/O ./O
The/O risk/O of/O postpartum/O thromboembolism/O decreases/O after/O the/O third/O postpartum/O week/O ,/O whereas/O the/O risk/O of/O ovulation/O increases/O after/O the/O third/O postpartum/O week/O ./O
COCs/B-DrugClass have/O been/O shown/O to/O increase/O both/O the/O relative/O and/O attributable/O risks/O of/O cerebrovascular/B-AdverseReaction events/I-AdverseReaction (/O thrombotic/O and/O hemorrhagic/B-AdverseReaction strokes/I-AdverseReaction )/O ,/O although/O ,/O in/O general/O ,/O the/O risk/O is/O greatest/O among/O older/O (/O 35/O years/O of/O age/O )/O ,/O hypertensive/O women/O who/O also/O smoke/O ./O
COCs/B-DrugClass also/O increase/O the/O risk/O for/O stroke/B-AdverseReaction in/O women/O with/O other/O underlying/O risk/O factors/O ./O
Oral/O contraceptives/O must/O be/O used/O with/O caution/O in/O women/O with/O cardiovascular/O disease/O risk/O factors/O ./O
Stop/O Natazia/O if/O there/O is/O unexplained/O loss/O of/O vision/O ,/O proptosis/O ,/O diplopia/O ,/O papilledema/O ,/O or/O retinal/O vascular/O lesions/O ./O
Evaluate/O for/O retinal/O vein/O thrombosis/O immediately/O ./O
[/O See/O Adverse/O Reactions/O (/O 6/O )/O ./O
]/O 5.2/O Carcinoma/O of/O the/O Breasts/O and/O Reproductive/O Organs/O Women/O who/O currently/O have/O or/O have/O had/O breast/O cancer/O should/O not/O use/O Natazia/O because/O breast/O cancer/O is/O a/O hormonally/O -/O sensitive/O tumor/O ./O
There/O is/O substantial/O evidence/O that/O COCs/O do/O not/B-Negation increase/O the/O incidence/O of/O breast/B-AdverseReaction cancer/I-AdverseReaction ./O
Although/O some/O past/O studies/O have/O suggested/O that/O COCs/O might/O increase/O the/O incidence/O of/O breast/B-AdverseReaction cancer/I-AdverseReaction ,/O more/O recent/O studies/O have/O not/B-Negation confirmed/I-Negation such/O findings/O ./O
Some/O studies/O suggest/O that/O COCs/B-DrugClass are/O associated/O with/O an/O increase/O in/O the/O risk/O of/O cervical/B-AdverseReaction cancer/I-AdverseReaction or/O intraepithelial/O neoplasia/O ./O
However/O ,/O there/O is/O controversy/O about/O the/O extent/O to/O which/O these/O findings/O may/O be/O due/O to/O differences/O in/O sexual/O behavior/O and/O other/O factors/O ./O
Endometrial/O biopsies/O performed/O in/O a/O subset/O of/O subjects/O in/O a/O Phase/O 3/O Natazia/O clinical/O trial/O did/O not/O reveal/O any/O unexpected/O or/O concerning/O findings/O for/O subjects/O taking/O COCs/O ./O
[/O See/O Adverse/O Reactions/O (/O 6.1/O )/O ./O
]/O 5.3/O Liver/O Disease/O Discontinue/O Natazia/O if/O jaundice/O develops/O ./O
Steroid/O hormones/O may/O be/O poorly/O metabolized/O in/O patients/O with/O impaired/O liver/O function/O ./O
Acute/O or/O chronic/O disturbances/O of/O liver/O function/O may/O necessitate/O the/O discontinuation/O of/O COC/O use/O until/O markers/O of/O liver/O function/O return/O to/O normal/O and/O COC/O causation/O has/O been/O excluded/O ./O
Hepatic/B-AdverseReaction adenomas/I-AdverseReaction are/O associated/O with/O COC/B-DrugClass use/O ./O
An/O estimate/O of/O the/O attributable/O risk/O is/O 3.3/O cases/100,000/O COC/O users/O ./O
Rupture/B-AdverseReaction of/I-AdverseReaction hepatic/I-AdverseReaction adenomas/I-AdverseReaction may/B-Factor cause/O death/B-AdverseReaction through/O intra/B-AdverseReaction -/I-AdverseReaction abdominal/O hemorrhage/O ./O
Studies/O have/O shown/O an/O increased/O risk/O of/O developing/O hepatocellular/B-AdverseReaction carcinoma/I-AdverseReaction in/O long/O -/O term/O (/O 8/O years/O )/O COC/B-DrugClass users/O ./O
However/O ,/O the/O attributable/O risk/O of/O liver/B-AdverseReaction cancers/I-AdverseReaction in/O COC/B-DrugClass users/O is/O less/O than/O one/O case/O per/O million/O users/O ./O
Oral/B-DrugClass contraceptive/I-DrugClass -/O related/O cholestasis/B-AdverseReaction may/O occur/O in/O women/O with/O a/O history/O of/O pregnancy/O -/O related/O cholestasis/O ./O
Women/O with/O a/O history/O of/O COC/B-DrugClass -/O related/O cholestasis/B-AdverseReaction may/O have/O the/O condition/O recur/O with/O subsequent/O COC/O use/O ./O
5.4/O High/O Blood/O Pressure/O For/O women/O with/O well/O -/O controlled/O hypertension/O ,/O monitor/O blood/O pressure/O and/O stop/O Natazia/O if/O blood/O pressure/O rises/O significantly/O ./O
Women/O with/O uncontrolled/O hypertension/O or/O hypertension/O with/O vascular/O disease/O should/O not/O use/O COCs/O ./O
An/O increase/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction has/O been/O reported/O in/O women/O taking/O COCs/B-DrugClass ,/O and/O this/O increase/O is/O more/O likely/O in/O older/O women/O and/O with/O extended/O duration/O of/O use/O ./O
The/O incidence/O of/O hypertension/B-AdverseReaction increases/O with/O increasing/O concentration/O of/O progestin/O ./O
5.5/O Gallbladder/O Disease/O Studies/O suggest/O a/O small/O increased/O relative/O risk/O of/O developing/O gallbladder/B-AdverseReaction disease/I-AdverseReaction among/O COC/B-DrugClass users/O ./O
5.6/O Carbohydrate/O and/O Lipid/O Metabolic/O Effects/O Carefully/O monitor/O prediabetic/O and/O diabetic/O women/O who/O are/O taking/O Natazia/O ./O
COCs/B-DrugClass may/O decrease/B-AdverseReaction glucose/I-AdverseReaction tolerance/I-AdverseReaction in/O a/O dose/O -/O related/O fashion/O ./O
Consider/O alternative/O contraception/O for/O women/O with/O uncontrolled/O dyslipidemia/O ./O
A/O small/O proportion/O of/O women/O will/O have/O adverse/B-AdverseReaction lipid/I-AdverseReaction changes/I-AdverseReaction while/O on/O COCs/B-DrugClass ./O
Women/O with/O hypertriglyceridemia/O ,/O or/O a/O family/O history/O thereof/O ,/O may/O be/O at/O an/O increased/O risk/O of/O pancreatitis/B-AdverseReaction when/O using/O COCs/B-DrugClass ./O
5.7/O Headache/O If/O a/O woman/O taking/O Natazia/O develops/O new/O headaches/O that/O are/O recurrent/O ,/O persistent/O ,/O or/O severe/B-Severity ,/O evaluate/O the/O cause/O and/O discontinue/O Natazia/O if/O indicated/O ./O
An/O increase/O in/O frequency/O or/O severity/O of/O migraine/B-AdverseReaction during/O COC/B-DrugClass use/O (/O which/O may/B-Factor be/O prodromal/O of/O a/O cerebrovascular/B-AdverseReaction event/I-AdverseReaction )/O may/O be/O a/O reason/O for/O immediate/O discontinuation/O of/O the/O COC/O ./O
5.8/O Bleeding/O Irregularities/O Breakthrough/B-AdverseReaction bleeding/I-AdverseReaction and/O spotting/B-AdverseReaction sometimes/O occur/O in/O patients/O on/O COCs/B-DrugClass ,/O especially/O during/O the/O first/O three/O months/O of/O use/O ./O
If/O bleeding/O persists/O or/O occurs/O after/O previously/O regular/O cycles/O ,/O check/O for/O causes/O such/O as/O pregnancy/O or/O malignancy/O ./O
If/O pathology/O and/O pregnancy/O are/O excluded/O ,/O bleeding/O irregularities/O may/O resolve/O over/O time/O or/O with/O a/O change/O to/O a/O different/O COC/O ./O
Women/O who/O are/O not/O pregnant/O and/O use/O Natazia/O ,/O may/B-Factor experience/O amenorrhea/B-AdverseReaction ./O
Based/O on/O patient/O diaries/O ,/O amenorrhea/O occurs/O in/O approximately/O 16/O %/O of/O cycles/O in/O women/O using/O Natazia/O ./O
Pregnancy/O should/O be/O ruled/O out/O in/O the/O event/O of/O amenorrhea/O occurring/O in/O two/O or/O more/O consecutive/O cycles/O ./O
Some/O women/O may/B-Factor encounter/O amenorrhea/B-AdverseReaction or/O oligomenorrhea/B-AdverseReaction after/O stopping/O COCs/O ,/O especially/O when/O such/O a/O condition/O was/O pre/O -/O existent/O ./O
Based/O on/O patient/O diaries/O from/O three/O clinical/O trials/O evaluating/O the/O safety/O and/O efficacy/O of/O Natazia/O for/O contraception/O ,/O 10/O -/O 23/O %/O of/O women/O experienced/O intracyclic/B-AdverseReaction bleeding/I-AdverseReaction per/O cycle/O ./O
5.9/O COC/O Use/O Before/O or/O During/O Early/O Pregnancy/O Extensive/O epidemiological/O studies/O have/O revealed/O no/B-Negation increased/O risk/O of/O birth/B-AdverseReaction defects/I-AdverseReaction in/O women/O who/O have/O used/O oral/O contraceptives/O prior/O to/O pregnancy/O ./O
Studies/O also/O do/O not/B-Negation suggest/O a/O teratogenic/B-AdverseReaction effect/I-AdverseReaction ,/O particularly/O in/O so/O far/O as/O cardiac/B-AdverseReaction anomalies/I-AdverseReaction and/O limb/B-AdverseReaction -/I-AdverseReaction reduction/O defects/O are/O concerned/O ,/O when/O taken/O inadvertently/O during/O early/O pregnancy/O ./O
Oral/O contraceptive/O use/O should/O be/O discontinued/O if/O pregnancy/O is/O confirmed/O ./O
The/O administration/O of/O oral/O contraceptives/O to/O induce/O withdrawal/O bleeding/O should/O not/O be/O used/O as/O a/O test/O for/O pregnancy/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
5.10/O Depression/O Women/O with/O a/O history/O of/O depression/O should/O be/O carefully/O observed/O and/O Natazia/O discontinued/O if/O depression/O recurs/O to/O a/O serious/O degree/O ./O
5.11/O Interference/O with/O Laboratory/O Tests/O The/O use/O of/O COCs/O may/O change/O the/O results/O of/O some/O laboratory/O tests/O ,/O such/O as/O coagulation/O factors/O ,/O lipids/O ,/O glucose/O tolerance/O ,/O and/O binding/O proteins/O ./O
Women/O on/O thyroid/O hormone/O replacement/O therapy/O may/O need/O increased/O doses/O of/O thyroid/O hormone/O because/O serum/O concentrations/O of/O thyroid/B-AdverseReaction -/I-AdverseReaction binding/I-AdverseReaction globulin/O increase/O with/O use/O of/O COCs/B-DrugClass [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.12/O Monitoring/O A/O woman/O who/O is/O taking/O COCs/O should/O have/O a/O yearly/O visit/O with/O her/O healthcare/O provider/O for/O a/O blood/O pressure/O check/O and/O for/O other/O indicated/O healthcare/O ./O
5.13/O Drug/O Interactions/O Women/O who/O take/O medications/O that/O are/O strong/O cytochrome/O P450/O 3A4/O (/O CYP3A4/O )/O inducers/O (/O for/O example/O ,/O carbamazepine/O ,/O phenytoin/O ,/O rifampicin/O ,/O and/O St./O John/O 's/O wort/O )/O should/O not/O choose/O Natazia/O as/O their/O oral/O contraceptive/O while/O using/O these/O inducers/O and/O for/O at/O least/O 28/O days/O after/O discontinuation/O of/O these/O inducers/O due/O to/O the/O possibility/O of/O decreased/O contraceptive/O efficacy/O ./O
[/O See/O Drug/O Interactions/O (/O 7.1/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ./O
]/O 5.14/O Other/O Conditions/O In/O women/O with/O hereditary/O angioedema/O ,/O exogenous/O estrogens/O may/B-Factor induce/O or/O exacerbate/O symptoms/O of/O angioedema/B-AdverseReaction ./O
Chloasma/B-AdverseReaction may/B-Factor occasionally/O occur/O ,/O especially/O in/O women/O with/O a/O history/O of/O chloasma/O gravidarum/O ./O
Women/O with/O a/O tendency/O to/O chloasma/O should/O avoid/O exposure/O to/O the/O sun/O or/O ultraviolet/O radiation/O while/O taking/O COCs/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Common/O adverse/O reactions/O (/O reported/O in/O 4/O %/O of/O patients/O treated/O with/O NESINA/O 25/O mg/O and/O more/O frequently/O than/O in/O patients/O who/O received/O placebo/O )/O are/O :/O nasopharyngitis/B-AdverseReaction ,/O headache/B-AdverseReaction and/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Takeda/O Pharmaceuticals/O at/O 1/O -/O 877-TAKEDA-7/O (/O 1/O -/O 877/O -/O 825/O -/O 3327/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Approximately/O 8500/O patients/O with/O type/O 2/O diabetes/O have/O been/O treated/O with/O NESINA/O in/O 14/O randomized/O ,/O double/O -/O blind/O ,/O controlled/O clinical/O trials/O with/O approximately/O 2900/O subjects/O randomized/O to/O placebo/O and/O approximately/O 2200/O to/O an/O active/O comparator/O ./O
The/O mean/O exposure/O to/O NESINA/O was/O 40/O weeks/O with/O more/O than/O 2400/O subjects/O treated/O for/O more/O than/O one/O year/O ./O
Among/O these/O patients/O ,/O 63/O %/O had/O a/O history/O of/O hypertension/O ,/O 51/O %/O had/O a/O history/O of/O dyslipidemia/O ,/O 25/O %/O had/O a/O history/O of/O myocardial/O infarction/O ,/O 8/O %/O had/O a/O history/O of/O unstable/O angina/O and/O 7/O %/O had/O a/O history/O of/O congestive/O heart/O failure/O ./O
The/O mean/O duration/O of/O diabetes/O was/O seven/O years/O ,/O the/O mean/O body/O mass/O index/O (/O BMI/O )/O was/O 31/O kg/O m/O 2/O (/O 51/O %/O of/O patients/O had/O a/O BMI/O 30/O kg/O m/O 2/O )/O ,/O and/O the/O mean/O age/O was/O 57/O years/O (/O 24/O %/O of/O patients/O 65/O years/O of/O age/O )/O ./O
Two/O placebo/O -/O controlled/O monotherapy/O trials/O of/O 12/O and/O 26/O weeks/O of/O duration/O were/O conducted/O in/O patients/O treated/O with/O NESINA/O 12.5/O mg/O daily/O ,/O NESINA/O 25/O mg/O daily/O and/O placebo/O ./O
Four/O placebo/O -/O controlled/O add/O -/O on/O combination/O therapy/O trials/O of/O 26/O weeks/O duration/O were/O also/O conducted/O :/O with/O metformin/O ,/O with/O a/O sulfonylurea/O ,/O with/O a/O thiazolidinedione/O and/O with/O insulin/O ./O
Four/O placebo/O -/O controlled/O and/O one/O active/O -/O controlled/O trials/O of/O 16/O weeks/O up/O through/O two/O years/O in/O duration/O were/O conducted/O in/O combination/O with/O metformin/O ,/O in/O combination/O with/O pioglitazone/O and/O with/O pioglitazone/O added/O to/O a/O background/O of/O metformin/O therapy/O ./O
Three/O active/O -/O controlled/O trials/O of/O 52/O weeks/O in/O duration/O were/O conducted/O in/O patients/O treated/O with/O pioglitazone/O and/O metformin/O ,/O in/O combination/O with/O metformin/O and/O as/O monotherapy/O compared/O to/O glipizide/O ./O
In/O a/O pooled/O analysis/O of/O these/O 14/O controlled/O clinical/O trials/O ,/O the/O overall/O incidence/O of/O adverse/O events/O was/O 66/O %/O in/O patients/O treated/O with/O NESINA/O 25/O mg/O compared/O to/O 62/O %/O with/O placebo/O and/O 70/O %/O with/O active/O comparator/O ./O
Overall/O discontinuation/O of/O therapy/O due/O to/O adverse/O events/O was/O 4.7/O %/O with/O NESINA/O 25/O mg/O compared/O to/O 4.5/O %/O with/O placebo/O or/O 6.2/O %/O with/O active/O comparator/O ./O
Adverse/O reactions/O reported/O in/O 4/O %/O of/O patients/O treated/O with/O NESINA/O 25/O mg/O and/O more/O frequently/O than/O in/O patients/O who/O received/O placebo/O are/O summarized/O in/O Table/O 1/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O Reported/O in/O 4/O %/O Patients/O Treated/O with/O NESINA/O 25/O mg/O and/O More/O Frequently/O Than/O in/O Patients/O Given/O Placebo/O in/O Pooled/O Studies/O Number/O of/O Patients/O (/O %/O )/O NESINA25/O mg/O Placebo/O Active/O Comparator/O N=5902/O N=2926/O N=2257/O Nasopharyngitis/B-AdverseReaction 257/O (/O 4.4/O )/O 89/O (/O 3.0/O )/O 113/O (/O 5.0/O )/O Headache/B-AdverseReaction 247/O (/O 4.2/O )/O 72/O (/O 2.5/O )/O 121/O (/O 5.4/O )/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 247/O (/O 4.2/O )/O 61/O (/O 2.1/O )/O 113/O (/O 5.0/O )/O Pancreatitis/O In/O the/O clinical/O trial/O program/O ,/O pancreatitis/B-AdverseReaction was/O reported/O in/O 11/O of/O 5902/O (/O 0.2/O %/O )/O patients/O receiving/O NESINA/O 25/O mg/O daily/O compared/O to/O five/O of/O 5183/O (/O 0.1/O %/O )/O patients/O receiving/O all/O comparators/O ./O
Hypersensitivity/O Reactions/O In/O a/O pooled/O analysis/O ,/O the/O overall/O incidence/O of/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction was/O 0.6/O %/O with/O NESINA/O 25/O mg/O compared/O to/O 0.8/O %/O with/O all/O comparators/O ./O
A/O single/O event/O of/O serum/B-AdverseReaction sickness/I-AdverseReaction was/O reported/O in/O a/O patient/O treated/O with/O NESINA/O 25/O mg/O ./O
Hypoglycemia/O Hypoglycemic/B-AdverseReaction events/I-AdverseReaction were/O documented/O based/O upon/O a/O blood/O glucose/O value/O and/or/O clinical/O signs/O and/O symptoms/O of/O hypoglycemia/B-AdverseReaction ./O
In/O the/O monotherapy/O study/O ,/O the/O incidence/O of/O hypoglycemia/B-AdverseReaction was/O 1.5/O %/O in/O patients/O treated/O with/O NESINA/O compared/O to/O 1.6/O %/O with/O placebo/O ./O
The/O use/O of/O NESINA/O as/O add/O -/O on/O therapy/O to/O glyburide/O or/O insulin/O did/O not/O increase/O the/O incidence/O of/O hypoglycemia/B-AdverseReaction compared/O to/O placebo/O ./O
In/O a/O monotherapy/O study/O comparing/O NESINA/O to/O a/O sulfonylurea/O in/O elderly/O patients/O ,/O the/O incidence/O of/O hypoglycemia/B-AdverseReaction was/O 5.4/O %/O with/O NESINA/O compared/O to/O 26/O %/O with/O glipizide/O (/O Table/O 2/O )/O ./O
Table/O 2/O ./O
Incidence/O and/O Rate/O of/O HypoglycemiaAdverse/B-AdverseReaction reactions/O of/O hypoglycemia/B-AdverseReaction were/O based/O on/O all/O reports/O of/O symptomatic/B-Severity and/O asymptomatic/O hypoglycemia/B-AdverseReaction ;/O a/O concurrent/O glucose/O measurement/O was/O not/O required/O ;/O intent/O -/O to/O -/O treat/O population/O ./O
in/O Placebo/O and/O Active/O -/O Controlled/O Studies/O when/O NESINA/O Was/O Used/O as/O Add/O -/O On/O Therapy/O to/O Glyburide/O ,/O Insulin/O ,/O Metformin/O ,/O Pioglitazone/O or/O Compared/O to/O Glipizide/O Add/O -/O On/O to/O Glyburide(26/O Weeks/O )/O NESINA/O 25/O mg+/O Glyburide/O Placebo+/O Glyburide/O N=198/O N=99/O Overall/O (/O %/O )/O 19/O (/O 9.6/O )/O 11/O (/O 11.1/O )/O Severe/O (/O %/O )/O Severe/B-Severity events/O of/O hypoglycemia/B-AdverseReaction were/O defined/O as/O those/O events/O requiring/O medical/O assistance/O or/O exhibiting/O depressed/O level/O or/O loss/O of/O consciousness/O or/O seizure/O ./O
0/O 1/O (/O 1/O )/O Add/O -/O On/O to/O Insulin/O (/O +/O /-/O Metformin)(26/O Weeks/O )/O NESINA/O 25/O mg+/O Insulin/O (/O +/O /-/O Metformin/O )/O Placebo+/O Insulin/O (/O +/O /-/O Metformin/O )/O N=129/O N=129/O Overall/O (/O %/O )/O 35/O (/O 27/O )/O 31/O (/O 24/O )/O Severe/O (/O %/O )/O 1/O (/O 0.8/O )/O 2/O (/O 1.6/O )/O Add/O -/O On/O to/O Metformin(26/O Weeks/O )/O NESINA/O 25/O mg+/O Metformin/O Placebo+/O Metformin/O N=207/O N=104/O Overall/O (/O %/O )/O 0/O 3/O (/O 2.9/O )/O Severe/O (/O %/O )/O 0/O 0/O Add/O -/O On/O to/O Pioglitazone(+/-/O Metformin/O or/O Sulfonylurea)(26/O Weeks/O )/O NESINA/O 25/O mg+/O Pioglitazone/O Placebo+/O Pioglitazone/O N=199/O N=97/O Overall/O (/O %/O )/O 14/O (/O 7.0/O )/O 5/O (/O 5.2/O )/O Severe/O (/O %/O )/O 0/O 1/O (/O 1/O )/O Compared/O to/O Glipizide(52/O Weeks/O )/O NESINA/O 25/O mg/O Glipizide/O N=222/O N=219/O Overall/O (/O %/O )/O 12/O (/O 5.4/O )/O 57/O (/O 26/O )/O Severe/O (/O %/O )/O 0/O 3/O (/O 1.4/O )/O Add/O -/O On/O to/O Metformin(26/O Weeks/O )/O NESINA/O 25/O mg/O Metformin/O 500/O mg/O twice/O daily/O N=112/O N=109/O Overall/O (/O %/O )/O 2/O (/O 1.8/O )/O 2/O (/O 1.8/O )/O Severe/O (/O %/O )/O 0/O 0/O Add/O -/O On/O to/O Metformin/O Compared/O to/O Glipizide(52/O Weeks/O )/O NESINA/O 25/O mg+/O Metformin/O Glipizide/O +/O Metformin/O N=877/O N=869/O Overall/O (/O %/O )/O 12/O (/O 1.4/O )/O 207/O (/O 23.8/O )/O Severe/O (/O %/O )/O 0/O 4/O (/O 0.5/O )/O Vital/O Signs/O No/B-Negation clinically/O meaningful/O changes/B-AdverseReaction in/I-AdverseReaction vital/I-AdverseReaction signs/I-AdverseReaction or/O in/O electrocardiograms/O were/O observed/O in/O patients/O treated/O with/O NESINA/O ./O
Laboratory/O Tests/O No/O clinically/O meaningful/O changes/O in/O hematology/O ,/O serum/O chemistry/O or/O urinalysis/O were/O observed/O in/O patients/O treated/O with/O NESINA/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O the/O postmarketing/O use/O of/O NESINA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction including/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O urticaria/B-AdverseReaction and/O severe/B-Severity cutaneous/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O hepatic/B-AdverseReaction enzyme/I-AdverseReaction elevations/I-AdverseReaction ,/O fulminant/B-AdverseReaction hepatic/I-AdverseReaction failure/I-AdverseReaction ,/O severe/B-Severity and/O disabling/B-Severity arthralgia/B-AdverseReaction and/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1,5.2,5.3,5.5/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Acute/B-AdverseReaction pancreatitis/I-AdverseReaction :/O There/O have/O been/O postmarketing/O reports/O of/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction ./O
If/O pancreatitis/O is/O suspected/O ,/O promptly/O discontinue/O NESINA/O ./O
(/O 5.1/O )/O Hypersensitivity/B-AdverseReaction :/O There/O have/O been/O postmarketing/O reports/O of/O serious/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction in/O patients/O treated/O with/O NESINA/O such/O as/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction and/O severe/B-Severity cutaneous/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ./O
In/O such/O cases/O ,/O promptly/O discontinue/O NESINA/O ,/O assess/O for/O other/O potential/O causes/O ,/O institute/O appropriate/O monitoring/O and/O treatment/O and/O initiate/O alternative/O treatment/O for/O diabetes/O ./O
(/O 5.2/O )/O Hepatic/B-AdverseReaction effects/I-AdverseReaction :/O Postmarketing/O reports/O of/O hepatic/B-AdverseReaction failure/I-AdverseReaction ,/O sometimes/O fatal/B-AdverseReaction ./O
Causality/O can/O not/O be/O excluded/O ./O
If/O liver/O injury/O is/O detected/O ,/O promptly/O interrupt/O NESINA/O and/O assess/O patient/O for/O probable/O cause/O ,/O then/O treat/O cause/O if/O possible/O ,/O to/O resolution/O or/O stabilization/O ./O
Do/O not/O restart/O NESINA/O if/O liver/O injury/O is/O confirmed/O and/O no/O alternative/O etiology/O can/O be/O found/O ./O
(/O 5.3/O )/O Hypoglycemia/B-AdverseReaction :/O When/O an/O insulin/O secretagogue/O (/O e.g./O ,/O sulfonylurea/O )/O or/O insulin/O is/O used/O in/O combination/O with/O NESINA/O ,/O a/O lower/O dose/O of/O the/O insulin/O secretagogue/O or/O insulin/O may/O be/O required/O to/O minimize/O the/O risk/O of/O hypoglycemia/O ./O
(/O 5.4/O )/O Arthralgia/B-AdverseReaction :/O Severe/B-Severity and/O disabling/B-Severity arthralgia/B-AdverseReaction has/O been/O reported/O in/O patients/O taking/O DPP-4/B-DrugClass inhibitors/I-DrugClass ./O
Consider/O as/O a/O possible/O cause/O for/O severe/O joint/O pain/O and/O discontinue/O drug/O if/O appropriate/O ./O
(/O 5.5/O )/O Macrovascular/O outcomes/O :/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O NESINA/O or/O any/O other/O antidiabetic/O drug/O ./O
(/O 5.6/O )/O 5.1/O Pancreatitis/O There/O have/O been/O postmarketing/O reports/O of/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction in/O patients/O taking/O NESINA/O ./O
After/O initiation/O of/O NESINA/O ,/O patients/O should/O be/O observed/O carefully/O for/O signs/O and/O symptoms/O of/O pancreatitis/O ./O
If/O pancreatitis/O is/O suspected/O ,/O NESINA/O should/O promptly/O be/O discontinued/O and/O appropriate/O management/O should/O be/O initiated/O ./O
It/O is/O unknown/O whether/O patients/O with/O a/O history/O of/O pancreatitis/O are/O at/O increased/O risk/O for/O the/O development/O of/O pancreatitis/O while/O using/O NESINA/O ./O
5.2/O Hypersensitivity/O Reactions/O There/O have/O been/O postmarketing/O reports/O of/O serious/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction in/O patients/O treated/O with/O NESINA/O ./O
These/O reactions/O include/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction and/O severe/B-Severity cutaneous/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ./O
If/O a/O serious/O hypersensitivity/O reaction/O is/O suspected/O ,/O discontinue/O NESINA/O ,/O assess/O for/O other/O potential/O causes/O for/O the/O event/O and/O institute/O alternative/O treatment/O for/O diabetes/O [/O seeAdverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
Use/O caution/O in/O a/O patient/O with/O a/O history/O of/O angioedema/O with/O another/O DPP-4/O inhibitor/O because/O it/O is/O unknown/O whether/O such/O patients/O will/O be/O predisposed/O to/O angioedema/O with/O NESINA/O ./O
5.3/O Hepatic/O Effects/O There/O have/O been/O postmarketing/O reports/O of/O fatal/B-AdverseReaction and/O nonfatal/B-Severity hepatic/B-AdverseReaction failure/I-AdverseReaction in/O patients/O taking/O NESINA/O ,/O although/O some/O of/O the/O reports/O contain/O insufficient/O information/O necessary/O to/O establish/O the/O probable/O cause/O [/O seeAdverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
In/O randomized/O controlled/O studies/O ,/O serum/O alanine/O aminotransferase/O (/O ALT/O )/O elevations/O greater/O than/O three/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/I-Severity ULN/O )/O were/O observed/O :/O 1.3/O %/O in/O alogliptin/O -/O treated/O patients/O and/O 1.5/O %/O in/O all/O comparator/O -/O treated/O patients/O ./O
Patients/O with/O type/O 2/O diabetes/O may/O have/O fatty/O liver/O disease/O ,/O which/O may/O cause/O liver/O test/O abnormalities/O ,/O and/O they/O may/O also/O have/O other/O forms/O of/O liver/O disease/O ,/O many/O of/O which/O can/O be/O treated/O or/O managed/O ./O
Therefore/O ,/O obtaining/O a/O liver/O test/O panel/O and/O assessing/O the/O patient/O before/O initiating/O NESINA/O therapy/O is/O recommended/O ./O
In/O patients/O with/O abnormal/O liver/O tests/O ,/O NESINA/O should/O be/O initiated/O with/O caution/O ./O
Measure/O liver/O tests/O promptly/O in/O patients/O who/O report/O symptoms/O that/O may/O indicate/O liver/O injury/O ,/O including/O fatigue/O ,/O anorexia/O ,/O right/O upper/O abdominal/O discomfort/O ,/O dark/O urine/O or/O jaundice/O ./O
In/O this/O clinical/O context/O ,/O if/O the/O patient/O is/O found/O to/O have/O clinically/O significant/O liver/O enzyme/O elevations/O and/O if/O abnormal/O liver/O tests/O persist/O or/O worsen/O ,/O NESINA/O should/O be/O interrupted/O and/O investigation/O done/O to/O establish/O the/O probable/O cause/O ./O
NESINA/O should/O not/O be/O restarted/O in/O these/O patients/O without/O another/O explanation/O for/O the/O liver/O test/O abnormalities/O ./O
5.4/O Use/O with/O Medications/O Known/O to/O Cause/O Hypoglycemia/O Insulin/O and/O insulin/O secretagogues/O ,/O such/O as/O sulfonylureas/O ,/O are/O known/O to/O cause/O hypoglycemia/O ./O
Therefore/O ,/O a/O lower/O dose/O of/O insulin/O or/O insulin/O secretagogue/O may/O be/O required/O to/O minimize/O the/O risk/O of/O hypoglycemia/O when/O used/O in/O combination/O with/O NESINA/O ./O
5.5/O Severe/O and/O Disabling/O Arthralgia/O There/O have/O been/O postmarketing/O reports/O of/O severe/B-Severity and/O disabling/B-Severity arthralgia/B-AdverseReaction in/O patients/O taking/O DPP-4/B-DrugClass inhibitors/I-DrugClass ./O
The/O time/O to/O onset/O of/O symptoms/O following/O initiation/O of/O drug/O therapy/O varied/O from/O one/O day/O to/O years/O ./O
Patients/O experienced/O relief/O of/O symptoms/O upon/O discontinuation/O of/O the/O medication/O ./O
A/O subset/O of/O patients/O experienced/O a/O recurrence/O of/O symptoms/O when/O restarting/O the/O same/O drug/O or/O a/O different/O DPP-4/O inhibitor/O ./O
Consider/O DPP-4/O inhibitors/O as/O a/O possible/O cause/O for/O severe/O joint/O pain/O and/O discontinue/O drug/O if/O appropriate/O ./O
5.6/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O NESINA/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Ophthalmic/B-AdverseReaction Adverse/I-AdverseReaction Reaction/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 2/O %/O )/O are/O local/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction irritation/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction infection/I-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction and/O headache/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O LEO/O Pharma/O Inc./O at/O 1/O -/O 877/O -/O 494/O -/O 4536/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O data/O described/O below/O reflect/O exposure/O to/O Picato/O (/O r/O )/O gel/O in/O 499/O subjects/O with/O actinic/O keratosis/O ,/O including/O 274/O subjects/O exposed/O to/O Picato/O (/O r/O )/O gel/O field/O treatment/O (/O skin/O area/O of/O 25/O cm/O 2/O in/O the/O face/O or/O scalp/O regions/O )/O at/O a/O concentration/O of/O 0.015/O %/O once/O daily/O for/O 3/O consecutive/O days/O ,/O and/O 225/O subjects/O exposed/O to/O Picato/O (/O r/O )/O gel/O field/O treatment/O (/O skin/O area/O of/O 25/O cm/O 2/O in/O the/O trunk/O or/O extremities/O regions/O )/O at/O a/O concentration/O of/O 0.05/O %/O once/O daily/O for/O 2/O consecutive/O days/O ./O
Local/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O erythema/O ,/O flaking/O scaling/O ,/O crusting/O ,/O swelling/O ,/O vesiculation/O pustulation/O ,/O and/O erosion/O ulceration/O were/O assessed/O within/O the/O selected/O treatment/O area/O and/O graded/O by/O the/O investigator/O on/O a/O scale/O of/O 0/O to/O 4/O ./O
A/O grade/O of/O 0/O represented/O no/O reaction/O present/O in/O the/O treated/O area/O ,/O and/O a/O grade/O of/O 4/O indicated/O a/O marked/O and/O severe/O skin/O reaction/O that/O extended/O beyond/O the/O treated/O area/O ./O
Table/O 1/O Investigator/O Assessment/O of/O Maximal/O Local/B-AdverseReaction Skin/I-AdverseReaction Reactions/I-AdverseReaction in/O the/O Treatment/O Area/O during/O the/O 57/O Days/O Post/O Treatment/O Period/O (/O face/O scalp/O trials/O )/O Face/O and/O Scalp/O (/O n=545/O )/O Picato(r/O )/O gel/O ,/O 0.015/O %/O once/O daily/O for/O 3/O days/O Skin/O reactions/O Any/O Gradea/O Baseline/O Grade/O 4/O Picato(r/O )/O gel/O (/O n=274/O )/O Vehicle/O (/O n=271/O )/O Picato(r/O )/O gel/O (/O n=274/O )/O Vehicle/O (/O n=271/O )/O Erythema/O 258/O (/O 94/O %/O )/O 69/O (/O 25/O %/O )/O 66/O (/O 24/O %/O )/O 0/O (/O 0/O %/O )/O Flaking/O Scaling/O 233/O (/O 85/O %/O )/O 67/O (/O 25/O %/O )/O 25/O (/O 9/O %/O )/O 0/O (/O 0/O %/O )/O Crusting/O 220/O (/O 80/O %/O )/O 46/O (/O 17/O %/O )/O 16/O (/O 6/O %/O )/O 0/O (/O 0/O %/O )/O Swelling/O 217/O (/O 79/O %/O )/O 11/O (/O 4/O %/O )/O 14/O (/O 5/O %/O )/O 0/O (/O 0/O %/O )/O Vesiculation/O Pustulation/O 154/O (/O 56/O %/O )/O 1/O (/O 0/O %/O )/O 15/O (/O 5/O %/O )/O 0/O (/O 0/O %/O )/O Erosion/O Ulceration/O 87/O (/O 32/O %/O )/O 3/O (/O 1/O %/O )/O 1/O (/O 0/O %/O )/O 0/O (/O 0/O %/O )/O a/O Mild/O (/O grade/O 1/O )/O ,/O Moderate/O (/O grade/O 2/O -/O 3/O )/O or/O Severe/O (/O grade/O 4/O )/O ./O
Table/O 2/O Investigator/O Assessment/O of/O Maximal/O Local/B-AdverseReaction Skin/I-AdverseReaction Reactions/I-AdverseReaction in/O the/O Treatment/O Area/O during/O the/O 57/O Days/O Post/O Treatment/O Period/O (/O trunk/O extremities/O trials/O )/O Trunk/O and/O Extremities/O (/O n=457/O )/O Picato(r/O )/O gel/O ,/O 0.05/O %/O once/O daily/O for/O 2/O days/O Skin/O reactions/O Any/O Gradea/O Baseline/O Grade/O 4/O Picato(r/O )/O gel/O (/O n=225/O )/O Vehicle/O (/O n=232/O )/O Picato(r/O )/O gel/O (/O n=225/O )/O Vehicle/O (/O n=232/O )/O Erythema/O 207/O (/O 92/O %/O )/O 43/O (/O 19/O %/O )/O 34/O (/O 15/O %/O )/O 0/O (/O 0/O %/O )/O Flaking/O Scaling/O 203/O (/O 90/O %/O )/O 44/O (/O 19/O %/O )/O 18/O (/O 8/O %/O )/O 0/O (/O 0/O %/O )/O Crusting/O 167/O (/O 74/O %/O )/O 23/O (/O 10/O %/O )/O 8/O (/O 4/O %/O )/O 0/O (/O 0/O %/O )/O Swelling/O 143/O (/O 64/O %/O )/O 13/O (/O 6/O %/O )/O 7/O (/O 3/O %/O )/O 0/O (/O 0/O %/O )/O Vesiculation/O Pustulation/O 98/O (/O 44/O %/O )/O 2/O (/O 1/O %/O )/O 3/O (/O 1/O %/O )/O 0/O (/O 0/O %/O )/O Erosion/O Ulceration/O 58/O (/O 26/O %/O )/O 6/O (/O 3/O %/O )/O 2/O (/O 1/O %/O )/O 0/O (/O 0/O %/O )/O a/O Mild/O (/O grade/O 1/O )/O ,/O Moderate/O (/O grade/O 2/O -/O 3/O )/O or/O Severe/O (/O grade/O 4/O )/O ./O
Local/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction typically/O occurred/O within/O 1/O day/O of/O treatment/O initiation/O ,/O peaked/O in/O intensity/O up/O to/O 1/O week/O following/O completion/O of/O treatment/O ,/O and/O resolved/O within/O 2/O weeks/O for/O areas/O treated/O on/O the/O face/O and/O scalp/O ,/O and/O within/O 4/O weeks/O for/O areas/O treated/O on/O the/O trunk/O and/O extremities/O ./O
Adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O subjects/O treated/O with/O Picato/O (/O r/O )/O gel/O and/O at/O a/O higher/O frequency/O than/O the/O vehicle/O are/O presented/O in/O Table/O 3/O and/O Table/O 4/O ./O
Table/O 3/O Adverse/O reactions/O occurring/O in/O 2/O %/O of/O subjects/O treated/O with/O Picato/O (/O r/O )/O gel/O and/O at/O higher/O frequency/O than/O vehicle/O (/O face/O scalp/O trials/O )/O Face/O Scalp/O Adverse/O Reactions/O Picato(r/O )/O gel/O ,/O 0.015/O %/O (/O N=274/O )/O Vehicle/O (/O N=271/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 42/O (/O 15/O %/O )/O 1/O (/O 0/O %/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Pruritus/I-AdverseReaction 22/O (/O 8/O %/O )/O 3/O (/O 1/O %/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Infection/I-AdverseReaction 7/O (/O 3/O %/O )/O 0/O (/O 0/O %/O )/O Periorbital/B-AdverseReaction Edema/I-AdverseReaction 7/O (/O 3/O %/O )/O 0/O (/O 0/O %/O )/O Headache/B-AdverseReaction 6/O (/O 2/O %/O )/O 3/O (/O 1/O %/O )/O Table/O 4/O Adverse/O reactions/O occurring/O in/O 2/O %/O of/O subjects/O treated/O with/O Picato/O (/O r/O )/O gel/O and/O at/O higher/O frequency/O than/O vehicle/O (/O trunk/O extremities/O trials/O )/O Trunk/O Extremities/O Adverse/O Reactions/O Picato(r/O )/O gel/O ,/O 0.05/O %/O (/O N=225/O )/O Vehicle/O (/O N=232/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Pruritus/I-AdverseReaction 18/O (/O 8/O %/O )/O 0/O (/O 0/O %/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Irritation/I-AdverseReaction 8/O (/O 4/O %/O )/O 1/O (/O 0/O %/O )/O Nasopharyngitis/B-AdverseReaction 4/O (/O 2/O %/O )/O 2/O (/O 1/O %/O )/O Application/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 5/O (/O 2/O %/O )/O 0/O (/O 0/O %/O )/O Less/O common/O adverse/O reactions/O in/O subjects/O treated/O with/O Picato/O (/O r/O )/O included/O :/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O conjunctivitis/B-AdverseReaction ./O
A/O total/O of/O 108/O subjects/O treated/O with/O Picato/O (/O r/O )/O gel/O on/O the/O face/O scalp/O and/O 38/O subjects/O treated/O on/O the/O trunk/O extremities/O were/O followed/O for/O 12/O months/O ./O
Results/O from/O these/O studies/O did/O not/O change/O the/O safety/O profile/O of/O Picato/O (/O r/O )/O gel/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O Picato/O (/O r/O )/O (/O ingenol/O mebutate/O )/O gel/O ,/O 0.015/O %/O and/O 0.05/O %/O :/O hypersensitivity/B-AdverseReaction ,/O allergic/B-AdverseReaction contact/I-AdverseReaction dermatitis/I-AdverseReaction ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction ,/O chemical/B-AdverseReaction conjunctivitis/I-AdverseReaction ,/O and/O corneal/B-AdverseReaction burn/I-AdverseReaction ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Avoid/O treatment/O in/O the/O periocular/O area/O ./O
Eye/B-AdverseReaction disorders/I-AdverseReaction ,/O including/O severe/B-Severity eye/B-AdverseReaction pain/I-AdverseReaction ,/O chemical/B-AdverseReaction conjunctivitis/I-AdverseReaction ,/O corneal/B-AdverseReaction burn/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction can/B-Factor occur/O after/O exposure/O ./O
Avoid/O accidental/O transfer/O of/O the/O drug/O into/O the/O eyes/O and/O to/O the/O periocular/O area/O ./O
If/O accidental/O exposure/O occurs/O ,/O flush/O eyes/O with/O water/O and/O seek/O medical/O care/O ./O
(/O 5.1/O )/O Local/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction can/B-Factor occur/O including/O severe/B-Severity reactions/O (/O e.g./O ,/O vesiculation/O pustulation/O ,/O erosion/O ulceration/O )/O ./O
Administration/O of/O Picato/O (/O r/O )/O gel/O is/O not/O recommended/O until/O skin/O is/O healed/O from/O any/O previous/O drug/O or/O surgical/O treatment/O ./O
(/O 5.3/O )/O 5.1/O Ophthalmic/O Adverse/O Reactions/O Avoid/O treatment/O in/O the/O periocular/O area/O ./O
Eye/B-AdverseReaction disorders/I-AdverseReaction ,/O including/O severe/B-Severity eye/B-AdverseReaction pain/I-AdverseReaction ,/O chemical/B-AdverseReaction conjunctivitis/I-AdverseReaction ,/O corneal/B-AdverseReaction burn/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction can/B-Factor occur/O after/O exposure/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
To/O avoid/O transfer/O of/O the/O drug/O into/O the/O eyes/O and/O to/O the/O periocular/O area/O during/O and/O after/O application/O ,/O patients/O should/O wash/O hands/O well/O after/O applying/O Picato/O (/O r/O )/O gel/O ./O
If/O accidental/O exposure/O occurs/O ,/O the/O area/O should/O be/O flushed/O with/O water/O and/O the/O patient/O should/O seek/O medical/O care/O as/O soon/O as/O possible/O ./O
5.2/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction and/O allergic/B-AdverseReaction contact/I-AdverseReaction dermatitis/I-AdverseReaction ,/O have/O been/O reported/O post/O -/O marketing/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
If/O anaphylactic/O or/O other/O clinically/O significant/O hypersensitivity/O reactions/O occur/O ,/O discontinue/O Picato/O (/O r/O )/O immediately/O and/O institute/O appropriate/O medical/O therapy/O ./O
5.3/O Local/O Skin/O Reactions/O Severe/B-Severity skin/B-AdverseReaction reactions/I-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction treated/I-AdverseReaction area/I-AdverseReaction ,/O including/O erythema/O ,/O crusting/O ,/O swelling/O ,/O vesiculation/O postulation/O ,/O and/O erosion/O ulceration/O ,/O can/B-Factor occur/O after/O topical/O application/O of/O Picato/O (/O r/O )/O gel/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Administration/O of/O Picato/O (/O r/O )/O gel/O is/O not/O recommended/O until/O the/O skin/O is/O healed/O from/O any/O previous/O drug/O or/O surgical/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O described/O in/O more/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O of/O the/O label/O :/O Retinal/B-AdverseReaction abnormalities/I-AdverseReaction and/O potential/B-Factor vision/B-AdverseReaction loss/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Urinary/B-AdverseReaction retention/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Skin/B-AdverseReaction discoloration/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Neuropsychiatric/B-AdverseReaction symptoms/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Dizziness/B-AdverseReaction and/O somnolence/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O QT/B-AdverseReaction interval/I-AdverseReaction effect/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Suicidal/B-AdverseReaction behavior/I-AdverseReaction and/O ideation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Withdrawal/B-AdverseReaction seizures/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 4/O %/O and/O twice/O placebo/O )/O were/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O tremor/B-AdverseReaction ,/O abnormal/B-AdverseReaction coordination/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction ,/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O aphasia/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O and/O balance/B-AdverseReaction disorder/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 888/O -/O 825/O -/O 5249/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
POTIGA/O was/O administered/O as/O adjunctive/O therapy/O to/O 1,365/O patients/O with/O epilepsy/O in/O all/O controlled/O and/O uncontrolled/O clinical/O studies/O during/O the/O premarketing/O development/O ./O
A/O total/O of/O 801/O patients/O were/O treated/O for/O at/O least/O 6/O months/O ,/O 585/O patients/O were/O treated/O for/O 1/O year/O or/O longer/O ,/O and/O 311/O patients/O were/O treated/O for/O at/O least/O 2/O years/O ./O
Adverse/O Reactions/O Leading/O to/O Discontinuation/O in/O All/O Controlled/O Clinical/O Studies/O In/O the/O 3/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O studies/O ,/O 199/O of/O 813/O patients/O (/O 25/O %/O )/O receiving/O POTIGA/O and/O 45/O of/O 427/O patients/O (/O 11/O %/O )/O receiving/O placebo/O discontinued/O treatment/O because/O of/O adverse/O reactions/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O withdrawal/O in/O patients/O receiving/O POTIGA/O were/O dizziness/B-AdverseReaction (/O 6/O %/O )/O ,/O confusional/B-AdverseReaction state/I-AdverseReaction (/O 4/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 3/O %/O )/O ,/O and/O somnolence/B-AdverseReaction (/O 3/O %/O )/O ./O
Common/O Adverse/O Reactions/O in/O All/O Controlled/O Clinical/O Studies/O Overall/O ,/O the/O most/O frequently/O reported/O adverse/O reactions/O in/O patients/O receiving/O POTIGA/O (/O 4/O %/O and/O occurring/O approximately/O twice/O the/O placebo/O rate/O )/O were/O dizziness/B-AdverseReaction (/O 23/O %/O )/O ,/O somnolence/B-AdverseReaction (/O 22/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 15/O %/O )/O ,/O confusional/B-AdverseReaction state/I-AdverseReaction (/O 9/O %/O )/O ,/O vertigo/B-AdverseReaction (/O 8/O %/O )/O ,/O tremor/B-AdverseReaction (/O 8/O %/O )/O ,/O abnormal/B-AdverseReaction coordination/I-AdverseReaction (/O 7/O %/O )/O ,/O diplopia/B-AdverseReaction (/O 7/O %/O )/O ,/O disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction (/O 6/O %/O )/O ,/O memory/B-AdverseReaction impairment/I-AdverseReaction (/O 6/O %/O )/O ,/O asthenia/B-AdverseReaction (/O 5/O %/O )/O ,/O blurred/B-AdverseReaction vision/I-AdverseReaction (/O 5/O %/O )/O ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction (/O 4/O %/O )/O ,/O aphasia/B-AdverseReaction (/O 4/O %/O )/O ,/O dysarthria/B-AdverseReaction (/O 4/O %/O )/O ,/O and/O balance/B-AdverseReaction disorder/I-AdverseReaction (/O 4/O %/O )/O (/O see/O Table/O 4/O )/O ./O
In/O most/O cases/O the/O reactions/O were/O of/O mild/O or/O moderate/O intensity/O ./O
Table/O 4/O ./O
Adverse/O Reactions/O Incidence/O in/O Placebo/O -/O Controlled/O Adjunctive/O Trials/O in/O Adult/O Patients/O with/O Partial/O -/O Onset/O Seizures/O (/O Adverse/O reactions/O in/O at/O least/O 2/O %/O of/O patients/O treated/O with/O POTIGA/O in/O any/O treatment/O group/O and/O numerically/O more/O frequent/O than/O in/O the/O placebo/O group/O ./O
)/O Body/O System/O Adverse/O Reaction/O Placebo/O POTIGA/O 600/O mg/O day/O 900/O mg/O day/O 1,200/O mg/O day/O All/O (/O N/O 427/O )/O %/O (/O n/O 281/O )/O %/O (/O n/O 273/O )/O %/O (/O n/O 259/O )/O %/O (/O N/O 813/O )/O %/O Eye/O Diplopia/B-AdverseReaction 2/O 8/O 6/O 7/O 7/O Blurred/B-AdverseReaction vision/I-AdverseReaction 2/O 2/O 4/O 10/O 5/O Gastrointestinal/O Nausea/B-AdverseReaction 5/O 6/O 6/O 9/O 7/O Constipation/B-AdverseReaction 1/O 1/O 4/O 5/O 3/O Dyspepsia/B-AdverseReaction 2/O 3/O 2/O 3/O 2/O General/O Fatigue/B-AdverseReaction 6/O 16/O 15/O 13/O 15/O Asthenia/B-AdverseReaction 2/O 4/O 6/O 4/O 5/O Infections/O and/O infestations/O Influenza/B-AdverseReaction 2/O 4/O 1/O 5/O 3/O Investigations/O Weight/B-AdverseReaction increased/I-AdverseReaction 1/O 2/O 3/O 3/O 3/O Nervous/O system/O Dizziness/B-AdverseReaction 9/O 15/O 23/O 32/O 23/O Somnolence/B-AdverseReaction 12/O 15/O 25/O 27/O 22/O Memory/B-AdverseReaction impairment/I-AdverseReaction 3/O 3/O 6/O 9/O 6/O Tremor/B-AdverseReaction 3/O 3/O 10/O 12/O 8/O Vertigo/B-AdverseReaction 2/O 8/O 8/O 9/O 8/O Abnormal/B-AdverseReaction coordination/I-AdverseReaction 3/O 5/O 5/O 12/O 7/O Disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction 1/O 6/O 6/O 7/O 6/O Gait/B-AdverseReaction disturbance/I-AdverseReaction 1/O 2/O 5/O 6/O 4/O Aphasia/B-AdverseReaction 1/O 1/O 3/O 7/O 4/O Dysarthria/B-AdverseReaction 1/O 4/O 2/O 8/O 4/O Balance/B-AdverseReaction disorder/I-AdverseReaction 1/O 3/O 3/O 5/O 4/O Paresthesia/B-AdverseReaction 2/O 3/O 2/O 5/O 3/O Amnesia/B-AdverseReaction 1/O 1/O 3/O 3/O 2/O Dysphasia/B-AdverseReaction 1/O 1/O 1/O 3/O 2/O Psychiatric/O Confusional/B-AdverseReaction state/I-AdverseReaction 3/O 4/O 8/O 16/O 9/O Anxiety/B-AdverseReaction 2/O 3/O 2/O 5/O 3/O Disorientation/B-AdverseReaction 1/O 1/O 1/O 5/O 2/O Psychotic/B-AdverseReaction disorder/I-AdverseReaction 0/O 0/O 1/O 2/O 1/O Renal/O and/O urinary/O Dysuria/B-AdverseReaction 1/O 1/O 2/O 4/O 2/O Urinary/B-AdverseReaction hesitation/I-AdverseReaction 1/O 2/O 1/O 4/O 2/O Hematuria/B-AdverseReaction 1/O 2/O 1/O 2/O 2/O Chromaturia/B-AdverseReaction 1/O 1/O 2/O 3/O 2/O Other/O adverse/O reactions/O reported/O in/O these/O 3/O studies/O in/O 2/O %/O of/O patients/O treated/O with/O POTIGA/O and/O numerically/O greater/O than/O placebo/O were/O increased/B-AdverseReaction appetite/I-AdverseReaction ,/O hallucinations/B-AdverseReaction ,/O myoclonus/B-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O hypokinesia/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O hyperhydrosis/B-AdverseReaction ,/O urinary/B-AdverseReaction retention/I-AdverseReaction ,/O malaise/B-AdverseReaction ,/O and/O increased/B-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction ./O
Most/O of/O the/O adverse/O reactions/O appear/O to/O be/O dose/O related/O (/O especially/O those/O classified/O as/O psychiatric/O and/O nervous/O system/O symptoms/O )/O ,/O including/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O tremor/B-AdverseReaction ,/O abnormal/B-AdverseReaction coordination/I-AdverseReaction ,/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O aphasia/B-AdverseReaction ,/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O dysuria/B-AdverseReaction ,/O and/O chromaturia/B-AdverseReaction ./O
POTIGA/O was/O associated/O with/O dose/O -/O related/O weight/B-AdverseReaction gain/I-AdverseReaction ,/O with/O mean/O weight/B-AdverseReaction increasing/I-AdverseReaction by/O 0.2/O kg/O ,/O 1.2/O kg/O ,/O 1.6/O kg/O ,/O and/O 2.7/O kg/O in/O the/O placebo/O ,/O 600/O mg/O per/O day/O ,/O 900/O mg/O per/O day/O ,/O and/O 1,200/O mg/O per/O day/O groups/O ,/O respectively/O ./O
Additional/O Adverse/O Reactions/O Observed/O during/O All/O Phase/O 2/O and/O 3/O Clinical/O Trials/O Following/O is/O a/O list/O of/O adverse/O reactions/O reported/O by/O patients/O treated/O with/O POTIGA/O during/O all/O clinical/O trials/O :/O rash/B-AdverseReaction ,/O nystagmus/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O muscle/B-AdverseReaction spasms/I-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O nephrolithiasis/B-AdverseReaction ,/O syncope/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O euphoric/B-AdverseReaction mood/I-AdverseReaction ,/O renal/B-AdverseReaction colic/I-AdverseReaction ,/O coma/B-AdverseReaction ,/O encephalopathy/B-AdverseReaction ./O
Comparison/O of/O Gender/O ,/O Age/O ,/O and/O Race/O The/O overall/O adverse/O reaction/O profile/O of/O POTIGA/O was/O similar/O for/O females/O and/O males/O ./O
There/O are/O insufficient/O data/O to/O support/O meaningful/O analyses/O of/O adverse/O reactions/O by/O age/O or/O race/O ./O
Approximately/O 86/O %/O of/O the/O population/O studied/O was/O Caucasian/O ,/O and/O 0.8/O %/O of/O the/O population/O was/O aged/O 65/O years/O or/O older/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O RETINAL/B-AdverseReaction ABNORMALITIES/I-AdverseReaction AND/O POTENTIAL/B-Factor VISION/B-AdverseReaction LOSS/I-AdverseReaction WARNING/O :/O RETINAL/B-AdverseReaction ABNORMALITIES/I-AdverseReaction AND/O POTENTIAL/B-Factor VISION/B-AdverseReaction LOSS/I-AdverseReaction POTIGA/O can/B-Factor cause/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction with/O funduscopic/O features/O similar/O to/O those/O seen/O in/O retinal/O pigment/O dystrophies/O ,/O which/O are/O known/O to/O result/O in/O damage/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction photoreceptors/I-AdverseReaction and/O vision/B-AdverseReaction loss/I-AdverseReaction ./O
Some/O patients/O with/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction have/O been/O found/O to/O have/O abnormal/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ./O
It/O is/O not/B-Factor possible/I-Factor to/I-Factor determine/I-Factor whether/O POTIGA/O caused/O this/O decreased/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ,/O as/O baseline/O assessments/O are/O not/O available/O for/O these/O patients/O ./O
Approximately/O one/O third/O of/O the/O patients/O who/O had/O eye/O examinations/O performed/O after/O approximately/O 4/O years/O of/O treatment/O were/O found/O to/O have/O retinal/B-AdverseReaction pigmentary/I-AdverseReaction abnormalities/I-AdverseReaction ./O
An/O earlier/O onset/O can/O not/O be/O ruled/O out/O ,/O and/O it/O is/O possible/O that/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction were/O present/O earlier/O in/O the/O course/O of/O exposure/O to/O POTIGA/O ./O
The/O rate/O of/O progression/O of/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction and/O their/O reversibility/O are/O unknown/O ./O
POTIGA/O should/O only/O be/O used/O in/O patients/O who/O have/O responded/O inadequately/O to/O several/O alternative/O treatments/O and/O for/O whom/O the/O benefits/O outweigh/O the/O potential/O risk/O of/O vision/O loss/O ./O
Patients/O who/O fail/O to/O show/O substantial/O clinical/O benefit/O after/O adequate/O titration/O should/O be/O discontinued/O from/O POTIGA/O ./O
All/O patients/O taking/O POTIGA/O should/O have/O baseline/O and/O periodic/O (/O every/O 6/O months/O )/O systematic/O visual/O monitoring/O by/O an/O ophthalmic/O professional/O ./O
Testing/O should/O include/O visual/O acuity/O and/O dilated/O fundus/O photography/O ./O
Additional/O testing/O may/O include/O fluorescein/O angiograms/O (/O FA/O )/O ,/O optical/O coherence/O tomography/O (/O OCT/O )/O ,/O perimetry/O ,/O and/O electroretinograms/O (/O ERG/O )/O ./O
If/O retinal/O pigmentary/O abnormalities/O or/O vision/O changes/O are/O detected/O ,/O POTIGA/O should/O be/O discontinued/O unless/O no/O other/O suitable/O treatment/O options/O are/O available/O and/O the/O benefits/O of/O treatment/O outweigh/O the/O potential/O risk/O of/O vision/O loss/O ./O
EXCERPT/O :/O WARNING/O :/O RETINAL/B-AdverseReaction ABNORMALITIES/I-AdverseReaction AND/O POTENTIAL/B-Factor VISION/B-AdverseReaction LOSS/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
POTIGA/O can/O cause/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction with/O funduscopic/O features/O similar/O to/O those/O seen/O in/O retinal/O pigment/O dystrophies/O ,/O which/O are/O known/O to/O result/O in/O damage/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction photoreceptors/I-AdverseReaction and/O vision/B-AdverseReaction loss/I-AdverseReaction ./O
(/O 5.1/O )/O Some/O patients/O with/O retinal/O abnormalities/O have/O been/O found/O to/O have/O abnormal/O visual/O acuity/O ./O
It/O is/O not/B-Factor possible/I-Factor to/I-Factor determine/I-Factor whether/O POTIGA/O caused/O this/O decreased/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ./O
(/O 5.1/O )/O The/O rate/O of/O progression/O of/O retinal/O abnormalities/O and/O their/O reversibility/O are/O unknown/O ./O
(/O 5.1/O )/O Patients/O who/O fail/O to/O show/O substantial/O clinical/O benefit/O after/O adequate/O titration/O should/O be/O discontinued/O from/O POTIGA/O ./O
(/O 5.1/O )/O All/O patients/O taking/O POTIGA/O should/O have/O baseline/O and/O periodic/O (/O every/O 6/O months/O )/O systematic/O visual/O monitoring/O by/O an/O ophthalmic/O professional/O ./O
Testing/O should/O include/O visual/O acuity/O and/O dilated/O fundus/O photography/O ./O
(/O 5.1/O )/O If/O retinal/O pigmentary/O abnormalities/O or/O vision/O changes/O are/O detected/O ,/O POTIGA/O should/O be/O discontinued/O unless/O no/O other/O suitable/O treatment/O options/O are/O available/O and/O the/O benefits/O of/O treatment/O outweigh/O the/O potential/O risk/O of/O vision/O loss/O ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Urinary/B-AdverseReaction retention/I-AdverseReaction :/O Patients/O should/O be/O carefully/O monitored/O for/O urologic/O symptoms/O ./O
(/O 5.2/O )/O POTIGA/O can/B-Factor cause/O skin/B-AdverseReaction discoloration/I-AdverseReaction ./O
If/O a/O patient/O develops/O skin/O discoloration/O ,/O serious/O consideration/O should/O be/O given/O to/O an/O alternative/O treatment/O ./O
(/O 5.3/O )/O Neuropsychiatric/B-AdverseReaction symptoms/I-AdverseReaction :/O Monitor/O for/O confusional/O state/O ,/O psychotic/O symptoms/O ,/O and/O hallucinations/O ./O
(/O 5.4/O )/O Monitor/O for/O dizziness/O and/O somnolence/O ./O
(/O 5.5/O )/O QT/B-AdverseReaction prolongation/I-AdverseReaction :/O QT/O interval/O should/O be/O monitored/O in/O patients/O taking/O concomitant/O medications/O known/O to/O increase/O the/O QT/O interval/O or/O with/O certain/O heart/O conditions/O ./O
(/O 5.6/O )/O Monitor/O for/O suicidal/O thoughts/O or/O behaviors/O ./O
(/O 5.7/O )/O 5.1/O Retinal/O Abnormalities/O and/O Potential/O Vision/O Loss/O POTIGA/O can/B-Factor cause/O abnormalities/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction retina/I-AdverseReaction ./O
The/O abnormalities/O seen/O in/O patients/O treated/O with/O POTIGA/O have/O funduscopic/O features/O similar/O to/O those/O seen/O in/O retinal/O pigment/O dystrophies/O that/O are/O known/O to/O result/O in/O damage/B-AdverseReaction to/I-AdverseReaction photoreceptors/I-AdverseReaction and/O vision/B-AdverseReaction loss/I-AdverseReaction ./O
The/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction observed/O with/O POTIGA/O have/O been/O reported/O in/O patients/O who/O were/O originally/O enrolled/O in/O clinical/O trials/O with/O POTIGA/O and/O who/O have/O generally/O taken/O the/O drug/O for/O a/O long/O period/O of/O time/O in/O 2/O ongoing/O extension/O trials/O ./O
Approximately/O one/O third/O of/O the/O patients/O who/O had/O eye/O examinations/O performed/O after/O approximately/O 4/O years/O of/O treatment/O were/O found/O to/O have/O retinal/B-AdverseReaction pigmentary/I-AdverseReaction abnormalities/I-AdverseReaction ./O
However/O ,/O an/O earlier/O onset/O can/O not/O be/O ruled/O out/O ,/O and/O it/O is/O possible/O that/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction were/O present/O earlier/O in/O the/O course/O of/O exposure/O to/O POTIGA/O ./O
POTIGA/O causes/O skin/O ,/O scleral/O ,/O nail/O ,/O and/O mucous/B-AdverseReaction membrane/I-AdverseReaction discoloration/I-AdverseReaction and/O it/O is/O not/O clear/O whether/O this/O discoloration/B-AdverseReaction is/O related/O to/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Approximately/O 15/O %/O of/O patients/O with/O retinal/B-AdverseReaction pigmentary/I-AdverseReaction abnormalities/I-AdverseReaction had/O no/B-Negation such/O discoloration/B-AdverseReaction ./O
Funduscopic/B-AdverseReaction abnormalities/I-AdverseReaction have/O most/O commonly/O been/O described/O as/O perivascular/O pigmentation/O (/O bone/O spicule/O pattern/O )/O in/O the/O retinal/O periphery/O and/or/O as/O areas/O of/O focal/B-AdverseReaction retinal/I-AdverseReaction pigment/I-AdverseReaction epithelium/I-AdverseReaction clumping/I-AdverseReaction ./O
Although/O some/O of/O the/O patients/O with/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction have/O been/O found/O to/O have/O abnormal/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ,/O it/O is/O not/O possible/O to/O assess/O whether/B-Factor POTIGA/O caused/O their/O decreased/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ,/O as/O baseline/O assessments/O are/O not/O available/O for/O these/O patients/O ./O
Two/O patients/O with/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction have/O had/O more/O extensive/O diagnostic/O retinal/O evaluations/O ./O
The/O results/O of/O these/O evaluations/O were/O consistent/O with/O a/O retinal/B-AdverseReaction dystrophy/I-AdverseReaction ,/O including/O abnormalities/B-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction electroretinogram/I-AdverseReaction and/O electrooculogram/O of/O both/O patients/O ,/O with/O abnormal/B-AdverseReaction fluorescein/I-AdverseReaction angiography/I-AdverseReaction and/O diminished/B-AdverseReaction sensitivity/I-AdverseReaction on/I-AdverseReaction visual/I-AdverseReaction field/I-AdverseReaction testing/O in/O one/O patient/O ./O
The/O rate/O of/O progression/O of/O retinal/B-AdverseReaction abnormalities/I-AdverseReaction and/O the/O reversibility/O after/O drug/O discontinuation/O are/O unknown/O ./O
Because/B-Factor of/O the/O observed/O ophthalmologic/O adverse/O reactions/O ,/O POTIGA/O should/O only/O be/O used/O in/O patients/O who/O have/O responded/O inadequately/O to/O several/O alternative/O treatments/O and/O for/O whom/O the/O benefits/O outweigh/O the/O risk/O of/O retinal/O abnormalities/O and/O potential/O vision/O loss/O ./O
Patients/O who/O fail/O to/O show/O substantial/O clinical/O benefit/O after/O adequate/O titration/O should/O be/O discontinued/O from/O POTIGA/O ./O
Patients/O should/O have/O baseline/O ophthalmologic/O testing/O by/O an/O ophthalmic/O professional/O and/O follow/O -/O up/O testing/O every/O 6/O months/O ./O
The/O best/O method/O of/O detection/O of/O these/O abnormalities/O and/O the/O optimal/O frequency/O of/O periodic/O ophthalmologic/O monitoring/O are/O unknown/O ./O
Patients/O who/O can/O not/O be/O monitored/O should/O usually/O not/O be/O treated/O with/O POTIGA/O ./O
The/O ophthalmologic/O monitoring/O program/O should/O include/O visual/O acuity/O testing/O and/O dilated/O fundus/O photography/O ./O
Additional/O testing/O may/O include/O fluorescein/O angiograms/O (/O FA/O )/O ,/O optical/O coherence/O tomography/O (/O OCT/O )/O ,/O perimetry/O ,/O and/O electroretinograms/O (/O ERG/O )/O ./O
If/O retinal/O pigmentary/O abnormalities/O or/O vision/O changes/O are/O detected/O ,/O POTIGA/O should/O be/O discontinued/O unless/O no/O other/O suitable/O treatment/O options/O are/O available/O and/O the/O benefits/O of/O treatment/O outweigh/O the/O potential/O risk/O of/O vision/O loss/B-Factor ./O
5.2/O Urinary/O Retention/O POTIGA/O caused/O urinary/B-AdverseReaction retention/I-AdverseReaction in/O clinical/O trials/O ./O
Urinary/B-AdverseReaction retention/I-AdverseReaction was/O generally/O reported/O within/O the/O first/O 6/O months/O of/O treatment/O ,/O but/O was/O also/O observed/O later/O ./O
Urinary/B-AdverseReaction retention/I-AdverseReaction was/O reported/O as/O an/O adverse/O event/O in/O 29/O of/O 1,365/O (/O approximately/O 2/O %/O )/O patients/O treated/O with/O POTIGA/O in/O the/O open/O -/O label/O and/O placebo/O -/O controlled/O epilepsy/O database/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Of/O these/O 29/O patients/O ,/O 5/O (/O 17/O %/O )/O required/O catheterization/O ,/O with/O post/O -/O voiding/O residuals/O of/O up/O to/O 1,500/O mL./O POTIGA/O was/O discontinued/O in/O 3/O of/O the/O 5/O patients/O who/O required/O catheterization/O ,/O and/O all/O were/O able/O to/O void/O spontaneously/O ;/O however/O ,/O 1/O of/O the/O 3/O patients/O continued/O intermittent/O self/O -/O catheterization/O ./O
Two/O patients/O continued/O treatment/O with/O POTIGA/O and/O were/O able/O to/O void/O spontaneously/O after/O catheter/O removal/O ./O
Hydronephrosis/B-AdverseReaction occurred/O in/O 2/O patients/O ,/O one/O of/O whom/O had/O associated/O renal/B-AdverseReaction function/I-AdverseReaction impairment/I-AdverseReaction that/O resolved/O upon/O discontinuation/O of/O POTIGA/O ./O
Hydronephrosis/B-AdverseReaction was/O not/B-Negation reported/O in/O placebo/B-Factor patients/O ./O
In/O the/O placebo/O -/O controlled/O epilepsy/O trials/O ,/O "/O urinary/B-AdverseReaction retention/I-AdverseReaction ,/O "/O "/O urinary/B-AdverseReaction hesitation/I-AdverseReaction ,/O "/O and/O "/O dysuria/B-AdverseReaction "/O were/O reported/O in/O 0.9/O %/O ,/O 2.2/O %/O ,/O and/O 2.3/O %/O of/O patients/O on/O POTIGA/O ,/O respectively/O ,/O and/O in/O 0.5/O %/O ,/O 0.9/O %/O ,/O and/O 0.7/O %/O of/O patients/O on/O placebo/O ,/O respectively/O ./O
Because/B-Factor of/O the/O increased/O risk/O of/O urinary/O retention/O on/O POTIGA/O ,/O urologic/O symptoms/O should/O be/O carefully/O monitored/O ./O
Closer/O monitoring/O is/O recommended/O for/O patients/O who/O have/O other/O risk/O factors/O for/O urinary/O retention/O (/O e.g./O ,/O benign/O prostatic/O hyperplasia/O [/O BPH/O ]/O )/O ,/O patients/O who/O are/O unable/O to/O communicate/O clinical/O symptoms/O (/O e.g./O ,/O cognitively/O impaired/O patients/O )/O ,/O or/O patients/O who/O use/O concomitant/O medications/O that/O may/O affect/O voiding/O (/O e.g./O ,/O anticholinergics/O )/O ./O
In/O these/O patients/O ,/O a/O comprehensive/O evaluation/O of/O urologic/O symptoms/O prior/O to/O and/O during/O treatment/O with/O POTIGA/O may/O be/O appropriate/B-Factor ./O
5.3/O Skin/O Discoloration/O POTIGA/O can/B-Factor cause/O skin/B-AdverseReaction discoloration/I-AdverseReaction ./O
The/O skin/B-AdverseReaction discoloration/I-AdverseReaction is/O generally/O described/O as/O blue/O ,/O but/O has/O also/O been/O described/O as/O grey/O -/O blue/O or/O brown/O ./O
It/O is/O predominantly/O on/O or/O around/O the/O lips/O or/O in/O the/O nail/O beds/O of/O the/O fingers/O or/O toes/O ,/O but/O more/O widespread/O involvement/O of/O the/O face/O and/O legs/O has/O also/O been/O reported/O ./O
Discoloration/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction palate/I-AdverseReaction ,/O sclera/O ,/O and/O conjunctiva/O has/O also/O been/O reported/O ./O
Approximately/O 10/O %/O of/O patients/O in/O long/O -/O term/O clinical/O trials/O developed/O skin/B-AdverseReaction discoloration/I-AdverseReaction ,/O generally/O after/O 2/O or/O more/O years/O of/O treatment/O and/O at/O higher/O doses/O (/O 900/O mg/O or/O greater/O )/O of/O POTIGA/O ./O
Among/O patients/O in/O whom/O the/O status/O of/O both/O skin/O ,/O nail/O ,/O lip/O ,/O or/O mucous/B-AdverseReaction membrane/I-AdverseReaction discoloration/I-AdverseReaction and/O retinal/B-AdverseReaction pigmentary/I-AdverseReaction abnormalities/I-AdverseReaction are/O reported/O ,/O approximately/O a/O quarter/O of/O those/O with/O skin/O ,/O nail/O ,/O lip/O ,/O or/O mucous/B-AdverseReaction membrane/I-AdverseReaction discoloration/I-AdverseReaction had/O concurrent/O retinal/B-AdverseReaction pigmentary/I-AdverseReaction abnormalities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Information/O on/O the/O consequences/O ,/O reversibility/O ,/O time/O to/O onset/O ,/O and/O pathophysiology/O of/O the/O skin/B-AdverseReaction abnormalities/I-AdverseReaction remains/O incomplete/O ./O
The/O possibility/O of/O more/O extensive/O systemic/O involvement/O has/O not/O been/O excluded/O ./O
If/O a/O patient/O develops/O skin/O discoloration/O ,/O serious/O consideration/O should/O be/O given/O to/O changing/O to/O an/O alternate/O medication/O ./O
5.4/O Neuropsychiatric/O Symptoms/O Confusional/B-AdverseReaction state/I-AdverseReaction ,/O psychotic/B-AdverseReaction symptoms/I-AdverseReaction ,/O and/O hallucinations/B-AdverseReaction were/O reported/O more/O frequently/O as/O adverse/O reactions/O in/O patients/O treated/O with/O POTIGA/O than/O in/O those/O treated/O with/O placebo/O in/O placebo/O -/O controlled/O epilepsy/O trials/O (/O see/O Table/O 2/O )/O ./O
Discontinuations/O resulting/O from/O these/O reactions/O were/O more/O common/O in/O the/O drug/O -/O treated/O group/O (/O see/O Table/O 2/O )/O ./O
These/O effects/O were/O dose/O -/O related/O and/O generally/O appeared/O within/O the/O first/O 8/O weeks/O of/O treatment/O ./O
Half/O of/O the/O patients/O in/O the/O controlled/O trials/O who/O discontinued/O POTIGA/O due/O to/O hallucinations/B-AdverseReaction or/O psychosis/B-AdverseReaction required/O hospitalization/O ./O
Approximately/O two/O -/O thirds/O of/O patients/O with/O psychosis/B-AdverseReaction in/O controlled/O trials/O had/O no/O prior/O psychiatric/O history/O ./O
The/O psychiatric/B-AdverseReaction symptoms/I-AdverseReaction in/O the/O vast/O majority/O of/O patients/O in/O both/O controlled/O and/O open/O -/O label/O trials/O resolved/O within/O 7/O days/O of/O discontinuation/O of/O POTIGA/O ./O
Rapid/O titration/O at/O greater/O than/O the/O recommended/O doses/O appeared/O to/O increase/O the/O risk/B-Factor of/O psychosis/B-AdverseReaction and/O hallucinations/B-AdverseReaction ./O
Table/O 2/O ./O
Major/O Neuropsychiatric/B-AdverseReaction Symptoms/I-AdverseReaction in/O Placebo/O -/O Controlled/O Epilepsy/O Trials/O Adverse/O Reaction/O Number/O (/O %/O )/O with/O Adverse/O Reaction/O Number/O (/O %/O )/O Discontinuing/O POTIGA/O (/O n/O 813/O )/O Placebo/O (/O n/O 427/O )/O POTIGA/O (/O n/O 813/O )/O Placebo/O (/O n/O 427/O )/O Confusional/B-AdverseReaction state/I-AdverseReaction 75/O (/O 9/O %/O )/O 11/O (/O 3/O %/O )/O 32/O (/O 4/O %/O )/O 4/O (/O 1/O %/O )/O Psychosis/B-AdverseReaction 9/O (/O 1/O %/O )/O 0/O 6/O (/O 1/O %/O )/O 0/O Hallucinationsa/B-AdverseReaction 14/O (/O 2/O %/O )/O 2/O (/O 1/O %/O )/O 6/O (/O 1/O %/O )/O 0/O a/O Hallucinations/B-AdverseReaction includes/O visual/O ,/O auditory/O ,/O and/O mixed/B-AdverseReaction hallucinations/I-AdverseReaction ./O
5.5/O Dizziness/O and/O Somnolence/O POTIGA/O causes/O dose/O -/O related/O increases/O in/O dizziness/B-AdverseReaction and/O somnolence/B-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O placebo/O -/O controlled/O trials/O in/O patients/O with/O epilepsy/O ,/O dizziness/B-AdverseReaction was/O reported/O in/O 23/O %/O of/O patients/O treated/O with/O POTIGA/O and/O 9/O %/O of/O patients/O treated/O with/O placebo/O ./O
Somnolence/B-AdverseReaction was/O reported/O in/O 22/O %/O of/O patients/O treated/O with/O POTIGA/O and/O 12/O %/O of/O patients/O treated/O with/O placebo/O ./O
In/O these/O trials/O 6/O %/O of/O patients/O on/O POTIGA/O and/O 1.2/O %/O on/O placebo/O discontinued/O treatment/O because/O of/O dizziness/B-AdverseReaction ;/O 3/O %/O of/O patients/O on/O POTIGA/O and/O 1.0/O %/O on/O placebo/O discontinued/O because/O of/O somnolence/B-AdverseReaction ./O
Most/O of/O these/O adverse/O reactions/O were/O mild/O to/O moderate/O in/O intensity/O and/O occurred/O during/O the/O titration/O phase/O ./O
For/O those/O patients/O continued/O on/O POTIGA/O ,/O dizziness/B-AdverseReaction and/O somnolence/B-AdverseReaction appeared/O to/O diminish/O with/O continued/O use/O ./O
5.6/O QT/O Interval/O Effect/O A/O study/O of/O cardiac/O conduction/O showed/O that/O POTIGA/O produced/O a/O mean/O 7.7-msec/B-Severity QT/B-AdverseReaction prolongation/I-AdverseReaction in/O healthy/O volunteers/O titrated/O to/O 400/O mg/O 3/O times/O daily/O ./O
The/O QT/B-AdverseReaction -/O prolonging/O effect/O occurred/O within/O 3/O hours/O ./O
The/O QT/O interval/O should/O be/O monitored/O when/O POTIGA/O is/O prescribed/O with/O medicines/O known/O to/O increase/O QT/O interval/O and/O in/O patients/O with/O known/O prolonged/O QT/O interval/O ,/O congestive/O heart/O failure/O ,/O ventricular/O hypertrophy/O ,/O hypokalemia/O ,/O or/O hypomagnesemia/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.7/O Suicidal/O Behavior/O and/O Ideation/O Antiepileptic/O drugs/O (/O AEDs/O )/O ,/O including/O POTIGA/O ,/O increase/O the/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O in/O patients/O taking/O these/O drugs/O for/O any/O indication/O ./O
Patients/O treated/O with/O any/O AED/O for/O any/O indication/O should/O be/O monitored/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O behavior/O ,/O and/or/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ./O
Pooled/O analyses/O of/O 199/O placebo/O -/O controlled/O clinical/O trials/O (/O mono-/O and/O adjunctive/O -/O therapy/O )/O of/O 11/O different/O AEDs/O showed/O that/O patients/O randomized/O to/O one/O of/O the/O AEDs/O had/O approximately/O twice/O the/O risk/B-Factor (/O adjusted/O relative/O risk/O 1.8/O ,/O 95/O %/O confidence/O interval/O [/O CI/O ]/O :/O 1.2/O ,/O 2.7/O )/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O compared/O with/O patients/O randomized/O to/O placebo/O ./O
In/O these/O trials/O ,/O which/O had/O a/O median/O treatment/O duration/O of/O 12/O weeks/O ,/O the/O estimated/O incidence/O of/O suicidal/B-AdverseReaction behavior/I-AdverseReaction or/O ideation/O among/O 27,863/O AED/O -/O treated/O patients/O was/O 0.43/O %/O compared/O with/O 0.24/O %/O among/O 16,029/O placebo/O -/O treated/O patients/O ,/O representing/O an/O increase/O of/O approximately/O 1/O case/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O for/O every/O 530/O patients/O treated/O ./O
There/O were/O 4/O suicides/B-AdverseReaction in/O drug/O -/O treated/O patients/O in/O the/O trials/O and/O none/O in/O placebo/O -/O treated/O patients/O ,/O but/O the/O number/B-Factor is/I-Factor too/I-Factor small/I-Factor to/O allow/O any/O conclusion/O about/O drug/O effect/O on/O suicide/B-AdverseReaction ./O
The/O increased/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O with/O AEDs/B-DrugClass was/O observed/O as/O early/O as/O 1/O week/O after/O starting/O treatment/O with/O AEDs/O and/O persisted/O for/O the/O duration/O of/O treatment/O assessed/O ./O
Because/O most/O trials/O included/O in/O the/O analysis/O did/O not/O extend/O beyond/O 24/O weeks/O ,/O the/O risk/O of/O suicidal/O thoughts/O or/O behavior/O beyond/O 24/O weeks/O could/O not/O be/O assessed/O ./O
The/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O generally/O consistent/O among/O drugs/O in/O the/O data/O analyzed/O ./O
The/O finding/O of/O increased/O risk/O with/O AEDs/O of/O varying/O mechanism/O of/O action/O and/O across/O a/O range/O of/O indications/O suggests/O that/O the/O risk/O applies/O to/O all/O AEDs/O used/O for/O any/O indication/O ./O
The/O risk/O did/O not/O vary/O substantially/O by/O age/O (/O 5/O to/O 100/O years/O )/O in/O the/O clinical/O trials/O analyzed/O ./O
Table/O 3/O shows/O absolute/O and/O relative/O risk/O by/O indication/O for/O all/O evaluated/O AEDs/O ./O
Table/O 3/O ./O
Risk/B-Factor of/O Suicidal/B-AdverseReaction Thoughts/I-AdverseReaction or/O Behaviors/O by/O Indication/O for/O Antiepileptic/O Drugs/O in/O the/O Pooled/O Analysis/O Indication/O Placebo/O Patients/O with/O Events/O per/O 1,000/O Patients/O Drug/O Patients/O with/O Events/O per/O 1,000/O Patients/O Relative/O Risk/O :/O Incidence/O of/O Events/O in/O Drug/O Patients/O Incidence/O in/O Placebo/O Patients/O Risk/O Difference/O :/O Additional/O Drug/O Patients/O with/O Events/O per/O 1,000/O Patients/O Epilepsy/O 1.0/O 3.4/O 3.5/O 2.4/O Psychiatric/O 5.7/O 8.5/O 1.5/O 2.9/O Other/O 1.0/O 1.8/O 1.9/O 0.9/O Total/O 2.4/O 4.3/O 1.8/O 1.9/O The/O relative/O risk/B-Factor for/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O higher/O in/O clinical/O trials/O in/O patients/O with/O epilepsy/O than/O in/O clinical/O trials/O in/O patients/O with/O psychiatric/O or/O other/O conditions/O ,/O but/O the/O absolute/O risk/O differences/O were/O similar/O for/O epilepsy/O and/O psychiatric/O indications/O ./O
Anyone/O considering/O prescribing/O POTIGA/O or/O any/O other/O AED/O must/O balance/O this/O risk/O with/O the/O risk/O of/O untreated/O illness/O ./O
Epilepsy/O and/O many/O other/O illnesses/O for/O which/O AEDs/O are/O prescribed/O are/O themselves/O associated/O with/O morbidity/O and/O mortality/O and/O an/O increased/O risk/O of/O suicidal/O thoughts/O and/O behavior/O ./O
Should/O suicidal/O thoughts/O and/O behavior/O emerge/O during/O treatment/O ,/O the/O prescriber/O needs/O to/O consider/O whether/O the/O emergence/O of/O these/O symptoms/O in/O any/O given/O patient/O may/O be/O related/O to/O the/O illness/O being/O treated/O ./O
Patients/O ,/O their/O caregivers/O ,/O and/O families/O should/O be/O informed/O that/O AEDs/O increase/O the/O risk/O of/O suicidal/O thoughts/O and/O behavior/O and/O should/O be/O advised/O of/O the/O need/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O the/O signs/O and/O symptoms/O of/O depression/O ;/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ;/O or/O the/O emergence/O of/O suicidal/O thoughts/O ,/O behavior/O ,/O or/O thoughts/O about/O self/O -/O harm/O ./O
Behaviors/O of/O concern/O should/O be/O reported/O immediately/O to/O healthcare/O providers/O ./O
5.8/O Withdrawal/O Seizures/O As/O with/O all/O AEDs/O ,/O when/O POTIGA/O is/O discontinued/O ,/O it/O should/O be/O withdrawn/O gradually/O when/O possible/O to/O minimize/O the/O potential/O of/O increased/O seizure/O frequency/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
The/O dosage/O of/O POTIGA/O should/O be/O reduced/O over/O a/O period/O of/O at/O least/O 3/O weeks/O ,/O unless/O safety/O concerns/O require/O abrupt/O withdrawal/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Use/O in/O Elderly/O Patients/O with/O Dementia/O -/O Related/O Psychosis/O [/O seeBoxed/O Warningand/O Warnings/O and/O Precautions/O (/O 5.1and5.2/O )/O ]/O Neuroleptic/B-AdverseReaction Malignant/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Tardive/B-AdverseReaction Dyskinesia/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Metabolic/B-AdverseReaction Changes/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Contraindications/O ,/O Warnings/O and/O Precautions/O (/O 5.6/O )/O and/O Patient/O Counseling/O Information/O (/O 17/O )/O ]/O Application/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction including/O oral/O ulcers/O ,/O blisters/O ,/O peeling/O sloughing/O and/O inflammation/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O Orthostatic/B-AdverseReaction Hypotension/I-AdverseReaction ,/O Syncope/B-AdverseReaction ,/O and/O other/O Hemodynamic/B-AdverseReaction Effects/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Leukopenia/B-AdverseReaction ,/O Neutropenia/B-AdverseReaction ,/O and/O Agranulocytosis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O QT/B-AdverseReaction Interval/I-AdverseReaction Prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O Hyperprolactinemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O Seizures/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.11/O )/O ]/O Potential/B-Factor for/O Cognitive/O and/O Motor/B-AdverseReaction Impairment/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.12/O )/O ]/O Body/O Temperature/O Regulation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.13/O )/O ]/O Suicide/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.14/O )/O ]/O Dysphagia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.15/O )/O ]/O Use/O in/O Patients/O with/O Concomitant/O Illness/O [/O see/O Warnings/O and/O Precautions/O (/O 5.16/O )/O ]/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O and/O at/O least/O twice/O the/O rate/O of/O placebo/O )/O reported/O with/O acute/O treatment/O in/O adults/O with/O schizophrenia/O were/O akathisia/B-AdverseReaction ,/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction ,/O and/O somnolence/B-AdverseReaction ./O
The/O safety/O profile/O of/O SAPHRIS/O in/O the/O maintenance/O treatment/O of/O schizophrenia/O in/O adults/O was/O similar/O to/O that/O seen/O with/O acute/O treatment/O ./O
The/O most/O common/O adverse/O reactions/O (/O 5/O %/O and/O at/O least/O twice/O the/O rate/O of/O placebo/O )/O reported/O with/O acute/O monotherapy/O treatment/O of/O manic/O or/O mixed/O episodes/O associated/O with/O bipolar/O I/O disorder/O in/O adults/O were/O somnolence/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction other/B-Factor than/I-Factor akathisia/B-AdverseReaction ,/O and/O increased/B-AdverseReaction weight/I-AdverseReaction and/O during/O the/O adjunctive/O therapy/O trial/O in/O bipolar/O I/O disorder/O in/O adults/O were/O somnolence/B-AdverseReaction and/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction ./O
The/O adult/O information/O below/O is/O derived/O from/O a/O clinical/O trial/O database/O for/O SAPHRIS/O consisting/O of/O over/O 4565/O patients/O and/or/O healthy/O subjects/O exposed/O to/O one/O or/O more/O sublingual/O doses/O of/O SAPHRIS/O ./O
A/O total/O of/O 1314/O SAPHRIS/O -/O treated/O patients/O were/O treated/O for/O at/O least/O 24/O weeks/O and/O 785/O SAPHRIS/O -/O treated/O patients/O had/O at/O least/O 52/O weeks/O of/O exposure/O at/O therapeutic/O doses/O ./O
In/O a/O 3-week/O monotherapy/O trial/O ,/O the/O most/O common/O adverse/O reactions/O (/O 5/O %/O and/O at/O least/O twice/O the/O rate/O of/O placebo/O )/O reported/O in/O pediatric/O patients/O with/O bipolar/O I/O disorder/O treated/O with/O SAPHRIS/O were/O somnolence/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O oral/B-AdverseReaction paresthesia/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O increased/B-AdverseReaction appetite/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O increased/B-AdverseReaction weight/I-AdverseReaction ./O
No/O new/O major/O safety/O findings/O were/O reported/O from/O a/O 50-week/O ,/O open/O -/O label/O ,/O uncontrolled/O safety/O trial/O ./O
A/O total/O of/O 651/O pediatric/O patients/O were/O treated/O with/O SAPHRIS/O ./O
Of/O these/O patients/O ,/O 352/O pediatric/O patients/O were/O treated/O with/O SAPHRIS/O for/O at/O least/O 180/O days/O and/O 58/O pediatric/O patients/O treated/O with/O SAPHRIS/O had/O at/O least/O 1/O year/O of/O exposure/O ./O
The/O safety/O of/O SAPHRIS/O was/O evaluated/O in/O 403/O pediatric/O patients/O with/O bipolar/O I/O disorder/O who/O participated/O in/O a/O 3-week/O ,/O placebo/O -/O controlled/O ,/O double/O -/O blind/O trial/O ,/O of/O whom/O 302/O patients/O received/O SAPHRIS/O at/O fixed/O doses/O ranging/O from/O 2.5/O mg/O to/O 10/O mg/O twice/O daily/O ./O
The/O stated/O frequencies/O of/O adverse/O reactions/O represent/O the/O proportion/O of/O individuals/O who/O experienced/O a/O treatment/O -/O emergent/O adverse/O event/O of/O the/O type/O listed/O ./O
A/O reaction/O was/O considered/O treatment/O emergent/O if/O it/O occurred/O for/O the/O first/O time/O or/O worsened/O while/O receiving/O therapy/O following/O baseline/O evaluation/O ./O
EXCERPT/O :/O Commonly/O observed/O adverse/O reactions/O (/O incidence/O 5/O %/O and/O at/O least/O twice/O that/O for/O placebo/O )/O were/O (/O 6.1/O )/O :/O Schizophrenia/O Adults/O :/O akathisia/B-AdverseReaction ,/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction ,/O somnolence/B-AdverseReaction ./O
Bipolar/O Disorder/O Adults/O (/O Monotherapy/O )/O :/O somnolence/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction other/B-Factor than/I-Factor akathisia/B-AdverseReaction ,/O increased/B-AdverseReaction weight/I-AdverseReaction ./O
Bipolar/O Disorder/O Pediatric/O Patients/O (/O Monotherapy/O )/O :/O somnolence/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O oral/B-AdverseReaction paresthesia/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O increased/B-AdverseReaction appetite/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O increased/B-AdverseReaction weight/I-AdverseReaction ./O
Bipolar/O Disorder/O Adults/O (/O Adjunctive/O )/O :/O somnolence/B-AdverseReaction ,/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Forest/O Laboratories/O ,/O LLC/O ./O
at/O 1/O -/O 800/O -/O 678/O -/O 1605/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Adult/O Patients/O with/O Schizophrenia/O :/O The/O following/O findings/O are/O based/O on/O the/O short/O -/O term/O placebo/O -/O controlled/O pre/O -/O marketing/O trials/O for/O schizophrenia/O (/O a/O pool/O of/O three/O 6-week/O fixed/O -/O dose/O trials/O and/O one/O 6-week/O flexible/O -/O dose/O trial/O )/O in/O which/O sublingual/O SAPHRIS/O was/O administered/O in/O doses/O ranging/O from/O 5/O to/O 10/O mg/O twice/O daily/O ./O
Adverse/O Reactions/O Associated/O with/O Discontinuation/O of/O Treatment/O :/O A/O total/O of/O 9/O %/O of/O SAPHRIS/O -/O treated/O patients/O and/O 10/O %/O of/O placebo/O -/O treated/O patients/O discontinued/O due/O to/O adverse/O reactions/O ./O
There/O were/O no/O drug/O -/O related/O adverse/O reactions/O associated/O with/O discontinuation/O in/O patients/O treated/O with/O SAPHRIS/O at/O the/O rate/O of/O at/O least/O 1/O %/O and/O at/O least/O twice/O the/O placebo/O rate/O ./O
Adverse/O Reactions/O Occurring/O at/O an/O Incidence/O of/O 2/O %/O or/O More/O in/O SAPHRIS/O -/O Treated/O Patients/O with/O Schizophrenia/O :/O Adverse/O reactions/O associated/O with/O the/O use/O of/O SAPHRIS/O (/O incidence/O of/O 2/O %/O or/O greater/O ,/O rounded/O to/O the/O nearest/O percent/O ,/O and/O SAPHRIS/O incidence/O greater/O than/O placebo/O )/O that/O occurred/O during/O acute/O therapy/O (/O up/O to/O 6-weeks/O in/O patients/O with/O schizophrenia/O )/O are/O shown/O in/O Table/O 8/O ./O
Table/O 8/O :/O Adverse/O Reactions/O Reported/O in/O 2/O %/O or/O More/O of/O Adult/O Patients/O in/O Any/O SAPHRIS/O Dose/O Group/O and/O Which/O Occurred/O at/O Greater/O Incidence/O Than/O in/O the/O Placebo/O Group/O in/O 6-Week/O Schizophrenia/O Trials/O Akathisia/B-AdverseReaction includes/O :/O akathisia/B-AdverseReaction and/O hyperkinesia/B-AdverseReaction ./O
Extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction included/O dystonia/B-AdverseReaction ,/O oculogyration/B-AdverseReaction ,/O dyskinesia/B-AdverseReaction ,/O tardive/B-AdverseReaction dyskinesia/I-AdverseReaction ,/O muscle/B-AdverseReaction rigidity/I-AdverseReaction ,/O parkinsonism/B-AdverseReaction ,/O tremor/B-AdverseReaction ,/O and/O extrapyramidal/B-AdverseReaction disorder/I-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O ./O
?/O Somnolence/B-AdverseReaction includes/O the/O following/O events/O :/O somnolence/B-AdverseReaction ,/O sedation/B-AdverseReaction ,/O and/O hypersomnia/B-AdverseReaction ./O
S/O Also/O includes/O the/O Flexible/O -/O dose/O trial/O (/O N=90/O )/O ./O
System/O Organ/O Class//O Preferred/O Term/O Placebo/O N=378/O %/O SAPHRIS/O 5/O mg/O twice/O daily/O N=274/O %/O SAPHRIS/O 10/O mg/O twice/O daily/O N=208/O %/O All/O SAPHRIS/O S/O 5/O mg/O or/O 10/O mg/O twice/O daily/O N=572/O %/O Gastrointestinal/O disorders/O Constipation/B-AdverseReaction 6/O 7/O 4/O 5/O Dry/B-AdverseReaction mouth/I-AdverseReaction 1/O 3/O 1/O 2/O Oral/B-AdverseReaction hypoesthesia/I-AdverseReaction 1/O 6/O 7/O 5/O Salivary/B-AdverseReaction hypersecretion/I-AdverseReaction 0/O 1/O 4/O 2/O Stomach/B-AdverseReaction discomfort/I-AdverseReaction 1/O 1/O 3/O 2/O Vomiting/B-AdverseReaction 5/O 4/O 7/O 5/O General/O disorders/O Fatigue/B-AdverseReaction 3/O 4/O 3/O 3/O Irritability/B-AdverseReaction 1/O 2/O 1/O 2/O Investigations/O Increased/B-AdverseReaction weight/I-AdverseReaction 1/O 2/O 2/O 3/O Metabolism/O disorders/O Increased/B-AdverseReaction appetite/I-AdverseReaction 1/O 3/O 0/O 2/O Nervous/O system/O disorders/O Akathisia/B-AdverseReaction 3/O 4/O 11/O 6/O Dizziness/B-AdverseReaction 4/O 7/O 3/O 5/O Extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O 7/O 9/O 12/O 10/O Somnolence/B-AdverseReaction ?/O 7/O 15/O 13/O 13/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 13/O 16/O 15/O 15/O Vascular/O disorders/O Hypertension/B-AdverseReaction 2/O 2/O 3/O 2/O Dose/O -/O Related/O Adverse/O Reactions/O :/O In/O the/O short/O term/O schizophrenia/O trials/O the/O incidence/O of/O akathisia/B-AdverseReaction appeared/O to/O be/O dose/O -/O related/O (/O seeTable/O 8)/O ./O
Monotherapy/O in/O Adult/O Patients/O with/O Bipolar/O Mania/O :/O The/O following/O findings/O are/O based/O on/O the/O short/O -/O term/O placebo/O -/O controlled/O trials/O for/O bipolar/O mania/O (/O a/O pool/O of/O two/O 3-week/O flexible/O -/O dose/O trials/O )/O in/O which/O sublingual/O SAPHRIS/O was/O administered/O in/O doses/O of/O 5/O mg/O or/O 10/O mg/O twice/O daily/O ./O
Adverse/O Reactions/O Associated/O with/O Discontinuation/O of/O Treatment/O :/O Approximately/O 10/O %/O (/O 38/379/O )/O of/O SAPHRIS/O -/O treated/O patients/O in/O short/O -/O term/O ,/O placebo/O -/O controlled/O trials/O discontinued/O treatment/O due/O to/O an/O adverse/O reaction/O ,/O compared/O with/O about/O 6/O %/O (/O 12/203/O )/O on/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O associated/O with/O discontinuation/O in/O patients/O treated/O with/O SAPHRIS/O (/O rates/O at/O least/O 1/O %/O and/O at/O least/O twice/O the/O placebo/O rate/O )/O were/O anxiety/B-AdverseReaction (/O 1.1/O %/O )/O and/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction (/O 1.1/O %/O )/O compared/O to/O placebo/O (/O 0/O %/O )/O ./O
Adverse/O Reactions/O Occurring/O at/O an/O Incidence/O of/O 2/O %/O or/O More/O Among/O SAPHRIS/O -/O Treated/O (/O Monotherapy/O )/O patients/O with/O Bipolar/O I/O Disorder/O :/O Adverse/O reactions/O associated/O with/O the/O use/O of/O SAPHRIS/O (/O incidence/O of/O 2/O %/O or/O greater/O ,/O rounded/O to/O the/O nearest/O percent/O ,/O and/O SAPHRIS/O incidence/O greater/O than/O placebo/O )/O that/O occurred/O during/O acute/O monotherapy/O (/O up/O to/O 3-weeks/O in/O patients/O with/O bipolar/O mania/O )/O are/O shown/O in/O Table/O 9/O ./O
Table/O 9/O :/O Adverse/O Reactions/O Reported/O in/O 2/O %/O or/O More/O of/O Adult/O Patients/O in/O Any/O SAPHRIS/O Dose/O Group/O and/O Which/O Occurred/O at/O Greater/O Incidence/O Than/O in/O the/O Placebo/O Group/O in/O 3-Week/O Bipolar/O Mania/O Trials/O SAPHRIS/O 5/O mg/O to/O 10/O mg/O twice/O daily/O with/O flexible/O dosing/O ./O
Extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction included/O :/O dystonia/B-AdverseReaction ,/O blepharospasm/B-AdverseReaction ,/O torticollis/B-AdverseReaction ,/O dyskinesia/B-AdverseReaction ,/O tardive/B-AdverseReaction dyskinesia/I-AdverseReaction ,/O muscle/B-AdverseReaction rigidity/I-AdverseReaction ,/O parkinsonism/B-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O masked/B-AdverseReaction facies/I-AdverseReaction ,/O and/O tremor/B-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O ./O
?/O Somnolence/B-AdverseReaction includes/O the/O following/O events/O :/O somnolence/B-AdverseReaction ,/O sedation/B-AdverseReaction ,/O and/O hypersomnia/B-AdverseReaction ./O
System/O Organ/O Class/O Preferred/O Term/O Placebo/O N=203/O %/O SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O N=379/O %/O Gastrointestinal/O disorders/O Dry/B-AdverseReaction mouth/I-AdverseReaction 1/O 3/O Dyspepsia/B-AdverseReaction 2/O 4/O Oral/B-AdverseReaction hypoesthesia/I-AdverseReaction 1/O 4/O Toothache/B-AdverseReaction 2/O 3/O General/O disorders/O Fatigue/B-AdverseReaction 2/O 4/O Investigations/O Increased/B-AdverseReaction weight/I-AdverseReaction 1/O 5/O Metabolism/O disorders/O Increased/B-AdverseReaction appetite/I-AdverseReaction 1/O 4/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 1/O 3/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 1/O 2/O Nervous/O system/O disorders/O Akathisia/B-AdverseReaction 2/O 4/O Dizziness/B-AdverseReaction 3/O 11/O Dysgeusia/B-AdverseReaction 1/O 3/O Headache/B-AdverseReaction 11/O 12/O Other/O extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O 2/O 7/O Somnolence/B-AdverseReaction ?/O 6/O 24/O Psychiatric/O disorders/O Anxiety/B-AdverseReaction 2/O 4/O Depression/B-AdverseReaction 1/O 2/O Insomnia/B-AdverseReaction 5/O 6/O Monotherapy/O in/O Pediatric/O Patients/O with/O Bipolar/O Mania/O :/O The/O following/O findings/O are/O based/O on/O a/O 3-week/O ,/O placebo/O -/O controlled/O trial/O for/O bipolar/O mania/O in/O which/O SAPHRIS/O was/O administered/O at/O doses/O of/O 2.5/O mg/O ,/O 5/O mg/O ,/O or/O 10/O mg/O twice/O daily/O ./O
Adverse/O Reactions/O Leading/O to/O Discontinuation/O of/O Treatment/O :/O A/O total/O of/O 6.7/O %/O (/O 7/104/O )/O of/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 5.1/O %/O (/O 5/99/O )/O of/O patients/O treated/O with/O SAPHRIS/O 5/O mg/O twice/O daily/O ,/O and/O 5.1/O %/O (/O 5/99/O )/O of/O patients/O treated/O with/O SAPHRIS/O 10/O mg/O twice/O daily/O discontinued/O treatment/O due/O to/O adverse/O reactions/O compared/O to/O 4/O %/O (/O 4/101/O )/O on/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O that/O led/O to/O discontinuation/O in/O pediatric/O patients/O treated/O with/O SAPHRIS/O (/O rates/O at/O least/O 2/O %/O in/O any/O SAPHRIS/O arm/O and/O at/O least/O twice/O the/O placebo/O rate/O )/O were/O somnolence/B-AdverseReaction (/O 3/O %/O in/O the/O 2.5/O mg/O twice/O daily/O group/O ,/O 1/O %/O in/O the/O 5/O mg/O twice/O daily/O group/O ,/O and/O 2/O %/O in/O the/O 10/O mg/O twice/O daily/O group/O )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 2/O %/O in/O the/O 10/O mg/O twice/O daily/O group/O )/O ,/O and/O nausea/B-AdverseReaction (/O 2/O %/O in/O the/O 10/O mg/O twice/O daily/O group/O )/O No/O placebo/O -/O treated/O patients/O dropped/O out/O for/O these/O events/O ./O
Adverse/O Reactions/O Occurring/O with/O SAPHRIS/O at/O an/O Incidence/O of/O 2/O %/O or/O More/O in/O SAPHRIS/O -/O treated/O Bipolar/O Patients/O :/O Adverse/O reactions/O associated/O with/O the/O use/O of/O SAPHRIS/O (/O incidence/O of/O 2/O %/O in/O any/O SAPHRIS/O dose/O group/O and/O greater/O than/O placebo/O )/O that/O occurred/O during/O acute/O therapy/O are/O shown/O in/O Table/O 10/O ./O
Table/O 10/O :/O Adverse/O Reactions/O Reported/O in/O 2/O %/O or/O More/O of/O Pediatric/O Patients/O (/O Ages/O 10/O to/O 17/O Years/O )/O in/O Any/O SAPHRIS/O Dose/O Group/O and/O Which/O Occurred/O at/O Greater/O Incidence/O Than/O in/O the/O Placebo/O Group/O in/O a/O 3-Week/O Bipolar/O Mania/O Trial/O 1Includes/O the/O preferred/O terms/O tachycardia/B-AdverseReaction and/O heart/B-AdverseReaction rate/I-AdverseReaction increased/I-AdverseReaction ./O
2Includes/O the/O preferred/O terms/O oral/B-AdverseReaction hypoesthesia/I-AdverseReaction ,/O oral/B-AdverseReaction paresthesia/I-AdverseReaction ,/O and/O oral/B-AdverseReaction dysesthesia/I-AdverseReaction ./O
3Includes/O the/O preferred/O terms/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction lower/I-AdverseReaction ,/O and/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ./O
4Includes/O the/O preferred/O terms/O fatigue/B-AdverseReaction and/O lethargy/B-AdverseReaction ./O
5Includes/O the/O preferred/O terms/O hyperinsulinemia/B-AdverseReaction and/O blood/B-AdverseReaction insulin/I-AdverseReaction increased/I-AdverseReaction ./O
6Includes/O the/O preferred/O terms/O somnolence/B-AdverseReaction ,/O sedation/B-AdverseReaction ,/O and/O hypersomnia/B-AdverseReaction ./O
System/O Organ/O Class//O AE/O Preferred/O Term/O Placebo/O N=101/O Placebo/O SAPHRIS/O 2.5/O mg/O twice/O daily/O N=104/O 2.5/O mg/O SAPHRIS/O 5/O mg/O twice/O daily/O N=99/O 5/O mg/O SAPHRIS/O 10/O mg/O twice/O daily/O N=99/O 10/O mg/O All/O SAPHRIS/O 2.5/O ,/O 5/O ,/O and/O 10/O mg/O N=101/O %/O N=104/O %/O N=99/O %/O N=99/O %/O N=302/O %/O Cardiac/O Disorders/O Tachycardia/B-AdverseReaction 1/O 0/O 3/O 0/O 1/O 1/O Gastrointestinal/O Disorders/O Oral/B-AdverseReaction paraesthesia/I-AdverseReaction 2/O 4/O 25/O 25/O 30/O 27/O Nausea/B-AdverseReaction 3/O 6/O 6/O 6/O 6/O Vomiting/B-AdverseReaction 3/O 4/O 4/O 4/O 4/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 3/O 7/O 9/O 3/O 5/O 6/O Glossodynia/B-AdverseReaction 0/O 0/O 2/O 0/O 1/O General/O Disorders/O and/O Administrative/O Site/O Disorders/O Fatigue/B-AdverseReaction 4/O 5/O 4/O 8/O 14/O 9/O Irritability/B-AdverseReaction 1/O 1/O 1/O 2/O 1/O Injury/O ,/O Poisoning/O ,/O and/O Procedural/O Complications/O Muscle/B-AdverseReaction strain/I-AdverseReaction 0/O 0/O 0/O 2/O 1/O Investigations/O Increased/B-AdverseReaction weight/I-AdverseReaction 0/O 6/O 2/O 2/O 3/O Hyperinsulinemia/B-AdverseReaction 5/O 0/O 1/O 3/O 1/O 2/O ALT/B-AdverseReaction increased/I-AdverseReaction 0/O 0/O 0/O 2/O 1/O AST/B-AdverseReaction increased/I-AdverseReaction 0/O 0/O 0/O 2/O 1/O Metabolism/O and/O Nutrition/O Disorders/O Increased/B-AdverseReaction appetite/I-AdverseReaction 2/O 10/O 9/O 6/O 8/O Dehydration/B-AdverseReaction 1/O 0/O 2/O 0/O 1/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Myalgia/B-AdverseReaction 0/O 0/O 2/O 1/O 1/O Nervous/O System/O Disorders/O Somnolence/B-AdverseReaction 6/O 12/O 46/O 53/O 49/O 49/O Headache/B-AdverseReaction 6/O 8/O 11/O 9/O 9/O Dizziness/B-AdverseReaction 3/O 6/O 10/O 5/O 7/O Dysgeusia/B-AdverseReaction 2/O 4/O 5/O 9/O 6/O Akathisia/B-AdverseReaction 0/O 2/O 2/O 1/O 2/O Parkinsonism/B-AdverseReaction 0/O 1/O 0/O 2/O 1/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 3/O 3/O 4/O 3/O 3/O Suicidal/B-AdverseReaction ideation/I-AdverseReaction 1/O 4/O 1/O 3/O 3/O Anger/B-AdverseReaction 0/O 0/O 0/O 2/O 1/O Reproductive/O System/O and/O Breast/O Disorders/O Dysmenorrhea/B-AdverseReaction 1/O 0/O 2/O 0/O 1/O Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 2/O 0/O 3/O 1/O 1/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 1/O 0/O 2/O 0/O 1/O Dyspnea/B-AdverseReaction 0/O 0/O 2/O 0/O 1/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Rash/B-AdverseReaction 1/O 0/O 1/O 2/O 1/O Dose/O -/O Related/O Adverse/O Reactions/O :/O In/O the/O short/O term/O pediatric/O bipolar/O trials/O the/O incidence/O of/O fatigue/B-AdverseReaction appeared/O to/O be/O dose/O -/O related/O (/O see/O Table/O 10/O )/O Adjunctive/O Therapy/O in/O Adult/O Patients/O with/O Bipolar/O Mania/O :/O The/O following/O findings/O are/O based/O on/O a/O 12/O week/O placebo/O -/O controlled/O trial/O (/O with/O a/O 3/O week/O efficacy/O endpoint/O )/O in/O adult/O patients/O with/O bipolar/O mania/O in/O which/O sublingual/O SAPHRIS/O was/O administered/O in/O doses/O of/O 5/O mg/O or/O 10/O mg/O twice/O daily/O as/O adjunctive/O therapy/O with/O lithium/O or/O valproate/O ./O
Adverse/O Reactions/O Associated/O with/O Discontinuation/O of/O Treatment/O :/O Approximately/O 16/O %/O (/O 25/158/O )/O of/O SAPHRIS/O -/O treated/O patients/O discontinued/O treatment/O due/O to/O an/O adverse/O reaction/O ,/O compared/O with/O about/O 11/O %/O (/O 18/166/O )/O on/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O associated/O with/O discontinuation/O in/O subjects/O treated/O with/O SAPHRIS/O (/O rates/O at/O least/O 1/O %/O and/O at/O least/O twice/O the/O placebo/O rate/O )/O were/O depression/B-AdverseReaction (/O 2.5/O %/O )/O ,/O suicidal/B-AdverseReaction ideation/I-AdverseReaction (/O 2.5/O %/O )/O ,/O bipolar/B-AdverseReaction I/I-AdverseReaction disorder/I-AdverseReaction (/O 1.9/O %/O )/O ,/O insomnia/B-AdverseReaction (/O 1.9/O %/O )/O and/O depressive/B-AdverseReaction symptoms/I-AdverseReaction (/O 1.3/O %/O )/O ./O
Adverse/O Reactions/O Occurring/O at/O an/O Incidence/O of/O 2/O %/O or/O More/O Among/O SAPHRIS/O -/O Treated/O (/O Adjunctive/O )/O Bipolar/O Patients/O :/O Adverse/O reactions/O associated/O with/O the/O use/O of/O SAPHRIS/O (/O incidence/O of/O 2/O %/O or/O greater/O ,/O rounded/O to/O the/O nearest/O percent/O ,/O and/O SAPHRIS/O incidence/O greater/O than/O placebo/O )/O that/O occurred/O during/O acute/O adjunctive/O therapy/O at/O 3/O weeks/O ,/O a/O time/O when/O most/O of/O the/O patients/O were/O still/O participating/O in/O the/O trial/O ,/O are/O shown/O in/O Table/O 11/O ./O
Table/O 11/O :/O Adverse/O Reactions/O Reported/O in/O 2/O %/O or/O More/O of/O Adult/O Patients/O In/O Any/O SAPHRIS/O -/O Dose/O Group/O and/O Which/O Occurred/O at/O Greater/O Incidence/O Than/O in/O the/O Placebo/O Group/O at/O 3/O Weeks/O in/O Adjunctive/O Bipolar/O Mania/O Trials/O SAPHRIS/O 5/O mg/O to/O 10/O mg/O twice/O daily/O with/O flexible/O dosing/O ./O
Extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction included/O :/O dystonia/B-AdverseReaction ,/O parkinsonism/B-AdverseReaction ,/O oculogyration/B-AdverseReaction ,/O and/O tremor/B-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O ./O
?/O Somnolence/B-AdverseReaction includes/O the/O following/O events/O :/O somnolence/B-AdverseReaction and/O sedation/B-AdverseReaction ./O
System/O Organ/O Class/O Preferred/O Term/O Placebo/O N=166/O %/O SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O N=158/O %/O Gastrointestinal/O disorders/O Dyspepsia/B-AdverseReaction 2/O 3/O Oral/B-AdverseReaction hypoesthesia/I-AdverseReaction 0/O 5/O General/O disorders/O Fatigue/B-AdverseReaction 2/O 4/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 1/O 3/O Investigations/O Increased/B-AdverseReaction weight/I-AdverseReaction 0/O 3/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 2/O 4/O Other/O extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction (/O excluding/B-Negation akathisia/B-AdverseReaction )/O 5/O 6/O Somnolence/B-AdverseReaction ?/O 10/O 22/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 8/O 10/O Vascular/O disorders/O Hypertension/B-AdverseReaction 1/O 3/O Dystonia/O :/O Symptoms/O of/O dystonia/B-AdverseReaction ,/O prolonged/B-AdverseReaction abnormal/I-AdverseReaction contractions/I-AdverseReaction of/I-AdverseReaction muscle/I-AdverseReaction groups/I-AdverseReaction ,/O may/B-Factor occur/O in/O susceptible/O individuals/O during/O the/O first/O few/O days/O of/O treatment/O ./O
Dystonic/B-AdverseReaction symptoms/I-AdverseReaction include/O :/O spasm/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction neck/I-AdverseReaction muscles/I-AdverseReaction ,/O sometimes/O progressing/O to/O tightness/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction throat/I-AdverseReaction ,/O swallowing/B-AdverseReaction difficulty/I-AdverseReaction ,/O difficulty/B-AdverseReaction breathing/I-AdverseReaction ,/O and/or/O protrusion/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction tongue/I-AdverseReaction ./O
While/O these/O symptoms/O can/O occur/O at/O low/O doses/O ,/O they/O occur/O more/O frequently/O and/O with/O greater/O severity/O with/O high/O potency/O and/O at/O higher/O doses/O of/O first/O generation/O antipsychotic/O drugs/O ./O
An/O elevated/O risk/B-Factor of/O acute/B-AdverseReaction dystonia/I-AdverseReaction is/O observed/O in/O males/O and/O younger/O age/O groups/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ,/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Extrapyramidal/O Symptoms/O :/O In/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O schizophrenia/O and/O bipolar/O mania/O adult/O trials/O ,/O data/O was/O objectively/O collected/O on/O the/O Simpson/O Angus/O Rating/O Scale/O for/O extrapyramidal/B-AdverseReaction symptoms/I-AdverseReaction (/O EPS/B-AdverseReaction )/O ,/O the/O Barnes/O Akathisia/O Scale/O (/O for/O akathisia/B-AdverseReaction )/O and/O the/O Assessments/O of/O Involuntary/O Movement/O Scales/O (/O for/O dyskinesias/B-AdverseReaction )/O ./O
The/O mean/O change/O from/O baseline/O for/O the/O all/O -/O SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O treated/O group/O was/O comparable/O to/O placebo/O in/O each/O of/O the/O rating/O scale/O scores/O ./O
In/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O schizophrenia/O adult/O trials/O ,/O the/O incidence/O of/O reported/O EPS/B-AdverseReaction -/I-AdverseReaction related/O events/O ,/O excluding/B-Negation events/O related/O to/O akathisia/B-AdverseReaction ,/O for/O SAPHRIS/O -/O treated/O patients/O was/O 10/O %/O versus/O 7/O %/O for/O placebo/O ;/O and/O the/O incidence/O of/O akathisia/B-AdverseReaction -/O related/O events/O for/O SAPHRIS/O -/O treated/O patients/O was/O 6/O %/O versus/O 3/O %/O for/O placebo/O ./O
In/O short/O -/O term/O placebo/O -/O controlled/O bipolar/O mania/O adult/O trials/O ,/O the/O incidence/O of/O EPS/B-AdverseReaction -/I-AdverseReaction related/O events/O ,/O excluding/B-Negation events/O related/O to/O akathisia/B-AdverseReaction ,/O for/O SAPHRIS/O -/O treated/O patients/O was/O 7/O %/O versus/O 2/O %/O for/O placebo/O ;/O and/O the/O incidence/O of/O akathisia/B-AdverseReaction -/O related/O events/O for/O SAPHRIS/O -/O treated/O patients/O was/O 4/O %/O versus/O 2/O %/O for/O placebo/O ./O
In/O a/O 3-week/O ,/O placebo/O -/O controlled/O pediatric/O trial/O with/O bipolar/O I/O disorder/O ,/O the/O incidences/O of/O EPS/B-AdverseReaction -/I-AdverseReaction related/O events/O ,/O excluding/B-Negation events/O related/O to/O akathisia/B-AdverseReaction ,/O were/O 4/O %/O ,/O 3/O %/O ,/O and/O 5/O %/O for/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O ,/O 5/O mg/O ,/O and/O 10/O mg/O twice/O daily/O ,/O respectively/O ,/O as/O compared/O to/O 3/O %/O for/O placebo/O -/O treated/O patients/O ./O
EPS/B-AdverseReaction -/I-AdverseReaction related/O events/O include/O :/O bradykinesia/B-AdverseReaction ,/O dyskinesia/B-AdverseReaction ,/O dystonia/B-AdverseReaction ,/O oromandibular/B-AdverseReaction dystonia/I-AdverseReaction ,/O muscle/B-AdverseReaction contractions/I-AdverseReaction involuntary/I-AdverseReaction ,/O muscle/B-AdverseReaction twitching/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction stiffness/I-AdverseReaction ,/O parkinsonism/B-AdverseReaction ,/O protrusion/B-AdverseReaction tongue/I-AdverseReaction ,/O resting/B-AdverseReaction tremor/I-AdverseReaction ,/O and/O tremor/B-AdverseReaction ./O
For/O events/O of/O akathisia/B-AdverseReaction ,/O incidences/O were/O 2/O %/O ,/O 2/O %/O ,/O and/O 1/O %/O for/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O ,/O 5/O mg/O ,/O and/O 10/O mg/O twice/O daily/O ,/O respectively/O ,/O as/O compared/O to/O 0/O %/O for/O placebo/O -/O treated/O patients/O ./O
Other/O Findings/O :/O Oral/B-AdverseReaction hypoesthesia/I-AdverseReaction and/or/O oral/B-AdverseReaction paresthesia/I-AdverseReaction may/O occur/O directly/O after/O administration/O of/O SAPHRIS/O and/O usually/O resolves/O within/O 1/O hour/O ./O
Laboratory/O Test/O Abnormalities/O :/O Transaminases/O :/O Transient/O elevations/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction transaminases/I-AdverseReaction (/O primarily/O ALT/O )/O in/O the/O short/O -/O term/O schizophrenia/O and/O bipolar/O mania/O adult/O trials/O were/O more/O common/O in/O treated/O patients/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O schizophrenia/O adult/O trials/O ,/O the/O mean/O increase/B-AdverseReaction in/I-AdverseReaction transaminase/I-AdverseReaction levels/I-AdverseReaction for/O SAPHRIS/O -/O treated/O patients/O was/O 1.6/O units/O L/O compared/O to/O a/O decrease/O of/O 0.4/O units/O L/O for/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O transaminase/B-AdverseReaction elevations/I-AdverseReaction =3/O times/O ULN/O (/O at/O Endpoint/O )/O was/O 0.9/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 1.3/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O adult/O mania/O trials/O ,/O the/O mean/O increase/B-AdverseReaction in/I-AdverseReaction transaminase/I-AdverseReaction levels/I-AdverseReaction for/O SAPHRIS/O -/O treated/O patients/O was/O 8.9/O units/O L/O compared/O to/O a/O decrease/O of/O 4.9/O units/O L/O in/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O transaminase/B-AdverseReaction elevations/I-AdverseReaction =3/O times/O upper/O limit/O of/O normal/O (/O ULN/O )/O (/O at/O Endpoint/O )/O was/O 2.5/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 0.6/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O a/O 52-week/O ,/O double/O -/O blind/O ,/O comparator/O -/O controlled/O trial/O that/O included/O primarily/O adult/O patients/O with/O schizophrenia/O ,/O the/O mean/O increase/O from/O baseline/O of/O ALT/O was/O 1.7/B-Severity units/I-Severity L./O In/O a/O 3-week/O ,/O placebo/O -/O controlled/O pediatric/O trial/O with/O bipolar/O I/O disorder/O ,/O transient/O elevations/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction transaminases/I-AdverseReaction (/O primarily/O ALT/O )/O were/O more/O common/O in/O treated/O patients/O ./O
The/O proportion/O of/O pediatric/O patients/O with/O ALT/B-AdverseReaction elevations/I-AdverseReaction =3/O times/O upper/O limit/O of/O normal/O (/O ULN/O )/O was/O 2.4/O %/O for/O patients/O treated/O with/O SAPHRIS/O 10/O mg/O twice/O daily/O versus/O none/O for/O the/O other/O SAPHRIS/O dose/O groups/O and/O placebo/O -/O treated/O patients/O ./O
Prolactin/O :/O In/O short/O -/O term/O ,/O placebo/O -/O controlled/O adult/O schizophrenia/O trials/O ,/O the/O mean/O decreases/B-AdverseReaction in/I-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction were/O 6.5/O ng/O mL/O for/O SAPHRIS/O -/O treated/O patients/O compared/O to/O 10.7/O ng/O mL/O for/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O prolactin/B-AdverseReaction elevations/I-AdverseReaction 4/B-Severity times/I-Severity ULN/I-Severity (/O at/O Endpoint/O )/O were/O 2.6/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 0.6/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O mania/O adult/O trials/O ,/O the/O mean/O increase/B-AdverseReaction in/I-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction was/O 4.9/O ng/O mL/O for/O SAPHRIS/O -/O treated/O patients/O compared/O to/O a/O decrease/O of/O 0.2/O ng/O mL/O for/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O prolactin/B-AdverseReaction elevations/I-AdverseReaction 4/B-Severity times/I-Severity ULN/I-Severity (/O at/O Endpoint/O )/O were/O 2.3/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 0.7/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O a/O long/O -/O term/O (/O 52-week/O )/O ,/O double/O -/O blind/O ,/O comparator/O -/O controlled/O adult/O trial/O that/O included/O primarily/O patients/O with/O schizophrenia/O ,/O the/O mean/O decrease/B-AdverseReaction in/I-AdverseReaction prolactin/I-AdverseReaction from/O baseline/O for/O SAPHRIS/O -/O treated/O patients/O was/O 26.9/O ng/O mL./O In/O a/O 3-week/O ,/O placebo/O -/O controlled/O pediatric/O trial/O with/O bipolar/O I/O disorder/O ,/O the/O mean/O increases/O (/O at/O Endpoint/O )/O in/O prolactin/O levels/O were/O 3.2/O ng/O mL/O for/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 2.1/O ng/O mL/O for/O patients/O treated/O with/O SAPHRIS/O 5/O mg/O twice/O daily/O ,/O and/O 6.4/O ng/O mL/O for/O patients/O treated/O with/O SAPHRIS/O 10/O mg/O twice/O daily/O compared/O to/O an/O increase/O of/O 2.5/O ng/O mL/O for/O placebo/O -/O treated/O patients/O ./O
There/O were/O no/B-Negation reports/O of/O prolactin/B-AdverseReaction elevations/I-AdverseReaction 4/B-Severity times/I-Severity ULN/I-Severity (/O at/O Endpoint/O )/O for/O patients/O treated/O with/O SAPHRIS/O or/O placebo/O ./O
Galactorrhea/B-AdverseReaction or/O dysmenorrhea/B-AdverseReaction were/O reported/O in/O 0/O %/O of/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 2/O %/O of/O patients/O treated/O with/O SAPHRIS/O 5/O mg/O twice/O daily/O ,/O and/O 1/O %/O of/O patients/O treated/O with/O SAPHRIS/O 10/O mg/O twice/O daily/O compared/O to/O 1/O %/O of/O placebo/O -/O treated/O patients/O ./O
There/O were/O no/B-Negation reports/O of/O gynecomastia/B-AdverseReaction in/O this/O trial/O ./O
Creatine/O Kinase/O (/O CK/O )/O :/O The/O proportion/O of/O adult/O patients/O with/O CK/B-AdverseReaction elevations/I-AdverseReaction 3/B-Severity times/I-Severity ULN/I-Severity at/O any/O time/O were/O 6.4/O %/O and/O 11.1/O %/O for/O patients/O treated/O with/O SAPHRIS/O 5/O mg/O twice/O daily/O and/O 10/O mg/O twice/O daily/O ,/O respectively/O ,/O as/O compared/O to/O 6.7/O %/O for/O placebo/O -/O treated/O patients/O in/O short/O -/O term/O ,/O fixed/O -/O dose/O trials/O in/O schizophrenia/O and/O bipolar/O mania/O ./O
The/O clinical/O relevance/O of/O this/O finding/O is/O unknown/O ./O
The/O proportion/O of/O patients/O with/O CK/B-AdverseReaction elevations/I-AdverseReaction =3/O times/O ULN/O during/O a/O 3-week/O trial/O in/O pediatric/O bipolar/O I/O disorder/O at/O any/O time/O were/O 1/O %/O ,/O 0/O %/O ,/O and/O 1/O %/O for/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O ,/O 5/O mg/O ,/O and/O 10/O mg/O twice/O daily/O ,/O respectively/O ,/O versus/O 3/O %/O for/O placebo/O -/O treated/O patients/O ./O
Other/O Adverse/O Reactions/O Observed/O During/O the/O Premarketing/O Evaluation/O of/O SAPHRIS/O :/O Following/O is/O a/O list/O of/O MedDRA/O terms/O that/O reflect/O adverse/O reactions/O reported/O by/O patients/O treated/O with/O sublingual/O SAPHRIS/O at/O multiple/O doses/O of/O 5/O mg/O twice/O daily/O during/O any/O phase/O of/O a/O trial/O within/O the/O database/O of/O adult/O patients/O ./O
The/O reactions/O listed/O are/O those/O that/O could/O be/O of/O clinical/O importance/O ,/O as/O well/O as/O reactions/O that/O are/O plausibly/O drug/O -/O related/O on/O pharmacologic/O or/O other/O grounds/O ./O
Reactions/O already/O listed/O for/O either/O adults/O or/O pediatric/O patients/O in/O other/O parts/O of/O Adverse/O Reactions/O (/O 6/O )/O ,/O or/O those/O considered/O in/O Contraindications/O (/O 4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5/O )/O or/O Overdosage/O (/O 10/O )/O are/O not/O included/O ./O
Reactions/O are/O further/O categorized/O by/O MedDRA/O system/O organ/O class/O and/O listed/O in/O order/O of/O decreasing/O frequency/O according/O to/O the/O following/O definitions/O :/O those/O occurring/O in/O at/O least/O 1/100/O patients/O (/O frequent/O )/O (/O only/O those/O not/O already/O listed/O in/O the/O tabulated/O results/O from/O placebo/O -/O controlled/O trials/O appear/O in/O this/O listing/O )/O ;/O those/O occurring/O in/O 1/100/O to/O 1/1000/O patients/O (/O infrequent/O )/O ;/O and/O those/O occurring/O in/O fewer/O than/O 1/1000/O patients/O (/O rare/O )/O ./O
Blood/O and/O lymphatic/O disorders/O :/O infrequent/O :/O anemia/B-AdverseReaction ;/O rare/O :/O thrombocytopenia/B-AdverseReaction Cardiac/O disorders/O :/O infrequent/O :/O temporary/B-AdverseReaction bundle/I-AdverseReaction branch/I-AdverseReaction block/I-AdverseReaction Eye/O disorders/O :/O infrequent/O :/O accommodation/B-AdverseReaction disorder/I-AdverseReaction Gastrointestinal/O disorders/O :/O infrequent/O :/O swollen/B-AdverseReaction tongue/I-AdverseReaction General/O disorders/O :/O rare/O :/O idiosyncratic/B-AdverseReaction drug/I-AdverseReaction reaction/I-AdverseReaction Investigations/O :/O infrequent/O :/O hyponatremia/B-AdverseReaction Nervous/O system/O disorders/O :/O infrequent/O :/O dysarthria/B-AdverseReaction Following/O is/O a/O list/O of/O MedDRA/O terms/O not/O already/O listed/O either/O for/O adults/O or/O pediatric/O patients/O in/O other/O parts/O of/O Adverse/O Reactions/O (/O 6/O )/O ,/O or/O those/O considered/O in/O Contraindications/O (/O 4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5/O )/O or/O Overdosage/O (/O 10/O )/O that/O reflect/O adverse/O reactions/O reported/O by/O pediatric/O patients/O (/O Ages/O 10/O to/O 17/O years/O )/O treated/O with/O sublingual/O SAPHRIS/O at/O doses/O of/O 2.5/O mg/O ,/O 5/O mg/O ,/O or/O 10/O mg/O twice/O daily/O during/O any/O phase/O of/O a/O trial/O within/O the/O database/O of/O pediatric/O patients/O ./O
Eye/O disorders/O :/O infrequent/O :/O diplopia/B-AdverseReaction ,/O vision/B-AdverseReaction blurred/I-AdverseReaction Gastrointestinal/O disorders/O :/O infrequent/O :/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction Injury/O ,/O Poisoning/O ,/O and/O Procedural/O Complications/O :/O infrequent/O :/O fall/B-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O infrequent/O :/O photosensitivity/B-AdverseReaction reaction/I-AdverseReaction Renal/O and/O urinary/O disorders/O :/O infrequent/O :/O enuresis/B-AdverseReaction 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O SAPHRIS/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
In/O many/O cases/O ,/O the/O occurrence/O of/O these/O adverse/O reactions/O led/O to/O discontinuation/O of/O therapy/O ./O
Application/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O primarily/O in/O the/O sublingual/O area/O ,/O have/O been/O reported/O ./O
These/O application/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction included/O oral/O ulcers/O ,/O blisters/O ,/O peeling/O sloughing/O ,/O and/O inflammation/O ./O
Choking/B-AdverseReaction has/O been/O reported/O by/O patients/O ,/O some/O of/O whom/O may/B-Factor have/O also/O experienced/O oropharyngeal/B-AdverseReaction muscular/I-AdverseReaction dysfunction/I-AdverseReaction or/O hypoesthesia/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O WARNING/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/B-Factor of/O death/B-AdverseReaction ./O
SAPHRIS/O (/O r/O )/O (/O asenapine/O )/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.2/O )/O ]/O ./O
WARNING/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction IN/O ELDERLY/O PATIENTS/O WITH/O DEMENTIA/O -/O RELATED/O PSYCHOSIS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction ./O
SAPHRIS/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O ./O
(/O 5.1/O ,/O 5.2/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Cerebrovascular/B-AdverseReaction Adverse/I-AdverseReaction Events/I-AdverseReaction :/O An/O increased/O incidence/O of/O cerebrovascular/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O e.g./O ,/O stroke/B-AdverseReaction ,/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction )/O has/O been/O seen/O in/O elderly/O patients/O with/O dementia/O -/O related/O psychoses/O treated/O with/O atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass ./O
(/O 5.2/O )/O Neuroleptic/B-AdverseReaction Malignant/I-AdverseReaction Syndrome/I-AdverseReaction :/O Manage/O with/O immediate/O discontinuation/O and/O close/O monitoring/O ./O
(/O 5.3/O )/O Tardive/B-AdverseReaction Dyskinesia/I-AdverseReaction :/O Discontinue/O if/O clinically/O appropriate/O ./O
(/O 5.4/O )/O dispatch/O :/O unexpected/O key/O :/O list/O in/O dispatch/O table/O :/O {/O '/O caption/O '/O :/O function/O print_caption/O at/O 0x1c6c8c0/O ,/O '/O text/O '/O :/O function/O print_text/O at/O 0x1c6c500/O }/O Metabolic/B-AdverseReaction Changes/I-AdverseReaction :/O Atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass have/O been/O associated/O with/O metabolic/B-AdverseReaction changes/I-AdverseReaction that/O may/O increase/O cardiovascular/O cerebrovascular/B-AdverseReaction risk/I-AdverseReaction ./O
These/O metabolic/B-AdverseReaction changes/I-AdverseReaction include/O hyperglycemia/B-AdverseReaction ,/O dyslipidemia/B-AdverseReaction ,/O and/O weight/B-AdverseReaction gain/I-AdverseReaction ./O
(/O 5.5/O )/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction and/O angioedema/B-AdverseReaction ,/O have/O been/O observed/O ./O
(/O 5.6/O )/O Orthostatic/B-AdverseReaction Hypotension/I-AdverseReaction ,/O Syncope/B-AdverseReaction ,/O and/O Other/O Hemodynamic/B-AdverseReaction Effects/I-AdverseReaction :/O Dizziness/B-AdverseReaction ,/O tachycardia/B-AdverseReaction or/O bradycardia/B-AdverseReaction ,/O and/O syncope/B-AdverseReaction may/B-Factor occur/O ,/O especially/O early/O in/O treatment/O ./O
Use/O with/O caution/O in/O patients/O with/O known/O cardiovascular/O or/O cerebrovascular/O disease/O ,/O and/O in/O antipsychotic/O -/O naive/O patients/O ./O
(/O 5.7/O )/O Leukopenia/B-AdverseReaction ,/O Neutropenia/B-AdverseReaction ,/O and/O Agranulocytosis/B-AdverseReaction have/O been/O reported/O with/O antipsychotics/B-DrugClass ./O
Patients/O with/O a/O pre/O -/O existing/O low/O white/O blood/O cell/O count/O (/O WBC/O )/O or/O a/O history/O of/O leukopenia/O neutropenia/O should/O have/O their/O complete/O blood/O count/O (/O CBC/O )/O monitored/O frequently/O during/O the/O first/O few/O months/O of/O therapy/O and/O SAPHRIS/O should/O be/O discontinued/O at/O the/O first/O sign/O of/O a/O decline/O in/O WBC/O in/O the/O absence/O of/O other/O causative/O factors/O ./O
(/O 5.8/O )/O QT/B-AdverseReaction Prolongation/I-AdverseReaction :/O Increases/B-AdverseReaction in/I-AdverseReaction QT/I-AdverseReaction interval/I-AdverseReaction ;/O avoid/O use/O with/O drugs/O that/O also/O increase/O the/O QT/O interval/O and/O in/O patients/O with/O risk/O factors/O for/O prolonged/O QT/O interval/O ./O
(/O 5.9/O )/O Seizures/B-AdverseReaction :/O Use/O cautiously/O in/O patients/O with/O a/O history/O of/O seizures/O or/O with/O conditions/O that/O lower/O the/O seizure/O threshold/O ./O
(/O 5.11/O )/O Potential/B-Factor for/O Cognitive/O and/O Motor/B-AdverseReaction Impairment/I-AdverseReaction :/O Use/O caution/O when/O operating/O machinery/O ./O
(/O 5.12/O )/O Suicide/B-AdverseReaction :/O The/O possibility/O of/O a/O suicide/O attempt/O is/O inherent/O in/O schizophrenia/O and/O bipolar/O disorder/O ./O
Closely/O supervise/O high/O -/O risk/O patients/O ./O
(/O 5.14/O )/O 5.1/O Increased/O Mortality/O in/O Elderly/O Patients/O with/O Dementia/O -/O Related/O Psychosis/O Elderly/O patients/O with/O dementia/O -/O related/O psychosis/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass are/O at/O an/O increased/O risk/O of/O death/B-AdverseReaction ./O
Analyses/O of/O 17/O placebo/O -/O controlled/O trials/O (/O modal/O duration/O of/O 10/O weeks/O )/O ,/O largely/O in/O patients/O taking/O atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass ,/O revealed/O a/O risk/O of/O death/B-AdverseReaction in/O the/O drug/O -/O treated/O patients/O of/O between/O 1.6/O to/O 1.7/O times/O that/O seen/O in/O placebo/O -/O treated/O patients/O ./O
Over/O the/O course/O of/O a/O typical/O 10-week/O controlled/O trial/O ,/O the/O rate/O of/O death/B-AdverseReaction in/O drug/O -/O treated/O patients/O was/O about/O 4.5/O %/O ,/O compared/O to/O a/O rate/O of/O about/O 2.6/O %/O in/O the/O placebo/O group/O ./O
Although/O the/O causes/O of/O death/B-AdverseReaction were/O varied/O ,/O most/O of/O the/O deaths/B-AdverseReaction appeared/O to/O be/O either/O cardiovascular/O (/O e.g./O ,/O heart/B-AdverseReaction failure/I-AdverseReaction ,/O sudden/B-AdverseReaction death/I-AdverseReaction )/O or/O infectious/O (/O e.g./O ,/O pneumonia/B-AdverseReaction )/O in/O nature/O ./O
Observational/O studies/O suggest/O that/O ,/O similar/O to/O atypical/O antipsychotic/O drugs/O ,/O treatment/O with/O conventional/O antipsychotic/O drugs/O may/O increase/O mortality/O ./O
The/O extent/O to/O which/O the/O findings/O of/O increased/B-AdverseReaction mortality/I-AdverseReaction in/O observational/O studies/O may/O be/O attributed/O to/O the/O antipsychotic/B-DrugClass drug/I-DrugClass as/O opposed/O to/O some/O characteristic(s/O )/O of/O the/O patients/O is/O not/O clear/O ./O
SAPHRIS/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O [/O seeBoxed/O Warningand/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
5.2/O Cerebrovascular/O Adverse/O Events/O ,/O Including/O Stroke/O ,/O In/O Elderly/O Patients/O with/O Dementia/O -/O Related/O Psychosis/O In/O placebo/O -/O controlled/O trials/O with/O risperidone/B-DrugClass ,/O aripiprazole/B-DrugClass ,/O and/O olanzapine/B-DrugClass in/O elderly/O subjects/O with/O dementia/O ,/O there/O was/O a/O higher/O incidence/O of/O cerebrovascular/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction (/O cerebrovascular/B-AdverseReaction accidents/I-AdverseReaction and/O transient/B-AdverseReaction ischemic/I-AdverseReaction attacks/I-AdverseReaction )/O including/O fatalities/B-AdverseReaction compared/O to/O placebo/O -/O treated/O subjects/O ./O
SAPHRIS/O is/O not/O approved/O for/O the/O treatment/O of/O patients/O with/O dementia/O -/O related/O psychosis/O [/O see/O alsoBoxed/O Warningand/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5.3/O Neuroleptic/O Malignant/O Syndrome/O A/O potentially/B-Factor fatal/B-AdverseReaction symptom/O complex/O sometimes/O referred/O to/O as/O Neuroleptic/B-AdverseReaction Malignant/I-AdverseReaction Syndrome/I-AdverseReaction (/O NMS/B-AdverseReaction )/O has/O been/O reported/O in/O association/O with/O administration/O of/O antipsychotic/O drugs/O ,/O including/O SAPHRIS/O ./O
Clinical/O manifestations/O of/O NMS/B-AdverseReaction are/O hyperpyrexia/B-AdverseReaction ,/O muscle/B-AdverseReaction rigidity/I-AdverseReaction ,/O altered/B-AdverseReaction mental/I-AdverseReaction status/I-AdverseReaction ,/O and/O evidence/O of/O autonomic/B-AdverseReaction instability/I-AdverseReaction (/O irregular/B-AdverseReaction pulse/I-AdverseReaction or/O blood/O pressure/O ,/O tachycardia/B-AdverseReaction ,/O diaphoresis/B-AdverseReaction ,/O and/O cardiac/B-AdverseReaction dysrhythmia/I-AdverseReaction )/O ./O
Additional/O signs/O may/B-Factor include/O elevated/B-AdverseReaction creatine/I-AdverseReaction phosphokinase/I-AdverseReaction ,/O myoglobinuria/B-AdverseReaction (/O rhabdomyolysis/B-AdverseReaction )/O ,/O and/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ./O
The/O diagnostic/O evaluation/O of/O patients/O with/O this/O syndrome/O is/O complicated/O ./O
It/O is/O important/O to/O exclude/O cases/O where/O the/O clinical/O presentation/O includes/O both/O serious/O medical/O illness/O (/O e.g./O pneumonia/O ,/O systemic/O infection/O )/O and/O untreated/O or/O inadequately/O treated/O extrapyramidal/O signs/O and/O symptoms/O (/O EPS/O )/O ./O
Other/O important/O considerations/O in/O the/O differential/O diagnosis/O include/O central/O anticholinergic/O toxicity/O ,/O heat/O stroke/O ,/O drug/O fever/O ,/O and/O primary/O central/O nervous/O system/O pathology/O ./O
The/O management/O of/O NMS/O should/O include/O :/O 1/O )/O immediate/O discontinuation/O of/O antipsychotic/O drugs/O and/O other/O drugs/O not/O essential/O to/O concurrent/O therapy/O ;/O 2/O )/O intensive/O symptomatic/O treatment/O and/O medical/O monitoring/O ;/O and/O 3/O )/O treatment/O of/O any/O concomitant/O serious/O medical/O problems/O for/O which/O specific/O treatments/O are/O available/O ./O
There/O is/O no/O general/O agreement/O about/O specific/O pharmacological/O treatment/O regimens/O for/O NMS/O ./O
If/O a/O patient/O requires/O antipsychotic/O drug/O treatment/O after/O recovery/O from/O NMS/O ,/O the/O potential/O reintroduction/O of/O drug/O therapy/O should/O be/O carefully/O considered/O ./O
The/O patient/O should/O be/O carefully/O monitored/O ,/O since/O recurrences/O of/O NMS/O have/O been/O reported/O ./O
5.4/O Tardive/O Dyskinesia/O A/O syndrome/O of/O potentially/B-Severity irreversible/I-Severity ,/O involuntary/B-AdverseReaction ,/I-AdverseReaction dyskinetic/I-AdverseReaction movements/O can/O develop/O in/O patients/O treated/O with/O antipsychotic/B-DrugClass drugs/I-DrugClass ./O
Although/O the/O prevalence/O of/O the/O syndrome/O appears/O to/O be/O highest/O among/O the/O elderly/O ,/O especially/O elderly/O women/O ,/O it/O is/O impossible/O to/O rely/O upon/O prevalence/O estimates/O to/O predict/O ,/O at/O the/O inception/O of/O antipsychotic/O treatment/O ,/O which/O patients/O are/O likely/O to/O develop/O the/O syndrome/O ./O
Whether/O antipsychotic/B-DrugClass drug/I-DrugClass products/O differ/O in/O their/O potential/O to/O cause/O Tardive/B-AdverseReaction Dyskinesia/I-AdverseReaction (/O TD/B-AdverseReaction )/O is/O unknown/O ./O
The/O risk/O of/O developing/O TD/B-AdverseReaction and/O the/O likelihood/O that/O it/O will/O become/O irreversible/B-Severity are/O believed/O to/O increase/O as/O the/O duration/O of/O treatment/O and/O the/O total/O cumulative/O dose/O of/O antipsychotic/B-DrugClass drugs/I-DrugClass administered/O to/O the/O patient/O increase/O ./O
However/O ,/O the/O syndrome/O can/O develop/O ,/O although/O much/O less/O commonly/O ,/O after/O relatively/O brief/O treatment/O periods/O at/O low/O doses/O ./O
There/O is/O no/O known/O treatment/O for/O established/O cases/O of/O TD/O ,/O although/O the/O syndrome/O may/O remit/O ,/O partially/O or/O completely/O ,/O if/O antipsychotic/O treatment/O is/O withdrawn/O ./O
Antipsychotic/O treatment/O ,/O itself/O ,/O however/O ,/O may/O suppress/O (/O or/O partially/O suppress/O )/O the/O signs/O and/O symptoms/O of/O the/O syndrome/O and/O thereby/O may/O possibly/O mask/O the/O underlying/O process/O ./O
The/O effect/O that/O symptomatic/O suppression/O has/O upon/O the/O long/O -/O term/O course/O of/O the/O syndrome/O is/O unknown/O ./O
Given/O these/O considerations/O ,/O SAPHRIS/O should/O be/O prescribed/O in/O a/O manner/O that/O is/O most/O likely/O to/O minimize/O the/O occurrence/O of/O TD/O ./O
Chronic/O antipsychotic/O treatment/O should/O generally/O be/O reserved/O for/O patients/O who/O suffer/O from/O a/O chronic/O illness/O that/O (/O 1/O )/O is/O known/O to/O respond/O to/O antipsychotic/O drugs/O ,/O and/O (/O 2/O )/O for/O whom/O alternative/O ,/O equally/O effective/O ,/O but/O potentially/O less/O harmful/O treatments/O are/O not/O available/O or/O appropriate/O ./O
In/O patients/O who/O do/O require/O chronic/O treatment/O ,/O the/O smallest/O dose/O and/O the/O shortest/O duration/O of/O treatment/O producing/O a/O satisfactory/O clinical/O response/O should/O be/O sought/O ./O
The/O need/O for/O continued/O treatment/O should/O be/O reassessed/O periodically/O ./O
If/O signs/O and/O symptoms/O of/O TD/O appear/O in/O a/O patient/O on/O SAPHRIS/O ,/O drug/O discontinuation/O should/O be/O considered/O ./O
However/O ,/O some/O patients/O may/O require/O treatment/O with/O SAPHRIS/O despite/O the/O presence/O of/O the/O syndrome/O ./O
5.5/O Metabolic/O Changes/O Atypical/B-DrugClass antipsychotic/I-DrugClass drugs/I-DrugClass have/O been/O associated/O with/O metabolic/B-AdverseReaction changes/I-AdverseReaction that/O may/O increase/O cardiovascular/O cerebrovascular/O risk/O ./O
These/O metabolic/B-AdverseReaction changes/I-AdverseReaction include/O hyperglycemia/B-AdverseReaction ,/O dyslipidemia/B-AdverseReaction ,/O and/O body/B-AdverseReaction weight/I-AdverseReaction gain/I-AdverseReaction ./O
While/O all/O of/O the/O drugs/B-DrugClass in/I-DrugClass the/I-DrugClass class/I-DrugClass have/O been/O shown/O to/O produce/O some/O metabolic/B-AdverseReaction changes/I-AdverseReaction ,/O each/O drug/O has/O its/O own/O specific/O risk/O profile/O ./O
Hyperglycemia/O and/O Diabetes/O Mellitus/O Hyperglycemia/B-AdverseReaction ,/O in/O some/O cases/O extreme/B-Severity and/O associated/O with/O ketoacidosis/B-AdverseReaction or/O hyperosmolar/B-AdverseReaction coma/I-AdverseReaction or/O death/B-AdverseReaction ,/O has/O been/O reported/O in/O patients/O treated/O with/O atypical/B-DrugClass antipsychotics/I-DrugClass ./O
Assessment/O of/O the/O relationship/O between/O atypical/O antipsychotic/O use/O and/O glucose/O abnormalities/O is/O complicated/O by/O the/O possibility/O of/O an/O increased/O background/O risk/O of/O diabetes/O mellitus/O in/O patients/O with/O schizophrenia/O and/O the/O increasing/O incidence/O of/O diabetes/O mellitus/O in/O the/O general/O population/O ./O
Given/O these/O confounders/O ,/O the/O relationship/O between/O atypical/B-DrugClass antipsychotic/I-DrugClass use/O and/O hyperglycemia/B-AdverseReaction -/O related/O adverse/O reactions/O is/O not/O completely/O understood/O ./O
However/O ,/O epidemiological/O studies/O suggest/O an/O increased/O risk/O of/O treatment/O -/O emergent/O hyperglycemia/B-AdverseReaction -/O related/O adverse/O events/O in/O patients/O treated/O with/O the/O atypical/B-DrugClass antipsychotics/I-DrugClass included/O in/O these/O studies/O ./O
Precise/O risk/O estimates/O for/O hyperglycemia/B-AdverseReaction -/O related/O adverse/O events/O in/O patients/O treated/O with/O atypical/B-DrugClass antipsychotics/I-DrugClass are/O not/O available/O ./O
Patients/O with/O an/O established/O diagnosis/O of/O diabetes/O mellitus/O who/O are/O started/O on/O atypical/O antipsychotics/O should/O be/O monitored/O regularly/O for/O worsening/O of/O glucose/O control/O ./O
Patients/O with/O risk/O factors/O for/O diabetes/O mellitus/O (/O e.g./O ,/O obesity/O ,/O family/O history/O of/O diabetes/O )/O who/O are/O starting/O treatment/O with/O atypical/O antipsychotics/O should/O undergo/O fasting/O blood/O glucose/O testing/O at/O the/O beginning/O of/O treatment/O and/O periodically/O during/O treatment/O ./O
Any/O patient/O treated/O with/O atypical/O antipsychotics/O should/O be/O monitored/O for/O symptoms/O of/O hyperglycemia/O including/O polydipsia/O ,/O polyuria/O ,/O polyphagia/O ,/O and/O weakness/O ./O
Patients/O who/O develop/O symptoms/O of/O hyperglycemia/O during/O treatment/O with/O atypical/O antipsychotics/O should/O undergo/O fasting/O blood/O glucose/O testing/O ./O
In/O some/O cases/O ,/O hyperglycemia/O has/O resolved/O when/O the/O atypical/O antipsychotic/O was/O discontinued/O ;/O however/O ,/O some/O patients/O required/O continuation/O of/O anti/O -/O diabetic/O treatment/O despite/O discontinuation/O of/O the/O antipsychotic/O drug/O ./O
Adult/O Patients/O :/O Pooled/O data/O from/O the/O short/O -/O term/O placebo/O -/O controlled/O schizophrenia/O and/O bipolar/O mania/O trials/O are/O presented/O in/O Table/O 1/O ./O
TABLE/O 1/O :/O Changes/O in/O Fasting/O Glucose/O in/O Adult/O Patients/O N/O Number/O of/O patients/O who/O had/O assessments/O at/O both/O Baseline/O and/O Endpoint/O ./O
N/O Number/O of/O patients/O at/O risk/O at/O Baseline/O with/O assessments/O at/O both/O Baseline/O and/O Endpoint/O ./O
S/O Includes/O patients/O treated/O with/O flexible/O dose/O of/O SAPHRIS/O 5/O or/O 10/O mg/O twice/O daily/O (/O N=90/O )/O ./O
SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O with/O flexible/O dosing/O ./O
Schizophrenia/O (/O 6-weeks/O )/O Bipolar/O (/O 3-weeks/O )/O Placebo/O SAPHRIS/O Placebo/O SAPHRIS5/O or/O 10/O mgtwice/O daily/O 5/O mgtwice/O daily/O 10/O mgtwice/O daily/O 5/O or/O 10/O mgtwice/O daily/O S/O Mean/O Change/O from/O Baseline/O in/O Fasting/O Glucose/O at/O Endpoint/O Change/O from/O Baseline/O (/O mg/O dL/O )/O (/O N/O )/O -0.2(232/O )/O 3.8(158/O )/O 1.1(153/O )/O 3.2(377/O )/O -0.6(89/O )/O -0.6(156/O )/O Proportion/O of/O Patients/O with/O Shifts/O from/O Baseline/O to/O Endpoint/O Normal/O to/O High<100/O to/O 126/O mg/O dL/O 4.1/O %/O 4.5/O %/O 4.5/O %/O 5.0/O %/O 3.3/O %/O 2.7/O %/O (/O n/O N/O )/O (/O 7/170/O )/O (/O 5/111/O )/O (/O 5/111/O )/O (/O 13/262/O )/O (/O 2/61/O )/O (/O 3/111/O )/O Borderline/O to/O High>=100/O and/O 126to/O 126/O mg/O dL/O 5.9/O %/O 6.8/O %/O 6.3/O %/O 10.5/O %/O 0.0/O %/O 11.4/O %/O (/O n/O N/O )/O (/O 3/51/O )/O (/O 3/44/O )/O (/O 2/32/O )/O (/O 10/95/O )/O (/O 0/23/O )/O (/O 4/35/O )/O In/O a/O 52-week/O ,/O double/O -/O blind/O ,/O comparator/O -/O controlled/O trial/O that/O included/O primarily/O patients/O with/O schizophrenia/O ,/O the/O mean/O increase/O from/O baseline/O of/O fasting/O glucose/O was/O 2.4/O mg/O dL./O Pediatric/O Patients/O :/O Data/O from/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O trial/O in/O pediatric/O patients/O with/O bipolar/O I/O disorder/O are/O shown/O in/O Table/O 2/O ./O
TABLE/O 2/O :/O Changes/O in/O Fasting/O Glucose/O in/O Pediatric/O Subjects/O Bipolar/O I/O Disorder/O (/O 3-weeks/O )/O Placebo/O SAPHRIS2.5/O mgtwice/O daily/O SAPHRIS5/O mgtwice/O daily/O SAPHRIS10/O mgtwice/O daily/O Mean/O Change/O from/O Baseline/O in/O Fasting/O Glucose/O at/O Endpoint/O Change/O from/O Baseline/O (/O mg/O dL/O )/O (/O N/O )/O -2.24(56/O )/O 1.43(51/O )/O -0.45(57/O )/O 0.34(52/O )/O Proportion/O of/O Subjects/O with/O Shifts/O from/O Baseline/O to/O Endpoint/O Normal/O to/O High>45/O &/O 100/O to/O 126/O mg/O dL/O 0/O %/O 0/O %/O 1.8/O %/O 0/O %/O (/O n/O N/O )/O (/O 0/56/O )/O (/O 0/51/O )/O (/O 1/57/O )/O (/O 0/52/O )/O Dyslipidemia/B-AdverseReaction Undesirable/B-AdverseReaction alterations/I-AdverseReaction in/I-AdverseReaction lipids/I-AdverseReaction have/O been/O observed/O in/O patients/O treated/O with/O atypical/B-DrugClass antipsychotics/I-DrugClass ./O
Adult/O Patients/O :/O Pooled/O data/O from/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O schizophrenia/O and/O bipolar/O mania/O trials/O are/O presented/O in/O Table/O 3/O ./O
TABLE/O 3/O :/O Changes/O in/O Lipids/O in/O Adult/O Patients/O N/O Number/O of/O subjects/O who/O had/O assessments/O at/O both/O Baseline/O and/O Endpoint/O ./O
S/O Includes/O subjects/O treated/O with/O flexible/O dose/O of/O SAPHRIS/O 5/O or/O 10/O mg/O twice/O daily/O (/O N=90/O )/O ./O
SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O with/O flexible/O dosing/O ./O
Schizophrenia/O (/O 6-weeks/O )/O Bipolar/O (/O 3-weeks/O )/O Placebo/O SAPHRIS/O Placebo/O SAPHRIS5/O or/O 10/O mgtwice/O daily/O 5/O mgtwice/O daily/O 10/O mgtwice/O daily/O 5/O or/O 10/O mgtwice/O daily/O S/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O Total/O cholesterol(N/O )/O -2.2(351/O )/O -2.4(258/O )/O 3.3(199/O )/O 0.4(539/O )/O -1.5(163/O )/O 1.1(322/O )/O LDL/O (/O N/O )/O 0.1(285/O )/O -0.2(195/O )/O 2.6(195/O )/O 1.3(465/O )/O 1.9(158/O )/O 1.6(304/O )/O HDL/O (/O N/O )/O 0.5(290/O )/O 0.4(199/O )/O 1.0(199/O )/O 0.5(480/O )/O 0.0(163/O )/O 0.9(322/O )/O Fasting/O triglycerides/O (/O N/O )/O -7.6(233/O )/O -1.9(159/O )/O 0.1(154/O )/O 3.8(380/O )/O -17.9(129/O )/O -3.5(237/O )/O Proportion/O of/O Patients/O with/O Shifts/O from/O Baseline/O to/O Endpoint/O Total/O cholesterolNormal/O to/O High<200/O to/O 240(mg/O dL/O )/O (/O n/O N/O )/O 1.3%(3/225/O )/O 0.6%(1/161/O )/O 2.2%(3/134/O )/O 1.7%(6/343/O )/O 1.1%(1/95/O )/O 2.5%(5/204/O )/O LDLNormal/O to/O High<100/O to/O 160(mg/O dL/O )/O (/O n/O N/O )/O 1.7%(2/117/O )/O 0.0%(0/80/O )/O 1.2%(1/86/O )/O 1.0%(2/196/O )/O 1.9%(1/53/O )/O 0.0%(0/141/O )/O HDLNormal/O to/O Low>=40/O to/O 40/O (/O mg/O dL/O )/O (/O n/O N/O )/O 10.7%(21/196/O )/O 13.3%(18/135/O )/O 14.7%(20/136/O )/O 14.0%(45/322/O )/O 7.4%(9/122/O )/O 8.7%(21/242/O )/O Fasting/O triglyceridesNormal/O to/O High<150/O to/O 200/O (/O mg/O dL/O )/O (/O n/O N/O )/O 2.4%(4/167/O )/O 7.0%(8/115/O )/O 8.3%(9/108/O )/O 7.7%(20/260/O )/O 5.1%(4/78/O )/O 7.4%(11/148/O )/O In/O short/O -/O term/O schizophrenia/O trials/O ,/O the/O proportion/O of/O patients/O with/O total/B-AdverseReaction cholesterol/I-AdverseReaction elevations/I-AdverseReaction 240/B-Severity mg/I-Severity dL/O (/O at/O Endpoint/O )/O was/O 8.3/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 7/O %/O for/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O elevations/B-AdverseReaction in/I-AdverseReaction triglycerides/I-AdverseReaction 200/B-Severity mg/I-Severity dL/O (/O at/O Endpoint/O )/O was/O 13.2/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 10.5/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O mania/O trials/O ,/O the/O proportion/O of/O patients/O with/O total/B-AdverseReaction cholesterol/I-AdverseReaction elevations/I-AdverseReaction 240/B-Severity mg/I-Severity dL/O (/O at/O Endpoint/O )/O was/O 8.7/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 8.6/O %/O for/O placebo/O -/O treated/O patients/O ./O
The/O proportion/O of/O patients/O with/O elevations/B-AdverseReaction in/I-AdverseReaction triglycerides/I-AdverseReaction 200/B-Severity mg/I-Severity dL/O (/O at/O Endpoint/O )/O was/O 15.2/O %/O for/O SAPHRIS/O -/O treated/O patients/O versus/O 11.4/O %/O for/O placebo/O -/O treated/O patients/O ./O
In/O a/O 52-week/O ,/O double/O -/O blind/O ,/O comparator/O -/O controlled/O trial/O that/O included/O primarily/O patients/O with/O schizophrenia/O ,/O the/O mean/O decrease/O from/O baseline/O of/O total/O cholesterol/O was/O 6/O mg/O dL/O and/O the/O mean/O decrease/O from/O baseline/O of/O fasting/O triglycerides/O was/O 9.8/O mg/O dL./O Pediatric/O Patients/O :/O Data/O from/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O mania/O trial/O are/O presented/O in/O Table/O 4/O ./O
TABLE/O 4/O :/O Changes/O in/O Fasting/O Lipids/O in/O Pediatric/O Subjects/O N/O Number/O of/O patients/O who/O had/O assessments/O at/O both/O Baseline/O and/O Endpoint/O Bipolar/O I/O Disorder/O (/O 3-weeks/O )/O Placebo/O SAPHRIS2.5/O mgtwice/O daily/O SAPHRIS5/O mgtwice/O daily/O SAPHRIS10/O mgtwice/O daily/O Mean/O Change/O from/O Baseline/O (/O mg/O dL/O )/O Total/O fasting/O cholesterol/O (/O N/O )/O -2.3(57/O )/O 3.7(50/O )/O 7.2(57/O )/O 9.3(52/O )/O Fasting/O LDL(N/O )/O -2.5(57/O )/O -0.2(50/O )/O 3.0(57/O )/O 4.9(51/O )/O Fasting/O HDL(N/O )/O 1.6(57/O )/O 2.3(50/O )/O 1.5(57/O )/O 1.7(52/O )/O Fasting/O triglycerides/O (/O N/O )/O -6.6(57/O )/O 8.7(50/O )/O 13.4(57/O )/O 14.7(52/O )/O Proportion/O of/O Subjects/O with/O Shifts/O from/O Baseline/O to/O Endpoint/O Total/O fasting/O cholesterolNormal/O to/O High<170/O to/O 200(mg/O dL)(n/O N/O )/O 1.8%(1/57/O )/O 0%(0/50/O )/O 1.8%(1/57/O )/O 0%(0/52/O )/O Fasting/O LDLNormal/O to/O High<110/O to/O 130(n/O N/O )/O 1.8%(1/57/O )/O 2.0%(1/50/O )/O 1.8%(1/57/O )/O 0%(0/51/O )/O Fasting/O HDLNormal/O to/O Low>=40/O to/O 40/O (/O mg/O dL)(n/O N/O )/O 3.5%(2/57/O )/O 6.0%(3/50/O )/O 3.5%(2/57/O )/O 9.6%(5/52/O )/O Fasting/O triglyceridesNormal/O to/O High<150/O to/O 200/O (/O mg/O dL)(n/O N/O )/O 0%(0/57/O )/O 4.0%(2/50/O )/O 3.5%(2/57/O )/O 1.9%(1/52/O )/O Weight/O Gain/O Increases/B-AdverseReaction in/I-AdverseReaction weight/I-AdverseReaction have/O been/O observed/O in/O pre/O -/O marketing/O clinical/O trials/O with/O SAPHRIS/O ./O
Patients/O receiving/O SAPHRIS/O should/O receive/O regular/O monitoring/O of/O weight/O [/O see/O Patient/O Counseling/O Information/O (/O 17/O )/O ]/O ./O
Adult/O Patients/O :/O Pooled/O data/O on/O mean/O changes/O in/O body/O weight/O and/O the/O proportion/O of/O subjects/O meeting/O a/O weight/B-AdverseReaction gain/I-AdverseReaction criterion/O of/O 7/B-Severity %/O of/O body/O weight/O from/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O schizophrenia/O and/O bipolar/O mania/O trials/O are/O presented/O in/O Table/O 5/O ./O
Table/O 5/O :/O Change/O in/O Body/O Weight/O in/O Adult/O Patients/O from/O Baseline/O N/O Number/O of/O subjects/O who/O had/O assessments/O at/O both/O Baseline/O and/O Endpoint/O ./O
S/O Includes/O subjects/O treated/O with/O flexible/O dose/O of/O SAPHRIS/O 5/O or/O 10/O mg/O twice/O daily/O (/O N=90/O )/O ./O
SAPHRIS/O 5/O mg/O or/O 10/O mg/O twice/O daily/O with/O flexible/O dosing/O ./O
Schizophrenia/O (/O 6-weeks/O )/O Bipolar/O (/O 3-weeks/O )/O Placebo/O SAPHRIS/O Placebo/O SAPHRIS5/O or/O 10/O mgtwice/O daily/O 5/O mgtwice/O daily/O 10/O mgtwice/O daily/O 5/O or/O 10/O mgtwice/O daily/O S/O Change/O from/O Baseline/O (/O kg/O )/O (/O N/O )/O 0.0(348/O )/O 1.0(251/O )/O 0.9(200/O )/O 1.1(532/O )/O 0.2(171/O )/O 1.3(336/O )/O Proportion/O of/O Patients/O with/O a/O 7/B-Severity %/O Increase/B-AdverseReaction in/I-AdverseReaction Body/I-AdverseReaction Weight/I-AdverseReaction %/O with/O 7/B-Severity %/O increase/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction 1.6/O %/O 4.4/O %/O 4.8/O %/O 4.9/O %/O 0.5/O %/O 5.8/O %/O Adult/O Patients/O :/O In/O a/O 52-week/O ,/O double/O -/O blind/O ,/O comparator/O -/O controlled/O adult/O trial/O that/O included/O primarily/O patients/O with/O schizophrenia/O ,/O the/O mean/O weight/B-AdverseReaction gain/I-AdverseReaction from/O baseline/O was/O 0.9/O kg/O ./O
The/O proportion/O of/O patients/O with/O a/O 7/B-Severity %/O increase/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction (/O at/O Endpoint/O )/O was/O 14.7%.Table/O 5provides/O the/O mean/O weight/B-AdverseReaction change/I-AdverseReaction from/O baseline/O and/O the/O proportion/O of/O patients/O with/O a/O weight/B-AdverseReaction gain/I-AdverseReaction of/O 7/B-Severity %/O categorized/O by/O Body/O Mass/O Index/O (/O BMI/O )/O at/O baseline/O ./O
Table/O 6/O :/O Weight/O Change/O Results/O Categorized/O by/O BMI/O at/O Baseline/O :/O Comparator/O -/O Controlled/O 52-Week/O Study/O in/O Adults/O with/O Schizophrenia/O BMI/O 23/O SAPHRIS/O N=295/O BMI/O 23/O -/O 27/O SAPHRIS/O N=290/O BMI/O 27/O SAPHRIS/O N=302/O Mean/O change/O from/O Baseline/O (/O kg/O )/O 1.7/O 1/O 0/O %/O with/O 7/B-Severity %/O increase/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction 22/O %/O 13/O %/O 9/O %/O Pediatric/O Patients/O :/O Data/O on/O mean/O changes/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction and/O the/O proportion/O of/O pediatric/O patients/O meeting/O a/O weight/B-AdverseReaction gain/I-AdverseReaction criterion/O of/O 7/B-Severity %/O of/O body/O weight/O from/O the/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O mania/O trial/O are/O presented/O in/O Table/O 7/O ./O
To/O adjust/O for/O normal/O growth/O ,/O z/O -/O scores/O were/O derived/O (/O measured/O in/O standard/O deviations/O [/O SD/O ]/O )/O ,/O which/O normalize/O for/O the/O natural/O growth/O of/O pediatric/O patients/O by/O comparisons/O to/O age-/O and/O sex/O -/O matched/O population/O standards/O ./O
The/O distance/O of/O a/O z/O -/O score/O from/O 0/O represents/O the/O distance/O of/O a/O percentile/O from/O the/O median/O ,/O measured/O in/O standard/O deviations/O (/O SD/O )/O ./O
After/O adjusting/O for/O age/O and/O sex/O ,/O the/O mean/O change/O from/O baseline/O to/O endpoint/O in/O weight/O z/O -/O score/O for/O SAPHRS/O 2.5/O mg/O ,/O 5/O mg/O ,/O and/O 10/O mg/O twice/O daily/O ,/O was/O 0.11/O ,/O 0.08/O and/O 0.09/O SD/O versus/O 0.02/O SD/O for/O placebo/O ,/O respectively/O ./O
When/O treating/O pediatric/O patients/O ,/O weight/O gain/O should/O be/O monitored/O and/O assessed/O against/O that/O expected/O for/O normal/O growth/O ./O
Table/O 7/O :/O Change/O in/O Body/O Weight/O in/O Pediatric/O Subjects/O from/O Baseline/O N/O Number/O of/O subjects/O who/O had/O assessments/O at/O both/O Baseline/O and/O Endpoint/O ./O
Bipolar/O I/O Disorder/O (/O 3-weeks/O )/O Placebo/O SAPHRIS2.5/O mgtwice/O daily/O SAPHRIS5/O mgtwice/O daily/O SAPHRIS10/O mgtwice/O daily/O Change/O from/O Baseline/O (/O kg/O )/O (/O N/O )/O 0.5(89/O )/O 1.7(92/O )/O 1.6(90/O )/O 1.4(87/O )/O Proportion/O of/O Subjects/O with/O a/O 7/B-Severity %/O Increase/B-AdverseReaction in/I-AdverseReaction Body/I-AdverseReaction Weight/I-AdverseReaction %/O with/O 7/B-Severity %/O increase/B-AdverseReaction in/I-AdverseReaction body/I-AdverseReaction weight/I-AdverseReaction 1.1/O %/O 12.0/O %/O 8.9/O %/O 8.0/O %/O 5.6/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O observed/O in/O patients/O treated/O with/O SAPHRIS/O ./O
In/O several/O cases/O ,/O these/O reactions/O occurred/O after/O the/O first/O dose/O ./O
These/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction included/O :/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O swollen/B-AdverseReaction tongue/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O wheezing/B-AdverseReaction and/O rash/B-AdverseReaction ./O
5.7/O Orthostatic/O Hypotension/O ,/O Syncope/O ,/O and/O Other/O Hemodynamic/O Effects/O SAPHRIS/O may/B-Factor induce/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction and/O syncope/B-AdverseReaction in/O some/O patients/O ,/O especially/O early/O in/O treatment/O ,/O because/O of/O its/O alpha1-adrenergic/O antagonist/O activity/O ./O
In/O short/O -/O term/O schizophrenia/O adult/O trials/O ,/O syncope/B-AdverseReaction was/O reported/O in/O 0.2/O %/O (/O 1/572/O )/O of/O patients/O treated/O with/O therapeutic/O doses/O (/O 5/O mg/O or/O 10/O mg/O twice/O daily/O )/O of/O SAPHRIS/O ,/O compared/O to/O 0.3/O %/O (/O 1/378/O )/O of/O patients/O treated/O with/O placebo/O ./O
In/O short/O -/O term/O bipolar/O mania/O adult/O trials/O ,/O syncope/B-AdverseReaction was/O reported/O in/O 0.3/O %/O (/O 1/379/O )/O of/O patients/O treated/O with/O therapeutic/O doses/O (/O 5/O mg/O or/O 10/O mg/O twice/O daily/O )/O of/O SAPHRIS/O ,/O compared/O to/O 0/O %/O (/O 0/203/O )/O of/O patients/O treated/O with/O placebo/O ./O
During/O adult/O pre/O -/O marketing/O clinical/O trials/O with/O SAPHRIS/O ,/O including/O long/O -/O term/O trials/O without/O comparison/O to/O placebo/O ,/O syncope/B-AdverseReaction was/O reported/O in/O 0.6/O %/O (/O 11/1953/O )/O of/O patients/O treated/O with/O SAPHRIS/O ./O
In/O a/O 3-week/O ,/O bipolar/O mania/O pediatric/O trial/O ,/O syncope/B-AdverseReaction was/O reported/O in/O 1/O %/O (/O 1/104/O )/O of/O patients/O treated/O with/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 1/O %/O (/O 1/99/O )/O of/O patients/O treated/O with/O SAPHRIS/O 5/O mg/O twice/O daily/O ,/O and/O 0/O %/O (/O 0/99/O )/O for/O patients/O treated/O with/O SAPHRIS/O 10/O mg/O twice/O daily/O compared/O to/O 0/O %/O (/O 0/101/O )/O for/O patients/O treated/O with/O placebo/O ./O
Patients/O should/O be/O instructed/O about/O non/O -/O pharmacologic/O interventions/O that/O help/O to/O reduce/O the/O occurrence/O of/O orthostatic/O hypotension/O (/O e.g./O ,/O sitting/O on/O the/O edge/O of/O the/O bed/O for/O several/O minutes/O before/O attempting/O to/O stand/O in/O the/O morning/O and/O slowly/O rising/O from/O a/O seated/O position/O )/O ./O
SAPHRIS/O should/O be/O used/O with/O caution/O in/O (/O 1/O )/O patients/O with/O known/O cardiovascular/O disease/O (/O history/O of/O myocardial/O infarction/O or/O ischemic/O heart/O disease/O ,/O heart/O failure/O or/O conduction/O abnormalities/O )/O ,/O cerebrovascular/O disease/O ,/O or/O conditions/O which/O would/O predispose/O patients/O to/O hypotension/O (/O dehydration/O ,/O hypovolemia/O ,/O and/O treatment/O with/O antihypertensive/O medications/O )/O ;/O and/O (/O 2/O )/O in/O the/O elderly/O ./O
SAPHRIS/O should/O be/O used/O cautiously/O when/O treating/O patients/O who/O receive/O treatment/O with/O other/O drugs/O that/O can/O induce/O hypotension/O ,/O bradycardia/O ,/O respiratory/O or/O central/O nervous/O system/O depression/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
Monitoring/O of/O orthostatic/O vital/O signs/O should/O be/O considered/O in/O all/O such/O patients/O ,/O and/O a/O dose/O reduction/O should/O be/O considered/O if/O hypotension/O occurs/O ./O
5.8/O Leukopenia/O ,/O Neutropenia/O ,/O and/O Agranulocytosis/O In/O clinical/O trial/O and/O postmarketing/O experience/O ,/O leukopenia/B-AdverseReaction and/O neutropenia/B-AdverseReaction have/O been/O reported/O temporally/O related/O to/O antipsychotic/O agents/O ,/O including/O SAPHRIS/O ./O
Agranulocytosis/B-AdverseReaction (/O including/O fatal/B-AdverseReaction cases/O )/O has/O been/O reported/O with/O other/B-DrugClass agents/I-DrugClass in/I-DrugClass the/I-DrugClass class/I-DrugClass ./O
Possible/O risk/O factors/O for/O leukopenia/O neutropenia/O include/O pre/O -/O existing/O low/O white/O blood/O cell/O count/O (/O WBC)/absolute/O neutrophil/O count/O (/O ANC/O )/O and/O history/O of/O drug/O induced/O leukopenia/O neutropenia/O ./O
In/O patients/O with/O a/O pre/O -/O existing/O low/O WBC/O ANC/O or/O drug/O -/O induced/O leukopenia/O neutropenia/O ,/O perform/O a/O complete/O blood/O count/O (/O CBC/O )/O frequently/O during/O the/O first/O few/O months/O of/O therapy/O ./O
In/O such/O patients/O ,/O consider/O discontinuation/O of/O SAPHRIS/O at/O the/O first/O sign/O of/O a/O clinically/O significant/O decline/O in/O WBC/O in/O the/O absence/O of/O other/O causative/O factors/O ./O
Monitor/O patients/O with/O clinically/O significant/O neutropenia/O for/O fever/O or/O other/O symptoms/O or/O signs/O of/O infection/O and/O treat/O promptly/O if/O such/O symptoms/O or/O signs/O occur/O ./O
Discontinue/O SAPHRIS/O in/O patients/O with/O severe/O neutropenia/O (/O absolute/O neutrophil/O count/O 1000/O mm/O 3/O )/O and/O follow/O their/O WBC/O until/O recovery/O ./O
5.9/O QT/O Prolongation/O The/O effects/O of/O SAPHRIS/O on/O the/O QT/O QTc/O interval/O were/O evaluated/O in/O a/O dedicated/O adult/O QT/O study/O ./O
This/O trial/O involved/O SAPHRIS/O doses/O of/O 5/O mg/O ,/O 10/O mg/O ,/O 15/O mg/O ,/O and/O 20/O mg/O twice/O daily/O ,/O and/O placebo/O ,/O and/O was/O conducted/O in/O 151/O clinically/O stable/O patients/O with/O schizophrenia/O ,/O with/O electrocardiographic/O assessments/O throughout/O the/O dosing/O interval/O at/O baseline/O and/O steady/O state/O ./O
At/O these/O doses/O ,/O SAPHRIS/O was/O associated/O with/O increases/B-AdverseReaction in/I-AdverseReaction QTc/I-AdverseReaction interval/I-AdverseReaction ranging/O from/O 2/B-Severity to/I-Severity 5/B-Severity msec/I-Severity compared/O to/O placebo/O ./O
No/B-Negation patients/O treated/O with/O SAPHRIS/O experienced/O QTc/B-AdverseReaction increases/I-AdverseReaction 60/B-Severity msec/I-Severity from/O baseline/O measurements/O ,/O nor/B-Negation did/O any/O patient/O experience/O a/O QTc/B-AdverseReaction of/I-AdverseReaction 500/O msec/O ./O
Electrocardiogram/O (/O ECG/O )/O measurements/O were/O taken/O at/O various/O time/O points/O during/O the/O SAPHRIS/O clinical/O trial/O program/O (/O 5/O mg/O or/O 10/O mg/O twice/O daily/O doses/O )/O ./O
Post/O -/O baseline/O QT/B-AdverseReaction prolongations/I-AdverseReaction exceeding/O 500/B-Severity msec/I-Severity were/O reported/O at/O comparable/O rates/O for/O SAPHRIS/O and/O placebo/O in/O these/O short/O -/O term/O trials/O ./O
There/O were/O no/B-Negation reports/O of/O Torsade/B-AdverseReaction de/I-AdverseReaction Pointes/I-AdverseReaction or/O any/O other/O adverse/O reactions/O associated/O with/O delayed/B-AdverseReaction ventricular/I-AdverseReaction repolarization/I-AdverseReaction ./O
The/O use/O of/O SAPHRIS/O should/O be/O avoided/O in/O combination/O with/O other/O drugs/O known/O to/O prolong/O QTc/O including/O Class/O 1A/O antiarrhythmics/O (/O e.g./O ,/O quinidine/O ,/O procainamide/O )/O or/O Class/O 3/O antiarrhythmics/O (/O e.g./O ,/O amiodarone/O ,/O sotalol/O )/O ,/O antipsychotic/O medications/O (/O e.g./O ,/O ziprasidone/O ,/O chlorpromazine/O ,/O thioridazine/O )/O ,/O and/O antibiotics/O (/O e.g./O ,/O gatifloxacin/O ,/O moxifloxacin/O )/O ./O
SAPHRIS/O should/O also/O be/O avoided/O in/O patients/O with/O a/O history/O of/O cardiac/O arrhythmias/O and/O in/O other/O circumstances/O that/O may/O increase/O the/O risk/O of/O the/O occurrence/O of/O torsade/O de/O pointes/O and/or/O sudden/O death/O in/O association/O with/O the/O use/O of/O drugs/O that/O prolong/O the/O QTc/O interval/O ,/O including/O bradycardia/O ;/O hypokalemia/O or/O hypomagnesemia/O ;/O and/O presence/O of/O congenital/O prolongation/O of/O the/O QT/O interval/O ./O
5.10/O Hyperprolactinemia/O Like/O other/O drugs/O that/O antagonize/O dopamine/O D2receptors/O ,/O SAPHRIS/O can/B-Factor elevate/B-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction ,/O and/O the/O elevation/O can/O persist/O during/O chronic/O administration/O ./O
Hyperprolactinemia/B-AdverseReaction may/B-Factor suppress/B-AdverseReaction hypothalamic/I-AdverseReaction GnRH/I-AdverseReaction ,/O resulting/O in/O reduced/B-AdverseReaction pituitary/I-AdverseReaction gonadotropin/I-AdverseReaction secretion/I-AdverseReaction ./O
This/O ,/O in/O turn/O ,/O may/B-Factor inhibit/B-AdverseReaction reproductive/I-AdverseReaction function/I-AdverseReaction by/O impairing/B-AdverseReaction gonadal/I-AdverseReaction steroidogenesis/I-AdverseReaction in/O both/O female/O and/O male/O patients/O ./O
Galactorrhea/B-AdverseReaction ,/O amenorrhea/B-AdverseReaction ,/O gynecomastia/B-AdverseReaction ,/O and/O impotence/B-AdverseReaction have/O been/O reported/O in/O patients/O receiving/O prolactin/B-DrugClass -/I-DrugClass elevating/O compounds/O ./O
Long/O -/O standing/O hyperprolactinemia/B-AdverseReaction when/O associated/O with/O hypogonadism/B-AdverseReaction may/B-Factor lead/O to/O decreased/B-AdverseReaction bone/I-AdverseReaction density/I-AdverseReaction in/O both/O female/O and/O male/O subjects/O ./O
In/O SAPHRIS/O adult/O clinical/O trials/O ,/O the/O incidences/O of/O adverse/O events/O related/O to/O abnormal/B-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction were/O 0.4/O %/O versus/O 0/O %/O for/O placebo/O ./O
In/O a/O 3-week/O ,/O bipolar/O mania/O pediatric/O trial/O ,/O the/O incidence/O of/O adverse/O events/O related/O to/O abnormal/B-AdverseReaction prolactin/I-AdverseReaction levels/I-AdverseReaction were/O 0/O %/O in/O the/O SAPHRIS/O 2.5/O mg/O twice/O daily/O treatment/O group/O ,/O 2/O %/O in/O the/O SAPHRIS/O 5/O mg/O twice/O daily/O treatment/O group/O ,/O and/O 1/O %/O in/O the/O SAPHRIS/O 10/O mg/O twice/O daily/O treatment/O group/O versus/O to/O 1/O %/O for/O patients/O treated/O with/O placebo/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Tissue/O culture/O experiments/O indicate/O that/O approximately/O one/O -/O third/O of/O human/O breast/O cancers/O are/O prolactin/O -/O dependent/O in/O vitro/O ,/O a/O factor/O of/O potential/O importance/O if/O the/O prescription/O of/O these/O drugs/O is/O considered/O in/O a/O patient/O with/O previously/O -/O detected/O breast/O cancer/O ./O
Neither/O clinical/O studies/O nor/O epidemiologic/O studies/O conducted/O to/O date/O have/O shown/O an/O association/O between/O chronic/O administration/O of/O this/O class/O of/O drugs/O and/O tumorigenesis/B-AdverseReaction in/O humans/O ,/O but/O the/O available/O evidence/O is/O too/O limited/O to/O be/O conclusive/O ./O
5.11/O Seizures/O Seizures/B-AdverseReaction were/O reported/O in/O 0/O %/O and/O 0.3/O %/O (/O 0/572/O ,/O 1/379/O )/O of/O adult/O patients/O treated/O with/O doses/O of/O 5/O mg/O and/O 10/O mg/O twice/O daily/O of/O SAPHRIS/O ,/O respectively/O ,/O compared/O to/O 0/O %/O (/O 0/503/O ,/O 0/203/O )/O of/O patients/O treated/O with/O placebo/O in/O short/O -/O term/O schizophrenia/O and/O bipolar/O mania/O trials/O ,/O respectively/O ./O
During/O adult/O pre/O -/O marketing/O clinical/O trials/O with/O SAPHRIS/O ,/O including/O long/O -/O term/O trials/O without/O comparison/O to/O placebo/O ,/O seizures/B-AdverseReaction were/O reported/O in/O 0.3/O %/O (/O 5/1953/O )/O of/O patients/O treated/O with/O SAPHRIS/O ./O
There/O were/O no/B-Negation reports/O of/O seizures/B-AdverseReaction in/O pediatric/O patients/O treated/O with/O SAPHRIS/O in/O a/O 3-week/O -/O term/O ,/O bipolar/O mania/O trial/O ./O
As/O with/O other/O antipsychotic/O drugs/O ,/O SAPHRIS/O should/O be/O used/O with/O caution/O in/O patients/O with/O a/O history/O of/O seizures/O or/O with/O conditions/O that/O potentially/O lower/O the/O seizure/O threshold/O ./O
Conditions/O that/O lower/O the/O seizure/O threshold/O may/O be/O more/O prevalent/O in/O patients/O 65/O years/O or/O older/O ./O
5.12/O Potential/O for/O Cognitive/O and/O Motor/O Impairment/O Somnolence/B-AdverseReaction was/O reported/O in/O patients/O treated/O with/O SAPHRIS/O ./O
It/O was/O usually/O transient/O with/O the/O highest/O incidence/O reported/O during/O the/O first/O week/O of/O treatment/O ./O
In/O short/O -/O term/O ,/O fixed/O -/O dose/O ,/O placebo/O -/O controlled/O schizophrenia/O adult/O trials/O ,/O somnolence/B-AdverseReaction was/O reported/O in/O 15/O %/O (/O 41/274/O )/O of/O patients/O on/O SAPHRIS/O 5/O mg/O twice/O daily/O and/O in/O 13/O %/O (/O 26/208/O )/O of/O patients/O on/O SAPHRIS/O 10/O mg/O twice/O daily/O compared/O to/O 7/O %/O (/O 26/378/O )/O of/O placebo/O patients/O ./O
In/O short/O -/O term/O ,/O placebo/O -/O controlled/O bipolar/O mania/O adult/O trials/O of/O therapeutic/O doses/O (/O 5/O -/O 10/O mg/O twice/O daily/O )/O ,/O somnolence/B-AdverseReaction was/O reported/O in/O 24/O %/O (/O 90/379/O )/O of/O patients/O on/O SAPHRIS/O compared/O to/O 6/O %/O (/O 13/203/O )/O of/O placebo/O patients/O ./O
During/O adult/O pre/O -/O marketing/O clinical/O trials/O with/O SAPHRIS/O ,/O including/O long/O -/O term/O trials/O without/O comparison/O to/O placebo/O ,/O somnolence/B-AdverseReaction was/O reported/O in/O 18/O %/O (/O 358/1953/O )/O of/O patients/O treated/O with/O SAPHRIS/O ./O
Somnolence/B-AdverseReaction (/O including/O sedation/B-AdverseReaction )/O led/O to/O discontinuation/O in/O 0.6/O %/O (/O 12/1953/O )/O of/O patients/O in/O short/O -/O term/O ,/O placebo/O -/O controlled/O trials/O ./O
In/O a/O 3-week/O ,/O placebo/O -/O controlled/O ,/O bipolar/O I/O pediatric/O trial/O ,/O the/O incidence/O of/O somnolence/B-AdverseReaction (/O including/O sedation/B-AdverseReaction and/O hypersomnia/B-AdverseReaction )/O for/O placebo/O ,/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 5/O mg/O twice/O daily/O ,/O and/O 10/O mg/O twice/O daily/O ,/O was/O 12/O %/O (/O 12/101/O )/O ,/O 46/O %/O (/O 48/104/O )/O ,/O 53/O %/O (/O 52/99/O )/O ,/O and/O 49/O %/O (/O 49/99/O )/O ,/O respectively/O ./O
Somnolence/B-AdverseReaction led/O to/O discontinuation/O in/O 0/O %/O ,/O 3/O %/O ,/O 1/O %/O ,/O and/O 2/O %/O of/O patients/O treated/O with/O placebo/O ,/O and/O SAPHRIS/O 2.5/O mg/O twice/O daily/O ,/O 5/O mg/O twice/O daily/O ,/O and/O 10/O mg/O twice/O daily/O ,/O respectively/O ./O
Patients/O should/O be/O cautioned/O about/O performing/O activities/O requiring/O mental/O alertness/O ,/O such/O as/O operating/O hazardous/O machinery/O or/O operating/O a/O motor/O vehicle/O ,/O until/O they/O are/O reasonably/O certain/O that/O SAPHRIS/O therapy/O does/O not/O affect/O them/O adversely/O ./O
5.13/O Body/O Temperature/O Regulation/O Disruption/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction body/I-AdverseReaction 's/I-AdverseReaction ability/I-AdverseReaction to/I-AdverseReaction reduce/I-AdverseReaction core/I-AdverseReaction body/I-AdverseReaction temperature/O has/O been/O attributed/O to/O antipsychotic/B-DrugClass agents/I-DrugClass ./O
In/O the/O short/O -/O term/O placebo/O -/O controlled/O trials/O for/O both/O schizophrenia/O and/O acute/O bipolar/O disorder/O ,/O the/O incidence/O of/O adverse/O reactions/O suggestive/O of/O body/B-AdverseReaction temperature/I-AdverseReaction increases/I-AdverseReaction was/O low/O (/O 1/O %/O )/O and/O comparable/O to/O placebo/O (/O 0/O %/O )/O ./O
During/O clinical/O trials/O with/O SAPHRIS/O ,/O including/O long/O -/O term/O trials/O without/O comparison/O to/O placebo/O ,/O the/O incidence/O of/O adverse/O reactions/O suggestive/O of/O body/B-AdverseReaction temperature/I-AdverseReaction increases/I-AdverseReaction (/O pyrexia/B-AdverseReaction and/O feeling/B-AdverseReaction hot/I-AdverseReaction )/O was/O 1/O %/O ./O
Appropriate/O care/O is/O advised/O when/O prescribing/O SAPHRIS/O for/O patients/O who/O will/O be/O experiencing/O conditions/O that/O may/O contribute/O to/O an/O elevation/O in/O core/O body/O temperature/O ,/O e.g./O ,/O exercising/O strenuously/O ,/O exposure/O to/O extreme/O heat/O ,/O receiving/O concomitant/O medication/O with/O anticholinergic/O activity/O ,/O or/O being/O subject/O to/O dehydration/O ./O
5.14/O Suicide/O The/O possibility/O of/O a/O suicide/O attempt/O is/O inherent/O in/O psychotic/O illnesses/O and/O bipolar/O disorder/O ,/O and/O close/O supervision/O of/O high/O -/O risk/O patients/O should/O accompany/O drug/O therapy/O ./O
Prescriptions/O for/O SAPHRIS/O should/O be/O written/O for/O the/O smallest/O quantity/O of/O tablets/O consistent/O with/O good/O patient/O management/O in/O order/O to/O reduce/O the/O risk/O of/O overdose/O ./O
5.15/O Dysphagia/O Esophageal/B-AdverseReaction dysmotility/I-AdverseReaction and/O aspiration/B-AdverseReaction have/O been/O associated/O with/O antipsychotic/B-DrugClass drug/I-DrugClass use/O ./O
Dysphagia/B-AdverseReaction was/O reported/O in/O 0.2/O %/O and/O 0/O %/O (/O 1/572/O ,/O 0/379/O )/O of/O patients/O treated/O with/O therapeutic/O doses/O (/O 5/O -/O 10/O mg/O twice/O daily/O )/O of/O SAPHRIS/O as/O compared/O to/O 0/O %/O (/O 0/378/O ,/O 0/203/O )/O of/O patients/O treated/O with/O placebo/O in/O short/O -/O term/O schizophrenia/O and/O bipolar/O mania/O adult/O trials/O ,/O respectively/O ./O
During/O adult/O pre/O -/O marketing/O clinical/O trials/O with/O SAPHRIS/O ,/O including/O long/O -/O term/O trials/O without/O comparison/O to/O placebo/O ,/O dysphagia/B-AdverseReaction was/O reported/O in/O 0.1/O %/O (/O 2/1953/O )/O of/O patients/O treated/O with/O SAPHRIS/O ./O
Aspiration/O pneumonia/O is/O a/O common/O cause/O of/O morbidity/O and/O mortality/O in/O elderly/O patients/O ,/O in/O particular/O those/O with/O advanced/O Alzheimer/O 's/O dementia/O ./O
SAPHRIS/O is/O not/O indicated/O for/O the/O treatment/O of/O dementia/O -/O related/O psychosis/O ,/O and/O should/O not/O be/O used/O in/O patients/O at/O risk/O for/O aspiration/O pneumonia/O [/O see/O also/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5.16/O Use/O in/O Patients/O with/O Concomitant/O Illness/O Clinical/O experience/O with/O SAPHRIS/O in/O patients/O with/O certain/O concomitant/O systemic/O illnesses/O is/O limited/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
SAPHRIS/O has/O not/O been/O evaluated/O in/O patients/O with/O a/O recent/O history/O of/O myocardial/O infarction/O or/O unstable/O heart/O disease/O ./O
Patients/O with/O these/O diagnoses/O were/O excluded/O from/O pre/O -/O marketing/O clinical/O trials/O ./O
Because/O of/O the/O risk/O of/O orthostatic/O hypotension/O with/O SAPHRIS/O ,/O caution/O should/O be/O observed/O in/O cardiac/O patients/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O most/O serious/O adverse/O reactions/O were/O :/O Serious/B-Severity Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Malignancies/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O =3/O %/O )/O are/O :/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O viral/B-AdverseReaction infection/I-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O and/O rash/B-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contactJanssen/O Biotech/O ,/O Inc./O at/O 1/O -/O 800-JANSSEN/O (/O 1/O -/O 800/O -/O 526/O -/O 7736/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O data/O described/O below/O are/O based/O on/O one/O ,/O randomized/O ,/O double/O -/O blind/O ,/O controlled/O Phase/O 3/O trial/O in/O patients/O with/O RA/O receiving/O SIMPONI/O ARIA/O by/O intravenous/O infusion/O (/O Trial/O 1/O )/O ./O
The/O protocol/O included/O provisions/O for/O patients/O taking/O placebo/O to/O receive/O treatment/O with/O SIMPONI/O ARIA/O at/O Week/O 16/O or/O Week/O 24/O either/O by/O patient/O response/O (/O based/O on/O uncontrolled/O disease/O activity/O )/O or/O by/O design/O ,/O so/O that/O adverse/O events/O can/O not/O always/O be/O unambiguously/O attributed/O to/O a/O given/O treatment/O ./O
Comparisons/O between/O placebo/O and/O SIMPONI/O ARIA/O were/O based/O on/O the/O first/O 24/O weeks/O of/O exposure/O ./O
Trial/O 1/O included/O 197/O control/O -/O treated/O patients/O and/O 463/O SIMPONI/O ARIA/O -/O treated/O patients/O (/O which/O includes/O control/O -/O treated/O patients/O who/O switched/O to/O SIMPONI/O ARIA/O at/O Week/O 16/O )/O ./O
The/O proportion/O of/O patients/O who/O discontinued/O treatment/O due/O to/O adverse/O reactions/O in/O the/O controlled/O phase/O of/O Trial/O 1/O through/O Week/O 24/O was/O 3.5/O %/O for/O SIMPONI/O ARIA/O -/O treated/O patients/O and/O 0.5/O %/O for/O placebo/O -/O treated/O patients/O ./O
Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction was/O the/O most/O common/O adverse/O reaction/O reported/O in/O the/O trial/O through/O Week/O 24/O occurring/O in/O 6.5/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O as/O compared/O with/O 7.6/O %/O of/O control/O -/O treated/O patients/O ,/O respectively/O ./O
Infections/O Serious/B-Severity infections/B-AdverseReaction observed/O in/O SIMPONI/O ARIA/O -/O treated/O patients/O included/O sepsis/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O cellulitis/B-AdverseReaction ,/O abscess/B-AdverseReaction ,/O opportunistic/B-AdverseReaction infections/I-AdverseReaction ,/O tuberculosis/B-AdverseReaction (/O TB/B-AdverseReaction )/O ,/O and/O invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction ./O
Cases/O of/O TB/B-AdverseReaction included/O pulmonary/O and/O extrapulmonary/B-AdverseReaction TB/I-AdverseReaction ./O
The/O majority/O of/O the/O TB/B-AdverseReaction cases/O occurred/O in/O countries/O with/O a/O high/O incidence/O rate/O of/O TB/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
In/O the/O controlled/O phase/O of/O Trial/O 1/O through/O Week/O 24/O ,/O infections/B-AdverseReaction were/O observed/O in/O 27/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O compared/O with/O 24/O %/O of/O control/O -/O treated/O patients/O ,/O and/O serious/B-Severity infections/B-AdverseReaction were/O observed/O in/O 0.9/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O and/O 0.0/O %/O of/O control/O -/O treated/O patients/O ./O
Through/O Week/O 24/O ,/O the/O incidence/O of/O serious/B-Severity infections/B-AdverseReaction per/O 100/O patient/O -/O years/O of/O follow/O -/O up/O was/O 2.2/O (/O 95/O %/O CI/O 0.61/O ,/O 5.71/O )/O for/O the/O SIMPONI/O ARIA/O group/O ,/O and/O 0/O (/O 0.00/O ,/O 3.79/O )/O for/O the/O placebo/O group/O ./O
In/O the/O controlled/O and/O uncontrolled/O portions/O of/O Trial/O 1/O ,/O 958/O total/O patient/O -/O years/O of/O follow/O -/O up/O with/O a/O median/O follow/O -/O up/O of/O approximately/O 92/O weeks/O ,/O the/O incidence/O per/O 100/O patient/O -/O years/O of/O all/O serious/B-Severity infections/B-AdverseReaction was/O 4.07/O (/O CI/O :/O 2.90/O ,/O 5.57/O )/O in/O patients/O receiving/O SIMPONI/O ARIA/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
In/O the/O controlled/O and/O uncontrolled/O portions/O of/O Trial/O 1/O ,/O in/O SIMPONI/O ARIA/O treated/O patients/O ,/O the/O incidence/O of/O active/B-AdverseReaction TB/I-AdverseReaction per/O 100/O patient/O -/O years/O was/O 0.31/O (/O 95/O %/O CI/O :/O 0.06/O ;/O 0.92/O )/O and/O the/O incidence/O of/O other/O opportunistic/B-AdverseReaction infections/I-AdverseReaction per/O 100/O patient/O -/O years/O was/O 0.42/O (/O 95/O %/O CI/O :/O 0.11/O ,/O 1.07/O )/O ./O
Malignancies/O One/O case/O of/O malignancy/B-AdverseReaction other/O than/O lymphoma/B-AdverseReaction and/O NMSC/B-AdverseReaction with/O SIMPONI/O ARIA/O was/O reported/O through/O Week/O 24/O during/O the/O controlled/O phase/O of/O Trial/O 1/O ./O
In/O the/O controlled/O and/O uncontrolled/O portions/O through/O approximately/O 92/O weeks/O ,/O the/O incidence/O of/O malignancies/B-AdverseReaction per/O 100/O patient/O -/O years/O ,/O other/O than/O lymphoma/B-AdverseReaction and/O NMSC/B-AdverseReaction ,/O in/O SIMPONI/O ARIA/O -/O treated/O patients/O was/O 0.31/O (/O CI/O :/O 0.06/O ,/O 0.92/O )/O and/O the/O incidence/O of/O NMSC/B-AdverseReaction was/O 0.1/O (/O 95/O %/O CI/O :/O 0.00/O ,/O 0.58/O )/O ./O
Liver/O Enzyme/O Elevations/O There/O have/O been/O reports/O of/O severe/B-Severity hepatic/B-AdverseReaction reactions/I-AdverseReaction including/O acute/B-AdverseReaction liver/I-AdverseReaction failure/I-AdverseReaction in/O patients/O receiving/O TNF/B-DrugClass -/O blockers/O ./O
In/O the/O controlled/O phase/O of/O Trial/O 1/O ,/O through/O Week/O 24/O ,/O ALT/B-AdverseReaction elevations/I-AdverseReaction 5/B-Severity ULN/I-Severity occurred/O in/O 0.8/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O and/O 0/O %/O of/O control/O -/O treated/O patients/O and/O ALT/B-AdverseReaction elevations/I-AdverseReaction 3/B-Severity ULN/I-Severity occurred/O in/O 2.3/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O and/O 2.5/O %/O of/O control/O -/O treated/O patients/O ./O
Since/O many/O of/O the/O patients/O in/O the/O Phase/O 3/O trial/O were/O also/O taking/O medications/O that/O cause/O liver/O enzyme/O elevations/O (/O e.g./O ,/O nonsteroidal/O anti/O -/O inflammatory/O drugs/O [/O NSAIDs/O ]/O ,/O methotrexate/O [/O MTX/O ]/O ,/O or/O isoniazid/O prophylaxis/O )/O ,/O the/O relationship/O between/O SIMPONI/O ARIA/O and/O liver/O enzyme/O elevation/O is/O not/O clear/O ./O
Autoimmune/O Disorders/O and/O Autoantibodies/O The/O use/O of/O TNF/B-DrugClass -/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O ,/O has/O been/O associated/O with/O the/O formation/B-AdverseReaction of/I-AdverseReaction autoantibodies/I-AdverseReaction and/O ,/O rarely/O ,/O with/O the/O development/O of/O a/O lupus/B-AdverseReaction -/I-AdverseReaction like/O syndrome/O ./O
At/O Week/O 20/O in/O Trial/O 1/O ,/O 17/O %/O of/O SIMPONI/O ARIA/O -/O treated/O patients/O and/O 13/O %/O of/O control/O patients/O were/O newly/B-AdverseReaction ANA/I-AdverseReaction -/O positive/O (/O at/B-Severity titers/I-Severity of/I-Severity 1:160/I-Severity or/O greater/O )/O ./O
Of/O these/O patients/O ,/O one/O SIMPONI/O ARIA/O -/O treated/O patient/O and/O no/B-Negation control/O -/O treated/O patients/O had/O newly/B-AdverseReaction positive/I-AdverseReaction anti/I-AdverseReaction -/I-AdverseReaction dsDNA/O antibodies/O ./O
Administration/O Reactions/O In/O the/O controlled/O phase/O of/O Trial/O 1/O through/O Week/O 24/O ,/O 1.1/O %/O of/O SIMPONI/O ARIA/O infusions/O were/O associated/O with/O an/O infusion/B-AdverseReaction reaction/I-AdverseReaction compared/O with/O 0.2/O %/O of/O infusions/O in/O the/O control/O group/O ./O
The/O most/O common/O infusion/O reaction/O in/O SIMPONI/O ARIA/O treated/O patients/O was/O rash/B-AdverseReaction ./O
No/B-Negation serious/B-Severity infusion/B-AdverseReaction reactions/I-AdverseReaction were/O reported/O ./O
Immunogenicity/O Antibodies/O to/O SIMPONI/O ARIA/O were/O detected/O in/O 13/O (/O 3/O %/O )/O golimumab/O -/O treated/O patients/O following/O IV/O administration/O of/O SIMPONI/O ARIA/O in/O combination/O with/O MTX/O through/O Week/O 24/O of/O Trial/O 1/O ./O
All/O patients/O who/O were/O positive/O for/O antibodies/O to/O golimumab/O had/O neutralizing/O antibodies/O based/O on/O an/O in/O vitro/O cell/O -/O based/O assay/O ./O
The/O small/O number/O of/O patients/O positive/O for/O antibodies/O to/O SIMPONI/O ARIA/O limits/O the/O ability/O to/O draw/O definitive/O conclusions/O regarding/O the/O relationship/O between/O antibodies/O to/O golimumab/O and/O clinical/O efficacy/O or/O safety/O measures/O ./O
The/O data/O above/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O considered/O positive/O for/O antibodies/O to/O SIMPONI/O ARIA/O in/O an/O ELISA/O assay/O ./O
The/O ELISA/O assay/O is/O subject/O to/O interference/O by/O co/O -/O present/O golimumab/O and/O thus/O the/O results/O are/O an/O underestimate/O of/O the/O rate/O of/O product/O immunogenicity/O and/O are/O in/O addition/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O SIMPONI/O ARIA/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
Other/O Adverse/O Reactions/O Table/O 1/O summarizes/O the/O adverse/O drug/O reactions/O that/O occurred/O at/O a/O rate/O of/O at/O least/O 1/O %/O in/O the/O SIMPONI/O ARIA/O +/O MTX/O group/O with/O a/O higher/O incidence/O than/O in/O the/O placebo/O +/O MTX/O group/O during/O the/O controlled/O period/O of/O Trial/O 1/O through/O Week/O 24/O ./O
Table/O 1/O :/O Adverse/O Drug/O Reactions/O Reported/O by/O 1/O %/O of/O SIMPONI/O ARIA/O -/O Treated/O Patients/O and/O with/O a/O Higher/O Incidence/O than/O Placebo/O -/O Treated/O Patients/O in/O Trial/O 1/O through/O Week/O 24/O Placebo/O +/O MTX/O SIMPONI/O ARIA/O +/O MTX/O Patients/O treated/O 197/O 463/O Adverse/O Reaction/O Infections/O and/O Infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O such/O as/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O laryngitis/B-AdverseReaction ,/O and/O rhinitis/B-AdverseReaction )/O 12/O %/O 13/O %/O Viral/B-AdverseReaction infections/I-AdverseReaction (/O such/O as/O influenza/B-AdverseReaction and/O herpes/B-AdverseReaction )/O 3/O %/O 4/O %/O Bacterial/B-AdverseReaction infections/I-AdverseReaction 0/O %/O 1/O %/O Bronchitis/B-AdverseReaction 1/O %/O 3/O %/O Vascular/B-AdverseReaction disorders/I-AdverseReaction Hypertension/B-AdverseReaction 2/O %/O 3/O %/O Skin/O and/O subcutaneous/O disorders/O Rash/B-AdverseReaction 1/O %/O 3/O %/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 1/O %/O 2/O %/O Blood/O and/O lymphatic/B-AdverseReaction disorders/I-AdverseReaction Leukopenia/B-AdverseReaction 0/O %/O 1/O %/O Other/O and/O less/O common/O clinical/O trial/O adverse/O drug/O reactions/O Adverse/O drug/O reactions/O that/O do/O not/O appear/O in/O Table/O 1/O or/O that/O occurred/O 1/O %/O in/O SIMPONI/O ARIA/O -/O treated/O patients/O during/O Trial/O 1/O through/O Week/O 24/O that/O do/O not/O appear/O in/O the/O Warnings/O and/O Precautions/O section/O included/O the/O following/O events/O listed/O by/O system/O organ/O class/O :/O Infections/O and/O Infestations/O :/O Superficial/B-AdverseReaction fungal/I-AdverseReaction infection/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O abscess/B-AdverseReaction ,/O lower/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O pneumonia/B-AdverseReaction )/O ,/O pyelonephritis/B-AdverseReaction Investigations/O :/O Alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O neutrophil/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction Nervous/O system/O disorders/O :/O Dizziness/B-AdverseReaction ,/O paresthesia/B-AdverseReaction Gastrointestinal/O disorders/O :/O Constipation/B-AdverseReaction 6.2/O Post/O -/O marketing/O Experience/O There/O is/O no/O post/O -/O marketing/O experience/O available/O for/O SIMPONI/O ARIA/O ./O
The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O the/O subcutaneous/O formulation/O of/O golimumab/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O golimumab/O exposure/O ./O
Neoplasm/O Benign/O and/O Malignant/O :/O Melanoma/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Immune/O System/O Disorders/O :/O Serious/B-Severity systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction (/O including/O anaphylactic/B-AdverseReaction reaction/I-AdverseReaction )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O ,/O sarcoidosis/B-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Skin/B-AdverseReaction exfoliation/I-AdverseReaction ,/O bullous/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction EXCERPT/O :/O WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Serious/B-Severity infections/B-AdverseReaction leading/O to/O hospitalization/O or/O death/B-AdverseReaction including/O tuberculosis/B-AdverseReaction (/O TB/B-AdverseReaction )/O ,/O bacterial/B-AdverseReaction sepsis/I-AdverseReaction ,/O invasive/O fungal/O (/O such/O as/O histoplasmosis/B-AdverseReaction )/O ,/O and/O other/O opportunistic/B-AdverseReaction infections/I-AdverseReaction have/O occurred/O in/O patients/O receiving/O SIMPONI/O ARIA/O (/O 5.1/O )/O ./O
Discontinue/O SIMPONI/O ARIA/O if/O a/O patient/O develops/O a/O serious/O infection/O or/O sepsis/O (/O 5.1/O )/O ./O
Perform/O test/O for/O latent/O TB/O ;/O if/O positive/O ,/O start/O treatment/O for/O TB/O prior/O to/O starting/O SIMPONI/O ARIA/O (/O 5.1/O )/O ./O
Monitor/O all/O patients/O for/O active/O TB/O during/O treatment/O ,/O even/O if/O initial/O latent/O TB/O test/O is/O negative/O (/O 5.1/O )/O ./O
Lymphoma/B-AdverseReaction and/O other/O malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O in/O children/O and/O adolescent/O patients/O treated/O with/O TNF/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O (/O 5.2/O )/O ./O
SERIOUS/O INFECTIONS/O Patients/O treated/O with/O SIMPONI/O ARIA/O are/O at/O increased/O risk/B-Factor for/O developing/O serious/B-Severity infections/B-AdverseReaction that/O may/B-Factor lead/O to/O hospitalization/O or/O death/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Most/O patients/O who/O developed/O these/O infections/B-AdverseReaction were/O taking/O concomitant/O immunosuppressants/O such/O as/O methotrexate/O or/O corticosteroids/O ./O
Discontinue/O SIMPONI/O ARIA/O if/O a/O patient/O develops/O a/O serious/O infection/O ./O
Reported/O infections/O with/O TNF/O -/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O ,/O include/O :/O Active/B-AdverseReaction tuberculosis/I-AdverseReaction ,/O including/O reactivation/B-AdverseReaction of/I-AdverseReaction latent/I-AdverseReaction tuberculosis/I-AdverseReaction ./O
Patients/O with/O tuberculosis/B-AdverseReaction have/O frequently/O presented/O with/O disseminated/O or/O extrapulmonary/O disease/O ./O
Test/O patients/O for/O latent/O tuberculosis/O before/O SIMPONI/O ARIA/O use/O and/O during/O therapy/O ./O
Initiate/O treatment/O for/O latent/O tuberculosis/O prior/O to/O SIMPONI/O ARIA/O use/O ./O
Invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction ,/O including/O histoplasmosis/B-AdverseReaction ,/O coccidioidomycosis/B-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O aspergillosis/B-AdverseReaction ,/O blastomycosis/B-AdverseReaction and/O pneumocystosis/B-AdverseReaction ./O
Patients/O with/O histoplasmosis/O or/O other/O invasive/O fungal/O infections/O may/O present/O with/O disseminated/O ,/O rather/O than/O localized/O ,/O disease/O ./O
Antigen/O and/O antibody/O testing/O for/O histoplasmosis/O may/O be/O negative/O in/O some/O patients/O with/O active/O infection/O ./O
Consider/O empiric/O anti/O -/O fungal/O therapy/O in/O patients/O at/O risk/O for/O invasive/O fungal/O infections/O who/O develop/O severe/O systemic/O illness/O ./O
Bacterial/O ,/O viral/O ,/O and/O other/O infections/B-AdverseReaction due/I-AdverseReaction to/I-AdverseReaction opportunistic/I-AdverseReaction pathogens/I-AdverseReaction ,/O including/O Legionella/O and/O Listeria/O ./O
Consider/O the/O risks/O and/O benefits/O of/O treatment/O with/O SIMPONI/O ARIA/O prior/O to/O initiating/O therapy/O in/O patients/O with/O chronic/O or/O recurrent/O infection/O ./O
Monitor/O patients/O closely/O for/O the/O development/O of/O signs/O and/O symptoms/O of/O infection/O during/O and/O after/O treatment/O with/O SIMPONI/O ARIA/O ,/O including/O the/O possible/O development/O of/O tuberculosis/O in/O patients/O who/O tested/O negative/O for/O latent/O tuberculosis/O infection/O prior/O to/O initiating/O therapy/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
MALIGNANCY/O Lymphoma/B-AdverseReaction and/O other/O malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O in/O children/O and/O adolescent/O patients/O treated/O with/O TNF/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Serious/B-Severity infections/B-AdverseReaction -/O Do/O not/O start/O SIMPONI/O ARIA/O during/O an/O active/O infection/O ./O
If/O an/O infection/O develops/O ,/O monitor/O carefully/O ,/O and/O stop/O SIMPONI/O ARIA/O if/O infection/O becomes/O serious/O (/O 5.1/O )/O ./O
Invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction -/O For/O patients/O who/O develop/O a/O systemic/O illness/O on/O SIMPONI/O ARIA/O ,/O consider/O empiric/O antifungal/O therapy/O for/O those/O who/O reside/O in/O or/O travel/O to/O regions/O where/O mycoses/O are/O endemic/O (/O 5.1/O )/O ./O
Hepatitis/B-AdverseReaction B/I-AdverseReaction reactivation/I-AdverseReaction -/O Monitor/O HBV/O carriers/O during/O and/O several/O months/O after/O therapy/O ./O
If/O reactivation/O occurs/O ,/O stop/O SIMPONI/O ARIA/O and/O begin/O anti/O -/O viral/O therapy/O (/O 5.1/O )/O ./O
Malignancies/B-AdverseReaction -/O More/O cases/O of/O lymphoma/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O TNF/O -/O blockers/O compared/O with/O patients/O in/O the/O control/O groups/O ./O
Cases/O of/O other/O malignancies/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O TNF/O -/O blockers/O (/O 5.2/O )/O ./O
Heart/B-AdverseReaction failure/I-AdverseReaction -/O Worsening/O ,/O or/O new/O onset/O ,/O may/B-Factor occur/O ./O
Stop/O SIMPONI/O ARIA/O if/O new/O or/O worsening/O symptoms/O occur/O (/O 5.3/O )/O ./O
Demyelinating/B-AdverseReaction disease/I-AdverseReaction ,/O exacerbation/O or/O new/O onset/O ,/O may/B-Factor occur/O (/O 5.4/O )/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction :/O Serious/B-Severity systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction including/O anaphylaxis/B-AdverseReaction may/B-Factor occur/O (/O 5.10/O )/O ./O
5.1/O Serious/O Infections/O Patients/O treated/O with/O SIMPONI/O ARIA/O are/O at/O increased/O risk/B-Factor for/O developing/O serious/B-Severity infections/B-AdverseReaction involving/O various/O organ/O systems/O and/O sites/O that/O may/B-Factor lead/O to/O hospitalization/O or/O death/B-AdverseReaction ./O
Opportunistic/B-AdverseReaction infections/I-AdverseReaction due/O to/O bacterial/O ,/O mycobacterial/O ,/O invasive/O fungal/O ,/O viral/O ,/O or/O parasitic/O organisms/O including/O aspergillosis/B-AdverseReaction ,/O blastomycosis/B-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O coccidioidomycosis/B-AdverseReaction ,/O histoplasmosis/B-AdverseReaction ,/O legionellosis/B-AdverseReaction ,/O listeriosis/B-AdverseReaction ,/O pneumocystosis/B-AdverseReaction ,/O and/O tuberculosis/B-AdverseReaction have/O been/O reported/O with/O TNF/B-DrugClass -/O blockers/O ./O
Patients/O have/O frequently/O presented/O with/O disseminated/O rather/O than/O localized/O disease/O ./O
The/O concomitant/O use/O of/O a/O TNF/O -/O blocker/O and/O abatacept/O or/O anakinra/O was/O associated/O with/O a/O higher/O risk/O of/O serious/O infections/O ;/O therefore/O ,/O the/O concomitant/O use/O of/O SIMPONI/O ARIA/O and/O these/O biologic/O products/O is/O not/O recommended/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O ,/O 5.6/O )/O and/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
Treatment/O with/O SIMPONI/O ARIA/O should/O not/O be/O initiated/O in/O patients/O with/O an/O active/O infection/O ,/O including/O clinically/O important/O localized/O infections/O ./O
Patients/O greater/O than/O 65/O years/O of/O age/O ,/O patients/O with/O co/O -/O morbid/O conditions/O and/or/O patients/O taking/O concomitant/O immunosuppressants/O such/O as/O corticosteroids/O or/O methotrexate/O may/O be/O at/O greater/O risk/O of/O infection/O ./O
Consider/O the/O risks/O and/O benefits/O of/O treatment/O prior/O to/O initiating/O SIMPONI/O ARIA/O in/O patients/O :/O with/O chronic/O or/O recurrent/O infection/O ;/O who/O have/O been/O exposed/O to/O tuberculosis/O ;/O with/O a/O history/O of/O an/O opportunistic/O infection/O ;/O who/O have/O resided/O or/O traveled/O in/O areas/O of/O endemic/O tuberculosis/O or/O endemic/O mycoses/O ,/O such/O as/O histoplasmosis/O ,/O coccidioidomycosis/O ,/O or/O blastomycosis/O ;/O or/O with/O underlying/O conditions/O that/O may/O predispose/O them/O to/O infection/O ./O
Monitoring/O Closely/O monitor/O patients/O for/O the/O development/O of/O signs/O and/O symptoms/O of/O infection/O during/O and/O after/O treatment/O with/O SIMPONI/O ARIA/O ./O
Discontinue/O SIMPONI/O ARIA/O if/O a/O patient/O develops/O a/O serious/O infection/O ,/O an/O opportunistic/O infection/O ,/O or/O sepsis/O ./O
For/O patients/O who/O develop/O a/O new/O infection/O during/O treatment/O with/O SIMPONI/O ARIA/O ,/O perform/O a/O prompt/O and/O complete/O diagnostic/O workup/O appropriate/O for/O an/O immunocompromised/O patient/O and/O initiate/O appropriate/O antimicrobial/O therapy/O and/O closely/O monitor/O them/O ./O
Tuberculosis/O Cases/O of/O reactivation/B-AdverseReaction of/I-AdverseReaction tuberculosis/I-AdverseReaction or/O new/B-AdverseReaction tuberculosis/I-AdverseReaction infections/I-AdverseReaction have/O been/O observed/O in/O patients/O receiving/O TNF/O -/O blockers/O ,/O including/O patients/O who/O have/O previously/O received/O treatment/O for/O latent/O or/O active/O tuberculosis/O ./O
Evaluate/O patients/O for/O tuberculosis/O risk/O factors/O and/O test/O for/O latent/O infection/O prior/O to/O initiating/O SIMPONI/O ARIA/O and/O periodically/O during/O therapy/O ./O
Treatment/O of/O latent/O tuberculosis/O infection/O prior/O to/O therapy/O with/O TNF/O -/O blockers/O has/O been/O shown/O to/O reduce/O the/O risk/O of/O tuberculosis/O reactivation/O during/O therapy/O ./O
Prior/O to/O initiating/O SIMPONI/O ARIA/O ,/O assess/O if/O treatment/O for/O latent/O tuberculosis/O is/O needed/O ;/O An/O induration/O of/O 5/O mm/O or/O greater/O is/O a/O positive/O tuberculin/O skin/O test/O ,/O even/O for/O patients/O previously/O vaccinated/O with/O Bacille/O Calmette/O -/O Guerin/O (/O BCG/O )/O ./O
Consider/O anti/O -/O tuberculosis/O therapy/O prior/O to/O initiation/O of/O SIMPONI/O ARIA/O in/O patients/O with/O a/O past/O history/O of/O latent/O or/O active/O tuberculosis/O in/O whom/O an/O adequate/O course/O of/O treatment/O can/O not/O be/O confirmed/O ,/O and/O for/O patients/O with/O a/O negative/O test/O for/O latent/O tuberculosis/O but/O having/O risk/O factors/O for/O tuberculosis/O infection/O ./O
Consultation/O with/O a/O physician/O with/O expertise/O in/O the/O treatment/O of/O tuberculosis/O is/O recommended/O to/O aid/O in/O the/O decision/O whether/O initiating/O anti/O -/O tuberculosis/O therapy/O is/O appropriate/O for/O an/O individual/O patient/O ./O
Cases/O of/O active/O tuberculosis/O have/O occurred/O in/O patients/O treated/O with/O the/O subcutaneous/O formulation/O of/O golimumab/O during/O and/O after/O treatment/O for/O latent/O tuberculosis/O ./O
Monitor/O patients/O for/O the/O development/O of/O signs/O and/O symptoms/O of/O tuberculosis/O including/O patients/O who/O tested/O negative/O for/O latent/O tuberculosis/O infection/O prior/O to/O initiating/O therapy/O ,/O patients/O who/O are/O on/O treatment/O for/O latent/O tuberculosis/O ,/O or/O patients/O who/O were/O previously/O treated/O for/O tuberculosis/O infection/O ./O
Consider/O tuberculosis/O in/O the/O differential/O diagnosis/O in/O patients/O who/O develop/O a/O new/O infection/O during/O SIMPONI/O ARIA/O treatment/O ,/O especially/O in/O patients/O who/O have/O previously/O or/O recently/O traveled/O to/O countries/O with/O a/O high/O prevalence/O of/O tuberculosis/O ,/O or/O who/O have/O had/O close/O contact/O with/O a/O person/O with/O active/O tuberculosis/O ./O
Invasive/O Fungal/O Infections/O If/O patients/O develop/O a/O serious/O systemic/O illness/O and/O they/O reside/O or/O travel/O in/O regions/O where/O mycoses/O are/O endemic/O ,/O consider/O invasive/O fungal/O infection/O in/O the/O differential/O diagnosis/O ./O
Consider/O appropriate/O empiric/O antifungal/O therapy/O and/O take/O into/O account/O both/O the/O risk/O for/O severe/O fungal/O infection/O and/O the/O risks/O of/O antifungal/O therapy/O while/O a/O diagnostic/O workup/O is/O being/O performed/O ./O
Antigen/O and/O antibody/O testing/O for/O histoplasmosis/O may/O be/O negative/O in/O some/O patients/O with/O active/O infection/O ./O
To/O aid/O in/O the/O management/O of/O such/O patients/O ,/O consider/O consultation/O with/O a/O physician/O with/O expertise/O in/O the/O diagnosis/O and/O treatment/O of/O invasive/O fungal/O infections/O ./O
Hepatitis/O B/O Virus/O Reactivation/O The/O use/O of/O TNF/O -/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O ,/O has/O been/O associated/O with/O reactivation/B-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction virus/I-AdverseReaction (/O HBV/O )/O in/O patients/O who/O are/O chronic/O hepatitis/O B/O carriers/O (/O i.e./O ,/O surface/O antigen/O positive/O )/O ./O
In/O some/O instances/O ,/O HBV/B-AdverseReaction reactivation/I-AdverseReaction occurring/O in/O conjunction/O with/O TNF/O -/O blocker/O therapy/O has/O been/O fatal/B-AdverseReaction ./O
The/O majority/O of/O these/O reports/O have/O occurred/O in/O patients/O who/O received/O concomitant/O immunosuppressants/O ./O
All/O patients/O should/O be/O tested/O for/O HBV/O infection/O before/O initiating/O TNF/O -/O blocker/O therapy/O ./O
For/O patients/O who/O test/O positive/O for/O hepatitis/O B/O surface/O antigen/O ,/O consultation/O with/O a/O physician/O with/O expertise/O in/O the/O treatment/O of/O hepatitis/O B/O is/O recommended/O before/O initiating/O TNF/O -/O blocker/O therapy/O ./O
The/O risks/O and/O benefits/O of/O treatment/O should/O be/O considered/O prior/O to/O prescribing/O TNF/O -/O blockers/O ,/O including/O SIMPONI/O ARIA/O ,/O to/O patients/O who/O are/O carriers/O of/O HBV/O ./O
Adequate/O data/O are/O not/O available/O on/O whether/O anti/O -/O viral/O therapy/O can/O reduce/O the/O risk/O of/O HBV/O reactivation/O in/O HBV/O carriers/O who/O are/O treated/O with/O TNF/O -/O blockers/O ./O
Patients/O who/O are/O carriers/O of/O HBV/O and/O require/O treatment/O with/O TNF/O -/O blockers/O should/O be/O closely/O monitored/O for/O clinical/O and/O laboratory/O signs/O of/O active/O HBV/O infection/O throughout/O therapy/O and/O for/O several/O months/O following/O termination/O of/O therapy/O ./O
In/O patients/O who/O develop/O HBV/O reactivation/O ,/O TNF/O -/O blockers/O should/O be/O stopped/O and/O antiviral/O therapy/O with/O appropriate/O supportive/O treatment/O should/O be/O initiated/O ./O
The/O safety/O of/O resuming/O TNF/O -/O blockers/O after/O HBV/O reactivation/O has/O been/O controlled/O is/O not/O known/O ./O
Therefore/O ,/O prescribers/O should/O exercise/O caution/O when/O considering/O resumption/O of/O TNF/O -/O blockers/O in/O this/O situation/O and/O monitor/O patients/O closely/O ./O
5.2/O Malignancies/O Malignancies/O in/O Pediatric/O Patients/O Malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O among/O children/O ,/O adolescents/O ,/O and/O young/O adults/O who/O received/O treatment/O with/O TNF/O -/O blocking/O agents/O (/O initiation/O of/O therapy/O 18/O years/O of/O age/O )/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O ./O
Approximately/O half/O the/O cases/O were/O lymphomas/B-AdverseReaction ,/O including/O Hodgkin/O 's/O and/O non/B-AdverseReaction -/I-AdverseReaction Hodgkin/O 's/O lymphoma/O ./O
The/O other/O cases/O represented/O a/O variety/O of/O malignancies/B-AdverseReaction ,/O including/O rare/B-AdverseReaction malignancies/I-AdverseReaction that/O are/O usually/O associated/O with/O immunosuppression/B-AdverseReaction ,/O and/O malignancies/O that/O are/O not/O usually/O observed/O in/O children/O and/O adolescents/O ./O
The/O malignancies/O occurred/O after/O a/O median/O of/O 30/O months/O (/O range/O 1/O to/O 84/O months/O )/O after/O the/O first/O dose/O of/O TNF/O -/O blocker/O therapy/O ./O
Most/O of/O the/O patients/O were/O receiving/O concomitant/O immunosuppressants/O ./O
These/O cases/O were/O reported/O post/O -/O marketing/O and/O are/O derived/O from/O a/O variety/O of/O sources/O ,/O including/O registries/O and/O spontaneous/O post/O -/O marketing/O reports/O ./O
Use/O of/O SIMPONI/O ARIA/O in/O patients/O under/O 18/O years/O of/O age/O has/O not/O been/O established/O ./O
Malignancies/O in/O Adult/O Patients/O The/O risks/O and/O benefits/O of/O TNF/O -/O blocker/O treatment/O including/O SIMPONI/O ARIA/O should/O be/O considered/O prior/O to/O initiating/O therapy/O in/O patients/O with/O a/O known/O malignancy/O other/O than/O a/O successfully/O treated/O non/O -/O melanoma/O skin/O cancer/O (/O NMSC/O )/O or/O when/O considering/O continuing/O a/O TNF/O -/O blocker/O in/O patients/O who/O develop/O a/O malignancy/O ./O
In/O the/O controlled/O portions/O of/O clinical/O trials/O of/O TNF/O -/O blockers/O including/O the/O subcutaneous/O formulation/O of/O golimumab/O more/O cases/O of/O lymphoma/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O anti/O -/O TNF/O treatment/O compared/O with/O patients/O in/O the/O control/O groups/O ./O
Patients/O with/O RA/O and/O other/O chronic/O inflammatory/O diseases/O ,/O particularly/O patients/O with/O highly/O active/O disease/O and/or/O chronic/O exposure/O to/O immunosuppressant/O therapies/O ,/O may/O be/O at/O higher/O risk/B-Factor (/O up/O to/O several/O fold/O )/O than/O the/O general/O population/O for/O the/O development/O of/O lymphoma/B-AdverseReaction ,/O even/O in/O the/O absence/O of/O TNF/O -/O blocking/O therapy/O ./O
Cases/O of/O acute/O and/O chronic/B-AdverseReaction leukemia/I-AdverseReaction have/O been/O reported/O with/O post/O -/O marketing/O TNF/O -/O blocker/O use/O in/O rheumatoid/O arthritis/O and/O other/O indications/O ./O
Even/O in/O the/O absence/O of/O TNF/O -/O blocker/O therapy/O ,/O patients/O with/O rheumatoid/O arthritis/O may/O be/O at/O a/O higher/O risk/O (/O approximately/O 2-fold/O )/O than/O the/O general/O population/O for/O the/O development/O of/O leukemia/O ./O
Rare/O post/O -/O marketing/O cases/O of/O hepatosplenic/B-AdverseReaction T/I-AdverseReaction -/I-AdverseReaction cell/O lymphoma/O (/O HSTCL/B-AdverseReaction )/O have/O been/O reported/O in/O patients/O treated/O with/O TNF/O -/O blocking/O agents/O ./O
This/O rare/B-AdverseReaction type/I-AdverseReaction of/I-AdverseReaction T/I-AdverseReaction -/I-AdverseReaction cell/O lymphoma/O has/O a/O very/O aggressive/O disease/O course/O and/O is/O usually/O fatal/B-AdverseReaction ./O
Nearly/O all/O of/O the/O reported/O TNF/O -/O blocker/O associated/O cases/O have/O occurred/O in/O patients/O with/O Crohn/O 's/O disease/O or/O ulcerative/O colitis/O ./O
The/O majority/O were/O in/O adolescent/O and/O young/O adult/O males/O ./O
Almost/O all/O these/O patients/O had/O received/O treatment/O with/O azathioprine/O (/O AZA/O )/O or/O 6-mercaptopurine/O (/O 6-MP/O )/O concomitantly/O with/O a/O TNF/O -/O blocker/O at/O or/O prior/O to/O diagnosis/O ./O
A/O risk/O for/O the/O development/O for/O hepatosplenic/O T/O -/O cell/O lymphoma/O in/O patients/O treated/O with/O TNF/O -/O blockers/O can/O not/O be/O excluded/O ./O
Melanoma/B-AdverseReaction has/O been/O reported/O in/O patients/O treated/O with/O TNF/O -/O blocking/O agents/O ,/O including/O the/O subcutaneous/O formulation/O of/O golimumab/O ./O
Merkel/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction has/O been/O reported/O in/O patients/O treated/O with/O TNF/O -/O blocking/O agents/O ./O
Periodic/O skin/O examination/O is/O recommended/O for/O all/O patients/O ,/O particularly/O those/O with/O risk/O factors/O for/O skin/O cancer/O ./O
In/O controlled/O trials/O of/O other/O TNF/O -/O blockers/O in/O patients/O at/O higher/O risk/O for/O malignancies/O (/O e.g./O ,/O patients/O with/O COPD/O ,/O patients/O with/O Wegener/O 's/O granulomatosis/O treated/O with/O concomitant/O cyclophosphamide/O )/O a/O greater/O portion/O of/O malignancies/B-AdverseReaction occurred/O in/O the/O TNF/O -/O blocker/O group/O compared/O to/O the/O controlled/O group/O ./O
In/O an/O exploratory/O clinical/O trial/O evaluating/O the/O use/O of/O the/O subcutaneous/O formulation/O of/O golimumab/O in/O patients/O with/O severe/O persistent/O asthma/O ,/O more/O patients/O treated/O with/O golimumab/O reported/O malignancies/B-AdverseReaction compared/O with/O control/O patients/O ./O
The/O significance/O of/O this/O finding/O is/O unknown/O ./O
During/O the/O controlled/O portion/O of/O the/O Phase/O 3/O trial/O in/O RA/O for/O SIMPONI/O ARIA/O ,/O the/O incidence/O of/O malignancies/B-AdverseReaction other/O than/O lymphoma/O and/O NMSC/O per/O 100-patient/O -/O years/O of/O follow/O -/O up/O was/O 0.56/O (/O 95/O %/O CI/O :/O 0.01/O ,/O 3.11/O )/O in/O the/O SIMPONI/O ARIA/O group/O compared/O with/O an/O incidence/O of/O 0/O (/O 95/O %/O CI/O :/O 0.00/O ,/O 3.79/O )/O in/O the/O placebo/O group/O ./O
5.3/O Congestive/O Heart/O Failure/O Cases/O of/O worsening/B-AdverseReaction congestive/I-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction (/O CHF/O )/O and/O new/B-AdverseReaction onset/I-AdverseReaction CHF/I-AdverseReaction have/O been/O reported/O with/O TNF/O -/O blockers/O ,/O including/O SIMPONI/O ARIA/O ./O
In/O several/O exploratory/O trials/O of/O other/O TNF/O -/O blockers/O in/O the/O treatment/O of/O CHF/O ,/O there/O were/O greater/O proportions/O of/O TNF/O -/O blocker/O treated/O patients/O who/O had/O CHF/B-AdverseReaction exacerbations/I-AdverseReaction requiring/O hospitalization/O or/O increased/B-AdverseReaction mortality/I-AdverseReaction ./O
SIMPONI/O ARIA/O has/O not/O been/O studied/O in/O patients/O with/O a/O history/O of/O CHF/O and/O SIMPONI/O ARIA/O should/O be/O used/O with/O caution/O in/O patients/O with/O CHF/O ./O
If/O a/O decision/O is/O made/O to/O administer/O SIMPONI/O ARIA/O to/O RA/O patients/O with/O CHF/O ,/O these/O patients/O should/O be/O closely/O monitored/O during/O therapy/O ,/O and/O SIMPONI/O ARIA/O should/O be/O discontinued/O if/O new/O or/O worsening/O symptoms/O of/O CHF/O appear/O ./O
5.4/O Demyelinating/O Disorders/O Use/O of/O TNF/O -/O blockers/O ,/O of/O which/O SIMPONI/O ARIA/O is/O a/O member/O ,/O has/O been/O associated/O with/O rare/O cases/O of/O new/O onset/O or/O exacerbation/O of/O central/O nervous/O system/O (/O CNS/O )/O demyelinating/O disorders/O ,/O including/O multiple/B-AdverseReaction sclerosis/I-AdverseReaction (/O MS/B-AdverseReaction )/O and/O peripheral/B-AdverseReaction demyelinating/I-AdverseReaction disorders/I-AdverseReaction ,/O including/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O ./O
Cases/O of/O central/B-AdverseReaction demyelination/I-AdverseReaction ,/O MS/B-AdverseReaction ,/O optic/B-AdverseReaction neuritis/I-AdverseReaction ,/O and/O peripheral/B-AdverseReaction demyelinating/I-AdverseReaction polyneuropathy/I-AdverseReaction have/O rarely/O been/O reported/O in/O patients/O treated/O with/O the/O subcutaneous/O formulation/O of/O golimumab/O ./O
Prescribers/O should/O exercise/O caution/O in/O considering/O the/O use/O of/O TNF/O -/O blockers/O ,/O including/O SIMPONI/O ARIA/O ,/O in/O patients/O with/O central/O or/O peripheral/O nervous/O system/O demyelinating/O disorders/O ./O
Discontinuation/O of/O SIMPONI/O ARIA/O should/O be/O considered/O if/O these/O disorders/O develop/O ./O
5.5/O Use/O with/O Abatacept/O In/O controlled/O trials/O ,/O the/O concurrent/O administration/O of/O another/O TNF/O -/O blocker/O and/O abatacept/O was/O associated/O with/O a/O greater/O proportion/O of/O serious/O infections/O than/O the/O use/O of/O a/O TNF/O -/O blocker/O alone/O ;/O and/O the/O combination/O therapy/O ,/O compared/O to/O the/O use/O of/O a/O TNF/O -/O blocker/O alone/O ,/O has/O not/O demonstrated/O improved/O clinical/O benefit/O in/O the/O treatment/O of/O RA/O ./O
Therefore/O ,/O the/O combination/O of/O TNF/O -/O blockers/O including/O SIMPONI/O ARIA/O and/O abatacept/O is/O not/O recommended/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
5.6/O Use/O with/O Anakinra/O Concurrent/O administration/O of/O anakinra/O (/O an/O interleukin-1/O antagonist/O )/O and/O another/O TNF/O -/O blocker/O ,/O was/O associated/O with/O a/O greater/O portion/O of/O serious/O infections/O and/O neutropenia/O and/O no/O additional/O benefits/O compared/O with/O the/O TNF/O -/O blocker/O alone/O ./O
Therefore/O ,/O the/O combination/O of/O anakinra/O with/O TNF/O -/O blockers/O ,/O including/O SIMPONI/O ARIA/O ,/O is/O not/O recommended/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
5.7/O Switching/O Between/O Biological/O Disease/O Modifying/O Antirheumatic/O Drugs/O (/O DMARDs/O )/O Care/O should/O be/O taken/O when/O switching/O from/O one/O biologic/O product/O to/O another/O biologic/O product/O since/O overlapping/O biological/O activity/O may/O further/O increase/O the/O risk/O of/O infection/O ./O
5.8/O Hematologic/O Cytopenias/O There/O have/O been/O post/O -/O marketing/O reports/O of/O pancytopenia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O aplastic/B-AdverseReaction anemia/I-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction in/O patients/O receiving/O TNF/O -/O blockers/O ./O
In/O clinical/O studies/O ,/O cases/O of/O pancytopenia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction have/O also/O occurred/O in/O SIMPONI/O ARIA/O -/O treated/O patients/O ./O
Caution/O should/O be/O exercised/O when/O using/O TNF/O -/O blockers/O ,/O including/O SIMPONI/O ARIA/O ,/O in/O patients/O who/O have/O or/O have/O had/O significant/O cytopenias/O ./O
5.9/O Vaccinations/O Therapeutic/O Infectious/O Agents/O Live/O Vaccines/O Patients/O treated/O with/O SIMPONI/O ARIA/O may/O receive/O vaccinations/O ,/O except/O for/O live/O vaccines/O ./O
In/O patients/O receiving/O anti/O -/O TNF/O therapy/O ,/O limited/O data/O are/O available/O on/O the/O response/O to/O live/O vaccination/O ,/O or/O on/O the/O secondary/O transmission/O of/O infection/O by/O live/O vaccines/O ./O
Use/O of/O live/O vaccines/O could/O result/O in/O clinical/O infections/O ,/O including/O disseminated/O infections/O ./O
Therapeutic/O Infectious/O Agents/O Other/O uses/O of/O therapeutic/O infectious/O agents/O such/O as/O live/O attenuated/O bacteria/O (/O e.g./O ,/O BCG/O bladder/O instillation/O for/O the/O treatment/O of/O cancer/O )/O could/O result/O in/O clinical/O infections/O ,/O including/O disseminated/O infections/O ./O
It/O is/O recommended/O that/O therapeutic/O infectious/O agents/O not/O be/O given/O concurrently/O with/O SIMPONI/O ARIA/O ./O
5.10/O Hypersensitivity/O Reactions/O In/O post/O -/O marketing/O experience/O ,/O serious/B-Severity systemic/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O including/O anaphylactic/B-AdverseReaction reaction/I-AdverseReaction )/O have/O been/O reported/O following/O administration/O of/O the/O subcutaneous/O formulation/O of/O golimumab/O ./O
Some/O of/O these/O reactions/O occurred/O after/O the/O first/O administration/O of/O golimumab/O ./O
If/O an/O anaphylactic/O or/O other/O serious/O allergic/O reaction/O occurs/O ,/O administration/O of/O SIMPONI/O ARIA/O should/O be/O discontinued/O immediately/O and/O appropriate/O therapy/O instituted/O ./O
